Serial None None O
measurements None None O
of None None O
antineutrophil None None O
cytoplasmic None None O
autoantibodies None None O
in None None O
patients None None O
with None None O
systemic None None O
vasculitis None None O
. None None O

PURPOSE None None O
: None None O
To None None O
assess None None O
the None None O
value None None O
of None None O
serial None None O
determinations None None O
of None None O
antineutrophil None None O
cytoplasmic None None O
autoantibodies None None O
( None None O
ANCA None None O
) None None O
for None None O
monitoring None None O
disease None None O
activity None None O
in None None O
patients None None O
with None None O
systemic None None O
vasculitis None None O
. None None O

PATIENTS None None O
AND None None O
METHODS None None O
: None None O
Forty None None O
- None None O
three None None O
patients None None O
with None None O
histologically None None O
proven None None O
vasculitis None None O
( None None O
21 None None O
with None None O
Wegener None None O
's None None O
granulomatosis None None O
, None None O
17 None None O
with None None O
microscopic None None O
polyangiitis None None O
, None None O
and None None O
5 None None O
with None None O
renal None None O
- None None O
limited None None O
vasculitis None None O
) None None O
were None None O
studied None None O
for None None O
a None None O
median None None O
follow None None O
- None None O
up None None O
of None None O
22 None None O
months None None O
. None None O

Disease None None O
activity None None O
was None None O
prospectively None None O
assessed None None O
and None None O
quantified None None O
by None None O
the None None O
Birmingham None None O
Vasculitis None None O
Activity None None O
Score None None O
. None None O

A None None O
total None None O
of None None O
347 None None O
sera None None O
were None None O
analyzed None None O
for None None O
ANCA None None O
determination None None O
. None None O

RESULTS None None O
: None None O
Relapses None None O
occurred None None O
in None None O
23 None None O
( None None O
54% None None O
) None None O
of None None O
43 None None O
patients None None O
. None None O

Diagnostic None None O
category None None O
( None None O
Wegener None None O
's None None O
granulomatosis None None O
vs None None O
micropolyangiitis None None O
and None None O
renal None None O
- None None O
limited None None O
vasculitis None None O
) None None O
, None None O
severity None None O
of None None O
initial None None O
symptoms None None O
( None None O
mean None None O
vasculitis None None O
activity None None O
score None None O
, None None O
mean None None O
number None None O
of None None O
organs None None O
involved None None O
) None None O
, None None O
and None None O
ANCA None None O
pattern None None O
[ None None O
cytoplasmic None None O
- None None O
ANCA None None O
( None None O
c None None O
- None None O
ANCA None None O
) None None O
vs None None O
perinuclear None None O
- None None O
ANCA None None O
( None None O
p None None O
- None None O
ANCA None None O
) None None O
] None None O
did None None O
not None None O
significantly None None O
differ None None O
between None None O
relapsers None None O
and None None O
nonrelapsers None None O
. None None O

Lung None None O
involvement None None O
was None None O
more None None O
frequent None None O
at None None O
onset None None O
among None None O
relapsers None None O
[ None None O
16 None None O
of None None O
23 None None O
( None None O
70% None None O
) None None O
vs None None O
6 None None O
of None None O
20 None None O
( None None O
30% None None O
) None None O
; None None O
P None None O
= None None O
0.02 None None O
] None None O
. None None O

Relapses None None O
were None None O
slightly None None O
, None None O
but None None O
not None None O
significantly None None O
, None None O
more None None O
frequent None None O
in None None O
patients None None O
with None None O
Wegener None None O
's None None O
granulomatosis None None O
or None None O
a None None O
c None None O
- None None O
ANCA None None O
pattern None None O
. None None O

The None None O
percentage None None O
of None None O
relapsers None None O
was None None O
greater None None O
in None None O
patients None None O
with None None O
persistently None None O
positive None None O
ANCA None None O
than None None O
in None None O
patients None None O
with None None O
negative None None O
or None None O
decreasing None None O
ANCA None None O
titers None None O
( None None O
86% None None O
vs None None O
20% None None O
, None None O
P None None O
= None None O
0.0001 None None O
) None None O
. None None O

However None None O
, None None O
the None None O
predictive None None O
value None None O
of None None O
an None None O
increase None None O
in None None O
ANCA None None O
titers None None O
for None None O
the None None O
occurrence None None O
of None None O
a None None O
subsequent None None O
relapse None None O
was None None O
only None None O
28% None None O
( None None O
4 None None O
of None None O
14 None None O
) None None O
for None None O
c None None O
- None None O
ANCA None None O
, None None O
12% None None O
( None None O
2 None None O
of None None O
17 None None O
) None None O
for None None O
anti None None O
- None None O
proteinase None None O
3 None None O
- None None O
ANCA None None O
, None None O
and None None O
43% None None O
( None None O
6 None None O
of None None O
14 None None O
) None None O
for None None O
anti None None O
- None None O
myeloperoxidase None None O
- None None O
ANCA None None O
. None None O

An None None O
increase None None O
in None None O
ANCA None None O
occurred None None O
before None None O
or None None O
during None None O
relapse None None O
in None None O
33% None None O
( None None O
10 None None O
of None None O
30 None None O
) None None O
of None None O
cases None None O
for None None O
c None None O
- None None O
ANCA None None O
/ None None O
anti None None O
- None None O
proteinase None None O
3 None None O
antibodies None None O
, None None O
and None None O
73% None None O
( None None O
11 None None O
of None None O
15 None None O
) None None O
of None None O
cases None None O
for None None O
anti None None O
- None None O
myeloperoxidase None None O
antibodies None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
persistence None None O
of None None O
ANCA None None O
positivity None None O
is None None O
strongly None None O
associated None None O
with None None O
relapses None None O
. None None O

However None None O
, None None O
an None None O
increase None None O
in None None O
ANCA None None O
titers None None O
has None None O
a None None O
poor None None O
value None None O
for None None O
the None None O
early None None O
prediction None None O
of None None O
a None None O
subsequent None None O
relapse None None O
and None None O
should None None O
not None None O
be None None O
used None None O
as None None O
a None None O
sole None None O
parameter None None O
for None None O
therapeutic None None O
intervention None None O
. None None O

In None None O
addition None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
serial None None O
anti None None O
- None None O
myeloperoxidase None None O
determination None None O
may None None O
be None None O
useful None None O
as None None O
a None None O
prognostic None None O
marker None None O
in None None O
patients None None O
who None None O
are None None O
p None None O
- None None O
ANCA None None O
positive None None O
. None None O


The None None O
synthesis None None O
of None None O
a None None O
range None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
( None None I-IUPAC
1H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
pyridinones None None I-IUPAC
with None None O
potential None None O
for None None O
the None None O
chelation None None O
of None None O
iron None None I-TRIVIAL
( None None I-TRIVIAL
III None None I-TRIVIAL
) None None I-TRIVIAL
is None None O
described None None O
. None None O

The None None O
pKa None None O
values None None O
of None None O
respective None None O
ligands None None O
and None None O
the None None O
stability None None O
constants None None O
of None None O
their None None O
iron None None I-TRIVIAL
( None None I-TRIVIAL
III None None I-TRIVIAL
) None None I-TRIVIAL
complexes None None I-MODIFIER
are None None O
presented None None O
. None None O

The None None O
distribution None None O
coefficient None None O
values None None O
of None None O
a None None O
range None None O
of None None O
48 None None O
hydroxypyridinones None None I-FAMILY
and None None O
their None None O
corresponding None None O
iron None None I-TRIVIAL
( None None I-TRIVIAL
III None None I-TRIVIAL
) None None I-TRIVIAL
complexes None None I-MODIFIER
between None None O
1 None None I-TRIVIAL
- None None I-TRIVIAL
octanol None None I-TRIVIAL
and None None O
MOPS None None O
buffer None None O
( None None O
pH None None O
7.4 None None O
) None None O
are None None O
reported None None O
. None None O

The None None O
range None None O
of None None O
log None None O
Dcomplex None None O
values None None O
covers None None O
7 None None O
orders None None O
of None None O
magnitude None None O
. None None O

The None None O
results None None O
suggest None None O
the None None O
existence None None O
of None None O
a None None O
biphasic None None O
relationship None None O
between None None O
the None None O
distribution None None O
coefficient None None O
values None None O
of None None O
the None None O
chelator None None O
and None None O
the None None O
corresponding None None O
iron None None I-TRIVIAL
( None None I-TRIVIAL
III None None I-TRIVIAL
) None None I-TRIVIAL
complexes None None I-MODIFIER
. None None O

For None None O
ligands None None O
with None None O
a None None O
log None None O
Dligand None None O
= None None O
- None None O
1 None None O
, None None O
a None None O
linear None None O
relationship None None O
exists None None O
with None None O
a None None O
value None None O
of None None O
the None None O
slope None None O
2.53 None None O
, None None O
whereas None None O
with None None O
ligands None None O
with None None O
a None None O
log None None O
Dligand None None O
& None None O
lt None None O
; None None O
- None None O
1 None None O
, None None O
a None None O
linear None None O
relationship None None O
exists None None O
with None None O
a None None O
slope None None O
of None None O
0.49 None None O
. None None O

The None None O
reduced None None O
slope None None O
for None None O
the None None O
more None None O
hydrophilic None None O
molecules None None O
of None None O
the None None O
series None None O
offers None None O
some None None O
advantage None None O
for None None O
this None None O
type None None O
of None None O
hydroxypyridinone None None I-FAMILY
as None None O
the None None O
distribution None None O
coefficients None None O
for None None O
such None None O
complexes None None O
do None None O
not None None O
change None None O
so None None O
rapidly None None O
with None None O
increasing None None O
ligand None None O
hydrophilicity None None O
. None None O

The None None O
ability None None O
of None None O
selected None None O
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridinones None None I-IUPAC
to None None O
facilitate None None O
the None None O
excretion None None O
of None None O
iron None None O
in None None O
bile None None O
was None None O
investigated None None O
in None None O
non None None O
- None None O
iron None None O
- None None O
overloaded None None O
, None None O
bile None None O
duct None None O
- None None O
cannulated None None O
rats None None O
and None None O
in None None O
a None None O
[ None None I-IUPAC
59Fe None None I-IUPAC
] None None I-IUPAC
ferritin None None I-IUPAC
- None None O
loaded None None O
rat None None O
model None None O
. None None O

Both None None O
systems None None O
compare None None O
the None None O
ability None None O
of None None O
chelators None None O
to None None O
remove None None O
iron None None O
from None None O
the None None O
liver None None O
, None None O
the None None O
prime None None O
target None None O
organ None None O
in None None O
thalassemia None None O
. None None O

The None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
are None None O
demonstrated None None O
to None None O
be None None O
orally None None O
active None None O
under None None O
the None None O
in None None O
vivo None None O
conditions None None O
adopted None None O
. None None O

Thus None None O
both None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
hydroxyalkyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
pyridinones None None I-IUPAC
are None None O
able None None O
to None None O
remove None None O
iron None None I-TRIVIAL
from None None O
the None None O
liver None None O
. None None O

Although None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
hydroxypyridinones None None I-IUPAC
are None None O
active None None O
, None None O
they None None O
do None None O
not None None O
demonstrate None None O
any None None O
clear None None O
advantage None None O
over None None O
Deferiprone None None I-TRIVIAL
( None None O
1,2 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
) None None O
. None None O

Indeed None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxyalkyl None None I-IUPAC
) None None I-IUPAC
hydroxypyridinones None None I-IUPAC
which None None O
are None None O
known None None O
to None None O
be None None O
rapidly None None O
converted None None O
to None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carboxyalkyl None None I-IUPAC
) None None I-IUPAC
hydroxypyridinones None None I-IUPAC
are None None O
also None None O
marginally None None O
superior None None O
to None None O
Deferiprone None None I-TRIVIAL
. None None O

In None None O
contrast None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
hydroxyethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypyridin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
, None None O
which None None O
is None None O
not None None O
metabolized None None O
to None None O
the None None O
corresponding None None O
( None None I-TRIVIAL
carboxyalkyl None None I-TRIVIAL
) None None I-TRIVIAL
hydroxypyridinone None None I-TRIVIAL
, None None O
was None None O
found None None O
to None None O
be None None O
superior None None O
to None None O
Deferiprone None None I-TRIVIAL
and None None O
therefore None None O
deserves None None O
further None None O
consideration None None O
as None None O
an None None O
orally None None O
active None None O
iron None None O
chelator None None O
with None None O
potential None None O
for None None O
the None None O
treatment None None O
of None None O
iron None None I-TRIVIAL
overload None None O
associated None None O
with None None O
transfusion None None O
- None None O
dependent None None O
thalassemia None None O
. None None O


A None None O
series None None O
of None None O
analogues None None O
of None None O
the None None O
analgesic None None O
dipeptide None None O
derivative None None O
H None None O
- None None O
Lys None None O
- None None O
Trp None None O
( None None O
NPS None None O
) None None O
- None None O
OMe None None O
has None None O
been None None O
designed None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
the None None O
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitrophenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
NPS None None I-ABBREVIATION
) None None O
moiety None None I-MODIFIER
on None None O
the None None O
activity None None O
. None None O

The None None O
syntheses None None O
and None None O
antinociceptive None None O
effects None None O
of None None O
these None None O
analogues None None O
of None None O
general None None O
formula None None O
H None None O
- None None O
Lys None None O
- None None O
Trp None None O
( None None O
R None None O
) None None O
- None None O
OMe None None O
[ None None O
R None None O
= None None O
phenylsulfenyl None None I-PARTIUPAC
( None None O
PS None None I-ABBREVIATION
) None None O
( None None O
9 None None O
) None None O
; None None O
R None None O
= None None O
( None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
carbomethyoxyphenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
CmPS None None I-ABBREVIATION
) None None O
( None None O
10 None None O
) None None O
; None None O
R None None O
= None None O
( None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
nitrophenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
pNPS None None I-ABBREVIATION
) None None O
( None None O
11 None None O
) None None O
; None None O
R None None O
= None None O
( None None O
2,4 None None I-PARTIUPAC
- None None I-PARTIUPAC
dinitrophenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
DNPS None None I-ABBREVIATION
) None None O
( None None O
12 None None O
) None None O
; None None O
R None None O
= None None O
[ None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
acetylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
carbomethoxyethyl None None I-PARTIUPAC
] None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
AacCmES None None I-ABBREVIATION
) None None O
( None None O
13 None None O
) None None O
; None None O
R None None O
= None None O
[ None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
acetylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
phenyl None None I-PARTIUPAC
] None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
AacPS None None I-ABBREVIATION
) None None O
( None None O
17 None None O
) None None O
; None None O
R None None O
= None None O
tert None None I-PARTIUPAC
- None None I-PARTIUPAC
butylsulfenyl None None I-PARTIUPAC
( None None O
t None None I-ABBREVIATION
- None None I-ABBREVIATION
BuS None None I-ABBREVIATION
) None None O
( None None O
23 None None O
) None None O
; None None O
R None None O
= None None O
( None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
carbomethoxyethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
sulfenyl None None I-PARTIUPAC
( None None O
CmES None None I-ABBREVIATION
) None None O
( None None O
24 None None O
) None None O
] None None O
are None None O
described None None O
. None None O

Reaction None None O
of None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
- None None O
OMe None None O
( None None O
3 None None O
) None None O
with None None O
PS None None I-ABBREVIATION
- None None O
, None None O
CmPS None None I-ABBREVIATION
- None None O
, None None O
pNPS None None I-ABBREVIATION
- None None O
, None None O
DNPS None None I-ABBREVIATION
- None None O
, None None O
and None None O
AacCmES None None I-ABBREVIATION
- None None I-ABBREVIATION
Cl None None I-ABBREVIATION
afforded None None O
the None None O
corresponding None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
sulfenyl None None I-IUPAC
) None None I-IUPAC
tryptophan None None I-IUPAC
derivatives None None I-MODIFIER
, None None O
which None None O
on None None O
treatment None None O
with None None O
boron None None I-IUPAC
- None None I-IUPAC
tris None None I-IUPAC
( None None I-IUPAC
trifluoroacetate None None I-IUPAC
) None None I-IUPAC
/ None None O
trifluoroacetic None None I-IUPAC
acid None None I-IUPAC
or None None O
trimethylsilyl None None I-IUPAC
iodide None None I-IUPAC
in None None O
acetonitrile None None I-TRIVIAL
( None None O
Me3SiI None None I-SUM
/ None None O
CH3CN None None I-SUM
) None None O
provided None None O
9-13 None None O
, None None O
respectively None None O
. None None O

Sulfenylation None None O
of None None O
3 None None O
with None None O
NPS None None I-ABBREVIATION
- None None I-ABBREVIATION
Cl None None I-ABBREVIATION
gave None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
( None None O
NPS None None O
) None None O
- None None O
OMe None None O
, None None O
which None None O
, None None O
on None None O
catalytic None None O
hydrogenation None None O
of None None O
the None None O
nitro None None O
group None None O
using None None O
10% None None O
Pd None None O
/ None None O
C None None O
followed None None O
by None None O
acetylation None None O
of None None O
the None None O
resulting None None O
amino None None O
function None None O
and None None O
removal None None O
of None None O
the None None O
protecting None None O
Z None None O
groups None None O
, None None O
gave None None O
17 None None O
. None None O

Condensation None None O
of None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
tert None None I-PARTIUPAC
- None None I-PARTIUPAC
butylsulfenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carbomethoxyethyl None None I-IUPAC
) None None I-IUPAC
sulfenyl None None I-IUPAC
] None None I-IUPAC
tryptophan None None I-IUPAC
methyl None None I-IUPAC
ester None None I-IUPAC
, None None O
obtained None None O
by None None O
reaction None None O
of None None O
methyl None None I-IUPAC
3a None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1,2,3,3 None None I-IUPAC
a None None I-IUPAC
, None None I-IUPAC
8,8 None None I-IUPAC
a None None I-IUPAC
- None None I-IUPAC
hexahydropyrrolo None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
carboxyla None None I-IUPAC
te None None I-IUPAC
with None None O
the None None O
corresponding None None O
thiol None None O
, None None O
with None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
OSu None None O
afforded None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
( None None O
t None None O
- None None O
BuS None None O
) None None O
- None None O
OMe None None O
and None None O
Z None None O
- None None O
Lys None None O
( None None O
Z None None O
) None None O
- None None O
Trp None None O
( None None O
CmES None None O
) None None O
- None None O
OMe None None O
, None None O
which None None O
on None None O
treatment None None O
with None None O
Me3SiI None None I-SUM
/ None None O
CH3CN None None I-SUM
provided None None O
23 None None O
and None None O
24 None None O
, None None O
respectively None None O
. None None O

Intracerebroventricular None None O
administration None None O
of None None O
10 None None O
elicited None None O
a None None O
naloxone None None I-TRIVIAL
- None None O
reversible None None O
antinociceptive None None O
effect None None O
in None None O
mice None None O
similar None None O
to None None O
that None None O
of None None O
H None None O
- None None O
Lys None None O
- None None O
Trp None None O
( None None O
NPS None None O
) None None O
- None None O
OMe None None O
. None None O

No None None O
analgesia None None O
was None None O
however None None O
found None None O
with None None O
the None None O
phenylsulfenyl None None I-PARTIUPAC
or None None O
acyclic None None I-IUPAC
sulfenyl None None I-IUPAC
substituted None None I-IUPAC
dipeptides None None I-IUPAC
9 None None O
, None None O
11 None None O
, None None O
and None None O
17 None None O
or None None O
13 None None O
, None None O
23 None None O
, None None O
and None None O
24 None None O
. None None O

The None None O
Trp None None I-ABBREVIATION
( None None I-ABBREVIATION
DNPS None None I-ABBREVIATION
) None None I-ABBREVIATION
- None None O
containing None None O
analogue None None O
was None None O
neurotoxic None None O
. None None O

Structure None None O
- None None O
activity None None O
studies None None O
indicate None None O
that None None O
the None None O
role None None O
of None None O
the None None O
NPS None None I-ABBREVIATION
and None None O
CmPS None None I-ABBREVIATION
moieties None None B-MODIFIER
could None None O
be None None O
related None None O
to None None O
the None None O
adoption None None O
of None None O
a None None O
preferential None None O
active None None O
conformation None None O
. None None O


A None None O
series None None O
of None None O
substituted None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydronaphthoquinones None None I-IUPAC
, None None O
hydroindoloquinones None None I-TRIVIAL
, None None O
benzofuran None None I-IUPAC
- None None I-IUPAC
4,7 None None I-IUPAC
- None None I-IUPAC
dihydroquinones None None I-IUPAC
, None None O
and None None O
benzothiophene None None I-IUPAC
- None None I-IUPAC
4,7 None None I-IUPAC
- None None I-IUPAC
dihydroquinones None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
inhibitory None None O
activity None None O
against None None O
5 None None O
- None None O
lipoxygenase None None O
. None None O

These None None O
compounds None None O
were None None O
found None None O
to None None O
be None None O
active None None O
in None None O
vitro None None O
for None None O
LTC4 None None O
/ None None O
D4 None None O
inhibition None None O
with None None O
the None None O
potencies None None O
( None None O
IC50 None None O
's None None O
) None None O
ranging None None O
from None None O
0.2 None None O
to None None O
85 None None O
microM None None O
. None None O

Active None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydronaphthoquinone None None I-IUPAC
acetates None None I-IUPAC
( None None O
IC50 None None O
less None None O
than None None O
20 None None O
microM None None O
) None None O
were None None O
evaluated None None O
in None None O
an None None O
ex None None O
vivo None None O
LTB4 None None O
inhibition None None O
assay None None O
. None None O

The None None O
acetates None None I-FAMILY
of None None O
1,4 None None I-IUPAC
- None None I-IUPAC
dihydronaphthoquinones None None I-IUPAC
containing None None O
the None None O
alkyl None None I-PARTIUPAC
substituent None None B-MODIFIER
( None None I-MODIFIER
s None None I-MODIFIER
) None None I-MODIFIER
( None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
n None None I-PARTIUPAC
- None None I-PARTIUPAC
butyl None None I-PARTIUPAC
, None None O
11 None None O
, None None O
and None None O
2,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
diethyl None None I-PARTIUPAC
, None None O
15 None None O
) None None O
exhibited None None O
the None None O
best None None O
activity None None O
in None None O
LTC4 None None O
/ None None O
D4 None None O
inhibition None None O
( None None O
IC50 None None O
= None None O
0.2-0.4 None None O
microM None None O
, None None O
in None None O
vitro None None O
) None None O
as None None O
well None None O
as None None O
in None None O
LTB4 None None O
inhibition None None O
( None None O
60-75% None None O
inhibition None None O
) None None O
. None None O


The None None O
regulation None None O
of None None O
total None None O
creatine None None I-TRIVIAL
content None None O
in None None O
a None None O
myoblast None None O
cell None None O
line None None O
. None None O

Total None None O
cellular None None O
creatine None None I-TRIVIAL
content None None O
is None None O
an None None O
important None None O
bioenergetic None None O
parameter None None O
in None None O
skeletal None None O
muscle None None O
. None None O

To None None O
understand None None O
its None None O
regulation None None O
we None None O
investigated None None O
creatine None None I-TRIVIAL
transport None None O
and None None O
accumulation None None O
in None None O
the None None O
G8 None None O
cultured None None O
skeletal None None O
myoblast None None O
line None None O
. None None O

Like None None O
other None None O
cell None None O
types None None O
, None None O
these None None O
contain None None O
a None None O
creatine None None O
transporter None None O
, None None O
whose None None O
activity None None O
, None None O
measured None None O
using None None O
a None None O
radiolabelling None None O
technique None None O
, None None O
was None None O
saturable None None O
( None None O
Km None None O
= None None O
110 None None O
+ None None O
/ None None O
- None None O
25 None None O
microM None None O
) None None O
and None None O
largely None None O
dependent None None O
on None None O
extracellular None None O
[ None None O
Na+ None None O
] None None O
. None None O

To None None O
study None None O
sustained None None O
influences None None O
on None None O
steady None None O
state None None O
creatine None None I-TRIVIAL
concentration None None O
we None None O
measured None None O
total None None O
cellular None None O
creatine None None I-TRIVIAL
content None None O
using None None O
a None None O
fluorimetric None None O
method None None O
in None None O
48 None None O
h None None O
incubations None None O
. None None O

We None None O
found None None O
that None None O
the None None O
total None None O
cellular None None O
creatine None None I-TRIVIAL
content None None O
was None None O
relatively None None O
independent None None O
of None None O
extracellular None None O
creatine None None I-TRIVIAL
concentration None None O
, None None O
consistent None None O
with None None O
high None None O
affinity None None O
sodium None None I-TRIVIAL
- None None O
dependent None None O
uptake None None O
balanced None None O
by None None O
slow None None O
passive None None O
efflux None None O
. None None O

Accordingly None None O
, None None O
in None None O
creatine None None I-TRIVIAL
- None None O
free None None O
incubations None None O
net None None O
creatine None None I-TRIVIAL
efflux None None O
was None None O
slow None None O
( None None O
5 None None O
+ None None O
/ None None O
- None None O
1% None None O
of None None O
basal None None O
creatine None None I-TRIVIAL
content None None O
per None None O
day None None O
over None None O
6 None None O
days None None O
) None None O
, None None O
while None None O
creatine None None I-TRIVIAL
content None None O
in None None O
48 None None O
h None None O
incubations None None O
was None None O
reduced None None O
by None None O
28 None None O
+ None None O
/ None None O
- None None O
13% None None O
of None None O
control None None O
by None None O
the None None O
Na+ None None O
, None None O
K None None O
( None None O
+ None None O
) None None O
- None None O
ATPase None None O
inhibitor None None O
ouabain None None I-TRIVIAL
. None None O

Creatine None None I-TRIVIAL
accumulation None None O
after None None O
48 None None O
h None None O
was None None O
stimulated None None O
by None None O
treatment None None O
with None None O
the None None O
mixed None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
adrenergic None None O
agonist None None O
noradrenaline None None I-TRIVIAL
, None None O
the None None O
beta None None O
- None None O
adrenergic None None O
agonist None None O
isoproterenol None None I-TRIVIAL
, None None O
the None None O
beta None None O
2 None None O
- None None O
agonist None None O
clenbuterol None None I-TRIVIAL
and None None O
the None None O
cAMP None None I-TRIVIAL
analogue None None B-MODIFIER
N6 None None B-IUPAC
, None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
dibutyryladenosine None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
cyclic None None I-IUPAC
monophosphate None None I-IUPAC
, None None O
but None None O
was None None O
unaffected None None O
by None None O
the None None O
alpha None None O
1 None None O
adrenergic None None O
agonist None None O
methoxamine None None I-TRIVIAL
. None None O

The None None O
noradrenaline None None I-TRIVIAL
enhancement None None O
of None None O
creatine None None I-TRIVIAL
accumulation None None O
at None None O
48 None None O
h None None O
was None None O
inhibited None None O
by None None O
the None None O
mixed None None O
alpha None None O
- None None O
and None None O
beta None None O
- None None O
antagonist None None O
labetalol None None I-TRIVIAL
and None None O
by None None O
the None None O
beta None None O
- None None O
antagonist None None O
propranolol None None I-TRIVIAL
, None None O
but None None O
was None None O
unaffected None None O
by None None O
the None None O
alpha None None O
2 None None O
antagonist None None O
phentolamine None None I-TRIVIAL
; None None O
greater None None O
inhibition None None O
was None None O
caused None None O
by None None O
the None None O
beta None None O
2 None None O
antagonist None None O
butoxamine None None I-TRIVIAL
than None None O
the None None O
beta None None O
1 None None O
antagonist None None O
atenolol None None I-TRIVIAL
. None None O

Creatine None None I-TRIVIAL
accumulation None None O
at None None O
48 None None O
h None None O
was None None O
increased None None O
to None None O
230 None None O
+ None None O
/ None None O
- None None O
6% None None O
of None None O
control None None O
by None None O
insulin None None O
and None None O
by None None O
140 None None O
+ None None O
/ None None O
- None None O
13% None None O
by None None O
IGF None None O
- None None O
I None None O
( None None O
both None None O
at None None O
3 None None O
nM None None O
) None None O
. None None O

Creatine None None I-TRIVIAL
accumulation None None O
at None None O
48 None None O
h None None O
was None None O
also None None O
increased None None O
to None None O
280 None None O
+ None None O
/ None None O
- None None O
40% None None O
of None None O
control None None O
by None None O
3,3 None None I-IUPAC
' None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
triiodothyronine None None I-IUPAC
( None None O
at None None O
70 None None O
microM None None O
) None None O
and None None O
to None None O
220 None None O
+ None None O
/ None None O
- None None O
35% None None O
of None None O
control None None O
by None None O
amylin None None I-TRIVIAL
( None None O
60 None None O
nM None None O
) None None O
. None None O

As None None O
3,3 None None I-IUPAC
' None None I-IUPAC
, None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
triiodothyronine None None I-IUPAC
, None None O
amylin None None I-TRIVIAL
and None None O
isoproterenol None None I-TRIVIAL
all None None O
stimulate None None O
the None None O
Na+ None None O
, None None O
K None None O
( None None O
+ None None O
) None None O
- None None O
ATPase None None O
, None None O
we None None O
suggest None None O
that None None O
they None None O
stimulate None None O
Na None None I-SUM
( None None I-SUM
+ None None I-SUM
) None None I-SUM
- None None O
creatine None None I-TRIVIAL
cotransport None None O
indirectly None None O
by None None O
increasing None None O
the None None O
transmembrane None None O
[ None None O
Na+ None None I-SUM
] None None O
concentration None None O
gradient None None O
and None None O
membrane None None O
potential None None O
. None None O


Attenuation None None O
of None None O
cerebral None None O
vasospasm None None O
in None None O
rabbits None None O
using None None O
clonidine None None I-IUPAC
hydrochloride None None I-IUPAC
, None None O
a None None O
central None None O
adrenergic None None O
agonist None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
assess None None O
, None None O
firstly None None O
, None None O
if None None O
exclusion None None O
of None None O
central None None O
noradrenergic None None O
areas None None O
in None None O
the None None O
hypothalamus None None O
and None None O
brain None None O
stem None None O
with None None O
the None None O
central None None O
sympathetic None None O
blocker None None O
clonidine None None I-IUPAC
hydrochloride None None I-IUPAC
could None None O
prevent None None O
the None None O
development None None O
of None None O
chronic None None O
vasospasm None None O
following None None O
experimental None None O
subarachnoid None None O
haemorrhage None None O
in None None O
rabbits None None O
and None None O
, None None O
secondly None None O
, None None O
if None None O
, None None O
parallel None None O
with None None O
the None None O
effect None None O
on None None O
cerebral None None O
arteries None None O
, None None O
changes None None O
in None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
concentration None None O
in None None O
the None None O
hypothalamus None None O
and None None O
brain None None O
stem None None O
could None None O
also None None O
be None None O
detected None None O
. None None O

Experimental None None O
subarachnoid None None O
haemorrhage None None O
, None None O
in None None O
concentrations None None O
of None None O
1 None None O
ml None None O
of None None O
autologous None None O
arterial None None O
blood None None O
/ None None O
1 None None O
kg None None O
of None None O
body None None O
weight None None O
was None None O
carried None None O
out None None O
on None None O
18 None None O
New None None O
Zealand None None O
rabbits None None O
. None None O

Histological None None O
specimens None None O
were None None O
obtained None None O
by None None O
the None None O
method None None O
of None None O
perfusion None None O
fixation None None O
after None None O
the None None O
rabbits None None O
were None None O
sacrificed None None O
on None None O
day None None O
8 None None O
after None None O
subarachnoid None None O
haemorrhage None None O
. None None O

The None None O
spastic None None O
effect None None O
of None None O
experimentally None None O
induced None None O
subarachnoid None None O
haemorrhage None None O
was None None O
determined None None O
by None None O
assessing None None O
the None None O
intensity None None O
of None None O
corrugation None None O
of None None O
the None None O
intima None None O
of None None O
the None None O
rabbit None None O
basilar None None O
artery None None O
by None None O
the None None O
previously None None O
developed None None O
method None None O
of None None O
corrugation None None O
coefficient None None O
and None None O
computer None None O
image None None O
analysis None None O
. None None O

The None None O
concentration None None O
and None None O
localization None None O
of None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
in None None O
noradrenaline None None I-TRIVIAL
- None None O
containing None None O
neurons None None O
was None None O
immunohistochemically None None O
assessed None None O
( None None O
semiquantitatively None None O
as None None O
0 None None O
, None None O
1 None None O
and None None O
2 None None O
) None None O
with None None O
anti None None O
- None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
, None None O
at None None O
precisely None None O
defined None None O
sites None None O
of None None O
the None None O
hypothalamus None None O
and None None O
brain None None O
stem None None O
of None None O
the None None O
same None None O
rabbit None None O
. None None O

The None None O
results None None O
revealed None None O
less None None O
corrugated None None O
and None None O
smoother None None O
intima None None O
in None None O
the None None O
basilar None None O
artery None None O
and None None O
significantly None None O
lower None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
concentration None None O
in None None O
the None None O
control None None O
group None None O
of None None O
rabbits None None O
with None None O
sham None None O
subarachnoid None None O
haemorrhage None None O
and None None O
without None None O
any None None O
additional None None O
interventions None None O
( None None O
mean None None O
corrugation None None O
coefficient None None O
= None None O
1.123 None None O
+ None None O
/ None None O
- None None O
0.024 None None O
, None None O
P None None O
= None None O
0.35 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
; None None O
mean None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
= None None O
0.350 None None O
+ None None O
/ None None O
- None None O
0.071 None None O
, None None O
P None None O
= None None O
0.22 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
) None None O
, None None O
and None None O
smoother None None O
intima None None O
in None None O
the None None O
basilar None None O
artery None None O
with None None O
significantly None None O
lower None None O
concentration None None O
of None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
in None None O
the None None O
clonidine None None I-TRIVIAL
group None None B-MODIFIER
( None None O
rabbits None None O
with None None O
subarachnoid None None O
haemorrhage None None O
and None None O
central None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
blocker None None O
clonidine None None I-IUPAC
hydrochloride None None I-IUPAC
at None None O
a None None O
daily None None O
dose None None O
of None None O
0.03 None None O
mg None None O
/ None None O
kg None None O
of None None O
body None None O
weight None None O
for None None O
8 None None O
days None None O
; None None O
mean None None O
corrugation None None O
coefficient None None O
= None None O
1.177 None None O
+ None None O
/ None None O
- None None O
0.058 None None O
, None None O
P None None O
= None None O
1.7 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
; None None O
mean None None O
dopamine None None I-TRIVIAL
beta None None O
- None None O
hydroxylase None None O
= None None O
0.583 None None O
+ None None O
/ None None O
- None None O
0.175 None None O
, None None O
P None None O
= None None O
1.1 None None O
x None None O
10 None None O
( None None O
- None None O
3 None None O
) None None O
) None None O
. None None O

In None None O
comparison None None O
, None None O
the None None O
haemorrhage None None O
only None None O
group None None O
( None None O
rabbits None None O
with None None O
subarachnoid None None O
haemorrhage None None O
and None None O
without None None O
medication None None O
; None None O
mean None None O
corrugation None None O
coefficient None None O
= None None O
1.370 None None O
+ None None O
/ None None O
- None None O
0.101 None None O
; None None O
mean None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
= None None O
1.214 None None O
+ None None O
/ None None O
- None None O
0.313 None None O
) None None O
displayed None None O
intensive None None O
corrugation None None O
of None None O
the None None O
intima None None O
of None None O
the None None O
basilar None None O
artery None None O
and None None O
a None None O
significantly None None O
more None None O
intensive None None O
accumulation None None O
of None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
than None None O
did None None O
the None None O
control None None O
group None None O
and None None O
the None None O
clonidine None None O
group None None O
. None None O

The None None O
results None None O
of None None O
this None None O
study None None O
demonstrated None None O
that None None O
the None None O
central None None O
alpha None None O
( None None O
2 None None O
) None None O
- None None O
blocker None None O
clonidine None None I-IUPAC
hydrochloride None None I-IUPAC
effectively None None O
prevents None None O
vasospasm None None O
, None None O
and None None O
diminishes None None O
the None None O
concentration None None O
of None None O
cerebral None None O
dopamine None None O
beta None None O
- None None O
hydroxylase None None O
in None None O
the None None O
hypothalamus None None O
and None None O
brain None None O
stem None None O
after None None O
experimental None None O
subarachnoid None None O
haemorrhage None None O
in None None O
rabbits None None O
. None None O


Heterologous None None O
expression None None O
of None None O
lipoprotein None None O
- None None O
associated None None O
phospholipase None None O
A2 None None O
in None None O
different None None O
expression None None O
systems None None O
. None None O

Lipoprotein None None O
- None None O
associated None None O
phospholipase None None O
A None None O
( None None O
2 None None O
) None None O
( None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
) None None O
is None None O
a None None O
key None None O
enzyme None None O
involved None None O
in None None O
atherosclerosis None None O
, None None O
and None None O
has None None O
been None None O
considered None None O
as None None O
a None None O
new None None O
target None None O
for None None O
drug None None O
discovery None None O
. None None O

The None None O
major None None O
difficulty None None O
for None None O
high None None O
- None None O
throughput None None O
screening None None O
of None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
inhibitors None None O
and None None O
for None None O
functional None None O
studies None None O
was None None O
their None None O
fast None None O
and None None O
efficient None None O
production None None O
. None None O

Purification None None O
of None None O
native None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
from None None O
human None None O
plasma None None O
was None None O
complicated None None O
and None None O
produced None None O
a None None O
very None None O
low None None O
yield None None O
. None None O

We None None O
herein None None O
examined None None O
the None None O
feasibility None None O
of None None O
expressing None None O
and None None O
purifying None None O
recombinant None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
in None None O
different None None O
heterologous None None O
expression None None O
systems None None O
. None None O

The None None O
fusion None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
was None None O
expressed None None O
at None None O
high None None O
levels None None O
and None None O
exhibited None None O
strong None None O
enzyme None None O
activity None None O
in None None O
insect None None O
cell None None O
- None None O
baculovirus None None O
expression None None O
system None None O
. None None O

The None None O
functional None None O
enzyme None None O
could None None O
also None None O
be None None O
produced None None O
in None None O
Pichia None None O
pastoris None None O
. None None O

The None None O
inclusion None None O
of None None O
a None None O
Kozak None None O
sequence None None O
increased None None O
greatly None None O
the None None O
expression None None O
level None None O
of None None O
recombinant None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
in None None O
insect None None O
cells None None O
, None None O
but None None O
had None None O
little None None O
effect None None O
on None None O
the None None O
expression None None O
of None None O
recombinant None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
in None None O
P None None O
. None None O

pastoris None None O
and None None O
Escherichia None None O
coli None None O
. None None O

P None None O
. None None O

pastoris None None O
- None None O
produced None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
could None None O
be None None O
purified None None O
rapidly None None O
and None None O
conveniently None None O
through None None O
a None None O
one None None O
- None None O
step None None O
procedure None None O
, None None O
while None None O
baculovirus None None O
- None None O
produced None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
could None None O
be None None O
efficiently None None O
purified None None O
through None None O
a None None O
two None None O
- None None O
step None None O
procedure None None O
. None None O

This None None O
ability None None O
to None None O
readily None None O
produce None None O
recombinant None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
could None None O
provide None None O
a None None O
screening None None O
model None None O
for None None O
Lp None None O
- None None O
PLA None None O
( None None O
2 None None O
) None None O
inhibitors None None O
and None None O
will None None O
facilitate None None O
further None None O
studies None None O
on None None O
this None None O
enzyme None None O
. None None O


A None None O
series None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
thieno1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
s None None O
was None None O
synthesized None None O
and None None O
evaluated None None O
in None None O
vitro None None O
for None None O
inhibitory None None O
activity None None O
toward None None O
human None None O
leukocyte None None O
elastase None None O
( None None O
HLE None None O
) None None O
. None None O

The None None O
Gewald None None O
thiophen None None I-TRIVIAL
e None None O
synthesis None None O
was None None O
utilized None None O
to None None O
obtain None None O
several None None O
ethyl None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminothiophene None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
s None None O
. None None O

These None None O
precursors None None O
were None None O
subjected None None O
to None None O
a None None O
five None None O
- None None O
step None None O
route None None O
to None None O
obtain None None O
thieno2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
on None None I-IUPAC
es None None O
bearing None None O
various None None O
substituents None None O
at None None O
positions None None O
5 None None O
and None None O
6 None None O
. None None O

Bot None None O
h None None I-PARTIUPAC
thieno2 None None I-PARTIUPAC
, None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None O
d None None O
an None None O
d None None I-PARTIUPAC
thieno3 None None I-PARTIUPAC
, None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None O
d None None O
fuse None None O
d None None I-IUPAC
oxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
on None None I-IUPAC
es None None O
possess None None O
extraordinary None None O
chemical None None O
stability None None O
, None None O
which None None O
was None None O
expressed None None O
as None None O
rate None None O
constants None None O
of None None O
the None None O
alkaline None None O
hydrolysis None None O
. None None O

The None None O
kinetic None None O
parameters None None O
of None None O
the None None O
HLE None None O
inhibition None None O
were None None O
determined None None O
. None None O

The None None O
most None None O
potent None None O
compound None None O
, None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
1benzothieno2 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
d1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None O
, None None O
exhibited None None O
a None None O
K None None O
( None None O
i None None O
) None None O
value None None O
of None None O
5.8 None None O
n None None O
M None None I-IUPAC
. None None I-IUPAC

2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Diethylamino None None I-IUPAC
) None None I-IUPAC
thieno1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
 None None I-IUPAC
 None None I-IUPAC
xazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None O
act None None O
as None None O
acyl None None O
- None None O
enzyme None None O
inhibitors None None O
of None None O
HLE None None O
, None None O
similar None None O
to None None O
the None None O
inhibition None None O
of None None O
serine None None O
proteases None None O
by None None I-IUPAC
4H None None I-IUPAC
- None None I-IUPAC
3,1 None None I-IUPAC
- None None I-IUPAC
benzoxazin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None O
. None None O

The None None O
isoste None None O
ric None None I-IUPAC
benzene None None I-IUPAC
- None None I-IUPAC
thiop None None I-IUPAC
hene None None O
replacement None None O
accounts None None O
for None None O
an None None O
enhanced None None O
stability None None O
of None None O
the None None O
acyl None None O
- None None O
enzyme None None O
intermediates None None O
. None None O


Structure None None O
- None None O
activity None None O
relationships None None O
have None None O
been None None O
investigated None None O
for None None O
inhibition None None O
of None None O
DNA None None O
- None None O
dependent None None O
protein None None O
kinase None None O
( None None O
DNA None None O
- None None O
PK None None O
) None None O
and None None O
ATM None None O
kinase None None O
by None None O
a None None O
series None None O
of None None O
pyran None None I-FAMILY
- None None I-FAMILY
2 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
, None None O
pyran None None I-FAMILY
- None None I-FAMILY
4 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
, None None O
thiopyran None None I-FAMILY
- None None I-FAMILY
4 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
, None None O
and None None O
pyridin None None I-FAMILY
- None None I-FAMILY
4 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
. None None O

A None None O
wide None None O
range None None O
of None None O
IC50 None None O
values None None O
were None None O
observed None None O
for None None O
pyranones None None I-FAMILY
and None None O
thiopyranones None None I-FAMILY
substituted None None O
at None None O
the None None O
6 None None O
- None None O
position None None O
, None None O
with None None O
the None None O
3 None None O
- None None O
and None None O
5 None None O
- None None O
positions None None O
proving None None O
intolerant None None O
to None None O
substitution None None O
. None None O

Related None None O
pyran None None I-FAMILY
- None None I-FAMILY
2 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
, None None O
pyran None None I-FAMILY
- None None I-FAMILY
4 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
, None None O
and None None O
thiopyran None None I-FAMILY
- None None I-FAMILY
4 None None I-FAMILY
- None None I-FAMILY
ones None None I-FAMILY
showed None None O
similar None None O
IC50 None None O
values None None O
against None None O
DNA None None O
- None None O
PK None None O
, None None O
whereas None None O
the None None O
pyridin None None I-FAMILY
- None None I-FAMILY
4 None None I-FAMILY
- None None I-FAMILY
one None None I-FAMILY
system None None O
proved None None O
, None None O
in None None O
general None None O
, None None O
ineffective None None O
at None None O
inhibiting None None O
DNA None None O
- None None O
PK None None O
. None None O

Extended None None O
libraries None None O
exploring None None O
the None None O
6 None None O
- None None O
position None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
and None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholino None None I-IUPAC
- None None I-IUPAC
thiopyrano None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
identified None None O
the None None O
first None None O
highly None None O
potent None None O
and None None O
selective None None O
ATM None None O
inhibitor None None O
2 None None I-IUPAC
- None None I-IUPAC
morpholin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
thianthren None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
- None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
151C None None O
; None None O
ATM None None O
; None None O
IC50 None None O
= None None O
13 None None O
nM None None O
) None None O
and None None O
revealed None None O
constrained None None O
SARs None None O
for None None O
ATM None None O
inhibition None None O
compared None None O
with None None O
DNA None None O
- None None O
PK None None O
. None None O

One None None O
of None None O
the None None O
most None None O
potent None None O
DNA None None O
- None None O
PK None None O
inhibitors None None O
identified None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
morpholin None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
pyran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
16 None None O
; None None O
DNA None None O
- None None O
PK None None O
; None None O
IC50 None None O
= None None O
220 None None O
nM None None O
) None None O
effectively None None O
sensitized None None O
HeLa None None O
cells None None O
to None None O
the None None O
topoisomerase None None O
II None None O
inhibitor None None O
etoposide None None I-TRIVIAL
in None None O
vitro None None O
. None None O


Differential None None O
effects None None O
of None None O
luteinizing None None O
hormone None None O
- None None O
releasing None None O
hormone None None O
on None None O
follicle None None O
- None None O
stimulating None None O
hormone None None O
- None None O
dependent None None O
responses None None O
in None None O
rat None None O
granulosa None None O
cells None None O
and None None O
Sertoli None None O
cells None None O
in None None O
vitro None None O
. None None O

The None None O
abilities None None O
of None None O
LHRH None None O
and None None O
a None None O
potent None None O
LHRH None None O
agonist None None O
( None None O
[ None None O
D None None O
- None None O
Ser None None O
- None None O
( None None O
But None None O
) None None O
, None None O
6 None None O
, None None O
des None None O
- None None O
Gly None None O
- None None O
NH210 None None O
] None None O
LHRH None None O
ethylamide None None O
) None None O
inhibit None None O
FSH None None O
responses None None O
by None None O
rat None None O
granulosa None None O
cells None None O
and None None O
Sertoli None None O
cells None None O
in None None O
vitro None None O
have None None O
been None None O
compared None None O
. None None O

Granulosa None None O
cells None None O
isolated None None O
from None None O
22 None None O
- None None O
or None None O
25 None None O
- None None O
day None None O
- None None O
old None None O
diethylstilbestrol None None I-TRIVIAL
- None None O
primed None None O
rats None None O
and None None O
cultured None None O
under None None O
defined None None O
conditions None None O
for None None O
48 None None O
h None None O
with None None O
NIH None None I-TRIVIALVAR
- None None I-TRIVIALVAR
FSH None None I-TRIVIALVAR
- None None I-TRIVIALVAR
S13 None None I-TRIVIALVAR
( None None O
300 None None O
ng None None O
/ None None O
ml None None O
) None None O
or None None O
cholera None None I-TRIVIAL
toxin None None I-TRIVIAL
( None None O
0.1 None None O
microgram None None O
/ None None O
ml None None O
) None None O
showed None None O
increased None None O
aromatase None None O
activity None None O
, None None O
as None None O
determined None None O
by None None O
the None None O
release None None O
of None None O
3H2O None None O
from None None O
[ None None I-IUPAC
1 None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
testosterone None None I-IUPAC
. None None O

LHRH None None O
( None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
M None None O
) None None O
or None None O
th None None O
agonist None None O
( None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
) None None O
added None None O
simultaneously None None O
with None None O
FSH None None O
or None None O
cholera None None I-TRIVIAL
toxin None None I-TRIVIAL
inhibited None None O
the None None O
effects None None O
on None None O
the None None O
release None None O
of None None O
3H2O None None I-SUM
without None None O
influencing None None O
the None None O
protein None None O
content None None O
of None None O
the None None O
cell None None O
cultures None None O
. None None O

A None None O
smaller None None O
stimulation None None O
of None None O
3H2O None None I-SUM
production None None O
occurred None None O
with None None O
( None None I-IUPAC
Bu None None I-IUPAC
) None None I-IUPAC
2cAMP None None I-IUPAC
( None None O
1.0 None None O
mM None None O
) None None O
plus None None O
3 None None I-IUPAC
- None None I-IUPAC
isobutyl None None I-IUPAC
- None None I-IUPAC
l None None I-IUPAC
- None None I-IUPAC
methylxanthine None None I-IUPAC
( None None O
0.1 None None O
mM None None O
) None None O
, None None O
and None None O
this None None O
was None None O
partially None None O
suppressed None None O
in None None O
the None None O
presence None None O
of None None O
LHRH None None O
or None None O
the None None O
agonist None None O
. None None O

Parallel None None O
studies None None O
with None None O
Sertoli None None O
cells None None O
from None None O
15 None None O
- None None O
or None None O
20 None None O
- None None O
day None None O
- None None O
old None None O
rats None None O
demonstrated None None O
that None None O
culture None None O
under None None O
appropriate None None O
conditions None None O
with None None O
FSH None None O
, None None O
cholera None None I-TRIVIAL
toxin None None I-TRIVIAL
, None None O
or None None O
( None None I-IUPAC
Bu None None I-IUPAC
) None None I-IUPAC
2cAMP None None I-IUPAC
( None None O
0.5 None None O
mM None None O
) None None O
for None None O
24 None None O
h None None O
caused None None O
an None None O
increase None None O
in None None O
cellular None None O
aromatase None None O
activity None None O
and None None O
enhanced None None O
secretion None None O
into None None O
the None None O
medium None None O
of None None O
plasminogen None None O
activator None None O
. None None O

However None None O
, None None O
no None None O
inhibition None None O
by None None O
LHRH None None O
( None None O
10 None None O
( None None O
- None None O
7 None None O
) None None O
or None None O
10 None None O
( None None O
- None None O
9 None None O
) None None O
M None None O
) None None O
or None None O
the None None O
agonist None None O
( None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
or None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
) None None O
occurred None None O
when None None O
the None None O
peptides None None O
were None None O
added None None O
either None None O
simultaneously None None O
or None None O
24 None None O
h None None O
before None None O
the None None O
stimulatory None None O
agent None None O
. None None O

Similarly None None O
, None None O
Sertoli None None O
cells None None O
from None None O
11 None None O
- None None O
day None None O
- None None O
old None None O
rats None None O
treated None None O
daily None None O
with None None O
LHRH None None O
agonist None None O
for None None O
5 None None O
days None None O
in None None O
culture None None O
, None None O
showed None None O
no None None O
inhibition None None O
of None None O
aromatase None None O
activity None None O
after None None O
a None None O
4 None None O
- None None O
h None None O
stimulation None None O
with None None O
FSH None None O
or None None O
( None None I-IUPAC
Bu None None I-IUPAC
) None None I-IUPAC
2cAMP None None I-IUPAC
. None None O

FSH None None O
dose None None O
- None None O
response None None O
curves None None O
( None None O
0-300 None None O
ng None None O
/ None None O
ml None None O
) None None O
for None None O
aromatase None None O
activity None None O
were None None O
shown None None O
to None None O
be None None O
similar None None O
after None None O
5 None None O
days None None O
of None None O
culture None None O
with None None O
or None None O
without None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
LHRH None None O
agonist None None O
, None None O
indicating None None O
that None None O
the None None O
LHRH None None O
did None None O
not None None O
cause None None O
a None None O
shift None None O
in None None O
the None None O
sensitivity None None O
to None None O
FSH None None O
. None None O

The None None O
lack None None O
of None None O
inhibition None None O
was None None O
seen None None O
in None None O
Sertoli None None O
cell None None O
cultures None None O
maintained None None O
at None None O
37 None None O
or None None O
32 None None O
C None None O
. None None O

The None None O
enzyme None None O
digestion None None O
method None None O
used None None O
to None None O
isolated None None O
Sertoli None None O
cells None None O
was None None O
not None None O
responsible None None O
for None None O
the None None O
lack None None O
of None None O
effects None None O
of None None O
LHRH None None O
, None None O
since None None O
cell None None O
cultures None None O
prepared None None O
without None None O
the None None O
aid None None O
of None None O
proteolytic None None O
enzymes None None O
showed None None O
similar None None O
FSH None None O
stimulation None None O
of None None O
aromatase None None O
activity None None O
in None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
M None None O
agonist None None O
. None None O

Further None None O
, None None O
there None None O
was None None O
no None None O
evidence None None O
of None None O
degradation None None O
of None None O
the None None O
LHRH None None O
agonist None None O
when None None O
incubated None None O
with None None O
Sertoli None None O
cell None None O
cultures None None O
. None None O

From None None O
these None None O
studies None None O
, None None O
we None None O
conclude None None O
that None None O
1 None None O
) None None O
granulosa None None O
cells None None O
and None None O
Sertoli None None O
cells None None O
from None None O
immature None None O
rats None None O
differ None None O
in None None O
their None None O
responses None None O
to None None O
LHRH None None O
, None None O
and None None O
2 None None O
) None None O
the None None O
immature None None O
Sertoli None None O
cell None None O
is None None O
an None None O
unlikely None None O
target None None O
for None None O
a None None O
direct None None O
inhibiting None None O
influence None None O
of None None O
LHRH None None O
on None None O
spermatogenesis None None O
. None None O


We None None O
have None None O
previously None None O
described None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
7,8 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
6H None None I-IUPAC
- None None I-IUPAC
cyclohepta None None I-IUPAC
[ None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
isoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None I-ABBREVIATION
- None None I-ABBREVIATION
AHCP None None I-ABBREVIATION
) None None O
as None None O
a None None O
highly None None O
effective None None O
agonist None None O
at None None O
non None None O
- None None O
N None None O
- None None O
methyl None None O
- None None O
d None None O
- None None O
aspartate None None O
( None None O
non None None O
- None None O
NMDA None None O
) None None O
glutamate None None O
( None None O
Glu None None O
) None None O
receptors None None O
in None None O
vivo None None O
, None None O
which None None O
is None None O
more None None O
potent None None O
than None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methylisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
( None None O
AMPA None None I-ABBREVIATION
) None None O
but None None O
inactive None None O
at None None O
NMDA None None O
receptors None None O
. None None O

However None None O
, None None O
4 None None I-ABBREVIATION
- None None I-ABBREVIATION
AHCP None None I-ABBREVIATION
was None None O
found None None O
to None None O
be None None O
much None None O
weaker None None O
than None None O
AMPA None None I-ABBREVIATION
as None None O
an None None O
inhibitor None None O
of None None O
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
AMPA None None I-IUPAC
binding None None O
and None None O
to None None O
have None None O
limited None None O
effect None None O
in None None O
a None None O
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
H None None I-IUPAC
] None None I-IUPAC
kainic None None I-IUPAC
acid None None I-IUPAC
binding None None O
assay None None O
using None None O
rat None None O
cortical None None O
membranes None None O
. None None O

To None None O
shed None None O
light None None O
on None None O
the None None O
mechanism None None O
( None None O
s None None O
) None None O
underlying None None O
this None None O
quite None None O
enigmatic None None O
pharmacological None None O
profile None None O
of None None O
4 None None I-ABBREVIATION
- None None I-ABBREVIATION
AHCP None None I-ABBREVIATION
, None None O
we None None O
have None None O
now None None O
developed None None O
a None None O
synthesis None None O
of None None O
( None None I-ABBREVIATION
S None None I-ABBREVIATION
) None None I-ABBREVIATION
- None None I-ABBREVIATION
4 None None I-ABBREVIATION
- None None I-ABBREVIATION
AHCP None None I-ABBREVIATION
( None None O
6 None None O
) None None O
and None None O
( None None I-ABBREVIATION
R None None I-ABBREVIATION
) None None I-ABBREVIATION
- None None I-ABBREVIATION
4 None None I-ABBREVIATION
- None None I-ABBREVIATION
AHCP None None I-ABBREVIATION
( None None O
7 None None O
) None None O
. None None O

At None None O
cloned None None O
metabotropic None None O
Glu None None O
receptors None None O
mGluR1alpha None None O
( None None O
group None None O
I None None O
) None None O
, None None O
mGluR2 None None O
( None None O
group None None O
II None None O
) None None O
, None None O
and None None O
mGluR4a None None O
( None None O
group None None O
III None None O
) None None O
, None None O
neither None None O
6 None None O
nor None None O
7 None None O
showed None None O
significant None None O
agonist None None O
or None None O
antagonist None None O
effects None None O
. None None O

The None None O
stereoisomer None None O
6 None None O
, None None O
but None None O
not None None O
7 None None O
, None None O
activated None None O
cloned None None O
AMPA None None O
receptor None None O
subunits None None O
GluR1o None None O
, None None O
GluR3o None None O
, None None O
and None None O
GluR4o None None O
with None None O
EC None None O
( None None O
50 None None O
) None None O
values None None O
in None None O
the None None O
range None None O
4.5-15 None None O
microM None None O
and None None O
the None None O
coexpressed None None O
kainate None None I-TRIVIAL
- None None O
preferring None None O
subunits None None O
GluR6 None None O
+ None None O
KA2 None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
6.4 None None O
microM None None O
) None None O
. None None O

Compound None None O
6 None None O
, None None O
but None None O
not None None O
7 None None O
, None None O
proved None None O
to None None O
be None None O
a None None O
very None None O
potent None None O
agonist None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.13 None None O
microM None None O
) None None O
at None None O
the None None O
kainate None None I-TRIVIAL
- None None O
preferring None None O
GluR5 None None O
subunit None None O
, None None O
equipotent None None O
with None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyisothiazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None I-ABBREVIATION
S None None I-ABBREVIATION
) None None I-ABBREVIATION
- None None I-ABBREVIATION
Thio None None I-ABBREVIATION
- None None I-ABBREVIATION
ATPA None None I-ABBREVIATION
, None None O
4 None None O
] None None O
and None None O
almost None None O
4 None None O
times None None O
more None None O
potent None None O
than None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
tert None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyisoxazol None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propionic None None I-IUPAC
acid None None I-IUPAC
[ None None O
( None None I-ABBREVIATION
S None None I-ABBREVIATION
) None None I-ABBREVIATION
- None None I-ABBREVIATION
ATPA None None I-ABBREVIATION
, None None O
3 None None O
] None None O
. None None O

Compound None None O
6 None None O
thus None None O
represents None None O
a None None O
new None None O
structural None None O
class None None O
of None None O
GluR5 None None O
agonists None None O
. None None O

Molecular None None O
modeling None None O
and None None O
docking None None O
to None None O
a None None O
crystal None None O
structure None None O
of None None O
the None None O
extracellular None None O
binding None None O
domain None None O
of None None O
the None None O
AMPA None None I-ABBREVIATION
subunit None None O
GluR2 None None O
has None None O
enabled None None O
identification None None O
of None None O
the None None O
probable None None O
active None None O
conformation None None O
and None None O
binding None None O
mode None None O
of None None O
6 None None O
. None None O

We None None O
are None None O
able None None O
to None None O
rationalize None None O
the None None O
observed None None O
selectivities None None O
by None None O
comparing None None O
the None None O
docking None None O
of None None O
4 None None O
and None None O
6 None None O
to None None O
subtype None None O
constructs None None O
, None None O
i.e. None None O
, None None O
a None None O
crystal None None O
structure None None O
of None None O
the None None O
extracellular None None O
binding None None O
domain None None O
of None None O
GluR2 None None O
and None None O
a None None O
homology None None O
model None None O
of None None O
GluR5 None None O
. None None O


The None None O
synthesis None None O
of None None O
aminoaceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidides None None I-IUPAC
substituted None None I-MODIFIER
on None None O
the None None O
amide None None I-FAMILY
nitrogen None None B-TRIVIAL
with None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
diethylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
ethyl None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
aminoethyl None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyethyl None None I-PARTIUPAC
, None None O
and None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
ethoxyethyl None None I-PARTIUPAC
groups None None I-MODIFIER
is None None O
described None None O
. None None O

The None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
aminoethyl None None I-PARTIUPAC
derivatives None None I-MODIFIER
were None None O
prepared None None O
by None None O
treatment None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phthalimidoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidine None None I-IUPAC
with None None O
chloroacetyl None None I-IUPAC
chloride None None I-IUPAC
, None None O
followed None None O
by None None O
treatment None None O
with None None O
either None None O
potassium None None I-IUPAC
phthalmide None None I-IUPAC
or None None O
diethylamine None None I-TRIVIAL
. None None O

Hydrazinolysis None None O
of None None O
the None None O
phthalimides None None I-FAMILY
liberated None None O
the None None O
free None None O
amines None None I-FAMILY
. None None O

The None None O
remaining None None O
target None None O
compounds None None O
were None None O
produced None None O
by None None O
alkylation None None O
of None None O
lidocaine None None I-TRIVIAL
or None None O
of None None O
2 None None I-IUPAC
- None None I-IUPAC
phthalimidoaceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidide None None I-IUPAC
with None None O
the None None O
appropriate None None O
halide None None I-PARTIUPAC
and None None O
sodium None None I-IUPAC
hydride None None I-IUPAC
, None None O
followed None None O
by None None O
hydrazinolysis None None O
where None None O
necessary None None O
. None None O

All None None O
target None None O
compounds None None O
were None None O
evaluated None None O
for None None O
antiarrhythmic None None O
efficacy None None O
against None None O
chloroform None None I-TRIVIAL
- None None O
induced None None O
ventricular None None O
tachycardia None None O
, None None O
as None None O
well None None O
as None None O
for None None O
acute None None O
CNS None None O
toxicity None None O
in None None O
mice None None O
. None None O

Most None None O
of None None O
the None None O
target None None O
compounds None None O
were None None O
more None None O
potent None None O
than None None O
the None None O
corresponding None None O
secondary None None O
amides None None O
and None None O
had None None O
improved None None O
therapeutic None None O
margins None None O
toward None None O
CNS None None O
toxicity None None O
. None None O

The None None O
diamines None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoaceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidide None None I-IUPAC
( None None O
13 None None O
) None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
aceto None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
6' None None I-IUPAC
- None None I-IUPAC
xylidide None None I-IUPAC
( None None O
29 None None O
) None None O
are None None O
especially None None O
promising None None O
in None None O
this None None O
respect None None O
. None None O

Several None None O
compounds None None O
were None None O
tested None None O
as None None O
spinal None None O
anesthetics None None O
. None None O


Some None None O
novel None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acids None None I-IUPAC
have None None O
been None None O
prepared None None O
. None None O

At None None O
the None None O
N None None O
- None None O
1 None None O
position None None O
" None None O
standard None None O
" None None O
substitution None None O
was None None O
employed None None O
with None None O
the None None O
ethyl None None I-PARTIUPAC
, None None O
cyclopropyl None None I-PARTIUPAC
, None None O
and None None O
p None None I-PARTIUPAC
- None None I-PARTIUPAC
fluorophenyl None None I-PARTIUPAC
groups None None I-MODIFIER
being None None O
used None None O
. None None O

At None None O
C None None O
- None None O
7 None None O
the None None O
introduction None None O
of None None O
some None None O
novel None None O
piperazines None None I-FAMILY
was None None O
made None None O
. None None O

Most None None O
notably None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
piperazine None None I-IUPAC
( None None O
10 None None O
) None None O
and None None O
hexahydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
diazepine None None I-IUPAC
( None None O
16 None None O
, None None O
fluorohomopiperazine None None I-TRIVIAL
) None None O
at None None O
the None None O
quinolone None None I-TRIVIAL
C None None O
- None None O
7 None None O
position None None O
produced None None O
products None None O
with None None O
similar None None O
in None None O
vitro None None O
antibacterial None None O
activity None None O
as None None O
the None None O
ciprofloxacin None None I-TRIVIAL
reference None None O
. None None O

The None None O
in None None O
vivo None None O
efficacy None None O
of None None O
1 None None I-IUPAC
- None None I-IUPAC
cyclopropyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
fluoromethyl None None I-IUPAC
) None None I-IUPAC
piperazinyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
oxoquinoline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
20 None None O
) None None O
was None None O
excellent None None O
with None None O
better None None O
oral None None O
absorption None None O
than None None O
ciprofloxacin None None I-TRIVIAL
( None None O
2 None None O
) None None O
. None None O


The None None O
thermal None None O
Fischer None None O
indolization None None O
of None None O
hydrazones None None I-FAMILY
resulting None None O
from None None O
4 None None I-IUPAC
- None None I-IUPAC
hydrazino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
pyridin None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
and None None O
various None None O
beta None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
alpha None None I-IUPAC
- None None I-IUPAC
tetralones None None I-IUPAC
led None None O
to None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6,7 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
, None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
11 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
, None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
g None None I-IUPAC
] None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ones None None I-IUPAC
, None None O
respectively None None O
. None None O

After None None O
aromatization None None O
, None None O
these None None O
compounds None None O
were None None O
transformed None None O
by None None O
phosphorus None None I-IUPAC
oxychloride None None I-IUPAC
, None None O
giving None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
- None None I-PARTIUPAC
5H None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
[ None None I-PARTIUPAC
4,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
e None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
g None None I-PARTIUPAC
] None None I-PARTIUPAC
indoles None None I-PARTIUPAC
which None None O
were None None O
substituted None None O
by None None O
[ None None I-IUPAC
( None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
] None None I-IUPAC
amines None None I-IUPAC
. None None O

The None None O
resulting None None O
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
[ None None I-PARTIUPAC
( None None I-PARTIUPAC
dialkylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
alkyl None None I-PARTIUPAC
] None None I-PARTIUPAC
amino None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
- None None I-PARTIUPAC
5H None None I-PARTIUPAC
- None None I-PARTIUPAC
pyrido None None I-PARTIUPAC
- None None I-PARTIUPAC
[ None None I-PARTIUPAC
4,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
b None None I-PARTIUPAC
] None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
e None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
- None None I-PARTIUPAC
benzo None None I-PARTIUPAC
[ None None I-PARTIUPAC
g None None I-PARTIUPAC
] None None I-PARTIUPAC
indoles None None I-PARTIUPAC
, None None O
as None None O
well None None O
as None None O
hydroxy None None I-PARTIUPAC
derivatives None None B-MODIFIER
obtained None None O
by None None O
demethylation None None O
of None None O
methoxylated None None O
compounds None None O
with None None O
hydrobromic None None I-IUPAC
acid None None I-IUPAC
, None None O
were None None O
tested None None O
for None None O
antitumor None None O
activity None None O
in None None O
vitro None None O
( None None O
leukemic None None O
and None None O
solid None None O
tumor None None O
cells None None O
) None None O
and None None O
in None None O
vivo None None O
on None None O
various None None O
experimental None None O
tumor None None O
models None None O
using None None O
the None None O
standard None None O
NCI None None O
protocols None None O
. None None O

1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
Dialkylamino None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5H None None I-IUPAC
- None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
4,3 None None I-IUPAC
- None None I-IUPAC
b None None I-IUPAC
] None None I-IUPAC
benzo None None I-IUPAC
[ None None I-IUPAC
e None None I-IUPAC
] None None I-IUPAC
indoles None None I-IUPAC
appeared None None O
as None None O
a None None O
promising None None O
new None None O
class None None O
of None None O
antineoplastic None None O
agents None None O
. None None O


[ None None O
Synthesis None None O
and None None O
properties None None O
of None None O
carminomycinone None None I-TRIVIAL
derivatives None None B-MODIFIER
] None None O
The None None O
possibility None None O
of None None O
chemical None None O
modification None None O
of None None O
carminomycinone None None I-TRIVIAL
- None None I-TRIVIAL
aglycone None None I-TRIVIAL
( None None O
II None None O
) None None O
of None None O
carminomicin None None I-TRIVIAL
, None None O
a None None O
side None None O
product None None O
in None None O
the None None O
antibiotic None None O
production None None O
was None None O
studied None None O
. None None O

The None None O
methyl None None I-PARTIUPAC
group None None B-MODIFIER
C None None B-SUM
- None None I-SUM
14 None None I-SUM
was None None O
functionilized None None O
by None None O
introducing None None O
the None None O
bromine None None I-TRIVIAL
atom None None B-MODIFIER
and None None O
performing None None O
a None None O
number None None O
of None None O
exchange None None O
reactions None None O
with None None O
the None None O
bromine None None I-TRIVIAL
atom None None B-MODIFIER
. None None O

It None None O
was None None O
found None None O
that None None O
under None None O
definite None None O
conditions None None O
( None None O
1 None None O
. None None O

1 None None O
equiv None None O
. None None O

Br2 None None I-SUM
in None None O
dioxane None None I-TRIVIAL
, None None O
20 None None O
degrees None None O
, None None O
24 None None O
hours None None O
) None None O
carminomycinone None None I-TRIVIAL
( None None O
II None None O
) None None O
was None None O
subjected None None O
to None None O
selective None None O
bromination None None O
into None None O
the None None O
side None None O
acetyl None None I-TRIVIAL
group None None B-MODIFIER
with None None O
formation None None O
of None None O
14 None None I-IUPAC
- None None I-IUPAC
bromcarminomycinone None None I-IUPAC
( None None O
III None None O
) None None O
. None None O

On None None O
interaction None None O
with None None O
anhydrous None None O
potassium None None I-IUPAC
acetate None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
bromcarminomycinone None None I-IUPAC
( None None O
III None None O
) None None O
yield None None O
14 None None I-IUPAC
- None None I-IUPAC
acetoxycarminomycinone None None I-IUPAC
( None None O
IV None None O
) None None O
. None None O

In None None O
its None None O
turn None None O
the None None O
latter None None O
compound None None O
( None None O
IV None None O
) None None O
easily None None O
hydrolized None None O
to None None O
14 None None I-IUPAC
- None None I-IUPAC
oxycarminomycinone None None I-IUPAC
( None None O
V None None O
) None None O
in None None O
treatment None None O
with None None O
aqueous None None O
alkali None None O
or None None O
acid None None O
. None None O

14 None None I-IUPAC
- None None I-IUPAC
oxycarminomycinone None None I-IUPAC
( None None O
V None None O
) None None O
was None None O
also None None O
prepared None None O
with None None O
a None None O
high None None O
yield None None O
( None None O
80 None None O
per None None O
cent None None O
) None None O
by None None O
direct None None O
alkaline None None O
hydrolysis None None O
of None None O
14 None None I-IUPAC
- None None I-IUPAC
bromcarminomycinone None None I-IUPAC
( None None O
III None None O
) None None O
in None None O
treatment None None O
with None None O
0.1 None None O
N None None O
solution None None O
of None None O
sodium None None I-IUPAC
carbonate None None I-IUPAC
in None None O
a None None O
mixture None None O
of None None O
dioxane None None I-TRIVIAL
and None None O
water None None O
. None None O

The None None O
structure None None O
of None None O
14 None None O
- None None O
substituted None None O
derivatives None None I-MODIFIER
of None None O
carminomycinone None None I-TRIVIAL
was None None O
proved None None O
by None None O
analytical None None O
and None None O
spectral None None O
data None None O
and None None O
confirmed None None O
by None None O
their None None O
transformation None None O
. None None O

Thus None None O
, None None O
according None None O
to None None O
the None None O
data None None O
of None None O
mass None None O
- None None O
spectrometry None None O
14 None None I-IUPAC
- None None I-IUPAC
oxycarminomycinone None None I-IUPAC
( None None O
V None None O
) None None O
had None None O
a None None O
molecular None None O
weight None None O
of None None O
400 None None O
c None None O
. None None O

u None None O
. None None O

In None None O
treatment None None O
with None None O
an None None O
excess None None O
of None None O
acetic None None I-IUPAC
anhydride None None I-IUPAC
in None None O
pyridine None None I-TRIVIAL
it None None O
formed None None O
a None None O
hexa None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
derivative None None I-MODIFIER
, None None O
i.e. None None O
4 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
, None None I-IUPAC
9 None None I-IUPAC
, None None I-IUPAC
11 None None I-IUPAC
, None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
hexa None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
oxycarminomycinone None None I-IUPAC
( None None O
VI None None O
) None None O
. None None O

The None None O
aglycones None None I-FAMILY
( None None O
III None None O
- None None O
V None None O
) None None O
prepared None None O
by None None O
us None None O
may None None O
serve None None O
a None None O
starting None None O
material None None O
in None None O
chemical None None O
synthesis None None O
, None None O
as None None O
well None None O
as None None O
biosynthesis None None O
of None None O
semi None None O
- None None O
synthetic None None O
preparations None None O
of None None O
the None None O
carminomycin None None I-TRIVIAL
series None None B-MODIFIER
. None None O


Adenosine None None O
5' None None O
- None None O
triphosphate None None O
( None None O
ATP None None I-ABBREVIATION
) None None O
derivatives None None I-MODIFIER
of None None O
the None None O
types None None O
N6 None None I-ABBREVIATION
- None None I-ABBREVIATION
R None None I-ABBREVIATION
- None None I-ABBREVIATION
ATP None None I-ABBREVIATION
[ None None O
R None None O
= None None O
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
nNHCOCH2I None None I-SUM
, None None O
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
nNHCO None None I-SUM
- None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
mNHCOCH2I None None I-SUM
, None None O
or None None O
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
nCON None None I-SUM
( None None I-SUM
Me None None I-SUM
) None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
mN None None I-SUM
( None None I-SUM
Me None None I-SUM
) None None I-SUM
CO None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
nNHCOCH2I None None I-SUM
] None None O
, None None O
N6 None None I-ABBREVIATION
- None None I-ABBREVIATION
Me None None I-ABBREVIATION
- None None I-ABBREVIATION
N6 None None I-ABBREVIATION
- None None I-ABBREVIATION
R None None I-ABBREVIATION
- None None I-ABBREVIATION
ATP None None I-ABBREVIATION
[ None None O
R None None O
= None None O
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
nN None None I-SUM
- None None I-SUM
( None None I-SUM
Me None None I-SUM
) None None I-SUM
CO None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
mNHCOCH2I None None I-SUM
] None None O
, None None O
and None None O
8 None None I-ABBREVIATION
- None None I-ABBREVIATION
R None None I-ABBREVIATION
- None None I-ABBREVIATION
ATP None None I-ABBREVIATION
[ None None O
R None None O
= None None O
NM None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
nNHCOCH2I None None I-SUM
] None None O
with None None O
5 None None O
- None None O
- None None O
19 None None O
spacer None None O
atoms None None O
between None None O
N6 None None O
or None None O
C None None O
- None None O
8 None None O
and None None O
iodine None None I-TRIVIAL
have None None O
been None None O
evaluated None None O
as None None O
potential None None O
exo None None O
- None None O
ATP None None I-ABBREVIATION
- None None O
site None None O
- None None O
directed None None O
reagents None None O
for None None O
phosphokinases None None O
. None None O

Substrate None None O
and None None O
inhibitor None None O
properties None None O
indicated None None O
that None None O
the None None O
compounds None None O
possessed None None O
affinity None None O
for None None O
the None None O
ATP None None I-ABBREVIATION
sites None None O
of None None O
the None None O
muscle None None O
( None None O
M None None O
) None None O
, None None O
kidney None None O
( None None O
K None None O
) None None O
, None None O
and None None O
liver None None O
( None None O
L None None O
) None None O
isozymes None None O
of None None O
rat None None O
pyruvate None None O
kinase None None O
( None None O
PK None None O
) None None O
, None None O
of None None O
E None None O
. None None O

coli None None O
thymidine None None O
kinase None None O
( None None O
TK None None O
) None None O
, None None O
and None None O
of None None O
yeast None None O
hexokinase None None O
( None None O
HK None None O
) None None O
and None None O
rat None None O
KH None None O
I None None O
, None None O
II None None O
, None None O
and None None O
III None None O
isozymes None None O
. None None O

Tests None None O
for None None O
time None None O
- None None O
dependent None None O
loss None None O
of None None O
enzyme None None O
activity None None O
( None None O
inactivation None None O
) None None O
were None None O
performed None None O
under None None O
conditions None None O
in None None O
which None None O
a None None O
large None None O
proportion None None O
of None None O
each None None O
phosphokinase None None O
was None None O
present None None O
as None None O
an None None O
enzyme None None O
- None None O
inhibitor None None O
complex None None O
. None None O

No None None O
ATP None None I-ABBREVIATION
- None None O
site None None O
- None None O
directed None None O
inactivations None None O
resulted None None O
when None None O
the None None O
M None None O
, None None O
L None None O
, None None O
or None None O
K None None O
isozymes None None O
of None None O
PK None None O
were None None O
exposed None None O
for None None O
8 None None O
h None None O
, None None O
22 None None O
degrees None None O
C None None O
, None None O
to None None O
5 None None O
mM None None O
levels None None O
of None None O
18 None None O
ATP None None I-ABBREVIATION
derivatives None None B-MODIFIER
or None None O
6 None None O
analogous None None O
ADP None None I-ABBREVIATION
derivatives None None B-MODIFIER
or None None O
when None None O
yeast None None O
HK None None O
or None None O
rat None None O
KH None None O
I None None O
, None None O
II None None O
, None None O
or None None O
III None None O
was None None O
exposed None None O
for None None O
6 None None O
h None None O
, None None O
22 None None O
degrees None None O
C None None O
, None None O
to None None O
5 None None O
mM None None O
levels None None O
of None None O
28 None None O
ATP None None I-ABBREVIATION
derivatives None None B-MODIFIER
. None None O

Escherichia None None O
coli None None O
TK None None O
was None None O
inactivated None None O
by None None O
6 None None O
of None None O
25 None None O
ATP None None O
derivatives None None O
tested None None O
at None None O
10 None None O
mM None None O
, None None O
6 None None O
h None None O
, None None O
0 None None O
degrees None None O
C None None O
; None None O
inactivation None None O
was None None O
slowed None None O
by None None O
MgATP None None I-ABBREVIATION
in None None O
the None None O
case None None O
of None None O
N6 None None I-ABBREVIATION
- None None I-ABBREVIATION
CH3 None None I-ABBREVIATION
- None None I-ABBREVIATION
N6 None None I-ABBREVIATION
- None None I-ABBREVIATION
R None None I-ABBREVIATION
- None None I-ABBREVIATION
ATP None None I-ABBREVIATION
[ None None O
R None None O
= None None O
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
4N None None I-SUM
( None None I-SUM
CH3 None None I-SUM
) None None I-SUM
CO None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
5NHCOCH2I None None I-SUM
] None None O
. None None O

Only None None O
1% None None O
of None None O
298 None None O
enzyme None None O
- None None O
inhibitor None None O
combinations None None O
exhibited None None O
ATP None None I-ABBREVIATION
- None None O
site None None O
- None None O
directed None None O
inactivation None None O
, None None O
signifying None None O
that None None O
few None None O
suitably None None O
positioned None None O
and None None O
sufficiently None None O
reactive None None O
nucleophilic None None O
groups None None O
were None None O
present None None O
near None None O
the None None O
enzymic None None O
ATP None None I-ABBREVIATION
sites None None O
. None None O

Studies None None O
have None None O
now None None O
shown None None O
that None None O
exo None None O
- None None O
active None None O
- None None O
site None None O
- None None O
directed None None O
reagents None None O
can None None O
act None None O
as None None O
isozyme None None O
- None None O
or None None O
species None None O
- None None O
selective None None O
enzyme None None O
inhibitors None None O
. None None O

The None None O
present None None O
survey None None O
indicates None None O
that None None O
in None None O
many None None O
cases None None O
such None None O
reagents None None O
may None None O
be None None O
difficult None None O
of None None O
access None None O
when None None O
data None None O
are None None O
not None None O
available None None O
regarding None None O
structural None None O
or None None O
physicochemical None None O
features None None O
of None None O
the None None O
target None None O
enzyme None None O
adjacent None None O
to None None O
its None None O
catalytic None None O
site None None O
. None None O


Effect None None O
of None None O
recombinant None None O
human None None O
fibroblast None None O
interferon None None O
and None None O
mezerein None None I-TRIVIAL
on None None O
growth None None O
, None None O
differentiation None None O
, None None O
immune None None O
interferon None None O
binding None None O
and None None O
tumor None None O
associated None None O
antigen None None O
expression None None O
in None None O
human None None O
melanoma None None O
cells None None O
. None None O

The None None O
combination None None O
of None None O
recombinant None None O
human None None O
fibroblast None None O
interferon None None O
( None None O
INF None None O
- None None O
delta None None O
) None None O
and None None O
the None None O
antileukemic None None O
compound None None O
mezerein None None I-TRIVIAL
( None None O
MEZ None None I-ABBREVIATION
) None None O
results None None O
in None None O
a None None O
synergistic None None O
suppression None None O
in None None O
the None None O
growth None None O
of None None O
human None None O
melanoma None None O
cells None None O
and None None O
a None None O
concomitant None None O
increase None None O
in None None O
melanin None None I-TRIVIAL
synthesis None None O
. None None O

In None None O
the None None O
present None None O
study None None O
we None None O
have None None O
further None None O
analyzed None None O
this None None O
synergistic None None O
interaction None None O
and None None O
have None None O
also None None O
evaluated None None O
the None None O
effect None None O
of None None O
IFN None None O
- None None O
delta None None O
and None None O
MEZ None None I-ABBREVIATION
, None None O
alone None None O
and None None O
in None None O
combination None None O
, None None O
on None None O
recombinant None None O
human None None O
gamma None None O
interferon None None O
( None None O
IFN None None O
- None None O
gamma None None O
) None None O
binding None None O
and None None O
Class None None O
I None None O
HLA None None O
and None None O
melanoma None None O
associated None None O
antigen None None O
( None None O
MAA None None O
) None None O
expression None None O
in None None O
the None None O
HO None None O
- None None O
1 None None O
human None None O
melanoma None None O
cell None None O
line None None O
. None None O

Single None None O
cell None None O
clones None None O
isolated None None O
from None None O
the None None O
HO None None O
- None None O
1 None None O
cell None None O
line None None O
varied None None O
in None None O
their None None O
sensitivity None None O
to None None O
the None None O
antiproliferative None None O
effects None None O
of None None O
IFN None None O
- None None O
delta None None O
and None None O
MEZ None None I-ABBREVIATION
. None None O

With None None O
all None None O
twelve None None O
clones None None O
, None None O
however None None O
, None None O
the None None O
combination None None O
of None None O
IFN None None O
- None None O
delta None None O
plus None None O
MEZ None None I-ABBREVIATION
was None None O
more None None O
growth None None O
inhibitory None None O
than None None O
either None None O
agent None None O
used None None O
alone None None O
, None None O
even None None O
in None None O
HO None None O
- None None O
1 None None O
subclones None None O
displaying None None O
relative None None O
resistance None None O
to None None O
IFN None None O
- None None O
delta None None O
. None None O

By None None O
continuous None None O
growth None None O
in None None O
gradually None None O
increasing None None O
concentrations None None O
of None None O
IFN None None O
- None None O
delta None None O
, None None O
a None None O
variant None None O
population None None O
of None None O
HO None None O
- None None O
1 None None O
cells None None O
, None None O
HO None None O
- None None O
1 None None O
delta None None O
R None None O
- None None O
D None None O
, None None O
was None None O
generated None None O
which None None O
was None None O
more None None O
resistant None None O
to None None O
the None None O
antigrowth None None O
effects None None O
of None None O
IFN None None O
- None None O
delta None None O
than None None O
the None None O
original None None O
HO None None O
- None None O
1 None None O
parental None None O
cell None None O
line None None O
. None None O

In None None O
the None None O
IFN None None O
delta None None O
R None None O
- None None O
D None None O
cell None None O
line None None O
the None None O
combination None None O
of None None O
IFN None None O
- None None O
delta None None O
plus None None O
MEZ None None I-ABBREVIATION
synergistically None None O
suppressed None None O
growth None None O
. None None O

Exposure None None O
of None None O
HO None None O
- None None O
1 None None O
cells None None O
to None None O
2500 None None O
units None None O
/ None None O
ml None None O
IFN None None O
- None None O
delta None None O
or None None O
50 None None O
ng None None O
/ None None O
ml None None O
MEZ None None I-ABBREVIATION
for None None O
96 None None O
hr None None O
resulted None None O
in None None O
no None None O
change None None O
or None None O
an None None O
increase None None O
in None None O
the None None O
binding None None O
of None None O
labelled None None O
IFN None None O
- None None O
gamma None None O
to None None O
surface None None O
receptors None None O
, None None O
whereas None None O
the None None O
combination None None O
of None None O
IFN None None O
- None None O
delta None None O
plus None None O
MEZ None None I-ABBREVIATION
increased None None O
IFN None None O
- None None O
gamma None None O
binding None None O
2 None None O
- None None O
to None None O
- None None O
4 None None O
- None None O
fold None None O
in None None O
HO None None O
- None None O
1 None None O
cells None None O
. None None O

This None None O
increase None None O
was None None O
the None None O
result None None O
of None None O
an None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
receptors None None O
on None None O
treated None None O
cells None None O
coupled None None O
with None None O
a None None O
protection None None O
against None None O
a None None O
decrease None None O
in None None O
receptors None None O
observed None None O
for None None O
confluent None None O
untreated None None O
cells None None O
. None None O

Changes None None O
in None None O
IFN None None O
- None None O
gamma None None O
binding None None O
resulting None None O
from None None O
treatment None None O
with None None O
IFN None None O
- None None O
delta None None O
plus None None O
MEZ None None I-ABBREVIATION
were None None O
not None None O
associated None None O
with None None O
alterations None None O
in None None O
the None None O
binding None None O
affinity None None O
of None None O
INF None None O
- None None O
gamma None None O
to None None O
its None None O
receptor None None O
. None None O

Changes None None O
were None None O
also None None O
observed None None O
in None None O
the None None O
expression None None O
of None None O
HLA None None O
Class None None O
I None None O
antigens None None O
and None None O
MAAs None None O
following None None O
treatment None None O
of None None O
HO None None O
- None None O
1 None None O
cells None None O
with None None O
IFN None None O
- None None O
delta None None O
, None None O
MEZ None None I-ABBREVIATION
or None None O
IFN None None O
- None None O
delta None None O
plus None None O
MEZ None None I-ABBREVIATION
. None None O

IFN None None O
- None None O
delta None None O
and None None O
MEZ None None I-ABBREVIATION
increased None None O
the None None O
expression None None O
of None None O
HLA None None O
Class None None O
I None None O
antigens None None O
a None None O
96 None None O
kd None None O
MAA None None O
defined None None O
by None None O
MoAb None None O
CL203 None None O
, None None O
a None None O
100 None None O
kd None None O
MAA None None O
defined None None O
by None None O
MoAb None None O
376.96 None None O
and None None O
a None None O
115 None None O
kd None None O
MAA None None O
defined None None O
by None None O
MoAb None None O
345.134 None None O
but None None O
decreased None None O
the None None O
expression None None O
of None None O
a None None O
high None None O
molecular None None O
weight None None O
- None None O
melanoma None None O
associated None None O
antigen None None O
( None None O
HMW None None O
- None None O
MAA None None O
) None None O
defined None None O
by None None O
MoAb None None O
325.28 None None O
S None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Degarelix None None O
( None None O
FE200486 None None I-TRIVIALVAR
, None None O
Ac None None O
- None None O
d None None O
- None None O
2Nal None None O
( None None O
1 None None O
) None None O
- None None O
d None None O
- None None O
4Cpa None None O
( None None O
2 None None O
) None None O
- None None O
d None None O
- None None O
3Pal None None O
( None None O
3 None None O
) None None O
- None None O
Ser None None O
( None None O
4 None None O
) None None O
- None None O
4Aph None None O
( None None O
l None None O
- None None O
Hor None None O
) None None O
( None None O
5 None None O
) None None O
- None None O
d None None O
- None None O
4Aph None None O
( None None O
Cbm None None O
) None None O
( None None O
6 None None O
) None None O
- None None O
Leu None None O
( None None O
7 None None O
) None None O
- None None O
ILys None None O
( None None O
8 None None O
) None None O
- None None O
Pro None None O
( None None O
9 None None O
) None None O
- None None O
d None None O
- None None O
Ala None None O
( None None O
10 None None O
) None None O
- None None O
NH None None O
( None None O
2 None None O
) None None O
) None None O
is None None O
a None None O
potent None None O
and None None O
very None None O
long None None O
acting None None O
antagonist None None O
of None None O
gonadotropin None None O
- None None O
releasing None None O
hormone None None O
( None None O
GnRH None None O
) None None O
after None None O
subcutaneous None None O
administration None None O
in None None O
mammals None None O
including None None O
humans None None O
. None None O

Analogues None None O
of None None O
degarelix None None I-TRIVIAL
were None None O
synthesized None None O
, None None O
characterized None None O
, None None O
and None None O
screened None None O
for None None O
the None None O
antagonism None None O
of None None O
GnRH None None O
- None None O
induced None None O
response None None O
in None None O
a None None O
reporter None None O
gene None None O
assay None None O
in None None O
HEK None None O
- None None O
293 None None O
cells None None O
expressing None None O
the None None O
human None None O
GnRH None None O
receptor None None O
. None None O

The None None O
duration None None O
of None None O
action None None O
was None None O
also None None O
determined None None O
in None None O
the None None O
castrated None None O
male None None O
rat None None O
assay None None O
to None None O
measure None None O
the None None O
extent None None O
( None None O
efficacy None None O
and None None O
duration None None O
of None None O
action None None O
) None None O
of None None O
inhibition None None O
of None None O
luteinizing None None O
hormone None None O
( None None O
LH None None O
) None None O
release None None O
. None None O

Structurally None None O
, None None O
this None None O
series None None O
of None None O
analogues None None O
has None None O
novel None None O
substitutions None None O
at None None O
positions None None O
3 None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
and None None O
N None None O
( None None O
alpha None None O
) None None O
- None None O
methylation None None O
at None None O
positions None None O
6 None None O
, None None O
7 None None O
, None None O
and None None O
8 None None O
in None None O
the None None O
structure None None O
of None None O
degarelix None None I-TRIVIAL
. None None O

These None None O
substitutions None None O
were None None O
designed None None O
to None None O
probe None None O
the None None O
spatial None None O
limitations None None O
of None None O
the None None O
receptor None None O
's None None O
cavity None None O
and None None O
to None None O
map None None O
the None None O
steric None None O
and None None O
ionic None None O
boundaries None None O
. None None O

Some None None O
functional None None O
groups None None O
were None None O
introduced None None O
that None None O
were None None O
hypothesized None None O
to None None O
influence None None O
the None None O
phamacokinetic None None O
properties None None O
of None None O
the None None O
analogues None None O
such None None O
as None None O
bioavailability None None O
, None None O
solubility None None O
, None None O
intra None None O
- None None O
or None None O
intermolecular None None O
hydrogen None None O
bond None None O
forming None None O
capacity None None O
, None None O
and None None O
ability None None O
to None None O
bind None None O
carrier None None O
proteins None None O
. None None O

Substitutions None None O
at None None O
positions None None O
3 None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
pyridyl None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
d None None I-IUPAC
- None None I-IUPAC
Dap None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.71 None None O
nM None None O
) None None O
( None None O
5 None None O
) None None O
, None None O
7 None None O
( None None O
[ None None I-TRIVIAL
Pra None None I-TRIVIAL
( None None I-TRIVIAL
7 None None I-TRIVIAL
) None None I-TRIVIAL
] None None I-TRIVIAL
degarelix None None I-TRIVIAL
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
2.11 None None O
nM None None O
) None None O
( None None O
16 None None O
) None None O
, None None O
and None None O
8 None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
delta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
IGly None None I-IUPAC
) None None I-IUPAC
Orn None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.38 None None O
nM None None O
) None None O
( None None O
20 None None O
) None None O
and None None O
N None None O
- None None O
methylation None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
alpha None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
Leu None None I-IUPAC
( None None I-IUPAC
7 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.47 None None O
nM None None O
) None None O
( None None O
32 None None O
) None None O
yielded None None O
analogues None None O
that None None O
were None None O
equipotent None None O
to None None O
degarelix None None I-TRIVIAL
( None None O
2 None None O
) None None O
in None None O
vitro None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.64 None None O
nM None None O
) None None O
but None None O
shorter None None O
acting None None O
in None None O
vivo None None O
. None None O

Out None None O
of None None O
the None None O
33 None None O
novel None None O
analogues None None O
tested None None O
for None None O
the None None O
duration None None O
of None None O
action None None O
in None None O
this None None O
series None None O
, None None O
two None None O
analogues None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
epsilon None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
Lys None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.50 None None O
nM None None O
) None None O
( None None O
23 None None O
) None None O
and None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
beta None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
IbetaAla None None I-IUPAC
) None None I-IUPAC
Dap None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.98 None None O
nM None None O
) None None O
( None None O
26 None None O
) None None O
had None None O
antagonist None None O
potencies None None O
and None None O
duration None None O
of None None O
action None None O
similar None None O
to None None O
that None None O
of None None O
azaline None None I-TRIVIAL
B None None I-TRIVIAL
{ None None O
inhibited None None O
LH None None O
( None None O
& None None O
gt None None O
; None None O
80% None None O
) None None O
release None None O
for None None O
& None None O
gt None None O
; None None O
72 None None O
h None None O
after None None O
sc None None O
injection None None O
to None None O
castrated None None O
male None None O
rats None None O
at None None O
a None None O
standard None None O
dose None None O
of None None O
50 None None O
mug None None O
/ None None O
rat None None O
in None None O
5% None None O
mannitol None None O
} None None O
. None None O

Under None None O
similar None None O
conditions None None O
analogues None None O
( None None O
[ None None I-IUPAC
N None None I-IUPAC
( None None I-IUPAC
gamma None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
IGly None None I-IUPAC
) None None I-IUPAC
Dab None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.56 None None O
nM None None O
) None None O
( None None O
21 None None O
) None None O
and None None O
( None None O
[ None None I-IUPAC
IOrn None None I-IUPAC
( None None I-IUPAC
8 None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
degarelix None None I-IUPAC
, None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
1.72 None None O
nM None None O
) None None O
( None None O
18 None None O
) None None O
had None None O
a None None O
longer None None O
duration None None O
of None None O
action None None O
{ None None O
inhibited None None O
LH None None O
( None None O
& None None O
gt None None O
; None None O
96 None None O
h None None O
) None None O
release None None O
} None None O
than None None O
azaline None None I-TRIVIAL
B None None I-TRIVIAL
; None None O
however None None O
they None None O
were None None O
shorter None None O
acting None None O
than None None O
degarelix None None I-TRIVIAL
. None None O

Hydrophilicity None None O
of None None O
these None None O
analogues None None O
, None None O
a None None O
potential None None O
measure None None O
of None None O
their None None O
ability None None O
to None None O
be None None O
formulated None None O
for None None O
sustained None None O
release None None O
, None None O
was None None O
determined None None O
using None None O
RP None None O
- None None O
HPLC None None O
at None None O
neutral None None O
pH None None O
yielding None None O
analogues None None O
with None None O
shorter None None O
as None None O
well None None O
as None None O
longer None None O
retention None None O
times None None O
. None None O

No None None O
correlation None None O
was None None O
found None None O
between None None O
retention None None O
times None None O
and None None O
antagonist None None O
potency None None O
or None None O
duration None None O
of None None O
action None None O
. None None O


[ None None O
Method None None O
of None None O
determination None None O
of None None O
biogenic None None O
amines None None I-FAMILY
in None None O
wines None None O
by None None O
high None None O
- None None O
performance None None O
liquid None None O
chromatography None None O
with None None O
fluorescence None None O
detector None None O
and None None O
ultraviolet None None O
detector None None O
] None None O
OBJECTIVE None None O
: None None O
A None None O
pre None None O
- None None O
column None None O
derivation None None O
reversed None None O
- None None O
phase None None O
high None None O
- None None O
performance None None O
liquid None None O
chromatography None None O
method None None O
was None None O
developed None None O
for None None O
the None None O
determination None None O
of None None O
biogenic None None O
amines None None O
( None None O
tryptamine None None I-TRIVIAL
, None None O
phenylethyamine None None I-TRIVIAL
, None None O
putrescine None None I-TRIVIAL
, None None O
cadaverine None None I-TRIVIAL
, None None O
histamine None None I-TRIVIAL
, None None O
tyramine None None I-TRIVIAL
, None None O
spermidine None None I-TRIVIAL
, None None O
and None None O
spermine None None I-TRIVIAL
) None None O
in None None O
wines None None O
with None None O
fluorescecse None None O
detector None None O
( None None O
FLD None None O
) None None O
and None None O
ultraviolet None None O
detector None None O
( None None O
UVD None None O
) None None O
. None None O

METHODS None None O
: None None O
Liqiud None None O
- None None O
liqiud None None O
extraction None None O
( None None O
LLE None None O
) None None O
was None None O
used None None O
to None None O
clean None None O
up None None O
wine None None O
samples None None O
with None None O
chloroform None None I-TRIVIAL
/ None None O
butanol None None I-TRIVIAL
prior None None O
to None None O
derivatization None None O
with None None O
dansyl None None I-IUPAC
chloride None None I-IUPAC
, None None O
biogenic None None O
amines None None O
were None None O
separated None None O
using None None O
gradient None None O
elution None None O
. None None O

Mobile None None O
phase None None O
A None None O
was None None O
methanol None None O
and None None O
mobile None None O
phase None None O
B None None O
was None None O
water None None O
with None None O
the None None O
flow None None O
rate None None O
1.5 None None O
ml None None O
/ None None O
min None None O
. None None O

The None None O
column None None O
used None None O
was None None O
a None None O
CAPCELL None None O
PAK None None O
C18 None None O
MG None None O
( None None O
4.6 None None O
mm None None O
I None None O
. None None O

D None None O
. None None O

x None None O
150 None None O
mm None None O
, None None O
5 None None O
microm None None O
) None None O
and None None O
gradient None None O
elution None None O
at None None O
constant None None O
column None None O
tempereture None None O
with None None O
30 None None O
degrees None None O
C None None O
under None None O
fluorescence None None O
detector None None O
with None None O
Ex None None O
350nm None None O
and None None O
Em None None O
520nm None None O
, None None O
The None None O
method None None O
and None None O
ultraviolet None None O
detector None None O
with None None O
254nm None None O
. None None O

1,7 None None I-IUPAC
- None None I-IUPAC
Diaminoheptane None None I-IUPAC
was None None O
used None None O
as None None O
the None None O
internal None None O
standard None None O
( None None O
IS None None O
) None None O
. None None O

RESULTS None None O
: None None O
was None None O
linear None None O
for None None O
the None None O
amines None None O
studied None None O
at None None O
concentration None None O
ranging None None O
from None None O
0.05 None None O
to None None O
25 None None O
mg None None O
/ None None O
L None None O
, None None O
except None None O
for None None O
spermidine None None I-TRIVIAL
and None None O
spermine None None I-TRIVIAL
, None None O
which None None O
ranging None None O
from None None O
0.05 None None O
to None None O
15 None None O
mg None None O
/ None None O
L None None O
. None None O

The None None O
average None None O
recoveries None None O
ranged None None O
from None None O
79.2% None None O
to None None O
127.5% None None O
for None None O
all None None O
amines None None O
, None None O
The None None O
RSDs None None O
were None None O
less None None O
than None None O
10% None None O
. None None O

With None None O
this None None O
method None None O
, None None O
5 None None O
wine None None O
samples None None O
were None None O
determined None None O
, None None O
the None None O
results None None O
were None None O
favorable None None O
. None None O

CONCLUTION None None O
: None None O
method None None O
can None None O
be None None O
applied None None O
for None None O
determination None None O
of None None O
biogenic None None O
amines None None O
in None None O
wines None None O
. None None O


The None None O
isomeric None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
- None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyphenyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinolines None None I-IUPAC
, None None O
the None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
derivative None None I-MODIFIER
of None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
isomer None None I-MODIFIER
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4 None None I-IUPAC
- None None I-IUPAC
tetrahydroisoquinoline None None I-IUPAC
were None None O
synthesized None None O
and None None O
evaluated None None O
for None None O
dopamine None None O
D None None O
- None None O
1 None None O
antagonist None None O
activity None None O
. None None O

The None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
and None None O
the None None O
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
isomer None None I-MODIFIER
possessed None None O
similar None None O
potencies None None O
as None None O
D None None O
- None None O
1 None None O
antagonists None None O
. None None O

Introduction None None O
of None None O
the None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
group None None I-MODIFIER
enhanced None None O
potency None None O
about None None O
twofold None None O
. None None O

The None None O
" None None O
pharmacophore None None O
" None None O
for None None O
selective None None O
dopamine None None O
D None None O
- None None O
1 None None O
antagonist None None O
activity None None O
appears None None O
to None None O
be None None O
a None None O
tertiary None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
phenethylamine None None I-IUPAC
. None None O


In None None O
a None None O
continuing None None O
effort None None O
to None None O
design None None O
small None None O
- None None O
molecule None None O
inhibitors None None O
of None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
that None None O
combine None None O
the None None O
enzyme None None O
- None None O
binding None None O
selectivity None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
trimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
trimethoprim None None I-TRIVIAL
, None None O
TMP None None I-ABBREVIATION
) None None O
with None None O
the None None O
potency None None O
of None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
dimethoxybenzyl None None I-IUPAC
) None None I-IUPAC
pyrido None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
piritrexim None None I-TRIVIAL
, None None O
PTX None None I-ABBREVIATION
) None None O
, None None O
seven None None O
previously None None O
undescribed None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
substituted None None I-IUPAC
benzyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
pyrimidines None None I-IUPAC
were None None O
synthesized None None O
in None None O
which None None O
the None None O
substituent None None O
at None None O
the None None O
5' None None O
- None None O
position None None O
was None None O
a None None O
carboxyphenyl None None I-PARTIUPAC
group None None B-MODIFIER
linked None None O
to None None O
the None None O
benzyl None None I-PARTIUPAC
moiety None None B-MODIFIER
by None None O
a None None O
bridge None None O
of None None O
two None None O
or None None O
four None None O
atoms None None O
in None None O
length None None O
. None None O

The None None O
new None None O
analogues None None O
were None None O
all None None O
obtained None None O
from None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxybenzyl None None I-IUPAC
) None None I-IUPAC
pyrimidine None None I-IUPAC
via None None O
a None None O
Sonogashira None None O
reaction None None O
, None None O
followed None None O
, None None O
where None None O
appropriate None None O
, None None O
by None None O
catalytic None None O
hydrogenation None None O
. None None O

The None None O
new None None O
analogues None None O
were None None O
tested None None O
as None None O
inhibitors None None O
of None None O
DHFR None None O
from None None O
Pneumocystis None None O
carinii None None O
( None None O
Pc None None O
) None None O
, None None O
Toxoplasma None None O
gondii None None O
( None None O
Tg None None O
) None None O
, None None O
and None None O
Mycobacterium None None O
avium None None O
( None None O
Ma None None O
) None None O
, None None O
three None None O
life None None O
- None None O
threatening None None O
pathogens None None O
often None None O
found None None O
in None None O
AIDS None None O
patients None None O
and None None O
individuals None None O
whose None None O
immune None None O
system None None O
is None None O
impaired None None O
as None None O
a None None O
result None None O
of None None O
treatment None None O
with None None O
immunosuppressive None None O
chemotherapy None None O
or None None O
radiation None None O
. None None O

The None None O
selectivity None None O
index None None O
( None None O
SI None None O
) None None O
of None None O
each None None O
compound None None O
was None None O
obtained None None O
by None None O
dividing None None O
its None None O
50% None None O
inhibitory None None O
concentration None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
) None None O
against None None O
Pc None None O
, None None O
Tg None None O
, None None O
or None None O
Ma None None O
DHFR None None O
by None None O
its None None O
IC None None O
( None None O
50 None None O
) None None O
against None None O
rat None None O
DHFR None None O
. None None O

2,4 None None I-IUPAC
- None None I-IUPAC
Diamino None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxyphenyl None None I-IUPAC
) None None I-IUPAC
ethynylbenzyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
28 None None O
) None None O
, None None O
with None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
23 None None O
nM None None O
and None None O
an None None O
SI None None O
of None None O
28 None None O
in None None O
the None None O
Pc None None O
DHFR None None O
assay None None O
, None None O
had None None O
about None None O
the None None O
same None None O
potency None None O
as None None O
PTX None None I-ABBREVIATION
and None None O
was None None O
520 None None O
times None None O
more None None O
potent None None O
than None None O
TMP None None I-ABBREVIATION
. None None O

As None None O
an None None O
inhibitor None None O
of None None O
Tg None None O
DHFR None None O
, None None O
28 None None O
had None None O
an None None O
IC None None O
( None None O
50 None None O
) None None O
of None None O
5.5 None None O
nM None None O
( None None O
510 None None O
- None None O
fold None None O
lower None None O
than None None O
that None None O
of None None O
TMP None None I-ABBREVIATION
and None None O
similar None None O
to None None O
that None None O
of None None O
PTX None None I-ABBREVIATION
) None None O
and None None O
an None None O
SI None None O
value None None O
of None None O
120 None None O
( None None O
2 None None O
- None None O
fold None None O
better None None O
than None None O
TMP None None I-ABBREVIATION
and None None O
vastly None None O
superior None None O
to None None O
PTX None None I-ABBREVIATION
) None None O
. None None O

Against None None O
Ma None None O
DHFR None None O
, None None O
28 None None O
had None None O
IC None None O
( None None O
50 None None O
) None None O
and None None O
SI None None O
values None None O
of None None O
1.5 None None O
nM None None O
and None None O
430 None None O
, None None O
respectively None None O
, None None O
compared None None O
with None None O
300 None None O
nM None None O
and None None O
610 None None O
for None None O
TMP None None I-ABBREVIATION
. None None O

Although None None O
it None None O
had None None O
2.5 None None O
- None None O
fold None None O
lower None None O
potency None None O
than None None O
28 None None O
against None None O
Ma None None O
DHFR None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
= None None O
3.7 None None O
nM None None O
) None None O
and None None O
was None None O
substantially None None O
weaker None None O
against None None O
Pc None None O
and None None O
Tg None None O
DHFR None None O
, None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxyphenyl None None I-IUPAC
) None None I-IUPAC
ethynylbenzyl None None I-IUPAC
] None None I-IUPAC
pyrimidine None None I-IUPAC
( None None O
29 None None O
) None None O
, None None O
with None None O
the None None O
carboxy None None I-TRIVIAL
group None None B-MODIFIER
at None None O
the None None O
para None None O
rather None None O
than None None O
the None None O
meta None None O
position None None O
, None None O
displayed None None O
2200 None None O
- None None O
fold None None O
selectivity None None O
against None None O
the None None O
Ma None None O
enzyme None None O
and None None O
was None None O
the None None O
most None None O
selective None None O
2,4 None None I-IUPAC
- None None I-IUPAC
diamino None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
benzyl None None I-IUPAC
) None None I-IUPAC
pyrimidine None None I-IUPAC
inhibitor None None O
of None None O
this None None O
enzyme None None O
we None None O
have None None O
encountered None None O
to None None O
date None None O
. None None O

Additional None None O
bioassay None None O
data None None O
for None None O
these None None O
compounds None None O
are None None O
also None None O
reported None None O
. None None O


Parenteral None None O
hydroxypropyl None None I-IUPAC
cyclodextrins None None I-IUPAC
: None None O
intravenous None None O
and None None O
intracerebral None None O
administration None None O
of None None O
lipophiles None None O
. None None O

Hydroxypropyl None None I-IUPAC
cyclodextrins None None I-IUPAC
are None None O
nontoxic None None O
carbohydrate None None I-FAMILY
derivatives None None B-MODIFIER
of None None O
moderate None None O
molecular None None O
weight None None O
( None None O
1030-1750 None None O
Da None None O
) None None O
which None None O
form None None O
water None None O
- None None O
soluble None None O
complexes None None O
with None None O
many None None O
lipophiles None None O
. None None O

The None None O
fate None None O
of None None O
hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrin None None I-IUPAC
alone None None O
and None None O
in None None O
complex None None O
with None None O
testosterone None None I-TRIVIAL
or None None O
cholesterol None None I-TRIVIAL
injected None None O
intravenously None None O
or None None O
intracerebrally None None O
into None None O
rats None None O
was None None O
followed None None O
. None None O

More None None O
than None None O
90% None None O
of None None O
intravenously None None O
administered None None O
hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrin None None I-IUPAC
was None None O
cleared None None O
into None None O
urine None None O
in None None O
4 None None O
h None None O
, None None O
as None None O
previously None None O
described None None O
( None None O
Monbaliu None None O
, None None O
J None None O
. None None O

; None None O
Van None None O
Beijsterveld None None O
, None None O
L None None O
. None None O

; None None O
Meuldermans None None O
, None None O
W None None O
. None None O

; None None O
Szathmary None None O
, None None O
S None None O
. None None O

; None None O
Haykants None None O
, None None O
J None None O
. None None O

Abstracts None None O
, None None O
5th None None O
International None None O
Symposium None None O
on None None O
Cyclodextrins None None I-TRIVIAL
, None None O
Paris None None O
, None None O
1990 None None O
; None None O
Abstract None None O
65 None None O
) None None O
. None None O

After None None O
the None None O
injection None None O
of None None O
steroids None None O
in None None O
complex None None O
with None None O
hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrin None None I-IUPAC
into None None O
the None None O
tail None None O
vein None None O
of None None O
rats None None O
, None None O
the None None O
steroid None None O
component None None O
was None None O
released None None O
from None None O
the None None O
complex None None O
, None None O
before None None O
it None None O
reached None None O
the None None O
kidneys None None O
; None None O
the None None O
release None None O
occurred None None O
mainly None None O
into None None O
the None None O
proteins None None O
and None None O
lipoproteins None None O
of None None O
serum None None O
. None None O

Hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrins None None I-IUPAC
injected None None O
alone None None O
into None None O
the None None O
brain None None O
were None None O
cleared None None O
within None None O
less None None O
than None None O
24 None None O
h None None O
, None None O
presumably None None O
via None None O
the None None O
flow None None O
of None None O
interstitial None None O
and None None O
cerebrospinal None None O
fluids None None O
, None None O
and None None O
eventually None None O
were None None O
excreted None None O
in None None O
urine None None O
. None None O

Testosterone None None I-TRIVIAL
, None None O
incorporated None None O
in None None O
a None None O
hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrin None None I-IUPAC
complex None None I-MODIFIER
, None None O
after None None O
intracerebral None None O
injection None None O
was None None O
cleared None None O
from None None O
the None None O
brain None None O
even None None O
more None None O
rapidly None None O
than None None O
hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrin None None I-IUPAC
, None None O
presumably None None O
by None None O
crossing None None O
the None None O
blood None None O
- None None O
brain None None O
barrier None None O
and None None O
later None None O
removal None None O
to None None O
the None None O
liver None None O
by None None O
the None None O
specific None None O
carrier None None O
proteins None None O
in None None O
serum None None O
. None None O

Complexed None None O
cholesterol None None I-TRIVIAL
, None None O
in None None O
a None None O
similar None None O
experiment None None O
, None None O
was None None O
largely None None O
retained None None O
in None None O
the None None O
brain None None O
and None None O
its None None O
distribution None None O
there None None O
was None None O
uneven None None O
and None None O
remained None None O
that None None O
way None None O
for None None O
at None None O
least None None O
3 None None O
days None None O
. None None O

It None None O
is None None O
clear None None O
that None None O
lipophilic None None O
agents None None O
, None None O
after None None O
their None None O
incorporation None None O
into None None O
hydroxypropyl None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
cyclodextrin None None I-IUPAC
complexes None None I-MODIFIER
and None None O
subsequent None None O
in None None O
vivo None None O
administration None None O
, None None O
are None None O
rapidly None None O
released None None O
and None None O
exchanged None None O
into None None O
the None None O
plasma None None O
. None None O

In None None O
absence None None O
of None None O
plasma None None O
they None None O
enter None None O
tissues None None O
surrounding None None O
the None None O
injection None None O
site None None O
and None None O
thus None None O
are None None O
also None None O
promptly None None O
transferred None None O
into None None O
the None None O
organism None None O
's None None O
lipid None None I-FAMILY
systems None None O
. None None O

The None None O
manner None None O
in None None O
which None None O
different None None O
lipophilic None None O
agents None None O
are None None O
transported None None O
in None None O
vivo None None O
appears None None O
not None None O
to None None O
be None None O
greatly None None O
affected None None O
by None None O
their None None O
previous None None O
complexation None None O
; None None O
rather None None O
hydroxypropyl None None I-IUPAC
cyclodextrins None None I-IUPAC
just None None O
enable None None O
their None None O
entry None None O
in None None O
a None None O
larger None None O
amount None None O
and None None O
in None None O
an None None O
exchangeable None None O
, None None O
nonaggregated None None O
form None None O
. None None O


Inhibition None None O
of None None O
renin None None O
secretion None None O
by None None O
intrarenal None None O
alpha None None O
- None None O
adrenoceptor None None O
blockade None None O
. None None O

This None None O
study None None O
was None None O
designed None None O
to None None O
determine None None O
whether None None O
renal None None O
alpha None None O
- None None O
adrenoceptors None None O
can None None O
mediate None None O
tonic None None O
neural None None O
stimulation None None O
of None None O
renin None None O
secretion None None O
. None None O

The None None O
effect None None O
of None None O
alpha None None O
- None None O
adrenoceptor None None O
blockade None None O
by None None O
phenoxybenzamine None None I-TRIVIAL
( None None O
POB None None I-ABBREVIATION
) None None O
or None None O
prazosin None None I-TRIVIAL
on None None O
renin None None O
secretion None None O
rate None None O
( None None O
RSR None None O
) None None O
was None None O
studied None None O
in None None O
pentobarbital None None I-TRIVIAL
- None None O
anesthetized None None O
dogs None None O
in None None O
which None None O
renal None None O
perfusion None None O
pressure None None O
was None None O
held None None O
constant None None O
with None None O
an None None O
adjustable None None O
aortic None None O
clamp None None O
. None None O

POB None None I-ABBREVIATION
alone None None O
( None None O
100 None None O
micrograms None None O
. None None O

kg None None O
- None None O
1 None None O
. None None O

min None None O
- None None O
1 None None O
iv None None O
) None None O
did None None O
not None None O
change None None O
arterial None None O
plasma None None O
renin None None O
activity None None O
( None None O
PRA None None O
) None None O
. None None O

However None None O
, None None O
when None None O
beta None None O
- None None O
adrenoceptors None None O
were None None O
blocked None None O
by None None O
intravenous None None O
propranolol None None I-TRIVIAL
, None None O
intravenous None None O
POB None None I-ABBREVIATION
infusion None None O
( None None O
100 None None O
micrograms None None O
. None None O

kg None None O
- None None O
1 None None O
. None None O

min None None O
- None None O
1 None None O
) None None O
decreased None None O
PRA None None O
and None None O
RSR None None O
to None None O
48 None None O
+ None None O
/ None None O
- None None O
8 None None O
and None None O
21 None None O
+ None None O
/ None None O
- None None O
9% None None O
of None None O
previous None None O
levels None None O
within None None O
30 None None O
min None None O
. None None O

This None None O
effect None None O
was None None O
abolished None None O
by None None O
acute None None O
bilateral None None O
renal None None O
denervation None None O
. None None O

Direct None None O
intrarenal None None O
POB None None I-ABBREVIATION
infusion None None O
( None None O
10 None None O
or None None O
3.3 None None O
micrograms None None O
. None None O

kg None None O
- None None O
1 None None O
. None None O

min None None O
- None None O
1 None None O
) None None O
decreased None None O
RSR None None O
, None None O
whereas None None O
intravenous None None O
POB None None I-ABBREVIATION
( None None O
3.3 None None O
micrograms None None O
. None None O

kg None None O
- None None O
1 None None O
. None None O

min None None O
- None None O
1 None None O
) None None O
had None None O
no None None O
effect None None O
on None None O
either None None O
RSR None None O
or None None O
PRA None None O
in None None O
propranolol None None I-TRIVIAL
- None None O
pretreated None None O
dogs None None O
. None None O

Prazosin None None I-TRIVIAL
( None None O
1 None None O
microgram None None O
. None None O

kg None None O
- None None O
1 None None O
. None None O

min None None O
- None None O
1 None None O
iv None None O
) None None O
also None None O
significantly None None O
decreased None None O
PRA None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
when None None O
beta None None O
- None None O
adrenoceptors None None O
are None None O
blocked None None O
by None None O
propranolol None None I-TRIVIAL
, None None O
tonic None None O
neural None None O
stimulation None None O
of None None O
renin None None O
secretion None None O
is None None O
mediated None None O
by None None O
renal None None O
alpha None None O
- None None O
adrenoceptors None None O
. None None O


Metabolism None None O
of None None O
D None None I-IUPAC
- None None I-IUPAC
and None None O
L None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
in None None O
adipose None None O
tissue None None O
: None None O
a None None O
stereochemical None None O
probe None None O
for None None O
glycerokinase None None O
activity None None O
. None None O

Distributions None None O
of None None O
( None None I-SUM
14 None None I-SUM
) None None I-SUM
C None None I-SUM
have None None O
been None None O
determined None None O
in None None O
free None None O
glycerol None None I-TRIVIAL
, None None O
in None None O
glycerol None None I-TRIVIAL
from None None O
triglycerides None None I-FAMILY
, None None O
in None None O
glucose None None I-TRIVIAL
from None None O
glycogen None None I-TRIVIAL
, None None O
and None None O
in None None O
lactate None None O
after None None O
incubation None None O
of None None O
d None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
and None None O
l None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
with None None O
rat None None O
adipose None None O
tissue None None O
. None None O

The None None O
distributions None None O
are None None O
interpreted None None O
in None None O
terms None None O
of None None O
presently None None O
accepted None None O
possible None None O
reactions None None O
for None None O
the None None O
initial None None O
metabolism None None O
of None None O
glyceraldehyde None None I-TRIVIAL
. None None O

Formation None None O
of None None O
glycerol None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
from None None O
d None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
indicates None None O
that None None O
in None None O
adipose None None O
tissue None None O
glyceraldehyde None None I-TRIVIAL
is None None O
reduced None None O
to None None O
glycerol None None I-TRIVIAL
. None None O

Incorporation None None O
of None None O
( None None I-SUM
14 None None I-SUM
) None None I-SUM
C None None I-SUM
from None None O
d None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
into None None O
carbon None None I-TRIVIAL
3 None None O
of None None O
the None None O
glycerol None None I-TRIVIAL
of None None O
triglyceride None None I-FAMILY
indicates None None O
that None None O
d None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
is None None O
either None None O
phosphorylated None None O
or None None O
oxidized None None O
to None None O
d None None I-IUPAC
- None None I-IUPAC
glyceric None None I-IUPAC
acid None None I-IUPAC
, None None O
or None None O
both None None O
, None None O
in None None O
its None None O
initial None None O
metabolism None None O
. None None O

Incorporation None None O
of None None O
( None None I-SUM
14 None None I-SUM
) None None I-SUM
C None None I-SUM
from None None O
l None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
into None None O
carbon None None I-TRIVIAL
3 None None O
of None None O
glycerol None None I-TRIVIAL
indicates None None O
that None None O
l None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
is None None O
reduced None None O
to None None O
glycerol None None I-TRIVIAL
, None None O
which None None O
is None None O
phosphorylated None None O
and None None O
( None None O
or None None O
) None None O
converted None None O
to None None O
d None None I-IUPAC
- None None I-IUPAC
glyceric None None I-IUPAC
acid None None I-IUPAC
via None None O
l None None I-IUPAC
- None None I-IUPAC
glyceric None None I-IUPAC
acid None None I-IUPAC
. None None O

Some None None O
( None None I-SUM
14 None None I-SUM
) None None I-SUM
C None None I-SUM
from None None O
l None None I-IUPAC
- None None I-IUPAC
glyceraldehyde None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
14 None None I-IUPAC
) None None I-IUPAC
C None None I-IUPAC
is None None O
incorporated None None O
into None None O
carbon None None I-TRIVIAL
1 None None O
of None None O
glycerol None None I-TRIVIAL
of None None O
triglycerides None None I-FAMILY
and None None O
carbon None None I-TRIVIAL
4 None None O
of None None O
glycogen None None I-TRIVIAL
; None None O
the None None O
explanation None None O
for None None O
this None None O
incorporation None None O
is None None O
uncertain None None O
. None None O


Attenuation None None O
of None None O
glucocorticoid None None I-FAMILY
functions None None O
in None None O
an None None O
Anx None None O
- None None O
A1 None None O
- None None O
/ None None O
- None None O
cell None None O
line None None O
. None None O

The None None O
Ca None None O
( None None O
2+ None None O
) None None O
- None None O
and None None O
phospholipid None None O
- None None O
binding None None O
protein None None O
Anx None None O
- None None O
A1 None None O
( None None O
annexin None None O
1 None None O
; None None O
lipocortin None None O
1 None None O
) None None O
has None None O
been None None O
described None None O
both None None O
as None None O
an None None O
inhibitor None None O
of None None O
phospholipase None None O
A None None O
( None None O
2 None None O
) None None O
( None None O
PLA None None O
( None None O
2 None None O
) None None O
) None None O
activity None None O
and None None O
as None None O
a None None O
mediator None None O
of None None O
glucocorticoid None None I-FAMILY
- None None O
regulated None None O
cell None None O
growth None None O
and None None O
eicosanoid None None I-TRIVIAL
generation None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
, None None O
when None None O
compared None None O
with None None O
Anx None None O
- None None O
A1 None None O
( None None O
+ None None O
/ None None O
+ None None O
) None None O
cells None None O
, None None O
lung None None O
fibroblast None None O
cell None None O
lines None None O
derived None None O
from None None O
the None None O
Anx None None O
- None None O
A1 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
mouse None None O
exhibit None None O
an None None O
altered None None O
morphology None None O
characterized None None O
by None None O
a None None O
spindle None None O
- None None O
shaped None None O
appearance None None O
and None None O
an None None O
accumulation None None O
of None None O
intracellular None None O
organelles None None O
. None None O

Unlike None None O
their None None O
wild None None O
- None None O
type None None O
counterparts None None O
, None None O
Anx None None O
- None None O
A1 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
cells None None O
also None None O
overexpress None None O
cyclo None None O
- None None O
oxygenase None None O
2 None None O
( None None O
COX None None O
2 None None O
) None None O
, None None O
cytosolic None None O
PLA None None O
( None None O
2 None None O
) None None O
and None None O
secretory None None O
PLA None None O
( None None O
2 None None O
) None None O
and None None O
in None None O
response None None O
to None None O
fetal None None O
calf None None O
serum None None O
, None None O
exhibit None None O
an None None O
exaggerated None None O
release None None O
of None None O
eicosanoids None None I-TRIVIAL
, None None O
which None None O
is None None O
insensitive None None O
to None None O
dexamethasone None None I-TRIVIAL
( None None O
10 None None O
( None None O
- None None O
8 None None O
) None None O
- None None O
10 None None O
( None None O
- None None O
6 None None O
) None None O
M None None O
) None None O
inhibition None None O
. None None O

Proliferation None None O
and None None O
serum None None O
- None None O
induced None None O
progression None None O
of None None O
Anx None None O
- None None O
A1 None None O
( None None O
+ None None O
/ None None O
+ None None O
) None None O
cells None None O
from None None O
G None None O
( None None O
0 None None O
) None None O
/ None None O
G None None O
( None None O
1 None None O
) None None O
into None None O
S None None O
phase None None O
, None None O
and None None O
the None None O
associated None None O
expression None None O
of None None O
extracellular None None O
signal None None O
- None None O
regulated None None O
kinase None None O
2 None None O
( None None O
ERK2 None None O
) None None O
, None None O
cyclin None None O
- None None O
dependent None None O
kinase None None O
4 None None O
( None None O
cdk4 None None O
) None None O
and None None O
COX None None O
2 None None O
, None None O
is None None O
strongly None None O
inhibited None None O
by None None O
dexamethasone None None O
, None None O
whereas None None O
Anx None None O
- None None O
A1 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
cells None None O
are None None O
refractory None None O
to None None O
the None None O
drug None None O
. None None O

Loss None None O
of None None O
the None None O
response None None O
to None None O
dexamethasone None None I-TRIVIAL
in None None O
Anx None None O
- None None O
A1 None None O
( None None O
- None None O
/ None None O
- None None O
) None None O
cells None None O
occurs None None O
against None None O
a None None O
background None None O
of None None O
no None None O
apparent None None O
change None None O
in None None O
glucocorticoid None None O
receptor None None O
expression None None O
or None None O
sensitivity None None O
to None None O
non None None O
- None None O
steroidal None None O
anti None None O
- None None O
inflammatory None None O
drugs None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
observations None None O
suggest None None O
strongly None None O
that None None O
Anx None None O
- None None O
A1 None None O
functions None None O
as None None O
an None None O
inhibitor None None O
of None None O
signal None None O
- None None O
transduction None None O
pathways None None O
that None None O
lead None None O
to None None O
cell None None O
proliferation None None O
and None None O
may None None O
help None None O
to None None O
explain None None O
how None None O
glucocorticoids None None I-FAMILY
regulate None None O
these None None O
processes None None O
. None None O


Cognitive None None O
assessment None None O
of None None O
geriatric None None O
schizophrenic None None O
patients None None O
with None None O
severe None None O
impairment None None O
. None None O

There None None O
is None None O
evidence None None O
that None None O
some None None O
elderly None None O
patients None None O
with None None O
chronic None None O
schizophrenia None None O
experience None None O
marked None None O
impairments None None O
in None None O
cognitive None None O
functioning None None O
. None None O

Assessment None None O
of None None O
these None None O
patients None None O
may None None O
be None None O
difficult None None O
with None None O
traditional None None O
neuropsychological None None O
measures None None O
. None None O

The None None O
purpose None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
determine None None O
if None None O
cognitive None None O
functioning None None O
could None None O
be None None O
validly None None O
assessed None None O
with None None O
the None None O
Alzheimer None None O
's None None O
Disease None None O
Assessment None None O
Scale None None O
- None None O
Late None None O
Version None None O
Cognitive None None O
factor None None O
score None None O
( None None O
ADAS None None O
- None None O
L None None O
Cog None None O
) None None O
in None None O
patients None None O
whose None None O
scores None None O
on None None O
the None None O
Mini None None O
- None None O
Mental None None O
State None None O
Examination None None O
( None None O
MMSE None None O
) None None O
reflect None None O
profound None None O
cognitive None None O
impairment None None O
. None None O

Patients None None O
with None None O
MMSE None None O
scores None None O
from None None O
0 None None O
to None None O
10 None None O
were None None O
selected None None O
from None None O
a None None O
larger None None O
database None None O
. None None O

Neuropsychological None None O
instruments None None O
designed None None O
for None None O
the None None O
assessment None None O
of None None O
mild None None O
to None None O
moderate None None O
dementia None None O
were None None O
found None None O
to None None O
be None None O
inadequate None None O
in None None O
this None None O
profoundly None None O
impaired None None O
population None None O
, None None O
due None None O
to None None O
floor None None O
effects None None O
. None None O

In None None O
contrast None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
relationship None None O
between None None O
ADAS None None O
- None None O
L None None O
scores None None O
and None None O
several None None O
criterion None None O
measures None None O
, None None O
including None None O
the None None O
MMSE None None O
( None None O
R None None O
= None None O
- None None O
.71 None None O
, None None O
P None None O
< None None O
.001 None None O
) None None O
, None None O
the None None O
Social None None O
Adaptive None None O
Functions None None O
Evaluation None None O
( None None O
SAFE None None O
) None None O
social None None O
functions None None O
scale None None O
( None None O
R None None O
= None None O
.47 None None O
, None None O
P None None O
< None None O
.001 None None O
) None None O
, None None O
and None None O
the None None O
negative None None O
symptom None None O
total None None O
score None None O
of None None O
the None None O
Positive None None O
and None None O
Negative None None O
Syndrome None None O
Scale None None O
( None None O
PANSS None None O
) None None O
( None None O
R None None O
= None None O
.412 None None O
, None None O
P None None O
< None None O
.001 None None O
) None None O
. None None O

The None None O
MMSE None None O
was None None O
somewhat None None O
less None None O
strongly None None O
correlated None None O
with None None O
both None None O
social None None O
functions None None O
( None None O
R None None O
= None None O
- None None O
.401 None None O
, None None O
P None None O
< None None O
.001 None None O
) None None O
and None None O
the None None O
negative None None O
symptom None None O
total None None O
score None None O
of None None O
the None None O
PANSS None None O
( None None O
R None None O
= None None O
- None None O
.366 None None O
, None None O
P None None O
< None None O
.001 None None O
) None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
cognition None None O
can None None O
be None None O
reliably None None O
and None None O
validly None None O
assessed None None O
with None None O
instruments None None O
such None None O
as None None O
the None None O
ADAS None None O
- None None O
L None None O
that None None O
are None None O
designed None None O
for None None O
the None None O
assessment None None O
of None None O
severely None None O
impaired None None O
patients None None O
. None None O


Evidence None None O
for None None O
messenger None None O
ribonucleic None None O
acid None None O
of None None O
an None None O
ammonium None None O
- None None O
inducible None None O
glutamate None None O
dehydrogenase None None O
and None None O
synthesis None None O
, None None O
covalent None None O
modification None None O
, None None O
and None None O
degradation None None O
of None None O
enzyme None None O
subunits None None O
in None None O
uninduced None None O
Chlorella None None O
sorokiniana None None O
cells None None O
. None None O

The None None O
cells None None O
of None None O
Chlorella None None O
sorokiniana None None O
cultured None None O
in None None O
nitrate None None I-TRIVIAL
medium None None O
contain None None O
no None None O
detectable None None O
catalytic None None O
activity None None O
of None None O
an None None O
ammonium None None O
- None None O
inducible None None O
nicotinamide None None O
adenine None None O
dinucleotide None None O
phosphate None None O
- None None O
specific None None O
glutamate None None O
dehydrogenase None None O
( None None O
NADP None None O
- None None O
GDH None None O
) None None O
. None None O

However None None O
, None None O
several None None O
lines None None O
of None None O
experimental None None O
evidence None None O
indicated None None O
that None None O
the None None O
NADP None None O
- None None O
GDH None None O
messenger None None O
ribonucleic None None O
acid None None O
was None None O
present None None O
at None None O
high None None O
levels None None O
and None None O
was None None O
being None None O
translated None None O
in None None O
uninduced None None O
cells None None O
. None None O

First None None O
, None None O
binding None None O
studies None None O
with None None O
125I None None O
- None None O
labeled None None O
anti None None O
- None None O
NADP None None O
- None None O
GDH None None O
immunoglobulin None None O
G None None O
and None None O
total None None O
polysomes None None O
isolated None None O
from None None O
uninduced None None O
and None None O
induced None None O
cells None None O
showed None None O
that None None O
NADP None None O
- None None O
GDH None None O
subunits None None O
were None None O
being None None O
synthesized None None O
on None None O
polysomes None None O
from None None O
both None None O
types None None O
of None None O
cells None None O
. None None O

Second None None O
, None None O
when None None O
polyadenylic None None I-IUPAC
acid None None I-IUPAC
- None None O
containing None None O
ribonucleic None None O
acid None None O
was None None O
extracted None None O
from None None O
polysomes None None O
from None None O
uninduced None None O
and None None O
induced None None O
cells None None O
and None None O
placed None None O
into None None O
a None None O
messenger None None O
ribonucleic None None O
acid None None O
- None None O
dependent None None O
in None None O
vitro None None O
translation None None O
system None None O
, None None O
NADP None None O
- None None O
GDH None None O
subunits None None O
were None None O
synthesized None None O
from None None O
the None None O
ribonucleic None None O
acid None None O
from None None O
both None None O
sources None None O
. None None O

Third None None O
, None None O
when None None O
ammonia None None I-FAMILY
was None None O
added None None O
to None None O
uninduced None None O
cells None None O
, None None O
NADP None None O
- None None O
GDH None None O
antigen None None O
accumulated None None O
without None None O
an None None O
apparent None None O
induction None None O
lag None None O
. None None O

Fourth None None O
, None None O
by None None O
use None None O
of None None O
a None None O
specific None None O
immunoprecipitation None None O
procedure None None O
coupled None None O
to None None O
pulse None None O
- None None O
chase None None O
studies None None O
with None None O
[ None None I-IUPAC
35S None None I-IUPAC
] None None I-IUPAC
sulfate None None I-IUPAC
, None None O
it None None O
was None None O
shown None None O
that None None O
the None None O
NADP None None O
- None None O
GDH None None O
subunits None None O
are None None O
rapidly None None O
synthesized None None O
, None None O
covalently None None O
modified None None O
, None None O
and None None O
then None None O
degraded None None O
in None None O
uninduced None None O
cells None None O
. None None O


Nucleotide None None I-FAMILY
regulation None None O
of None None O
heat None None O
- None None O
stable None None O
enterotoxin None None O
receptor None None O
binding None None O
and None None O
of None None O
guanylate None None O
cyclase None None O
activation None None O
. None None O

Certain None None O
nucleotides None None I-FAMILY
were None None O
found None None O
to None None O
regulate None None O
the None None O
binding None None O
of None None O
the None None O
Escherichia None None O
coli None None O
heat None None O
- None None O
stable None None O
enterotoxin None None O
( None None O
STa None None O
) None None O
to None None O
its None None O
receptor None None O
in None None O
pig None None O
intestinal None None O
brush None None O
border None None O
membranes None None O
. None None O

ATP None None I-ABBREVIATION
and None None O
adenine None None I-TRIVIAL
nucleotide None None B-FAMILY
analogues None None B-MODIFIER
inhibited None None O
125I None None O
- None None O
STa None None O
binding None None O
, None None O
while None None O
guanine None None I-TRIVIAL
nucleotide None None B-FAMILY
analogues None None B-MODIFIER
stimulated None None O
binding None None O
, None None O
with None None O
maximal None None O
effects None None O
at None None O
0.5-1.0 None None O
mM None None O
. None None O

The None None O
strongest None None O
inhibitors None None O
were None None O
adenosine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
beta None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
imido None None I-IUPAC
] None None I-IUPAC
triphosphate None None I-IUPAC
( None None O
App None None I-ABBREVIATION
[ None None I-ABBREVIATION
NH None None I-ABBREVIATION
] None None I-ABBREVIATION
p None None I-ABBREVIATION
) None None O
( None None O
36% None None O
) None None O
and None None O
adenosine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
diphosphate None None I-IUPAC
( None None O
ADP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
) None None O
( None None O
41% None None O
) None None O
. None None O

Inhibition None None O
did None None O
not None None O
require None None O
Mg2+ None None I-SUM
, None None O
and None None O
was None None O
blocked None None O
by None None O
p None None I-IUPAC
- None None I-IUPAC
chloromercuribenzenesulphonate None None I-IUPAC
( None None O
PCMBS None None I-ABBREVIATION
) None None O
. None None O

Stimulation None None O
of None None O
binding None None O
required None None O
Mg2+ None None I-SUM
, None None O
was None None O
not None None O
prevented None None O
by None None O
PCMBS None None I-ABBREVIATION
and None None O
was None None O
maximal None None O
with None None O
GDP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
( None None O
41% None None O
) None None O
. None None O

While None None O
App None None I-ABBREVIATION
[ None None I-ABBREVIATION
NH None None I-ABBREVIATION
] None None I-ABBREVIATION
p None None I-ABBREVIATION
and None None O
MgGDP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
appeared None None O
to None None O
be None None O
acting None None O
at None None O
different None None O
sites None None O
, None None O
they None None O
also None None O
interfered None None O
with None None O
each None None O
other None None O
. None None O

These None None O
nucleotides None None I-FAMILY
exerted None None O
only None None O
inhibitory None None O
effects None None O
on None None O
STa None None O
- None None O
stimulated None None O
guanylate None None O
cyclase None None O
activity None None O
, None None O
in None None O
contrast None None O
with None None O
the None None O
stimulatory None None O
effects None None O
of None None O
adenine None None I-TRIVIAL
nucleotides None None O
on None None O
atrial None None O
natriuretic None None O
peptide None None O
( None None O
ANP None None O
) None None O
- None None O
stimulated None None O
guanylate None None O
cyclase None None O
. None None O

Inhibition None None O
by None None O
low None None O
concentrations None None O
of None None O
MgApp None None I-ABBREVIATION
[ None None I-ABBREVIATION
NH None None I-ABBREVIATION
] None None I-ABBREVIATION
p None None I-ABBREVIATION
and None None O
MgATP None None I-ABBREVIATION
was None None O
weaker None None O
above None None O
0.1 None None O
mM None None O
, None None O
while None None O
MgGDP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
and None None O
magnesium None None I-IUPAC
guanosine None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
triphosphate None None I-IUPAC
( None None O
MgGTP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
) None None O
inhibited None None O
in None None O
a None None O
single None None O
phase None None O
. None None O

Inhibition None None O
by None None O
MgApp None None I-ABBREVIATION
[ None None I-ABBREVIATION
NH None None I-ABBREVIATION
] None None I-ABBREVIATION
p None None I-ABBREVIATION
, None None O
at None None O
all None None O
concentrations None None O
, None None O
was None None O
competitive None None O
with None None O
the None None O
substrate None None O
( None None O
MgGTP None None I-ABBREVIATION
) None None O
, None None O
as None None O
was None None O
that None None O
by None None O
MgGDP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
and None None O
MgGTP None None I-ABBREVIATION
[ None None I-ABBREVIATION
S None None I-ABBREVIATION
] None None I-ABBREVIATION
. None None O

Whereas None None O
membrane None None O
guanylate None None O
cyclases None None O
usually None None O
show None None O
positively None None O
co None None O
- None None O
operative None None O
kinetics None None O
with None None O
respect None None O
to None None O
the None None O
substrate None None O
, None None O
STa None None O
- None None O
stimulated None None O
activity None None O
exhibited None None O
Michaelis None None O
- None None O
Menten None None O
kinetics None None O
with None None O
respect None None O
to None None O
MgGTP None None I-ABBREVIATION
. None None O

This None None O
changed None None O
to None None O
positive None None O
co None None O
- None None O
operativity None None O
when None None O
Lubrol None None I-TRIVIAL
PX None None I-TRIVIAL
was None None O
the None None O
activator None None O
, None None O
or None None O
when None None O
the None None O
substrate None None O
was None None O
MnGTP None None I-ABBREVIATION
. None None O

These None None O
results None None O
suggest None None O
the None None O
presence None None O
of None None O
both None None O
a None None O
regulatory None None O
and None None O
a None None O
catalytic None None O
nucleotide None None O
- None None O
binding None None O
site None None O
, None None O
which None None O
do None None O
not None None O
interact None None O
co None None O
- None None O
operatively None None O
with None None O
STa None None O
activation None None O
. None None O


The None None O
syntheses None None O
of None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
4 None None O
) None None O
, None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
5SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
20 None None O
) None None O
, None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
acetamidopiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
10 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
5SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
acetamidopiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
18 None None O
) None None O
, None None O
related None None O
to None None O
the None None O
specific None None O
gamma None None I-IUPAC
- None None I-IUPAC
aminobutyric None None I-IUPAC
acid None None I-IUPAC
( None None O
GABA None None I-ABBREVIATION
) None None O
uptake None None O
inhibitors None None O
( None None I-IUPAC
RS None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
nipecotic None None I-IUPAC
acid None None I-IUPAC
) None None O
and None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
21 None None O
) None None O
, None None O
are None None O
described None None O
. None None O

Furthermore None None O
, None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
related None None O
to None None O
the None None O
specific None None O
GABA None None I-ABBREVIATION
agonist None None O
piperidine None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
isonipecotic None None I-IUPAC
acid None None I-IUPAC
) None None O
, None None O
has None None O
been None None O
synthesized None None O
. None None O

The None None O
structures None None O
of None None O
4 None None O
, None None O
10 None None O
, None None O
14 None None O
, None None O
18 None None O
, None None O
and None None O
20 None None O
have None None O
been None None O
established None None O
by None None O
270 None None O
- None None O
MHz None None O
1H None None O
NMR None None O
spectroscopic None None O
analyses None None O
. None None O

The None None O
affinity None None O
of None None O
the None None O
compounds None None O
for None None O
the None None O
GABA None None O
receptors None None O
and None None O
for None None O
the None None O
neuronal None None O
( None None O
synaptosomal None None O
) None None O
GABA None None I-ABBREVIATION
uptake None None O
system None None O
in None None O
vitro None None O
has None None O
been None None O
measured None None O
. None None O

Compound None None O
14 None None O
interacts None None O
selectively None None O
with None None O
the None None O
GABA None None O
receptors None None O
but None None O
less None None O
effectively None None O
than None None O
isonipecotic None None I-IUPAC
acid None None I-IUPAC
and None None O
the None None O
cis None None O
- None None O
isomer None None O
22 None None O
. None None O

Compounds None None O
4 None None O
, None None O
18 None None O
, None None O
and None None O
20 None None O
are None None O
inhibitors None None O
of None None O
the None None O
GABA None None I-ABBREVIATION
uptake None None O
system None None O
, None None O
although None None O
much None None O
weaker None None O
than None None O
nipecotic None None I-IUPAC
acid None None I-IUPAC
and None None O
( None None I-IUPAC
3RS None None I-IUPAC
, None None I-IUPAC
4SR None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxypiperidine None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylic None None I-IUPAC
acid None None I-IUPAC
( None None O
21 None None O
) None None O
. None None O

Compound None None O
10 None None O
is None None O
inactive None None O
in None None O
both None None O
test None None O
systems None None O
. None None O


Novel None None O
genetic None None O
variations None None O
and None None O
haplotypes None None O
of None None O
hepatocyte None None O
nuclear None None O
factor None None O
4alpha None None O
( None None O
HNF4A None None O
) None None O
found None None O
in None None O
Japanese None None O
type None None O
II None None O
diabetic None None O
patients None None O
. None None O

Thirty None None O
- None None O
nine None None O
single None None O
nucleotide None None O
variations None None O
, None None O
including None None O
16 None None O
novel None None O
ones None None O
, None None O
were None None O
found None None O
in None None O
the None None O
5' None None O
promoter None None O
region None None O
, None None O
all None None O
of None None O
the None None O
exons None None O
and None None O
their None None O
surrounding None None O
introns None None O
of None None O
HNF4A None None O
in None None O
74 None None O
Japanese None None O
type None None O
II None None O
diabetic None None O
patients None None O
. None None O

The None None O
following None None O
novel None None O
variations None None O
were None None O
identified None None O
( None None O
based None None O
on None None O
the None None O
amino None None O
acid None None O
numbering None None O
of None None O
splicing None None O
variant None None O
2 None None O
) None None O
: None None O
- None None O
208G None None O
> None None O
C None None O
in None None O
the None None O
5' None None O
promoter None None O
region None None O
; None None O
1154C None None O
> None None O
T None None O
( None None O
A385V None None O
) None None O
and None None O
1193T None None O
> None None O
C None None O
( None None O
M398T None None O
) None None O
in None None O
the None None O
coding None None O
exons None None O
; None None O
1580G None None O
> None None O
A None None O
, None None O
1852G None None O
> None None O
T None None O
, None None O
2180C None None O
> None None O
T None None O
, None None O
2190G None None O
> None None O
A None None O
, None None O
and None None O
2362 None None O
_2380 None None O
delAAGAATGGTGTGGGAGAGG None None O
in None None O
the None None O
3' None None O
- None None O
untranslated None None O
region None None O
, None None O
and None None O
IVS1+ None None O
231G None None O
> None None O
A None None O
, None None O
IVS2 None None O
- None None O
83C None None O
> None None O
T None None O
, None None O
IVS3+ None None O
50C None None O
> None None O
T None None O
, None None O
IVS3 None None O
- None None O
54delC None None O
, None None O
IVS5+ None None O
173 None None O
_176 None None O
delTTAG None None O
, None None O
IVS5 None None O
- None None O
181 None None O
_ None None O
- None None O
180delAT None None O
, None None O
IVS8 None None O
- None None O
106A None None O
> None None O
G None None O
, None None O
and None None O
IVS9 None None O
- None None O
151A None None O
> None None O
C None None O
in None None O
the None None O
introns None None O
. None None O

The None None O
allele None None O
frequencies None None O
were None None O
0.311 None None O
for None None O
2362 None None O
_2380 None None O
delAAGAATGGTGTGGGAGAGG None None O
, None None O
0.054 None None O
for None None O
1580G None None O
> None None O
A None None O
, None None O
0.047 None None O
for None None O
1852G None None O
> None None O
T None None O
, None None O
0.020 None None O
for None None O
IVS1+ None None O
231G None None O
> None None O
A None None O
, None None O
0.014 None None O
for None None O
IVS9 None None O
- None None O
151A None None O
> None None O
C None None O
, None None O
and None None O
0.007 None None O
for None None O
the None None O
other None None O
11 None None O
variations None None O
. None None O

In None None O
addition None None O
, None None O
one None None O
known None None O
nonsynonymous None None O
single None None O
nucleotide None None O
polymorphism None None O
, None None O
416C None None O
> None None O
T None None O
( None None O
T139I None None O
) None None O
, None None O
was None None O
detected None None O
at None None O
a None None O
0.007 None None O
frequency None None O
. None None O

Based None None O
on None None O
the None None O
linkage None None O
disequilibrium None None O
profiles None None O
, None None O
the None None O
region None None O
analyzed None None O
was None None O
divided None None O
into None None O
three None None O
blocks None None O
. None None O

Haplotype None None O
analysis None None O
determined None None O
/ None None O
inferred None None O
10 None None O
, None None O
16 None None O
, None None O
and None None O
12 None None O
haplotypes None None O
for None None O
block None None O
1 None None O
, None None O
2 None None O
, None None O
and None None O
3 None None O
, None None O
respectively None None O
. None None O

Our None None O
results None None O
on None None O
HNF4A None None O
variations None None O
and None None O
haplotypes None None O
would None None O
be None None O
useful None None O
for None None O
pharmacogenetic None None O
studies None None O
in None None O
Japanese None None O
. None None O


Predictive None None O
clinical None None O
parameters None None O
for None None O
therapeutic None None O
efficacy None None O
of None None O
rosiglitazone None None I-TRIVIAL
in None None O
Korean None None O
type None None O
2 None None O
diabetes None None O
mellitus None None O
. None None O

This None None O
study None None O
evaluated None None O
the None None O
efficacy None None O
of None None O
rosiglitazone None None I-TRIVIAL
in None None O
non None None O
- None None O
obese None None O
and None None O
obese None None O
Korean None None O
type None None O
2 None None O
diabetic None None O
patients None None O
of None None O
long None None O
duration None None O
. None None O

A None None O
total None None O
of None None O
125 None None O
patients None None O
( None None O
M None None O
: None None O
F None None O
= None None O
44 None None O
: None None O
81 None None O
, None None O
mean None None O
age None None O
: None None O
58.4 None None O
+ None None O
/ None None O
- None None O
9.1 None None O
years None None O
, None None O
BMI None None O
: None None O
24.2 None None O
+ None None O
/ None None O
- None None O
2.7 None None O
kg None None O
/ None None O
m2 None None O
, None None O
duration None None O
of None None O
diabetes None None O
: None None O
11.0 None None O
+ None None O
/ None None O
- None None O
6.4 None None O
years None None O
) None None O
were None None O
randomly None None O
allocated None None O
to None None O
12 None None O
weeks None None O
of None None O
rosiglitazone None None I-TRIVIAL
treatment None None O
( None None O
4 None None O
mg None None O
per None None O
day None None O
) None None O
or None None O
a None None O
control None None O
group None None O
. None None O

Responders None None O
were None None O
defined None None O
as None None O
patients None None O
who None None O
experienced None None O
fasting None None O
plasma None None O
glucose None None I-TRIVIAL
( None None O
FPG None None O
) None None O
reduction None None O
of None None O
> None None O
20% None None O
or None None O
HbA1c None None O
reduction None None O
of None None O
> None None O
1 None None O
( None None O
% None None O
) None None O
. None None O

Rosiglitazone None None I-TRIVIAL
significantly None None O
improved None None O
glycemic None None O
control None None O
by None None O
reducing None None O
FPG None None O
and None None O
HbA1c None None O
( None None O
- None None O
3.4 None None O
mmol None None O
/ None None O
l None None O
and None None O
- None None O
1.1% None None O
, None None O
P None None O
< None None O
0.001 None None O
, None None O
respectively None None O
) None None O
. None None O

It None None O
also None None O
significantly None None O
increased None None O
HOMA None None O
( None None O
beta None None O
- None None O
cell None None O
function None None O
) None None O
( None None O
+ None None O
9.7 None None O
, None None O
P None None O
< None None O
0.01 None None O
) None None O
and None None O
QUICKI None None O
( None None O
+ None None O
0.029 None None O
, None None O
P None None O
< None None O
0.001 None None O
) None None O
, None None O
and None None O
decreased None None O
HOMA None None O
( None None O
IR None None O
) None None O
( None None O
- None None O
1.73 None None O
, None None O
P None None O
< None None O
0.001 None None O
) None None O
. None None O

Females None None O
and None None O
those None None O
with None None O
higher None None O
waist None None O
- None None O
hip None None O
ratio None None O
made None None O
up None None O
a None None O
greater None None O
portion None None O
of None None O
rosiglitazone None None O
- None None O
responders None None O
. None None O

Responders None None O
( None None O
45 None None O
patients None None O
, None None O
75% None None O
) None None O
also None None O
showed None None O
significantly None None O
higher None None O
FPG None None O
, None None O
HbA1c None None O
, None None O
systolic None None O
blood None None O
pressures None None O
, None None O
fasting None None O
insulin None None O
levels None None O
and None None O
HOMA None None O
( None None O
IR None None O
) None None O
, None None O
and None None O
lower None None O
QUICKI None None O
than None None O
nonresponders None None O
. None None O

Among None None O
these None None O
parameters None None O
of None None O
responders None None O
, None None O
waist None None O
- None None O
hip None None O
ratio None None O
of None None O
non None None O
- None None O
obese None None O
subgroup None None O
, None None O
initial None None O
glycemic None None O
control None None O
of None None O
obese None None O
subgroup None None O
, None None O
and None None O
systolic None None O
blood None None O
pressure None None O
of None None O
both None None O
subgroups None None O
lost None None O
their None None O
significance None None O
after None None O
subdivision None None O
analysis None None O
. None None O

However None None O
, None None O
the None None O
baseline None None O
HOMA None None O
( None None O
IR None None O
) None None O
and None None O
QUICKI None None O
were None None O
significantly None None O
correlated None None O
with None None O
the None None O
response None None O
rate None None O
to None None O
rosiglitazone None None I-TRIVIAL
. None None O

Moreover None None O
, None None O
in None None O
multiple None None O
logistic None None O
regression None None O
analysis None None O
, None None O
HOMA None None O
( None None O
IR None None O
) None None O
and None None O
QUICKI None None O
retained None None O
their None None O
significance None None O
as None None O
the None None O
independent None None O
predictors None None O
. None None O

Even None None O
in None None O
Korean None None O
type None None O
2 None None O
diabetic None None O
patients None None O
of None None O
long None None O
duration None None O
but None None O
with None None O
relatively None None O
preserved None None O
beta None None O
- None None O
cell None None O
function None None O
, None None O
rosiglitazone None None O
improved None None O
glycemic None None O
control None None O
, None None O
insulin None None O
sensitivity None None O
, None None O
and None None O
beta None None O
- None None O
cell None None O
function None None O
. None None O

In None None O
this None None O
ethnic None None O
group None None O
, None None O
female None None O
gender None None O
, None None O
central None None O
obesity None None O
, None None O
and None None O
especially None None O
severe None None O
insulin None None O
resistance None None O
were None None O
identified None None O
as None None O
predictive None None O
clinical None None O
parameters None None O
of None None O
rosiglitazone None None I-TRIVIAL
- None None O
responders None None O
. None None O


The None None O
synthesis None None O
of None None O
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
10 None None I-IUPAC
- None None I-IUPAC
propargyl None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dideazafolic None None I-IUPAC
acid None None I-IUPAC
and None None O
its None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
desamino None None I-PARTIUPAC
, None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
desamino None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
, None None O
and None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
desamino None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
analogues None None I-MODIFIER
is None None O
described None None O
. None None O

In None None O
general None None O
the None None O
synthetic None None O
route None None O
involved None None O
the None None O
coupling None None O
of None None O
diethyl None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
prop None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
ynylamino None None I-IUPAC
) None None I-IUPAC
benzoyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
with None None O
the None None O
appropriate None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
bromomethyl None None I-IUPAC
) None None I-IUPAC
quinazoline None None I-IUPAC
followed None None O
by None None O
deprotection None None O
with None None O
mild None None O
alkali None None O
. None None O

These None None O
four None None O
compounds None None O
together None None O
with None None O
the None None O
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
desamino None None I-PARTIUPAC
- None None I-PARTIUPAC
2 None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
analogue None None I-MODIFIER
were None None O
tested None None O
for None None O
their None None O
activity None None O
against None None O
L1210 None None O
thymidylate None None O
synthase None None O
( None None O
TS None None O
) None None O
. None None O

They None None O
were None None O
also None None O
examined None None O
for None None O
their None None O
inhibition None None O
of None None O
the None None O
growth None None O
of None None O
the None None O
L1210 None None O
cell None None O
line None None O
and None None O
of None None O
two None None O
mutant None None O
L1210 None None O
cell None None O
lines None None O
, None None O
the None None O
L1210 None None O
: None None O
R7A None None O
that None None O
overproduces None None O
dihydrofolate None None O
reductase None None O
( None None O
DHFR None None O
) None None O
and None None O
the None None O
L1210 None None O
: None None O
1565 None None O
that None None O
has None None O
impaired None None O
uptake None None O
of None None O
reduced None None O
folates None None O
. None None O

Compared None None O
with None None O
their None None O
non None None O
- None None O
fluorinated None None O
parent None None O
compounds None None O
, None None O
the None None O
2' None None I-PARTIUPAC
- None None I-PARTIUPAC
fluoro None None I-PARTIUPAC
analogues None None I-MODIFIER
were None None O
all None None O
approximately None None O
2 None None O
- None None O
fold None None O
more None None O
potent None None O
as None None O
TS None None O
inhibitors None None O
. None None O

Similarly None None O
, None None O
they None None O
also None None O
showed None None O
improved None None O
inhibition None None O
of None None O
L1210 None None O
cell None None O
growth None None O
( None None O
1.5-5 None None O
- None None O
fold None None O
) None None O
, None None O
and None None O
this None None O
activity None None O
was None None O
prevented None None O
by None None O
co None None O
- None None O
incubation None None O
with None None O
thymidine None None O
. None None O

All None None O
had None None O
retained None None O
or None None O
improved None None O
activity None None O
against None None O
both None None O
the None None O
L1210 None None O
: None None O
R7A None None O
and None None O
L1210 None None O
: None None O
1565 None None O
cell None None O
lines None None O
. None None O


A None None O
novel None None O
class None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
acyclic None None I-IUPAC
pyrimidine None None I-IUPAC
nucleosides None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxyethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
9a None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
ethoxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
9b None None O
) None None O
, None None O
and None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
hydroxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
( None None O
9c None None O
) None None O
, None None O
were None None O
synthesized None None O
by None None O
regiospecific None None O
addition None None O
of None None O
bromine None None I-IUPAC
azide None None I-IUPAC
to None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
vinyl None None I-PARTIUPAC
substituent None None I-MODIFIER
of None None O
the None None O
respective None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyluracils None None I-IUPAC
( None None O
2a None None O
- None None O
c None None O
) None None O
followed None None O
by None None O
treatment None None O
of None None O
the None None O
obtained None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azido None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
bromoethyl None None I-IUPAC
) None None I-IUPAC
compounds None None I-MODIFIER
( None None O
3a None None O
- None None O
c None None O
) None None O
with None None O
t None None I-TRIVIAL
- None None I-TRIVIAL
BuOK None None I-TRIVIAL
, None None O
to None None O
affect None None O
the None None O
base None None O
- None None O
catalyzed None None O
elimination None None O
of None None O
HBr None None I-SUM
. None None O

Thermal None None O
decomposition None None O
of None None O
9b None None O
and None None O
9c None None O
at None None O
110 None None O
degrees None None O
C None None O
in None None O
dioxane None None I-TRIVIAL
yielded None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azirinyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
uracil None None I-IUPAC
analogues None None I-MODIFIER
( None None O
10b None None O
, None None O
c None None O
) None None O
. None None O

The None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azidovinyl None None I-IUPAC
) None None I-IUPAC
uracil None None I-IUPAC
derivatives None None I-MODIFIER
9a None None O
- None None O
c None None O
were None None O
found None None O
to None None O
exhibit None None O
potent None None O
and None None O
selective None None O
in None None O
vitro None None O
anti None None O
- None None O
HBV None None O
activity None None O
against None None O
duck None None O
hepatitis None None O
B None None O
virus None None O
( None None O
DHBV None None O
) None None O
infected None None O
primary None None O
duck None None O
hepatocytes None None O
at None None O
low None None O
concentrations None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.01-0.1 None None O
microg None None O
/ None None O
mL None None O
range None None O
) None None O
. None None O

The None None O
most None None O
active None None O
anti None None O
- None None O
DHBV None None O
agent None None O
( None None O
9c None None O
) None None O
, None None O
possessing None None O
a None None O
[ None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
- None None I-PARTIUPAC
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
hydroxymethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
butyl None None I-PARTIUPAC
] None None I-PARTIUPAC
substituent None None I-MODIFIER
at None None O
N None None O
- None None O
1 None None O
, None None O
exhibited None None O
an None None O
activity None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
of None None O
0.01-0.05 None None O
microg None None O
/ None None O
mL None None O
) None None O
comparable None None O
to None None O
that None None O
of None None O
reference None None O
compound None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
, None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
thiacytidine None None I-IUPAC
( None None O
3 None None O
- None None O
TC None None O
) None None O
( None None O
EC None None O
( None None O
50 None None O
) None None O
= None None O
0.01-0.05 None None O
microg None None O
/ None None O
mL None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
related None None O
5 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
azirinyl None None I-IUPAC
) None None I-IUPAC
] None None I-IUPAC
uracil None None I-IUPAC
analogues None None I-MODIFIER
( None None O
10b None None O
, None None O
c None None O
) None None O
were None None O
devoid None None O
of None None O
anti None None O
- None None O
DHBV None None O
activity None None O
, None None O
indicating None None O
that None None O
an None None O
acyclic None None O
side None None O
chain None None O
at None None O
C None None O
- None None O
5 None None O
position None None O
of None None O
the None None O
pyrimidine None None I-FAMILY
ring None None O
is None None O
essential None None O
for None None O
anti None None O
- None None O
HBV None None O
activity None None O
. None None O

The None None O
pyrimidine None None I-FAMILY
nucleosides None None B-MODIFIER
( None None O
9a None None O
- None None O
c None None O
, None None O
10b None None O
, None None O
c None None O
) None None O
exhibited None None O
no None None O
cytotoxic None None O
activity None None O
against None None O
a None None O
panel None None O
of None None O
60 None None O
human None None O
cancer None None O
cell None None O
lines None None O
. None None O

All None None O
of None None O
the None None O
compounds None None O
investigated None None O
did None None O
not None None O
show None None O
any None None O
detectable None None O
toxicity None None O
to None None O
several None None O
stationary None None O
and None None O
proliferating None None O
host None None O
cell None None O
lines None None O
or None None O
to None None O
mitogen None None O
stimulated None None O
proliferating None None O
human None None O
T None None O
lymphocytes None None O
, None None O
up None None O
to None None O
the None None O
highest None None O
concentration None None O
tested None None O
. None None O


Antiestrogens None None O
reduce None None O
plasma None None O
levels None None O
of None None O
endothelin None None O
- None None O
1 None None O
without None None O
affecting None None O
nitrate None None I-IUPAC
levels None None O
in None None O
breast None None O
cancer None None O
patients None None O
. None None O

Tamoxifen None None I-TRIVIAL
protects None None O
against None None O
myocardial None None O
infarction None None O
through None None O
mechanisms None None O
that None None O
are None None O
poorly None None O
understood None None O
. None None O

We None None O
studied None None O
the None None O
effects None None O
of None None O
tamoxifen None None I-TRIVIAL
and None None O
another None None O
antiestrogen None None O
, None None O
toremifene None None I-TRIVIAL
, None None O
on None None O
the None None O
production None None O
of None None O
vasoconstrictive None None O
endothelin None None O
- None None O
1 None None O
and None None O
of None None O
vasodilatory None None O
nitric None None I-IUPAC
oxide None None I-IUPAC
in None None O
44 None None O
postmenopausal None None O
patients None None O
with None None O
breast None None O
cancer None None O
. None None O

These None None O
started None None O
treatment None None O
, None None O
in None None O
randomized None None O
order None None O
, None None O
with None None O
either None None O
tamoxifen None None I-TRIVIAL
( None None O
20 None None O
mg None None O
/ None None O
day None None O
; None None O
n None None O
= None None O
25 None None O
) None None O
or None None O
toremifene None None O
( None None O
40 None None O
mg None None O
/ None None O
day None None O
; None None O
n None None O
= None None O
19 None None O
) None None O
. None None O

Plasma None None O
samples None None O
collected None None O
before None None O
treatment None None O
and None None O
after None None O
6 None None O
and None None O
12 None None O
months None None O
of None None O
both None None O
regimens None None O
were None None O
assayed None None O
for None None O
endothelin None None O
- None None O
1 None None O
with None None O
a None None O
specific None None O
radioimmunoassay None None O
and None None O
for None None O
nitrite None None I-TRIVIAL
/ None None O
nitrate None None I-TRIVIAL
with None None O
a None None O
method None None O
based None None O
on None None O
the None None O
Griess None None O
reaction None None O
. None None O

The None None O
antiestrogen None None O
group None None O
as None None O
a None None O
whole None None O
showed None None O
a None None O
fall None None O
in None None O
endothelin None None O
- None None O
1 None None O
at None None O
6 None None O
months None None O
( None None O
5.9 None None O
+ None None O
/ None None O
- None None O
3.3% None None O
; None None O
p None None O
= None None O
0.06 None None O
) None None O
( None None O
mean None None O
+ None None O
/ None None O
- None None O
SE None None O
) None None O
and None None O
at None None O
12 None None O
months None None O
( None None O
7.1 None None O
+ None None O
/ None None O
- None None O
5.5% None None O
; None None O
p None None O
= None None O
0.03 None None O
) None None O
. None None O

This None None O
fall None None O
was None None O
solely None None O
due None None O
to None None O
toremifene None None I-TRIVIAL
, None None O
the None None O
use None None O
of None None O
which None None O
was None None O
associated None None O
with None None O
falls None None O
in None None O
endothelin None None O
- None None O
1 None None O
at None None O
6 None None O
months None None O
( None None O
12.9 None None O
+ None None O
/ None None O
- None None O
4.7% None None O
; None None O
p None None O
= None None O
0.01 None None O
) None None O
and None None O
12 None None O
months None None O
( None None O
9.2 None None O
+ None None O
/ None None O
- None None O
6.2% None None O
; None None O
p None None O
= None None O
0.06 None None O
) None None O
. None None O

The None None O
antiestrogen None None O
regimen None None O
failed None None O
to None None O
affect None None O
plasma None None O
nitric None None I-IUPAC
oxide None None I-IUPAC
significantly None None O
but None None O
nevertheless None None O
the None None O
ratio None None O
between None None O
nitric None None I-IUPAC
oxide None None I-IUPAC
and None None O
endothelin None None O
- None None O
1 None None O
rose None None O
by None None O
31.6 None None O
+ None None O
/ None None O
- None None O
13.3% None None O
at None None O
6 None None O
months None None O
and None None O
by None None O
35.6 None None O
+ None None O
/ None None O
- None None O
15.3% None None O
at None None O
12 None None O
months None None O
in None None O
the None None O
antiestrogen None None O
users None None O
, None None O
an None None O
effect None None O
similar None None O
in None None O
the None None O
tamoxifen None None I-TRIVIAL
and None None O
toremifene None None I-TRIVIAL
groups None None O
. None None O

We None None O
conclude None None O
that None None O
antiestrogens None None O
may None None O
protect None None O
against None None O
myocardial None None O
infarction None None O
by None None O
preventing None None O
the None None O
release None None O
of None None O
endothelin None None O
- None None O
1 None None O
and None None O
by None None O
shifting None None O
the None None O
balance None None O
between None None O
nitric None None I-IUPAC
oxide None None I-IUPAC
and None None O
endothelin None None O
- None None O
1 None None O
to None None O
the None None O
dominance None None O
of None None O
the None None O
former None None O
. None None O

Our None None O
data None None O
predict None None O
that None None O
toremifene None None I-TRIVIAL
and None None O
tamoxifen None None I-TRIVIAL
at None None O
the None None O
doses None None O
studied None None O
here None None O
will None None O
provide None None O
similar None None O
cardiovascular None None O
protection None None O
. None None O


A None None O
series None None O
of None None O
new None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
and None None O
uridine None None I-TRIVIAL
compounds None None B-MODIFIER
( None None O
11 None None O
, None None O
16 None None O
) None None O
was None None O
synthesized None None O
by None None O
the None None O
regiospecific None None O
addition None None O
of None None O
HOI None None I-SUM
to None None O
the None None O
vinyl None None I-TRIVIAL
substituent None None B-MODIFIER
of None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
10a None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
10b None None O
) None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
vinyluridine None None I-IUPAC
( None None O
10c None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodovinyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
4b None None O
) None None O
. None None O

Treatment None None O
of None None O
the None None O
iodohydrins None None I-FAMILY
11a None None O
- None None O
c None None O
with None None O
methanolic None None I-IUPAC
sulfuric None None I-IUPAC
acid None None I-IUPAC
afforded None None O
the None None O
corresponding None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
derivatives None None I-MODIFIER
( None None O
12a None None O
- None None O
c None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
reaction None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
11a None None O
) None None O
with None None O
sodium None None I-IUPAC
carbonate None None I-IUPAC
in None None O
methanol None None I-TRIVIAL
afforded None None O
a None None O
mixture None None O
of None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methoxyethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
13 None None O
) None None O
and None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
ribofuranosyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
furano None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
d None None I-IUPAC
] None None I-IUPAC
pyrimidin None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
( None None I-IUPAC
5H None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
14 None None O
) None None O
. None None O

The None None O
most None None O
active None None O
compound None None O
, None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
( None None O
12a None None O
, None None O
ID50 None None O
= None None O
0.1 None None O
micrograms None None O
/ None None O
mL None None O
) None None O
, None None O
which None None O
exhibited None None O
antiviral None None O
activity None None O
( None None O
HSV None None O
- None None O
1 None None O
) None None O
100 None None O
- None None O
fold None None O
higher None None O
than None None O
that None None O
of None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
analogue None None I-MODIFIER
( None None O
11a None None O
) None None O
, None None O
was None None O
less None None O
active None None O
than None None O
IVDU None None I-ABBREVIATION
or None None O
acyclovir None None I-TRIVIAL
( None None O
ID50 None None O
= None None O
0.01-0.1 None None O
micrograms None None O
/ None None O
mL None None O
range None None O
) None None O
. None None O

The None None O
C None None I-PARTIUPAC
- None None I-PARTIUPAC
5 None None I-PARTIUPAC
substituent None None I-MODIFIER
in None None O
the None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
series None None I-MODIFIER
was None None O
a None None O
determinant None None O
of None None O
cytotoxic None None O
activity None None O
, None None O
as None None O
determined None None O
in None None O
the None None O
in None None O
vitro None None O
L1210 None None O
screen None None O
, None None O
where None None O
the None None O
relative None None O
activity None None O
order None None O
was None None O
CH None None I-SUM
( None None I-SUM
OH None None I-SUM
) None None I-SUM
CHI2 None None I-SUM
( None None O
16 None None O
) None None O
greater None None O
than None None O
CH None None I-SUM
( None None I-SUM
OMe None None I-SUM
) None None I-SUM
CH2I None None I-SUM
( None None O
12a None None O
) None None O
greater None None O
than None None O
CH None None I-SUM
( None None I-SUM
OH None None I-SUM
) None None I-SUM
CH2I None None I-SUM
( None None O
11a None None O
) None None O
congruent None None O
to None None O
CH None None I-SUM
( None None I-SUM
OH None None I-SUM
) None None I-SUM
CH2OMe None None I-SUM
( None None O
13 None None O
) None None O
. None None O

The None None O
2' None None I-PARTIUPAC
- None None I-PARTIUPAC
substituent None None O
was None None O
also None None O
a None None O
determinant None None O
of None None O
cytotoxic None None O
activity None None O
in None None O
the None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
( None None O
11a None None O
- None None O
c None None O
) None None O
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
iodoethyl None None I-IUPAC
) None None I-IUPAC
series None None I-MODIFIER
of None None O
compounds None None O
, None None O
where None None O
the None None O
relative None None O
activity None None O
profile None None O
was None None O
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
greater None None O
than None None O
2' None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
deoxyuridine None None I-IUPAC
greater None None O
than None None O
uridine None None I-TRIVIAL
( None None O
11a None None O
greater None None O
than None None O
11b None None O
greater None None O
than None None O
or None None O
equal None None O
to None None O
11c None None O
; None None O
12a None None O
greater None None O
than None None O
12b None None O
greater None None O
than None None O
12c None None O
) None None O
. None None O

The None None O
most None None O
active None None O
cytotoxic None None O
agent None None O
( None None O
16 None None O
) None None O
, None None O
possessing None None O
a None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
1 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
- None None I-PARTIUPAC
2,2 None None I-PARTIUPAC
- None None I-PARTIUPAC
diiodoethyl None None I-PARTIUPAC
) None None I-PARTIUPAC
substituent None None I-MODIFIER
( None None O
ED50 None None O
= None None O
0.77 None None O
micrograms None None O
/ None None O
mL None None O
) None None O
, None None O
exhibited None None O
an None None O
activity None None O
approaching None None O
that None None O
of None None O
melphalan None None I-TRIVIAL
( None None O
ED50 None None O
= None None O
0.15 None None O
micrograms None None O
/ None None O
mL None None O
) None None O
. None None O

All None None O
compounds None None O
tested None None O
, None None O
except None None O
for None None O
13 None None O
and None None O
14 None None O
, None None O
exhibited None None O
high None None O
affinity None None O
( None None O
Ki None None O
= None None O
0.035-0.22 None None O
mM None None O
range None None O
relative None None O
to None None O
deoxyuridine None None I-TRIVIAL
, None None O
Ki None None O
= None None O
0.125 None None O
) None None O
for None None O
the None None O
murine None None O
NBMPR None None O
- None None O
sensitive None None O
erythrocyte None None O
nucleoside None None O
transport None None O
system None None O
, None None O
suggesting None None O
that None None O
these None None O
iodohydrins None None I-FAMILY
are None None O
good None None O
permeants None None O
of None None O
cell None None O
membranes None None O
. None None O


N None None O
- None None O
Methylacetazolamide None None O
was None None O
shown None None O
to None None O
be None None O
active None None O
topically None None O
in None None O
reducing None None O
intraocular None None O
pressure None None O
( None None O
IOP None None O
) None None O
to None None O
a None None O
small None None O
but None None O
statistically None None O
significant None None O
level None None O
in None None O
the None None O
normotensive None None O
rabbit None None O
eye None None O
. None None O

In None None O
vivo None None O
experiments None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
methylacetazolamide None None I-IUPAC
suggest None None O
that None None O
ocular None None O
metabolism None None O
to None None O
acetazolamide None None I-TRIVIAL
was None None O
responsible None None O
for None None O
the None None O
observed None None O
topical None None O
activity None None O
. None None O

Examination None None O
of None None O
initial None None O
rate None None O
kinetics None None O
of None None O
carbonic None None O
anhydrase None None O
catalyzed None None O
p None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
acetate None None I-IUPAC
hydrolysis None None O
showed None None O
that None None O
N None None I-IUPAC
- None None I-IUPAC
methylacetazolamide None None I-IUPAC
was None None O
a None None O
competitive None None O
inhibitor None None O
, None None O
in None None O
contrast None None O
to None None O
noncompetitive None None O
inhibition None None O
seen None None O
with None None O
acetazolamide None None I-TRIVIAL
and None None O
other None None O
primary None None O
sulfonamide None None I-TRIVIAL
inhibitors None None O
. None None O

N None None I-PARTIUPAC
- None None I-PARTIUPAC
Substituted None None I-PARTIUPAC
and None None O
unsubstituted None None I-PARTIUPAC
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
chlorobenzene None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
nitrobenzenesulfonamides None None I-IUPAC
were None None O
also None None O
synthesized None None O
, None None O
and None None O
their None None O
biochemical None None O
characteristics None None O
and None None O
in None None O
vivo None None O
ability None None O
to None None O
lower None None O
IOP None None O
when None None O
applied None None O
topically None None O
were None None O
determined None None O
. None None O

The None None O
primary None None O
sulfonamides None None I-FAMILY
were None None O
reversible None None O
noncompetitive None None O
inhibitors None None O
of None None O
carbonic None None O
anhydrase None None O
, None None O
with None None O
no None None O
effect None None O
on None None O
IOP None None O
after None None O
topical None None O
administration None None O
. None None O

4 None None I-PARTIUPAC
- None None I-PARTIUPAC
Nitrobenzene None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
4 None None I-IUPAC
- None None I-IUPAC
chlorobenzenesulfonamides None None I-IUPAC
containing None None O
both None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxy None None I-PARTIUPAC
and None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
substituents None None I-MODIFIER
were None None O
model None None O
irreversible None None O
inhibitors None None O
of None None O
carbonic None None O
anhydrase None None O
and None None O
exhibited None None O
a None None O
trend None None O
toward None None O
topical None None O
activity None None O
in None None O
reducing None None O
IOP None None O
in None None O
normotensive None None O
rabbit None None O
eyes None None O
. None None O

Therefore None None O
, None None O
this None None O
paper None None O
describes None None O
the None None O
synthesis None None O
and None None O
characterization None None O
of None None O
two None None O
types None None O
of None None O
carbonic None None O
anhydrase None None O
inhibitors None None O
; None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
sulfonamides None None I-IUPAC
are None None O
reversible None None O
competitive None None O
inhibitors None None O
of None None O
carbonic None None O
anhydrase None None O
, None None O
while None None O
the None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
sulfonamides None None I-IUPAC
are None None O
irreversible None None O
inhibitors None None O
. None None O


Condensation None None O
of None None O
14 None None I-IUPAC
- None None I-IUPAC
bromodaunorubicin None None I-IUPAC
with None None O
thiols None None I-FAMILY
in None None O
methanol None None I-TRIVIAL
, None None O
in None None O
the None None O
presence None None O
of None None O
potassium None None I-TRIVIAL
carbonate None None I-TRIVIAL
, None None O
resulted None None O
in None None O
the None None O
formation None None O
of None None O
14 None None I-PARTIUPAC
- None None I-PARTIUPAC
thia None None I-PARTIUPAC
analogues None None I-MODIFIER
of None None O
the None None O
antitumor None None O
antibiotic None None O
adriamycin None None I-TRIVIAL
. None None O

However None None O
, None None O
similar None None O
condensation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
iododaunorubicin None None I-IUPAC
with None None O
thiols None None O
invariably None None O
led None None O
to None None O
a None None O
redox None None O
reaction None None O
, None None O
with None None O
the None None O
formation None None O
of None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
daunorubicin None None I-IUPAC
and None None O
disulfides None None I-FAMILY
. None None O

Accordingly None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
bromodaunorubicin None None I-IUPAC
was None None O
used None None O
for None None O
reaction None None O
with None None O
thiols None None I-FAMILY
to None None O
yield None None O
thia None None O
analogues None None O
of None None O
the None None O
clinically None None O
active None None O
but None None O
non None None O
- None None O
DNA None None O
- None None O
binding None None O
adriamycin None None I-TRIVIAL
analogue None None B-MODIFIER
N None None B-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
adriamycin None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
valerate None None I-IUPAC
( None None O
AD None None O
32 None None O
) None None O
. None None O

Reaction None None O
of None None O
14 None None I-IUPAC
- None None I-IUPAC
bromoadunorubicin None None I-IUPAC
with None None O
alpha None None I-IUPAC
, None None I-IUPAC
omega None None I-IUPAC
- None None I-IUPAC
alkanedithiols None None I-IUPAC
gave None None O
bis None None I-TRIVIAL
( None None I-TRIVIAL
thiaadriamycin None None I-TRIVIAL
) None None I-TRIVIAL
analogues None None I-MODIFIER
as None None O
potential None None O
difunctional None None O
intercalating None None O
agents None None O
. None None O

The None None O
aforementioned None None O
products None None O
, None None O
plus None None O
two None None O
related None None O
phenylselena None None I-TRIVIAL
derivatives None None B-MODIFIER
, None None O
were None None O
examined None None O
for None None O
in None None O
vitro None None O
growth None None O
inhibition None None O
, None None O
in None None O
vivo None None O
antitumor None None O
activity None None O
, None None O
and None None O
, None None O
where None None O
appropriate None None O
, None None O
DNA None None O
binding None None O
. None None O

A None None O
number None None O
of None None O
agents None None O
, None None O
most None None O
notably None None O
14 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
carbethoxymethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
thiaadriamycin None None I-IUPAC
and None None O
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoroacetyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
selenaadriamycin None None I-IUPAC
, None None O
were None None O
active None None O
against None None O
murine None None O
L1210 None None O
leukemia None None O
in None None O
vivo None None O
. None None O

Several None None O
of None None O
the None None O
amino None None I-IUPAC
glycoside None None I-IUPAC
unsubstituted None None I-IUPAC
14 None None I-IUPAC
- None None I-IUPAC
thiaadriamycin None None I-IUPAC
analogues None None I-MODIFIER
exhibited None None O
DNA None None O
- None None O
binding None None O
properties None None O
equivalent None None O
to None None O
those None None O
of None None O
adriamycin None None I-TRIVIAL
. None None O


Enalapril None None I-TRIVIAL
in None None O
subantihypertensive None None O
dosage None None O
attenuates None None O
kidney None None O
proliferation None None O
and None None O
functional None None O
recovery None None O
in None None O
normotensive None None O
ablation None None O
nephropathy None None O
of None None O
the None None O
rat None None O
. None None O

Most None None O
studies None None O
on None None O
the None None O
antiproliferative None None O
action None None O
of None None O
angiotensin None None O
converting None None O
enzyme None None O
inhibitors None None O
( None None O
ACEI None None O
) None None O
were None None O
performed None None O
in None None O
a None None O
rat None None O
hypertensive None None O
remnant None None O
kidney None None O
model None None O
with None None O
5/6 None None O
kidney None None O
ablation None None O
which None None O
raised None None O
objections None None O
about None None O
the None None O
antihypertensive None None O
effect None None O
of None None O
ACEI None None O
and None None O
the None None O
influence None None O
of None None O
other None None O
antihypertensive None None O
drugs None None O
administered None None O
to None None O
remnant None None O
kidney None None O
control None None O
rats None None O
. None None O

To None None O
prevent None None O
these None None O
objections None None O
, None None O
a None None O
normotensive None None O
4/6 None None O
remnant None None O
kidney None None O
model None None O
was None None O
elaborated None None O
and None None O
a None None O
subantihypertensive None None O
dosage None None O
of None None O
enalapril None None I-TRIVIAL
was None None O
used None None O
to None None O
evaluate None None O
its None None O
antiproliferative None None O
action None None O
. None None O

Subtotally None None O
nephrectomized None None O
rats None None O
( None None O
Nx None None O
) None None O
markedly None None O
increased None None O
the None None O
remnant None None O
kidney None None O
weight None None O
during None None O
a None None O
4 None None O
- None None O
week None None O
period None None O
and None None O
this None None O
rise None None O
was None None O
prevented None None O
by None None O
the None None O
treatment None None O
with None None O
enalapril None None I-TRIVIAL
( None None O
NxE None None O
) None None O
( None None O
Nx None None O
+ None None O
297 None None O
+ None None O
/ None None O
- None None O
35 None None O
mg None None O
vs. None None O
sham None None O
- None None O
operated None None O
+ None None O
145 None None O
+ None None O
/ None None O
- None None O
32 None None O
mg None None O
, None None O
p None None O
< None None O
0.001 None None O
; None None O
NxE None None O
+ None None O
154 None None O
+ None None O
/ None None O
- None None O
35 None None O
mg None None O
vs. None None O
Nx None None O
p None None O
< None None O
0.001 None None O
) None None O
. None None O

While None None O
collagen None None O
concentration None None O
in None None O
the None None O
kidney None None O
cortex None None O
was None None O
not None None O
increased None None O
in None None O
sham None None O
- None None O
operated None None O
rats None None O
( None None O
Sham None None O
) None None O
in None None O
comparison None None O
with None None O
the None None O
control None None O
group None None O
( None None O
Ctrl None None O
) None None O
at None None O
the None None O
beginning None None O
of None None O
the None None O
study None None O
, None None O
the None None O
subsequent None None O
increase None None O
was None None O
significant None None O
in None None O
the None None O
Nx None None O
group None None O
and None None O
enalapril None None I-TRIVIAL
did None None O
not None None O
attenuate None None O
this None None O
increase None None O
( None None O
Sham None None O
148 None None O
+ None None O
/ None None O
- None None O
5 None None O
mg None None O
/ None None O
100 None None O
g None None O
w None None O
. None None O

w None None O
. None None O

vs. None None O
Nx None None O
164 None None O
+ None None O
/ None None O
- None None O
2 None None O
mg None None O
/ None None O
100 None None O
g None None O
w None None O
. None None O

w None None O
. None None O

, None None O
p None None O
< None None O
0.01 None None O
; None None O
NxE None None O
161 None None O
+ None None O
/ None None O
- None None O
4 None None O
mg None None O
/ None None O
100 None None O
g None None O
w None None O
. None None O

w None None O
. None None O

vs. None None O
Sham None None O
p None None O
< None None O
0.05 None None O
) None None O
. None None O

The None None O
tubular None None O
protein None None O
/ None None O
DNA None None O
ratio None None O
increase None None O
, None None O
which None None O
was None None O
significant None None O
in None None O
the None None O
Nx None None O
group None None O
, None None O
was None None O
inhibited None None O
by None None O
enalapril None None I-TRIVIAL
( None None O
Nx None None O
26.2 None None O
+ None None O
/ None None O
- None None O
10.5 None None O
vs. None None O
NxE None None O
15.3 None None O
+ None None O
/ None None O
- None None O
2.6 None None O
, None None O
p None None O
< None None O
0.05 None None O
) None None O
. None None O

The None None O
protein None None O
/ None None O
DNA None None O
ratio None None O
was None None O
much None None O
lower None None O
in None None O
glomeruli None None O
, None None O
with None None O
no None None O
significant None None O
changes None None O
in None None O
either None None O
the None None O
Nx None None O
or None None O
NxE None None O
groups None None O
. None None O

Serum None None O
urea None None I-TRIVIAL
concentrations None None O
were None None O
slightly None None O
higher None None O
in None None O
the None None O
Nx None None O
group None None O
than None None O
in None None O
the None None O
sham None None O
- None None O
operated None None O
group None None O
, None None O
but None None O
markedly None None O
elevated None None O
in None None O
the None None O
NxE None None O
group None None O
( None None O
Nx None None O
10.71 None None O
+ None None O
/ None None O
- None None O
0.76 None None O
mmol None None O
/ None None O
l None None O
vs. None None O
Sham None None O
6.10 None None O
+ None None O
/ None None O
- None None O
0.33 None None O
mmol None None O
/ None None O
l None None O
, None None O
p None None O
< None None O
0.001 None None O
; None None O
NxE None None O
28.9 None None O
+ None None O
/ None None O
- None None O
2.6 None None O
mmol None None O
/ None None O
l None None O
vs. None None O
Sham None None O
p None None O
< None None O
0.001 None None O
) None None O
. None None O

Creatinine None None I-TRIVIAL
concentrations None None O
in None None O
the None None O
Nx None None O
group None None O
were None None O
increased None None O
in None None O
comparison None None O
with None None O
the None None O
sham None None O
- None None O
operated None None O
group None None O
and None None O
markedly None None O
increased None None O
in None None O
the None None O
NxE None None O
group None None O
( None None O
Nx None None O
63.7 None None O
+ None None O
/ None None O
- None None O
3.56 None None O
micromol None None O
/ None None O
l None None O
vs. None None O
Sham None None O
37.2 None None O
+ None None O
/ None None O
- None None O
2.84 None None O
micromol None None O
/ None None O
l None None O
, None None O
p None None O
< None None O
0.001 None None O
; None None O
NxE None None O
107.0 None None O
+ None None O
/ None None O
- None None O
5.2 None None O
micromol None None O
/ None None O
l None None O
vs. None None O
Sham None None O
p None None O
< None None O
0.001 None None O
) None None O
. None None O

The None None O
clearance None None O
of None None O
creatinine None None I-TRIVIAL
was None None O
lower None None O
in None None O
the None None O
Nx None None O
group None None O
than None None O
in None None O
the None None O
sham None None O
- None None O
operated None None O
group None None O
and None None O
was None None O
markedly None None O
reduced None None O
in None None O
the None None O
NxE None None O
group None None O
( None None O
Nx None None O
0.89 None None O
+ None None O
/ None None O
- None None O
0.06 None None O
ml None None O
/ None None O
min None None O
. None None O

g None None O
kidney None None O
wt None None O
. None None O

vs. None None O
Sham None None O
1.05 None None O
+ None None O
/ None None O
- None None O
0.16 None None O
ml None None O
/ None None O
min None None O
x None None O
g None None O
kidney None None O
wt None None O
. None None O

, None None O
p None None O
< None None O
0.01 None None O
; None None O
NxE None None O
0.58 None None O
+ None None O
/ None None O
- None None O
0.029 None None O
ml None None O
/ None None O
min None None O
x None None O
g None None O
kidney None None O
wt None None O
. None None O

vs. None None O
Sham None None O
, None None O
p None None O
< None None O
0.001 None None O
) None None O
. None None O

Enalapril None None I-TRIVIAL
improved None None O
proteinuria None None O
in None None O
comparison None None O
with None None O
the None None O
Nx None None O
group None None O
( None None O
NxE None None O
5.6 None None O
+ None None O
/ None None O
- None None O
0.6 None None O
mg None None O
/ None None O
24 None None O
h None None O
vs. None None O
Nx None None O
16.1 None None O
+ None None O
/ None None O
- None None O
3.4 None None O
mg None None O
/ None None O
24 None None O
h None None O
, None None O
p None None O
< None None O
0.05 None None O
) None None O
. None None O

Thus None None O
remnant None None O
kidney None None O
proliferation None None O
is None None O
substantial None None O
even None None O
in None None O
normotensive None None O
rats None None O
. None None O

It None None O
includes None None O
both None None O
proliferation None None O
and None None O
collagen None None O
accumulation None None O
with None None O
partial None None O
recovery None None O
of None None O
kidney None None O
weight None None O
and None None O
function None None O
, None None O
but None None O
is None None O
accompanied None None O
by None None O
enhanced None None O
proteinuria None None O
. None None O

Enalapril None None I-TRIVIAL
attenuates None None O
the None None O
proliferation None None O
and None None O
decreases None None O
proteinuria None None O
but None None O
prolongs None None O
kidney None None O
function None None O
recovery None None O
. None None O


Replacing None None O
dietary None None O
palmitic None None I-IUPAC
acid None None I-IUPAC
with None None O
elaidic None None I-IUPAC
acid None None I-IUPAC
( None None O
t None None O
- None None O
C18 None None O
: None None O
1 None None O
delta9 None None O
) None None O
depresses None None O
HDL None None O
and None None O
increases None None O
CETP None None O
activity None None O
in None None O
cebus None None O
monkeys None None O
. None None O

The None None O
question None None O
whether None None O
dietary None None O
trans None None O
fatty None None O
acids None None O
affect None None O
lipoprotein None None O
metabolism None None O
similarly None None O
to None None O
specific None None O
saturated None None I-FAMILY
fatty None None I-FAMILY
acids None None I-FAMILY
was None None O
investigated None None O
in None None O
11 None None O
normolipemic None None O
cebus None None O
monkeys None None O
by None None O
exchanging None None O
5% None None O
dietary None None O
energy None None O
( None None O
% None None O
en None None O
) None None O
between None None O
elaidic None None I-PARTIUPAC
( None None O
t None None O
- None None O
C18 None None O
: None None O
1 None None O
delta9 None None O
) None None O
and None None O
palmitic None None I-IUPAC
acid None None I-IUPAC
( None None O
16 None None O
: None None O
0 None None O
) None None O
in None None O
two None None O
test None None O
diets None None O
( None None O
30% None None O
en None None O
fat None None O
+ None None O
100 None None O
mg None None O
cholesterol None None I-TRIVIAL
/ None None O
1000 None None O
kcal None None O
diet None None O
) None None O
conforming None None O
to None None O
the None None O
American None None O
Heart None None O
Association None None O
( None None O
AHA None None O
) None None O
Step None None O
1 None None O
guidelines None None O
. None None O

These None None O
were None None O
compared None None O
with None None O
a None None O
normal None None O
control None None O
diet None None O
rich None None O
in None None O
saturated None None O
fat None None O
and None None O
cholesterol None None I-TRIVIAL
( None None O
38% None None O
en None None O
fat None None O
+ None None O
180 None None O
mg None None O
cholesterol None None I-TRIVIAL
/ None None O
1000 None None O
kcal None None O
diet None None O
) None None O
. None None O

The None None O
control None None O
diet None None O
was None None O
fed None None O
initially None None O
for None None O
14 None None O
wk None None O
, None None O
followed None None O
by None None O
each None None O
of None None O
the None None O
the None None O
two None None O
test None None O
diets None None O
in None None O
a None None O
crossover None None O
design None None O
. None None O

Plasma None None O
lipid None None I-FAMILY
concentrations None None O
were None None O
determined None None O
four None None O
times None None O
between None None O
the None None O
6th None None O
and None None O
14th None None O
wk None None O
. None None O

Turnover None None O
studies None None O
( None None O
using None None O
125I None None O
- None None O
HDL None None O
and None None O
131I None None O
- None None O
LDL None None O
) None None O
were None None O
conducted None None O
after None None O
9 None None O
wk None None O
in None None O
each None None O
dietary None None O
period None None O
. None None O

Relative None None O
to None None O
the None None O
control None None O
diet None None O
, None None O
both None None O
test None None O
diets None None O
significantly None None O
reduced None None O
plasma None None O
total None None O
cholesterol None None I-TRIVIAL
( None None O
TC None None O
) None None O
, None None O
HDL None None O
cholesterol None None I-TRIVIAL
( None None O
HDL None None O
- None None O
C None None O
) None None O
and None None O
VLDL None None O
plus None None O
LDL None None O
cholesterol None None I-TRIVIAL
( None None O
LDL None None O
- None None O
C None None O
) None None O
concentrations None None O
; None None O
triglyceride None None I-FAMILY
( None None O
TG None None I-ABBREVIATION
) None None O
concentrations None None O
tended None None O
to None None O
be None None O
lower None None O
. None None O

However None None O
, None None O
the None None O
trans None None O
diet None None O
resulted None None O
in None None O
a None None O
significantly None None O
greater None None O
reduction None None O
in None None O
HDL None None O
- None None O
C None None O
than None None O
the None None O
palmitate None None O
diet None None O
( None None O
124 None None O
+ None None O
/ None None O
- None None O
17 None None O
, None None O
117 None None O
+ None None O
/ None None O
- None None O
18 None None O
and None None O
106 None None O
+ None None O
/ None None O
- None None O
13 None None O
mg None None O
/ None None O
dL None None O
for None None O
the None None O
control None None O
, None None O
palmitate None None O
and None None O
trans None None O
diets None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
palmitate None None I-TRIVIAL
diet None None O
significantly None None O
decreased None None O
the None None O
TC None None O
/ None None O
HDL None None O
- None None O
C None None O
ratio None None O
by None None O
11% None None O
when None None O
compared None None O
with None None O
the None None O
control None None O
diet None None O
( None None O
1.68 None None O
+ None None O
/ None None O
- None None O
0.17 None None O
vs. None None O
1.89 None None O
+ None None O
/ None None O
- None None O
0.30 None None O
) None None O
, None None O
whereas None None O
the None None O
trans None None O
diet None None O
had None None O
no None None O
effect None None O
( None None O
1.81 None None O
+ None None O
/ None None O
- None None O
0.20 None None O
vs. None None O
1.89 None None O
+ None None O
/ None None O
- None None O
0.30 None None O
) None None O
. None None O

Kinetic None None O
studies None None O
revealed None None O
that None None O
, None None O
relative None None O
to None None O
the None None O
control None None O
diet None None O
, None None O
both None None O
test None None O
diets None None O
significantly None None O
lowered None None O
the None None O
LDL None None O
apolipoprotein None None O
B None None O
( None None O
apoB None None O
) None None O
pool None None O
size None None O
, None None O
principally None None O
reflecting None None O
an None None O
increase None None O
in None None O
the None None O
LDL None None O
apoB None None O
fractional None None O
catabolic None None O
rate None None O
( None None O
FCR None None O
) None None O
related None None O
to None None O
the None None O
reduced None None O
cholesterol None None O
intake None None O
. None None O

Between None None O
the None None O
two None None O
test None None O
diets None None O
, None None O
no None None O
significant None None O
differences None None O
in None None O
LDL None None O
kinetic None None O
parameters None None O
were None None O
observed None None O
. None None O

Both None None O
test None None O
diets None None O
significantly None None O
decreased None None O
HDL None None O
apoA1 None None O
concentrations None None O
in None None O
comparison None None O
with None None O
the None None O
control None None O
diet None None O
, None None O
which None None O
was None None O
partly None None O
explained None None O
by None None O
an None None O
increase None None O
in None None O
the None None O
fractional None None O
catabolic None None O
rate None None O
of None None O
HDL None None O
. None None O

Of None None O
the None None O
two None None O
test None None O
diets None None O
, None None O
the None None O
trans None None O
diet None None O
was None None O
associated None None O
with None None O
a None None O
9.5% None None O
greater None None O
HDL None None O
FCR None None O
than None None O
the None None O
palmitate None None I-TRIVIAL
diet None None O
( None None O
P None None O
< None None O
0.08 None None O
) None None O
and None None O
a None None O
significant None None O
increase None None O
in None None O
plasma None None O
cholesteryl None None O
ester None None O
transfer None None O
protein None None O
( None None O
CETP None None O
) None None O
activity None None O
( None None O
% None None O
transfer None None O
114 None None O
+ None None O
/ None None O
- None None O
7 None None O
vs. None None O
91 None None O
+ None None O
/ None None O
- None None O
7 None None O
; None None O
P None None O
< None None O
0.03 None None O
) None None O
. None None O

Thus None None O
, None None O
palmitic None None I-IUPAC
acid None None I-IUPAC
- None None O
and None None O
elaidic None None I-IUPAC
acid None None I-IUPAC
- None None O
rich None None O
diets None None O
produced None None O
identical None None O
effects None None O
on None None O
LDL None None O
metabolism None None O
in None None O
normocholesterolemic None None O
cebus None None O
monkeys None None O
fed None None O
diets None None O
with None None O
low None None O
levels None None O
of None None O
cholesterol None None I-TRIVIAL
, None None O
whereas None None O
elaidic None None I-IUPAC
acid None None I-IUPAC
depressed None None O
HDL None None O
- None None O
C None None O
, None None O
attributable None None O
to None None O
both None None O
increased None None O
CETP None None O
activity None None O
and None None O
HDL None None O
clearance None None O
. None None O


Radiolabeled None None O
m None None I-IUPAC
- None None I-IUPAC
iodobenzylguanidine None None I-IUPAC
( None None O
MIBG None None I-ABBREVIATION
) None None O
is None None O
a None None O
tumor None None O
- None None O
seeking None None O
radioactive None None O
drug None None O
used None None O
in None None O
the None None O
diagnosis None None O
and None None O
treatment None None O
of None None O
pheochromocytomas None None O
and None None O
neuroblastomas None None O
. None None O

It None None O
is None None O
transported None None O
into None None O
the None None O
tumor None None O
cells None None O
by None None O
the None None O
neuronal None None O
norepinephrine None None I-TRIVIAL
( None None O
NE None None I-ABBREVIATION
) None None O
transporter None None O
( None None O
NET None None O
) None None O
which None None O
is None None O
expressed None None O
in None None O
almost None None O
all None None O
neuroblastoma None None O
cells None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
the None None O
synthesis None None O
and None None O
some None None O
pharmacological None None O
properties None None O
of None None O
a None None O
series None None O
of None None O
fluorescent None None O
compounds None None O
structurally None None O
related None None O
to None None O
the None None O
NET None None O
substrate None None O
, None None O
MIBG None None I-ABBREVIATION
, None None O
or None None O
to None None O
the None None O
NET None None O
inhibitors None None O
, None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2R None None I-IUPAC
, None None I-IUPAC
3S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
cocaine None None I-IUPAC
and None None O
nisoxetine None None I-TRIVIAL
. None None O

Three None None O
of None None O
10 None None O
synthesized None None O
fluorescent None None O
compounds None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthylmethyl None None I-IUPAC
) None None I-IUPAC
guanidinium None None I-IUPAC
sulfate None None I-IUPAC
( None None O
1 None None O
) None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dibenz None None I-IUPAC
[ None None I-IUPAC
b None None I-IUPAC
, None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
azepin None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
guanidinium None None I-IUPAC
sulfate None None I-IUPAC
( None None O
2 None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
2R None None I-IUPAC
, None None I-IUPAC
3S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2beta None None I-IUPAC
- None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
3beta None None I-IUPAC
- None None I-IUPAC
tropanyl None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
naphthalene None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
sulfonate None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
exhibited None None O
high None None O
affinity None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
about None None O
50 None None O
nM None None O
) None None O
for None None O
the None None O
NET None None O
. None None O

The None None O
nisoxetine None None I-TRIVIAL
derivatives None None B-MODIFIER
8 None None O
( None None O
rac None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
naphthale None None I-IUPAC
nesulfonamide None None I-IUPAC
) None None O
and None None O
9 None None O
( None None O
rac None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
methylamino None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
) None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
nitro None None I-IUPAC
- None None I-IUPAC
2,1 None None I-IUPAC
, None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzoxadiazole None None I-IUPAC
) None None O
and None None O
especially None None O
the None None O
guanidine None None I-TRIVIAL
derivative None None B-MODIFIER
4 None None O
( None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
phenyl None None I-IUPAC
- None None I-IUPAC
1,3 None None I-IUPAC
- None None I-IUPAC
butadienyl None None I-IUPAC
) None None I-IUPAC
benzyl None None I-IUPAC
] None None I-IUPAC
guanidinium None None I-IUPAC
sulfate None None I-IUPAC
) None None O
which None None O
are None None O
characterized None None O
by None None O
intermediate None None O
affinity None None O
for None None O
the None None O
NET None None O
( None None O
IC None None O
( None None O
50 None None O
) None None O
370-850 None None O
nM None None O
) None None O
caused None None O
significant None None O
and None None O
nisoxetine None None I-TRIVIAL
- None None O
sensitive None None O
cell None None O
fluorescence None None O
. None None O

At None None O
least None None O
the None None O
guanidine None None I-TRIVIAL
derivative None None B-MODIFIER
4 None None O
might None None O
represent None None O
a None None O
potentially None None O
useful None None O
agent None None O
for None None O
imaging None None O
of None None O
neuroblastoma None None O
cells None None O
. None None O


Influence None None O
of None None O
estrogens None None I-FAMILY
on None None O
the None None O
androgen None None I-FAMILY
metabolism None None O
in None None O
different None None O
subunits None None O
of None None O
human None None O
hair None None O
follicles None None O
. None None O

The None None O
molecular None None O
pathways None None O
involved None None O
in None None O
estrogen None None I-FAMILY
- None None O
mediated None None O
induction None None O
of None None O
hair None None O
growth None None O
in None None O
androgenetic None None O
alopecia None None O
are None None O
unknown None None O
. None None O

Some None None O
authors None None O
found None None O
that None None O
estradiol None None I-TRIVIAL
( None None O
E None None I-ABBREVIATION
) None None O
inhibited None None O
5alpha None None O
- None None O
reductase None None O
( None None O
5alpha None None O
- None None O
R None None O
) None None O
activity None None O
and None None O
therefore None None O
we None None O
addressed None None O
the None None O
question None None O
whether None None O
17alpha None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
17beta None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
are None None O
able None None O
to None None O
modulate None None O
the None None O
activity None None O
of None None O
5alpha None None O
- None None O
R None None O
, None None O
3beta None None O
- None None O
hydroxysteroid None None O
dehydrogenase None None O
( None None O
3beta None None O
- None None O
HSD None None O
) None None O
or None None O
17beta None None O
- None None O
hydroxysteroid None None O
dehydrogenase None None O
( None None O
17beta None None O
- None None O
HSD None None O
) None None O
in None None O
isolated None None O
compartments None None O
of None None O
human None None O
hair None None O
follicles None None O
. None None O

For None None O
this None None O
purpose None None O
, None None O
scalp None None O
biopsies None None O
from None None O
volunteers None None O
were None None O
taken None None O
and None None O
from None None O
each None None O
biopsy None None O
root None None O
sheaths None None O
, None None O
connective None None O
tissue None None O
sheaths None None O
and None None O
dermal None None O
papillae None None O
( None None O
DP None None O
) None None O
were None None O
dissected None None O
and None None O
incubated None None O
in None None O
the None None O
presence None None O
of None None O
3H None None I-IUPAC
- None None I-IUPAC
testosterone None None I-IUPAC
( None None O
T None None I-ABBREVIATION
) None None O
and None None O
, None None O
in None None O
addition None None O
, None None O
either None None O
17alpha None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
, None None O
17beta None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
, None None O
progesterone None None I-TRIVIAL
or None None O
finasteride None None I-TRIVIAL
for None None O
up None None O
to None None O
48 None None O
hrs None None O
. None None O

Thereafter None None O
high None None O
- None None O
performance None None O
liquid None None O
chromatography None None O
analysis None None O
of None None O
culture None None O
supernatants None None O
was None None O
performed None None O
to None None O
detect None None O
T None None O
- None None O
metabolites None None O
. None None O

At None None O
the None None O
tested None None O
concentrations None None O
, None None O
finasteride None None I-TRIVIAL
was None None O
found None None O
to None None O
be None None O
a None None O
major None None O
inhibitor None None O
of None None O
dihydrotestosterone None None I-TRIVIAL
( None None O
DHT None None I-ABBREVIATION
) None None O
formation None None O
. None None O

Even None None O
1 None None O
nM None None O
finasteride None None I-TRIVIAL
inhibited None None O
DHT None None I-ABBREVIATION
synthesis None None O
in None None O
DP None None O
by None None O
86% None None O
and None None O
1 None None O
nM None None O
progesterone None None O
by None None O
75% None None O
. None None O

Estrogens None None I-FAMILY
were None None O
less None None O
able None None O
to None None O
inhibit None None O
the None None O
synthesis None None O
of None None O
DHT None None I-ABBREVIATION
in None None O
DP None None O
( None None O
e.g. None None O
100 None None O
nM None None O
17alpha None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
: None None O
20% None None O
; None None O
100 None None O
nM None None O
17beta None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
: None None O
60% None None O
) None None O
. None None O

Whether None None O
E None None I-ABBREVIATION
directly None None O
inhibits None None O
5alpha None None O
- None None O
R None None O
in None None O
DP None None O
's None None O
or None None O
whether None None O
the None None O
effect None None O
of None None O
estrogens None None I-FAMILY
might None None O
be None None O
explained None None O
by None None O
an None None O
increased None None O
conversion None None O
of None None O
T None None I-ABBREVIATION
to None None O
the None None O
weaker None None O
androgens None None I-FAMILY
such None None O
as None None O
androstendione None None I-TRIVIAL
( None None O
via None None O
17beta None None O
- None None O
HSD None None O
) None None O
, None None O
androstenediol None None I-TRIVIAL
( None None O
via None None O
3beta None None O
- None None O
HSD None None O
) None None O
or None None O
17beta None None I-IUPAC
- None None I-IUPAC
E None None I-IUPAC
( None None O
via None None O
aromatase None None O
) None None O
, None None O
thereby None None O
diminishing None None O
the None None O
amount None None O
of None None O
T None None I-ABBREVIATION
available None None O
for None None O
the None None O
conversion None None O
to None None O
DHT None None I-ABBREVIATION
, None None O
remains None None O
to None None O
be None None O
shown None None O
. None None O


Involvement None None O
of None None O
phospholipase None None O
D2 None None O
in None None O
lysophosphatidate None None I-TRIVIAL
- None None O
induced None None O
transactivation None None O
of None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
receptor None None O
- None None O
beta None None O
in None None O
human None None O
bronchial None None O
epithelial None None O
cells None None O
. None None O

Lysophosphatidate None None I-TRIVIAL
( None None O
LPA None None I-ABBREVIATION
) None None O
mediates None None O
multiple None None O
cellular None None O
responses None None O
via None None O
heterotrimeric None None O
G None None O
protein None None O
coupled None None O
LPA None None O
- None None O
1 None None O
, None None O
LPA None None O
- None None O
2 None None O
, None None O
and None None O
LPA None None O
- None None O
3 None None O
receptors None None O
. None None O

Many None None O
G None None O
protein None None O
- None None O
coupled None None O
receptors None None O
stimulate None None O
ERK None None O
following None None O
tyrosine None None I-TRIVIAL
phosphorylation None None O
of None None O
growth None None O
factor None None O
receptors None None O
; None None O
however None None O
, None None O
the None None O
mechanism None None O
( None None O
s None None O
) None None O
of None None O
transactivation None None O
of None None O
receptor None None O
tyrosine None None O
kinases None None O
are None None O
not None None O
well None None O
defined None None O
. None None O

Here None None O
, None None O
we None None O
provide None None O
evidence None None O
for None None O
the None None O
involvement None None O
of None None O
phospholipase None None O
D None None O
( None None O
PLD None None O
) None None O
in None None O
LPA None None I-ABBREVIATION
- None None O
mediated None None O
transactivation None None O
of None None O
platelet None None O
- None None O
derived None None O
growth None None O
factor None None O
receptor None None O
- None None O
beta None None O
( None None O
PDGF None None O
- None None O
R None None O
beta None None O
) None None O
. None None O

In None None O
primary None None O
cultures None None O
of None None O
human None None O
bronchial None None O
epithelial None None O
cells None None O
( None None O
HBEpCs None None O
) None None O
, None None O
LPA None None I-ABBREVIATION
stimulated None None O
tyrosine None None I-TRIVIAL
phosphorylation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
and None None O
threonine None None I-TRIVIAL
/ None None O
tyrosine None None I-TRIVIAL
phosphorylation None None O
of None None O
ERK1/2 None None O
. None None O

The None None O
LPA None None I-ABBREVIATION
- None None O
mediated None None O
activation None None O
of None None O
ERK None None O
and None None O
tyrosine None None I-TRIVIAL
phosphorylation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
was None None O
attenuated None None O
by None None O
tyrphostin None None I-TRIVIAL
AG None None B-TRIVIALVAR
1296 None None I-TRIVIALVAR
, None None O
an None None O
inhibitor None None O
of None None O
PDGF None None O
- None None O
R None None O
kinase None None O
, None None O
suggesting None None O
transactivation None None O
of None None O
PDGF None None O
- None None O
R None None O
by None None O
LPA None None I-ABBREVIATION
. None None O

Furthermore None None O
, None None O
LPA None None I-ABBREVIATION
- None None O
, None None O
but None None O
not None None O
PDGF None None O
beta None None O
- None None O
chain None None O
homodimer None None O
- None None O
induced None None O
tyrosine None None O
phosphorylation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
was None None O
partially None None O
blocked None None O
by None None O
pertussis None None O
toxin None None O
, None None O
indicating None None O
coupling None None O
of None None O
LPA None None I-ABBREVIATION
- None None O
R None None O
( None None O
s None None O
) None None O
to None None O
Gi None None O
. None None O

Exposure None None O
of None None O
HBEpCs None None O
to None None O
LPA None None O
activated None None O
PLD None None O
. None None O

Butan None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
, None None O
which None None O
acts None None O
as None None O
an None None O
acceptor None None O
of None None O
phosphatidate None None I-TRIVIAL
generated None None O
by None None O
the None None O
PLD None None O
pathway None None O
, None None O
blocked None None O
LPA None None I-ABBREVIATION
- None None O
mediated None None O
transactivation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
. None None O

This None None O
effect None None O
was None None O
not None None O
seen None None O
with None None O
butan None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ol None None I-IUPAC
, None None O
suggesting None None O
PLD None None O
involvement None None O
. None None O

The None None O
role None None O
of None None O
PLD1 None None O
and None None O
PLD2 None None O
in None None O
the None None O
PDGF None None O
- None None O
R None None O
beta None None O
transactivation None None O
by None None O
LPA None None I-ABBREVIATION
was None None O
investigated None None O
by None None O
infection None None O
of None None O
cells None None O
with None None O
adenoviral None None O
constructs None None O
of None None O
wild None None O
type None None O
and None None O
catalytically None None O
inactive None None O
mutants None None O
of None None O
PLD None None O
. None None O

LPA None None I-ABBREVIATION
activated None None O
both None None O
PLD1 None None O
and None None O
PLD2 None None O
in None None O
HBEpCs None None O
; None None O
however None None O
, None None O
infection None None O
of None None O
cells None None O
with None None O
cDNA None None O
for None None O
wild None None O
type None None O
PLD2 None None O
, None None O
but None None O
not None None O
PLD1 None None O
, None None O
increased None None O
the None None O
tyrosine None None O
phosphorylation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
in None None O
response None None O
to None None O
LPA None None I-ABBREVIATION
. None None O

Also None None O
, None None O
the None None O
LPA None None I-ABBREVIATION
- None None O
mediated None None O
tyrosine None None I-TRIVIAL
phosphorylation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
was None None O
attenuated None None O
by None None O
the None None O
catalytically None None O
inactive None None O
mutant None None O
mPLD2 None None O
- None None O
K758R None None O
. None None O

Infection None None O
of None None O
HBEpCs None None O
with None None O
adenoviral None None O
constructs None None O
of None None O
wild None None O
type None None O
hPLD1 None None O
, None None O
mPLD2 None None O
, None None O
and None None O
the None None O
inactive None None O
mutants None None O
of None None O
hPLD1 None None O
and None None O
mPLD2 None None O
resulted None None O
in None None O
association None None O
of None None O
PLD2 None None O
wild None None O
type None None O
and None None O
inactive None None O
mutant None None O
proteins None None O
with None None O
the None None O
PDGF None None O
- None None O
R None None O
beta None None O
compared None None O
with None None O
PLD1 None None O
. None None O

These None None O
results None None O
show None None O
for None None O
the None None O
first None None O
time None None O
that None None O
transactivation None None O
of None None O
PDGF None None O
- None None O
R None None O
beta None None O
by None None O
LPA None None I-ABBREVIATION
in None None O
HBEpCs None None O
is None None O
regulated None None O
by None None O
PLD2 None None O
. None None O


Thyrotropin None None O
modulates None None O
low None None O
density None None O
lipoprotein None None O
binding None None O
activity None None O
in None None O
FRTL None None O
- None None O
5 None None O
thyroid None None O
cells None None O
. None None O

FRTL None None O
- None None O
5 None None O
cells None None O
possess None None O
high None None O
affinity None None O
low None None O
density None None O
lipoprotein None None O
( None None O
LDL None None O
) None None O
receptors None None O
which None None O
bind None None O
, None None O
internalize None None O
, None None O
and None None O
degrade None None O
LDL None None O
. None None O

When None None O
FRTL None None O
- None None O
5 None None O
cells None None O
are None None O
deprived None None O
of None None O
thyrotropin None None O
( None None O
TSH None None O
) None None O
the None None O
binding None None O
of None None O
LDL None None O
increases None None O
more None None O
than None None O
2 None None O
- None None O
fold None None O
. None None O

Upon None None O
addition None None O
of None None O
TSH None None O
, None None O
at None None O
a None None O
concentration None None O
of None None O
1 None None O
x None None O
10 None None O
( None None O
- None None O
10 None None O
) None None O
M None None O
or None None O
greater None None O
, None None O
LDL None None O
binding None None O
decreases None None O
rapidly None None O
and None None O
within None None O
24 None None O
h None None O
reaches None None O
the None None O
level None None O
which None None O
is None None O
typical None None O
of None None O
FRTL None None O
- None None O
5 None None O
cells None None O
chronically None None O
stimulated None None O
by None None O
TSH None None O
. None None O

The None None O
data None None O
available None None O
suggest None None O
that None None O
TSH None None O
- None None O
dependent None None O
down None None O
- None None O
regulation None None O
of None None O
LDL None None O
receptor None None O
activity None None O
is None None O
exerted None None O
through None None O
a None None O
reduction None None O
of None None O
the None None O
number None None O
of None None O
active None None O
LDL None None O
receptors None None O
, None None O
with None None O
no None None O
change None None O
in None None O
affinity None None O
. None None O

It None None O
is None None O
unlikely None None O
that None None O
the None None O
synthesis None None O
of None None O
LDL None None O
receptors None None O
is None None O
impaired None None O
, None None O
since None None O
LDL None None O
receptor None None O
messenger None None O
RNA None None O
is None None O
not None None O
decreased None None O
by None None O
TSH None None O
. None None O

The None None O
effect None None O
of None None O
the None None O
hormone None None O
on None None O
LDL None None O
receptor None None O
activity None None O
can None None O
be None None O
mimicked None None O
by None None O
8 None None I-IUPAC
- None None I-IUPAC
Br None None I-IUPAC
- None None I-IUPAC
cAMP None None I-IUPAC
and None None O
is None None O
completely None None O
abolished None None O
by None None O
the None None O
protein None None O
synthesis None None O
inhibitor None None O
cycloheximide None None I-TRIVIAL
but None None O
not None None O
by None None O
actinomycin None None I-TRIVIAL
D None None I-TRIVIAL
. None None O

TSH None None O
regulation None None O
of None None O
LDL None None O
receptor None None O
activity None None O
is None None O
lost None None O
in None None O
v None None O
- None None O
ras None None O
Ki None None O
- None None O
transformed None None O
FRTL None None O
- None None O
5 None None O
cells None None O
( None None O
Ki None None O
Mol None None O
) None None O
which None None O
also None None O
have None None O
lost None None O
TSH None None O
dependence None None O
for None None O
adenylate None None O
cyclase None None O
activation None None O
and None None O
growth None None O
. None None O

However None None O
, None None O
8 None None I-IUPAC
- None None I-IUPAC
Br None None I-IUPAC
- None None I-IUPAC
cAMP None None I-IUPAC
decreases None None O
LDL None None O
binding None None O
in None None O
Ki None None O
Mol None None O
FRTL None None O
- None None O
5 None None O
cells None None O
. None None O

The None None O
reduced None None O
availability None None O
of None None O
LDL None None O
receptor None None O
in None None O
TSH None None O
- None None O
stimulated None None O
FRTL None None O
- None None O
5 None None O
cells None None O
may None None O
be None None O
related None None O
to None None O
the None None O
increased None None O
membrane None None O
fluidity None None O
( None None O
Beguinot None None O
, None None O
F None None O
. None None O

, None None O
Beguinot None None O
, None None O
L None None O
. None None O

, None None O
Tramontano None None O
, None None O
D None None O
. None None O

, None None O
Duilio None None O
, None None O
C None None O
. None None O

, None None O
Formisano None None O
, None None O
S None None O
. None None O

, None None O
Bifulco None None O
, None None O
M None None O
. None None O

, None None O
Ambesi None None O
- None None O
Impiombato None None O
, None None O
F None None O
. None None O

S None None O
. None None O

, None None O
and None None O
Aloj None None O
, None None O
S None None O
. None None O

M None None O
. None None O

( None None O
1987 None None O
) None None O
J None None O
. None None O

Biol. None None O
Chem. None None O
262 None None O
, None None O
1575-1582 None None O
) None None O
or None None O
may None None O
reflect None None O
increased None None O
degradation None None O
of None None O
LDL None None O
receptors None None O
. None None O

We None None O
propose None None O
that None None O
a None None O
lower None None O
cholesterol None None O
uptake None None O
is None None O
needed None None O
in None None O
an None None O
actively None None O
proliferating None None O
cell None None O
population None None O
, None None O
to None None O
increase None None O
the None None O
production None None O
of None None O
isoprenoids None None I-FAMILY
whether None None O
it None None O
be None None O
for None None O
cholesterol None None I-TRIVIAL
biosynthesis None None O
or None None O
for None None O
the None None O
synthesis None None O
of None None O
other None None O
compounds None None O
requiring None None O
isoprenoid None None O
precursors None None O
. None None O


In None None O
order None None O
to None None O
develop None None O
tracers None None O
with None None O
higher None None O
specific None None O
activity None None O
to None None O
supplant None None O
the None None O
currently None None O
used None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
DPAT None None I-IUPAC
[ None None O
8 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylamino None None I-IUPAC
) None None I-IUPAC
tetralin None None I-IUPAC
] None None O
for None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
evaluation None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
, None None O
a None None O
new None None O
radioiodinated None None O
ligand None None O
was None None O
prepared None None O
. None None O

( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3' None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
tetralin None None I-IUPAC
( None None O
trans None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
PIPAT None None I-IUPAC
) None None O
, None None O
8 None None O
, None None O
was None None O
synthesized None None O
by None None O
a None None O
10 None None O
- None None O
step None None O
reaction None None O
. None None O

Binding None None O
studies None None O
with None None O
rat None None O
hippocampal None None O
membrane None None O
homogenates None None O
showed None None O
that None None O
8 None None O
exhibited None None O
a None None O
Ki None None O
value None None O
of None None O
0.92 None None O
nM None None O
against None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
DPAT None None I-IUPAC
. None None O

Radiolabeled None None O
[ None None I-PARTIUPAC
125I None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None O
was None None O
prepared None None O
from None None O
the None None O
corresponding None None O
tri None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
butyltin None None I-IUPAC
precursor None None O
via None None O
an None None O
oxidative None None O
iododestannylation None None O
reaction None None O
with None None O
sodium None None O
[ None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
iodide None None I-IUPAC
. None None O

Binding None None O
studies None None O
in None None O
the None None O
hippocampal None None O
homogenates None None O
revealed None None O
that None None O
[ None None I-PARTIUPAC
125I None None I-PARTIUPAC
] None None I-PARTIUPAC
- None None I-PARTIUPAC
8 None None O
bound None None O
to None None O
a None None O
single None None O
high None None O
- None None O
affinity None None O
site None None O
( None None O
Kd None None O
= None None O
0.38 None None O
+ None None O
/ None None O
- None None O
0.03 None None O
nM None None O
, None None O
Bmax None None O
= None None O
310 None None O
+ None None O
/ None None O
- None None O
20 None None O
fmol None None O
/ None None O
mg None None O
of None None O
protein None None O
) None None O
. None None O

Competition None None O
binding None None O
experiments None None O
clearly None None O
indicated None None O
that None None O
the None None O
new None None O
ligand None None O
displayed None None O
the None None O
expected None None O
5 None None O
- None None O
HT1A None None O
receptor None None O
binding None None O
profile None None O
. None None O

The None None O
rank None None O
order None None O
of None None O
potency None None O
was None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
PIPAT None None I-IUPAC
& None None O
gt None None O
; None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
DPAT None None I-IUPAC
& None None O
gt None None O
; None None O
WB4101 None None I-TRIVIAL
& None None O
gt None None O
; None None O
5 None None O
- None None O
HT None None O
& None None O
gt None None O
; None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
trans None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
PIPAT None None I-IUPAC
& None None O
gt None None O
; None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
OH None None I-IUPAC
- None None I-IUPAC
DPAT None None I-IUPAC
& None None O
gt None None O
; None None O
( None None I-IUPAC
R None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
propranolol None None I-IUPAC
& None None O
gt None None O
; None None O
spiperone None None I-TRIVIAL
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
ketanserin None None I-TRIVIAL
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
dopamine None None I-TRIVIAL
& None None O
gt None None O
; None None O
atropine None None I-TRIVIAL
. None None O

This None None O
new None None O
ligand None None O
offers None None O
several None None O
unique None None O
advantages None None O
, None None O
including None None O
high None None O
specific None None O
activity None None O
, None None O
high None None O
binding None None O
affinity None None O
, None None O
and None None O
low None None O
nonspecific None None O
binding None None O
, None None O
all None None O
of None None O
which None None O
make None None O
it None None O
an None None O
excellent None None O
probe None None O
for None None O
the None None O
investigation None None O
and None None O
characterization None None O
of None None O
5 None None O
- None None O
HT1A None None O
receptors None None O
. None None O


The None None O
synthesis None None O
and None None O
pharmacological None None O
profile None None O
of None None O
a None None O
series None None O
of None None O
neuroprotective None None O
adenosine None None O
agonists None None O
are None None O
described None None O
. None None O

Novel None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
with None None O
potent None None O
central None None O
nervous None None O
system None None O
effects None None O
and None None O
diminished None None O
influence None None O
on None None O
the None None O
cardiovascular None None O
system None None O
are None None O
reported None None O
and None None O
compared None None O
to None None O
selected None None O
reference None None O
adenosine None None O
agonists None None O
. None None O

The None None O
novel None None O
compounds None None O
featured None None O
are None None O
derived None None O
structurally None None O
from None None O
two None None O
key None None O
lead None None O
structures None None O
: None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
phenoxy None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None I-TRIVIALVAR
21-0041 None None I-TRIVIALVAR
, None None O
9 None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
) None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None I-TRIVIALVAR
90-1515 None None I-TRIVIALVAR
, None None O
4 None None O
) None None O
. None None O

The None None O
agonists None None O
are None None O
characterized None None O
in None None O
terms None None O
of None None O
their None None O
in None None O
vitro None None O
profiles None None O
, None None O
both None None O
binding None None O
and None None O
functional None None O
, None None O
and None None O
in None None O
vivo None None O
activity None None O
in None None O
relevant None None O
animal None None O
models None None O
. None None O

Neuroprotective None None O
properties None None O
assessed None None O
after None None O
postischemic None None O
dosing None None O
in None None O
a None None O
Mongolian None None O
gerbil None None O
severe None None O
temporary None None O
forebrain None None O
ischemia None None O
paradigm None None O
, None None O
using None None O
hippocampal None None O
CA1 None None O
damage None None O
endpoints None None O
, None None O
and None None O
the None None O
efficacy None None O
of None None O
these None None O
agonists None None O
in None None O
an None None O
A None None O
( None None O
1 None None O
) None None O
functional None None O
assay None None O
show None None O
similarities None None O
to None None O
some None None O
reference None None O
adenosine None None O
agonists None None O
. None None O

However None None O
, None None O
the None None O
new None None O
compounds None None O
we None None O
describe None None O
exhibit None None O
diminished None None O
cardiovascular None None O
effects None None O
in None None O
both None None O
anesthetized None None O
and None None O
awake None None O
rats None None O
when None None O
compared None None O
to None None O
reference None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
such None None O
as None None O
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
phenylisopropyladenosine None None I-IUPAC
( None None O
R None None I-ABBREVIATION
- None None I-ABBREVIATION
PIA None None I-ABBREVIATION
, None None O
5 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
cyclopentyladenosine None None I-IUPAC
( None None O
CPA None None I-ABBREVIATION
, None None O
2 None None O
) None None O
, None None O
4 None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
1S None None I-IUPAC
, None None I-IUPAC
trans None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxycyclopentyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
GR None None I-TRIVIALVAR
79236 None None I-TRIVIALVAR
, None None O
26 None None O
) None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
2' None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
methyladenosine None None I-IUPAC
( None None O
SDZ None None I-TRIVIALVAR
WAG None None I-TRIVIALVAR
994 None None I-TRIVIALVAR
, None None O
27 None None O
) None None O
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methylphenyl None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
Metrifudil None None I-TRIVIAL
, None None O
28 None None O
) None None O
. None None O

In None None O
mouse None None O
permanent None None O
middle None None O
cerebral None None O
artery None None O
occlusion None None O
focal None None O
ischemia None None O
, None None O
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzothiazolyl None None I-IUPAC
) None None I-IUPAC
thio None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
propyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None I-TRIVIALVAR
21-0136 None None I-TRIVIALVAR
, None None O
12 None None O
) None None O
exhibited None None O
significant None None O
neuroprotection None None O
at None None O
the None None O
remarkably None None O
low None None O
total None None O
intraperitoneal None None O
dose None None O
of None None O
0.1 None None O
mg None None O
/ None None O
kg None None O
, None None O
a None None O
dose None None O
at None None O
which None None O
no None None O
cardiovascular None None O
effects None None O
are None None O
observed None None O
in None None O
conscious None None O
rats None None O
. None None O

The None None O
novel None None O
agonists None None O
described None None O
inhibit None None O
6 None None I-IUPAC
, None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
ethyl None None I-IUPAC
- None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
carboline None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
carboxylate None None I-IUPAC
- None None O
induced None None O
seizures None None O
, None None O
and None None O
in None None O
mouse None None O
locomotor None None O
activity None None O
higher None None O
doses None None O
are None None O
required None None O
to None None O
reach None None O
ED None None O
( None None O
50 None None O
) None None O
values None None O
than None None O
for None None O
reference None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
. None None O

We None None O
conclude None None O
that None None O
two None None O
of None None O
the None None O
novel None None O
adenosine None None O
derivatives None None O
revealed None None O
herein None None O
, None None O
12 None None O
and None None O
5' None None I-IUPAC
- None None I-IUPAC
deoxy None None I-IUPAC
- None None I-IUPAC
5' None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
phenylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
piperidinyl None None I-IUPAC
] None None I-IUPAC
adenosine None None I-IUPAC
( None None O
NNC None None I-TRIVIALVAR
21-0147 None None I-TRIVIALVAR
, None None O
13 None None O
) None None O
, None None O
representatives None None O
of None None O
a None None O
new None None O
series None None O
of None None O
P None None O
( None None O
1 None None O
) None None O
ligands None None O
, None None O
reinforce None None O
the None None O
fact None None O
that None None O
novel None None O
selective None None O
adenosine None None O
A None None O
( None None O
1 None None O
) None None O
agonists None None O
have None None O
potential None None O
in None None O
the None None O
treatment None None O
of None None O
cerebral None None O
ischemia None None O
in None None O
humans None None O
. None None O


A None None O
series None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
quinolones None None I-IUPAC
has None None O
been None None O
prepared None None O
and None None O
evaluated None None O
for None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
antibacterial None None O
activity None None O
, None None O
and None None O
phototolerance None None O
in None None O
a None None O
mouse None None O
phototolerance None None O
assay None None O
. None None O

These None None O
analogues None None O
were None None O
compared None None O
to None None O
the None None O
corresponding None None O
series None None O
of None None O
6,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
difluoro None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
6 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
8H None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
( None None O
ciprofloxacin None None I-TRIVIAL
type None None O
) None None O
. None None O

Although None None O
their None None O
in None None O
vitro None None O
antibacterial None None O
activities None None O
are None None O
less None None O
than None None O
the None None O
6,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
difluoro None None I-PARTIUPAC
analogues None None I-MODIFIER
, None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
quinolones None None I-IUPAC
are None None O
generally None None O
equivalent None None O
to None None O
their None None O
8H None None I-PARTIUPAC
analogues None None B-MODIFIER
. None None O

In None None O
vivo None None O
, None None O
they None None O
are None None O
comparable None None O
to None None O
the None None O
6,8 None None I-PARTIUPAC
- None None I-PARTIUPAC
difluoro None None I-PARTIUPAC
series None None I-MODIFIER
and None None O
show None None O
up None None O
to None None O
10 None None O
- None None O
fold None None O
improvement None None O
in None None O
efficacy None None O
when None None O
compared None None O
to None None O
their None None O
ciprofloxacin None None I-TRIVIAL
counterparts None None O
vs None None O
Streptococcus None None O
pyogenes None None O
and None None O
Streptococcus None None O
pneumonia None None O
. None None O

In None None O
the None None O
phototolerance None None O
model None None O
, None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
trifluoromethyl None None I-IUPAC
) None None I-IUPAC
quinolones None None I-IUPAC
are None None O
comparable None None O
to None None O
the None None O
8H None None I-IUPAC
- None None I-IUPAC
quinolones None None I-IUPAC
. None None O

Both None None O
of None None O
these None None O
series None None O
display None None O
much None None O
higher None None O
no None None O
effect None None O
doses None None O
( None None O
greater None None O
tolerance None None O
) None None O
than None None O
the None None O
corresponding None None O
6,8 None None I-IUPAC
- None None I-IUPAC
difluoroquinolones None None I-IUPAC
. None None O


This None None O
study None None O
emphasizes None None O
the None None O
importance None None O
of None None O
the None None O
metabolic None None O
conversion None None O
of None None O
the None None O
enantiomers None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylpiperidine None None I-IUPAC
( None None O
3 None None I-ABBREVIATION
- None None I-ABBREVIATION
PPP None None I-ABBREVIATION
) None None O
into None None O
their None None O
catechol None None I-TRIVIAL
analogues None None B-MODIFIER
, None None O
the None None O
enantiomers None None O
of None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3,4 None None I-IUPAC
- None None I-IUPAC
dihydroxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
n None None I-IUPAC
- None None I-IUPAC
propylpiperidine None None I-IUPAC
. None None O

These None None O
isomers None None O
are None None O
both None None O
shown None None O
to None None O
be None None O
excellent None None O
substrates None None O
for None None O
COMT None None O
, None None O
with None None O
a None None O
slight None None O
preference None None O
for None None O
the None None O
S None None O
- None None O
( None None O
- None None O
) None None O
enantiomer None None O
. None None O

Assessment None None O
of None None O
the None None O
dopaminergic None None O
activity None None O
of None None O
these None None O
catechols None None O
and None None O
the None None O
results None None O
from None None O
the None None O
determination None None O
of None None O
brain None None O
levels None None O
of None None O
the None None O
enantiomers None None O
of None None O
3 None None I-ABBREVIATION
- None None I-ABBREVIATION
PPP None None I-ABBREVIATION
and None None O
their None None O
metabolites None None O
indicate None None O
that None None O
the None None O
metabolites None None O
probably None None O
do None None O
not None None O
alter None None O
the None None O
pharmacological None None O
profiles None None O
established None None O
for None None O
( None None I-PARTIUPAC
R None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
PPP None None I-IUPAC
. None None O

The None None O
conversion None None O
of None None O
the None None O
monophenols None None I-FAMILY
into None None O
catecholic None None O
metabolites None None O
is None None O
only None None O
1-5% None None O
, None None O
and None None O
the None None O
further None None O
conversion None None O
of None None O
these None None O
catecholic None None O
metabolites None None O
into None None O
methoxylated None None O
analogues None None O
is None None O
very None None O
rapid None None O
. None None O

However None None O
, None None O
the None None O
very None None O
interesting None None O
observation None None O
was None None O
made None None O
that None None O
, None None O
when None None O
inhibiting None None O
COMT None None O
by None None O
means None None O
of None None O
tropolone None None I-TRIVIAL
and None None O
subsequently None None O
treating None None O
the None None O
rats None None O
with None None O
high None None O
doses None None O
of None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
PPP None None I-IUPAC
( None None O
ip None None O
) None None O
, None None O
postsynaptic None None O
dopaminergic None None O
activity None None O
was None None O
elicited None None O
. None None O

This None None O
has None None O
never None None O
been None None O
seen None None O
for None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
PPP None None I-IUPAC
without None None O
tropolone None None I-TRIVIAL
pretreatment None None O
and None None O
might None None O
indicate None None O
that None None O
, None None O
in None None O
this None None O
special None None O
case None None O
, None None O
the None None O
catecholic None None O
metabolite None None O
affects None None O
the None None O
in None None O
vivo None None O
pharmacological None None O
profile None None O
of None None O
( None None I-IUPAC
S None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
PPP None None I-IUPAC
. None None O


Genetic None None O
absence None None O
epilepsy None None O
in None None O
rats None None O
from None None O
Strasbourg None None O
- None None O
- None None O
a None None O
review None None O
. None None O

We None None O
have None None O
selected None None O
a None None O
strain None None O
of None None O
rats None None O
and None None O
designated None None O
it None None O
the None None O
Genetic None None O
Absence None None O
Epilepsy None None O
Rat None None O
from None None O
Strasbourg None None O
( None None O
GAERS None None O
) None None O
. None None O

In None None O
this None None O
strain None None O
, None None O
100% None None O
of None None O
the None None O
animals None None O
present None None O
recurrent None None O
generalized None None O
non None None O
- None None O
convulsive None None O
seizures None None O
characterized None None O
by None None O
bilateral None None O
and None None O
synchronous None None O
spike None None O
- None None O
and None None O
- None None O
wave None None O
discharges None None O
accompanied None None O
with None None O
behavioural None None O
arrest None None O
, None None O
staring None None O
and None None O
sometimes None None O
twitching None None O
of None None O
the None None O
vibrissae None None O
. None None O

Spontaneous None None O
SWD None None O
( None None O
7-11 None None O
cps None None O
, None None O
300-1,000 None None O
microV None None O
, None None O
0.5-75 None None O
sec None None O
) None None O
start None None O
and None None O
end None None O
abruptly None None O
on None None O
a None None O
normal None None O
background None None O
EEG None None O
. None None O

They None None O
usually None None O
occur None None O
at None None O
a None None O
mean None None O
frequency None None O
of None None O
1.5 None None O
per None None O
min None None O
when None None O
the None None O
animals None None O
are None None O
in None None O
a None None O
state None None O
of None None O
quiet None None O
wakefulness None None O
. None None O

Drugs None None O
effective None None O
against None None O
absence None None O
seizures None None O
in None None O
humans None None O
( None None O
ethosuccimide None None I-TRIVIAL
, None None O
trimethadione None None I-TRIVIAL
, None None O
valproate None None I-TRIVIAL
, None None O
benzodiazepines None None I-TRIVIAL
) None None O
suppress None None O
the None None O
SWD None None O
dose None None O
- None None O
dependently None None O
, None None O
whereas None None O
drugs None None O
specific None None O
for None None O
convulsive None None O
or None None O
focal None None O
seizures None None O
( None None O
carbamazepine None None I-TRIVIAL
, None None O
phenytoin None None I-TRIVIAL
) None None O
are None None O
ineffective None None O
. None None O

SWD None None O
are None None O
increased None None O
by None None O
epileptogenic None None O
drugs None None O
inducing None None O
petit None None O
mal None None O
- None None O
like None None O
seizures None None O
, None None O
such None None O
as None None O
pentylenetetrazol None None I-TRIVIAL
, None None O
gamma None None I-IUPAC
- None None I-IUPAC
hydroxybutyrate None None I-IUPAC
, None None O
THIP None None I-ABBREVIATION
and None None O
penicillin None None I-TRIVIAL
. None None O

Depth None None O
EEG None None O
recordings None None O
and None None O
lesion None None O
experiments None None O
show None None O
that None None O
SWD None None O
in None None O
GAERs None None O
depend None None O
on None None O
cortical None None O
and None None O
thalamic None None O
structures None None O
with None None O
a None None O
possible None None O
rhythmic None None O
triggering None None O
by None None O
the None None O
lateral None None O
thalamus None None O
. None None O

Most None None O
neurotransmitters None None O
are None None O
involved None None O
in None None O
the None None O
control None None O
of None None O
SWD None None O
( None None O
dopamine None None I-TRIVIAL
, None None O
noradrenaline None None I-TRIVIAL
, None None O
NMDA None None I-ABBREVIATION
, None None O
acetylcholine None None I-TRIVIAL
) None None O
, None None O
but None None O
GABA None None I-ABBREVIATION
and None None O
gamma None None I-IUPAC
- None None I-IUPAC
hydroxybutyrate None None I-IUPAC
( None None O
GHB None None I-ABBREVIATION
) None None O
seem None None O
to None None O
play None None O
a None None O
critical None None O
role None None O
. None None O

SWD None None O
are None None O
genetically None None O
determined None None O
with None None O
an None None O
autosomal None None O
dominant None None O
inheritance None None O
. None None O

The None None O
variable None None O
expression None None O
of None None O
SWD None None O
in None None O
offsprings None None O
from None None O
GAERS None None O
x None None O
control None None O
reciprocal None None O
crosses None None O
may None None O
be None None O
due None None O
to None None O
the None None O
existence None None O
of None None O
multiple None None O
genes None None O
. None None O

Neurophysiological None None O
, None None O
behavioural None None O
, None None O
pharmacological None None O
and None None O
genetic None None O
studies None None O
demonstrate None None O
that None None O
spontaneous None None O
SWD None None O
in None None O
GAERS None None O
fulfill None None O
all None None O
the None None O
requirements None None O
for None None O
an None None O
experimental None None O
model None None O
of None None O
absence None None O
epilepsy None None O
. None None O

As None None O
the None None O
mechanisms None None O
underlying None None O
absence None None O
epilepsy None None O
in None None O
humans None None O
are None None O
still None None O
unknown None None O
, None None O
the None None O
analysis None None O
of None None O
the None None O
genetic None None O
thalamocortical None None O
dysfunction None None O
in None None O
GAERS None None O
may None None O
be None None O
fruitful None None O
in None None O
investigations None None O
of None None O
the None None O
pathogenesis None None O
of None None O
generalized None None O
non None None O
- None None O
convulsive None None O
seizures None None O
. None None O


Diphenol None None I-FAMILY
activation None None O
of None None O
the None None O
monophenolase None None O
and None None O
diphenolase None None O
activities None None O
of None None O
field None None O
bean None None O
( None None O
Dolichos None None O
lablab None None O
) None None O
polyphenol None None O
oxidase None None O
. None None O

This None None O
paper None None O
reports None None O
a None None O
study None None O
on None None O
the None None O
hydroxylation None None O
of None None O
ferulic None None I-IUPAC
acid None None I-IUPAC
and None None O
tyrosine None None I-TRIVIAL
by None None O
field None None O
bean None None O
( None None O
Dolichos None None O
lablab None None O
) None None O
polyphenol None None O
oxidase None None O
, None None O
a None None O
reaction None None O
that None None O
does None None O
not None None O
take None None O
place None None O
without None None O
the None None O
addition None None O
of None None O
catechol None None I-TRIVIAL
. None None O

A None None O
lag None None O
period None None O
similar None None O
to None None O
the None None O
characteristic None None O
lag None None O
of None None O
tyrosinase None None O
activity None None O
was None None O
observed None None O
, None None O
the None None O
length None None O
of None None O
which None None O
decreased None None O
with None None O
increasing None None O
catechol None None I-TRIVIAL
concentration None None O
and None None O
increased None None O
with None None O
increasing None None O
ferulic None None I-IUPAC
acid None None I-IUPAC
concentration None None O
. None None O

The None None O
activation None None O
constant None None O
K None None O
( None None O
a None None O
) None None O
of None None O
catechol None None I-TRIVIAL
for None None O
ferulic None None I-IUPAC
acid None None I-IUPAC
hydroxylation None None O
reaction None None O
was None None O
5 None None O
mM None None O
. None None O

The None None O
kinetic None None O
parameters None None O
of None None O
field None None O
bean None None O
polyphenol None None O
oxidase None None O
toward None None O
ferulic None None I-IUPAC
acid None None I-IUPAC
and None None O
tyrosine None None I-TRIVIAL
were None None O
evaluated None None O
in None None O
the None None O
presence None None O
of None None O
catechol None None I-TRIVIAL
. None None O

4 None None I-IUPAC
- None None I-IUPAC
Methyl None None I-IUPAC
catechol None None I-IUPAC
, None None O
L None None I-IUPAC
- None None I-IUPAC
dihydroxyphenylalanine None None I-IUPAC
, None None O
pyrogallol None None I-TRIVIAL
, None None O
and None None O
2,3,4 None None I-IUPAC
- None None I-IUPAC
trihydroxybenzoic None None I-IUPAC
acid None None I-IUPAC
, None None O
substrates None None O
with None None O
high None None O
binding None None O
affinity None None O
to None None O
field None None O
bean None None O
polyphenol None None O
oxidase None None O
, None None O
could None None O
stimulate None None O
this None None O
hydroxylation None None O
reaction None None O
. None None O

In None None O
contrast None None O
, None None O
diphenols None None I-FAMILY
such None None O
as None None O
protocatechuic None None I-IUPAC
acid None None I-IUPAC
, None None O
gallic None None I-IUPAC
acid None None I-IUPAC
, None None O
chlorogenic None None I-IUPAC
acid None None I-IUPAC
, None None O
and None None O
caffeic None None I-IUPAC
acid None None I-IUPAC
, None None O
which None None O
were None None O
not None None O
substrates None None O
for None None O
the None None O
oxidation None None O
reaction None None O
, None None O
were None None O
unable None None O
to None None O
bring None None O
about None None O
this None None O
activation None None O
. None None O

It None None O
is None None O
most None None O
likely None None O
that None None O
only None None O
o None None I-FAMILY
- None None I-FAMILY
diphenols None None I-FAMILY
that None None O
are None None O
substrates None None O
for None None O
the None None O
diphenolase None None O
serve None None O
as None None O
cosubstrates None None O
by None None O
donating None None O
electrons None None O
at None None O
the None None O
active None None O
site None None O
for None None O
the None None O
monophenolase None None O
activity None None O
. None None O

The None None O
reaction None None O
mechanism None None O
for None None O
this None None O
activation None None O
is None None O
consistent None None O
with None None O
that None None O
proposed None None O
for None None O
tyrosinase None None O
( None None O
Sanchez None None O
- None None O
Ferrer None None O
, None None O
A None None O
. None None O

; None None O
Rodriguez None None O
- None None O
Lopez None None O
, None None O
J None None O
. None None O

N None None O
. None None O

; None None O
Garcia None None O
- None None O
Canovas None None O
, None None O
F None None O
. None None O

; None None O
Garcia None None O
- None None O
Carmona None None O
, None None O
F None None O
. None None O

Biochim None None O
. None None O

Biophys None None O
. None None O

Acta None None O
1995 None None O
, None None O
1247 None None O
, None None O
1-11 None None O
) None None O
. None None O

The None None O
presence None None O
of None None O
o None None I-FAMILY
- None None I-FAMILY
diphenols None None I-FAMILY
, None None O
viz None None O
. None None O

catechol None None I-TRIVIAL
, None None O
L None None I-IUPAC
- None None I-IUPAC
dihydroxyphenylalanine None None I-IUPAC
, None None O
and None None O
4 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
catechol None None I-IUPAC
, None None O
is None None O
also None None O
necessary None None O
for None None O
the None None O
oxidation None None O
of None None O
the None None O
diphenols None None I-FAMILY
, None None O
caffeic None None I-TRIVIAL
acid None None I-TRIVIAL
, None None O
and None None O
catechin None None I-TRIVIAL
to None None O
their None None O
quinones None None I-FAMILY
by None None O
the None None O
field None None O
bean None None O
polyphenol None None O
oxidase None None O
. None None O

This None None O
oxidation None None O
reaction None None O
occurs None None O
immediately None None O
with None None O
no None None O
lag None None O
period None None O
and None None O
does None None O
not None None O
occur None None O
without None None O
the None None O
addition None None O
of None None O
diphenol None None I-FAMILY
. None None O

The None None O
kinetic None None O
parameters None None O
for None None O
caffeic None None I-TRIVIAL
acid None None I-TRIVIAL
( None None O
K None None O
( None None O
m None None O
) None None O
= None None O
0.08 None None O
mM None None O
, None None O
V None None O
( None None O
max None None O
) None None O
= None None O
32440 None None O
u None None O
/ None None O
mg None None O
) None None O
in None None O
the None None O
presence None None O
of None None O
catechol None None I-TRIVIAL
and None None O
the None None O
activation None None O
constant None None O
K None None O
( None None O
a None None O
) None None O
of None None O
catechol None None I-TRIVIAL
( None None O
4.6 None None O
mM None None O
) None None O
for None None O
this None None O
reaction None None O
were None None O
enumerated None None O
. None None O

The None None O
absence None None O
of None None O
a None None O
lag None None O
period None None O
for None None O
this None None O
reaction None None O
indicates None None O
that None None O
the None None O
diphenol None None I-FAMILY
mechanism None None O
of None None O
diphenolase None None O
activation None None O
differs None None O
from None None O
the None None O
way None None O
in None None O
which None None O
the None None O
same None None O
o None None I-FAMILY
- None None I-FAMILY
diphenols None None I-FAMILY
activate None None O
the None None O
monophenolase None None O
activity None None O
. None None O


In None None O
the None None O
present None None O
investigation None None O
, None None O
the None None O
last None None O
two None None O
possible None None O
modes None None O
of None None O
generating None None O
conformationally None None O
semirigid None None O
diacylglycerol None None I-TRIVIAL
( None None O
DAG None None I-ABBREVIATION
) None None O
analogues None None I-MODIFIER
embedded None None O
into None None O
five None None O
- None None O
membered None None O
ring None None O
lactones None None I-FAMILY
as None None O
templates None None O
III None None O
and None None O
IV None None O
are None None O
investigated None None O
. None None O

The None None O
first None None O
two None None O
templates None None O
studied None None O
in None None O
previous None None O
investigations None None O
corresponded None None O
to None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyribonolactone None None I-IUPAC
( None None O
template None None O
I None None O
) None None O
and None None O
4,4 None None I-IUPAC
- None None I-IUPAC
disubstituted None None I-IUPAC
gamma None None I-IUPAC
- None None I-IUPAC
butyrolactone None None I-IUPAC
( None None O
template None None O
II None None O
) None None O
, None None O
with None None O
the None None O
latter None None O
producing None None O
potent None None O
protein None None O
kinase None None O
C None None O
( None None O
PK None None O
- None None O
C None None O
) None None O
ligands None None O
with None None O
low None None O
nanomolar None None O
binding None None O
affinities None None O
. None None O

The None None O
templates None None O
reported None None O
in None None O
this None None O
work None None O
correspond None None O
to None None O
2,3 None None I-PARTIUPAC
- None None I-PARTIUPAC
dideoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
L None None I-PARTIUPAC
- None None I-PARTIUPAC
erythro None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
hexono None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
lactone None None I-IUPAC
( None None O
template None None O
III None None O
) None None O
and None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyapiolactone None None I-IUPAC
( None None O
template None None O
IV None None O
) None None O
. None None O

Compounds None None O
constructed None None O
with None None O
the None None O
dideoxy None None I-PARTIUPAC
- None None I-PARTIUPAC
L None None I-PARTIUPAC
- None None I-PARTIUPAC
erythro None None I-PARTIUPAC
- None None I-PARTIUPAC
or None None O
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
hexono None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
lactone None None I-IUPAC
template None None O
were None None O
synthesized None None O
stereospecifically None None O
from None None O
tri None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
acetyl None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
glucal None None I-IUPAC
and None None O
L None None I-IUPAC
- None None I-IUPAC
galactono None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
lactone None None I-IUPAC
, None None O
respectively None None O
. None None O

Compounds None None O
constructed None None O
with None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
deoxyapiolactone None None I-IUPAC
template None None O
were None None O
synthesized None None O
stereoselectively None None O
from None None O
di None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
isopropylidene None None I-IUPAC
- None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
D None None I-IUPAC
- None None I-IUPAC
apiose None None I-IUPAC
. None None O

Inhibition None None O
of None None O
the None None O
binding None None O
of None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
phorbol None None I-IUPAC
- None None I-IUPAC
12,13 None None I-IUPAC
- None None I-IUPAC
dibutyrate None None I-IUPAC
to None None O
PK None None O
- None None O
C None None O
alpha None None O
showed None None O
that None None O
only None None O
the None None O
threo None None I-FAMILY
- None None I-FAMILY
isomer None None I-FAMILY
, None None O
5 None None I-IUPAC
- None None I-IUPAC
O None None I-IUPAC
- None None I-IUPAC
tetradecanoyl None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dideoxy None None I-IUPAC
- None None I-IUPAC
L None None I-IUPAC
- None None I-IUPAC
threo None None I-IUPAC
- None None I-IUPAC
hexono None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
lactone None None I-IUPAC
( None None O
2 None None O
) None None O
was None None O
a None None O
good None None O
PK None None O
- None None O
C None None O
ligand None None O
( None None O
Ki None None O
= None None O
1 None None O
microM None None O
) None None O
. None None O

The None None O
rest None None O
of None None O
the None None O
ligands None None O
had None None O
poorer None None O
affinities None None O
with None None O
Ki None None O
values None None O
between None None O
10 None None O
and None None O
28 None None O
microM None None O
. None None O

With None None O
these None None O
results None None O
, None None O
the None None O
order None None O
of None None O
importance None None O
of None None O
five None None O
- None None O
membered None None O
ring None None O
lactones None None I-FAMILY
as None None O
competent None None O
templates None None O
for None None O
the None None O
construction None None O
of None None O
semirigid None None O
DAG None None I-ABBREVIATION
surrogates None None O
with None None O
effective None None O
PK None None O
- None None O
C None None O
binding None None O
affinity None None O
can None None O
be None None O
established None None O
as None None O
II None None O
& None None O
gt None None O
; None None O
& None None O
gt None None O
; None None O
I None None O
approximately None None O
III None None O
& None None O
gt None None O
; None None O
IV None None O
. None None O


Hypoxic None None O
cells None None O
are None None O
an None None O
important None None O
target None None O
for None None O
antitumor None None O
therapy None None O
because None None O
tumors None None O
are None None O
typically None None O
characterized None None O
by None None O
such None None O
cells None None O
. None None O

Virtually None None O
all None None O
tumors None None O
which None None O
are None None O
present None None O
as None None O
solid None None O
masses None None O
contain None None O
hypoxic None None O
cells None None O
, None None O
while None None O
normal None None O
cells None None O
generally None None O
have None None O
an None None O
adequate None None O
supply None None O
of None None O
oxygen None None O
. None None O

Accordingly None None O
, None None O
antitumor None None O
agents None None O
can None None O
be None None O
made None None O
selective None None O
for None None O
tumors None None O
by None None O
virtue None None O
of None None O
high None None O
activity None None O
under None None O
hypoxic None None O
conditions None None O
. None None O

The None None O
initial None None O
purpose None None O
of None None O
this None None O
work None None O
was None None O
to None None O
determine None None O
the None None O
influence None None O
of None None O
different None None O
groups None None O
in None None O
position None None O
3 None None O
. None None O

Thus None None O
, None None O
the None None O
synthesis None None O
of None None O
some None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
NH None None I-PARTIUPAC
- None None I-PARTIUPAC
substituted None None I-PARTIUPAC
derivatives None None I-MODIFIER
( None None O
2a None None O
, None None O
3a None None O
, None None O
4a None None O
) None None O
starting None None O
from None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitrile None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
1a None None O
) None None O
is None None O
described None None O
. None None O

Reductive None None O
deamination None None O
of None None O
compounds None None O
1a None None O
- None None O
k None None O
provides None None O
the None None O
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitriles None None I-IUPAC
5a None None O
- None None O
k None None O
, None None O
which None None O
are None None O
more None None O
potent None None O
, None None O
while None None O
selectivity None None O
is None None O
maintained None None O
or None None O
increased None None O
in None None O
some None None O
derivatives None None O
. None None O

The None None O
compound None None O
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
nitrophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitrile None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
5k None None O
) None None O
is None None O
150 None None O
- None None O
fold None None O
more None None O
potent None None O
than None None O
tirapazamine None None I-TRIVIAL
( None None O
3 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
benzotriazine None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
) None None O
, None None O
which None None O
has None None O
been None None O
used None None O
as None None O
a None None O
standard None None O
. None None O

Three None None O
derivatives None None O
( None None O
5g None None O
, None None O
i None None O
, None None O
k None None O
) None None O
show None None O
a None None O
hypoxic None None O
cytotoxicity None None O
ratio None None O
( None None O
HCR None None O
) None None O
& None None O
gt None None O
; None None O
or None None O
= None None O
200 None None O
, None None O
better None None O
than None None O
that None None O
of None None O
tirapazamine None None I-TRIVIAL
( None None O
HCR None None O
= None None O
75 None None O
) None None O
in None None O
V79 None None O
cells None None O
. None None O

Replacement None None O
of None None O
the None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
amino None None I-PARTIUPAC
group None None I-MODIFIER
by None None O
chlorine None None I-TRIVIAL
affords None None O
the None None O
potent None None O
but None None O
nonselective None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
derivatives None None I-MODIFIER
6a None None O
- None None O
k None None O
showing None None O
similar None None O
toxicities None None O
under None None O
both None None O
aerobic None None O
and None None O
hypoxic None None O
conditions None None O
. None None O

These None None O
compounds None None O
were None None O
used None None O
as None None O
intermediates None None O
for None None O
the None None O
synthesis None None O
of None None O
a None None O
new None None O
series None None O
of None None O
water None None O
- None None O
soluble None None O
compounds None None O
derived None None O
from None None O
3 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dialkylamino None None I-IUPAC
) None None I-IUPAC
alkyl None None I-IUPAC
[ None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
quinoxalinecarbonitrile None None I-IUPAC
1,4 None None I-IUPAC
- None None I-IUPAC
di None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
oxides None None I-IUPAC
10a None None O
- None None O
i None None O
and None None O
11a None None O
- None None O
i None None O
. None None O

The None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
and None None O
the None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
trifluoromethyl None None I-PARTIUPAC
derivatives None None I-MODIFIER
10b None None O
, None None O
f None None O
have None None O
demonstrated None None O
high None None O
potency None None O
( None None O
0.4 None None O
and None None O
0.3 None None O
microM None None O
) None None O
and None None O
excellent None None O
selectivity None None O
( None None O
HCR None None O
= None None O
250 None None O
and None None O
340 None None O
) None None O
. None None O

Several None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
chloro None None I-PARTIUPAC
analogues None None I-MODIFIER
, None None O
12b None None O
, None None O
13b None None O
.1 None None O
, None None O
b None None O
.2 None None O
, None None O
and None None O
14b None None O
, None None O
and None None O
the None None O
dimer None None O
16b None None O
have None None O
been None None O
prepared None None O
and None None O
evaluated None None O
in None None O
order None None O
to None None O
determine None None O
the None None O
optimum None None O
lateral None None O
chain None None O
in None None O
position None None O
3 None None O
, None None O
which None None O
appears None None O
to None None O
be None None O
the None None O
[ None None O
( None None I-PARTIUPAC
N None None I-PARTIUPAC
, None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethylamino None None I-PARTIUPAC
) None None I-PARTIUPAC
propyl None None I-PARTIUPAC
] None None I-PARTIUPAC
amino None None I-PARTIUPAC
moiety None None I-MODIFIER
. None None O


Activity None None O
of None None O
beta None None O
- None None O
lactamase None None O
inhibitor None None O
combinations None None O
on None None O
Escherichia None None O
coli None None O
isolates None None O
exhibiting None None O
various None None O
patterns None None O
of None None O
resistance None None O
to None None O
beta None None I-FAMILY
- None None I-FAMILY
lactam None None I-FAMILY
agents None None O
. None None O

The None None O
efficacy None None O
of None None O
the None None O
clinically None None O
available None None O
beta None None O
- None None O
lactam None None O
/ None None O
beta None None O
- None None O
lactamase None None O
inhibitor None None O
combinations None None O
( None None O
amoxicillin None None I-TRIVIAL
/ None None O
clavulanic None None I-TRIVIAL
acid None None I-TRIVIAL
( None None O
CA None None I-ABBREVIATION
) None None O
, None None O
ticarcillin None None I-TRIVIAL
/ None None O
CA None None I-ABBREVIATION
, None None O
amoxicillin None None I-TRIVIAL
/ None None O
sulbactam None None I-TRIVIAL
, None None O
and None None O
piperacillin None None I-TRIVIAL
/ None None O
tazobactam None None I-TRIVIAL
) None None O
was None None O
evaluated None None O
on None None O
300 None None O
amoxicillin None None I-TRIVIAL
- None None O
resistant None None O
Escherichia None None O
coli None None O
isolates None None O
having None None O
the None None O
main None None O
patterns None None O
of None None O
beta None None I-FAMILY
- None None I-FAMILY
lactam None None I-FAMILY
resistance None None O
. None None O

The None None O
patterns None None O
, None None O
which None None O
reflect None None O
the None None O
production None None O
of None None O
various None None O
beta None None O
- None None O
lactamase None None O
enzymes None None O
, None None O
were None None O
analyzed None None O
by None None O
a None None O
principal None None O
component None None O
analysis None None O
of None None O
susceptibility None None O
to None None O
11 None None O
beta None None I-FAMILY
- None None I-FAMILY
lactam None None I-FAMILY
antibiotics None None O
or None None O
beta None None I-FAMILY
- None None I-FAMILY
lactam None None I-FAMILY
/ None None O
beta None None O
- None None O
lactamase None None O
inhibitor None None O
combinations None None O
. None None O

Sixty None None O
- None None O
two None None O
percent None None O
of None None O
strains None None O
were None None O
not None None O
very None None O
susceptible None None O
to None None O
penicillins None None I-TRIVIAL
, None None O
cephalothin None None I-TRIVIAL
, None None O
or None None O
any None None O
beta None None I-FAMILY
- None None I-FAMILY
lactam None None I-FAMILY
/ None None O
beta None None O
- None None O
lactamase None None O
inhibitor None None O
combinations None None O
except None None O
for None None O
piperacillin None None I-TRIVIAL
/ None None O
tazobactam None None I-TRIVIAL
; None None O
these None None O
strains None None O
may None None O
represent None None O
high None None O
- None None O
level None None O
broad None None O
- None None O
spectrum None None O
beta None None O
- None None O
lactamase None None O
( None None O
so None None O
- None None O
called None None O
penicillinase None None O
) None None O
production None None O
phenotype None None O
or None None O
inhibitor None None O
- None None O
resistant None None O
TEM None None O
- None None O
like None None O
enzyme None None O
production None None O
phenotype None None O
. None None O

Of None None O
the None None O
strains None None O
, None None O
14.7% None None O
were None None O
resistant None None O
to None None O
amoxicillin None None I-TRIVIAL
and None None O
ticarcillin None None I-TRIVIAL
compatible None None O
with None None O
low None None O
- None None O
level None None O
broad None None O
- None None O
spectrum None None O
beta None None O
- None None O
lactamase None None O
production None None O
phenotype None None O
; None None O
5.7% None None O
were None None O
cefoxitin None None I-TRIVIAL
resistant None None O
and None None O
were None None O
postulated None None O
to None None O
present None None O
a None None O
high None None O
- None None O
level None None O
cephalosporinase None None O
production None None O
phenotype None None O
; None None O
and None None O
2.6% None None O
were None None O
resistant None None O
to None None O
cephalothin None None I-TRIVIAL
only None None O
, None None O
attributable None None O
to None None O
a None None O
low None None O
- None None O
level None None O
cephalosporinase None None O
production None None O
phenotype None None O
. None None O

Three None None O
percent None None O
of None None O
strains None None O
were None None O
intermediate None None O
or None None O
resistant None None O
to None None O
cefotaxime None None I-TRIVIAL
and None None O
may None None O
produce None None O
an None None O
extended None None O
- None None O
spectrum None None O
beta None None O
- None None O
lactamase None None O
, None None O
and None None O
the None None O
remaining None None O
strains None None O
( None None O
12 None None O
% None None O
) None None O
, None None O
resistant None None O
to None None O
all None None O
tested None None O
antibiotics None None O
except None None O
for None None O
cefotaxime None None I-TRIVIAL
and None None O
piperacillin None None I-TRIVIAL
/ None None O
tazobactam None None I-TRIVIAL
, None None O
were None None O
hypothesized None None O
to None None O
produce None None O
both None None O
broad None None O
- None None O
spectrum None None O
beta None None O
- None None O
lactamase None None O
plus None None O
cephalosporinase None None O
. None None O

The None None O
minimal None None O
inhibitory None None O
concentration None None O
( None None O
MIC None None O
) None None O
for None None O
these None None O
phenotype None None O
patterns None None O
indicated None None O
that None None O
combinations None None O
of None None O
CA None None I-ABBREVIATION
plus None None O
amoxicillin None None I-TRIVIAL
or None None O
ticarcillin None None I-TRIVIAL
, None None O
or None None O
sulbactam None None I-TRIVIAL
plus None None O
amoxicillin None None I-TRIVIAL
, None None O
restored None None O
the None None O
activity None None O
of None None O
penicillins None None I-TRIVIAL
against None None O
phenotype None None O
1 None None O
strains None None O
, None None O
whereas None None O
these None None O
combinations None None O
remained None None O
inactive None None O
against None None O
the None None O
other None None O
phenotype None None O
strains None None O
. None None O

Piperacillin None None I-TRIVIAL
plus None None O
tazobactam None None I-TRIVIAL
showed None None O
the None None O
best None None O
in None None O
vitro None None O
effect None None O
against None None O
the None None O
strains None None O
of None None O
all None None O
resistance None None O
phenotypes None None O
. None None O


The None None O
syntheses None None O
and None None O
anthelmintic None None O
activities None None O
of None None O
31 None None O
3 None None I-PARTIUPAC
- None None I-PARTIUPAC
and None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazoles None None I-IUPAC
are None None O
reported None None O
. None None O

In None None O
the None None O
primary None None O
anthelmintic None None O
screen None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
39 None None O
) None None O
showed None None O
100% None None O
nematocidal None None O
activity None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
63 None None O
) None None O
, None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
64 None None O
) None None O
, None None O
and None None O
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
furanyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
isothiocyanatophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,4 None None I-IUPAC
- None None I-IUPAC
oxadiazole None None I-IUPAC
( None None O
66 None None O
) None None O
showed None None O
100% None None O
taeniacidal None None O
activity None None O
when None None O
administered None None O
orally None None O
to None None O
mice None None O
. None None O

The None None O
two None None O
most None None O
active None None O
members None None O
of None None O
this None None O
series None None O
, None None O
39 None None O
and None None O
63 None None O
, None None O
were None None O
active None None O
against None None O
the None None O
gastrointestinal None None O
nematodes None None O
of None None O
sheep None None O
at None None O
100 None None O
mg None None O
/ None None O
kg None None O
. None None O

In None None O
addition None None O
, None None O
39 None None O
was None None O
also None None O
found None None O
to None None O
be None None O
active None None O
against None None O
hookworms None None O
in None None O
dogs None None O
at None None O
a None None O
single None None O
, None None O
oral None None O
dose None None O
of None None O
200 None None O
mg None None O
/ None None O
kg None None O
. None None O


Allopurinol None None I-TRIVIAL
induces None None O
renal None None O
toxicity None None O
by None None O
impairing None None O
pyrimidine None None I-FAMILY
metabolism None None O
in None None O
mice None None O
. None None O

We None None O
investigated None None O
the None None O
relationship None None O
between None None O
the None None O
toxic None None O
effect None None O
of None None O
allopurinol None None I-TRIVIAL
and None None O
pyrimidine None None I-FAMILY
metabolism None None O
in None None O
mice None None O
. None None O

Allopurinol None None I-TRIVIAL
- None None O
induced None None O
increases None None O
in None None O
plasma None None O
transaminase None None O
levels None None O
in None None O
dinitrofluorobenzene None None I-TRIVIAL
( None None O
DNFB None None I-ABBREVIATION
) None None O
- None None O
sensitized None None O
mice None None O
were None None O
not None None O
affected None None O
by None None O
uridine None None I-TRIVIAL
. None None O

In None None O
contrast None None O
, None None O
plasma None None O
creatinine None None I-TRIVIAL
and None None O
BUN None None O
tended None None O
to None None O
decrease None None O
18 None None O
hr None None O
after None None O
the None None O
last None None O
injection None None O
of None None O
uridine None None I-TRIVIAL
. None None O

Both None None O
plasma None None O
and None None O
urinary None None O
orotidine None None I-TRIVIAL
( None None O
OD None None I-ABBREVIATION
) None None O
were None None O
detected None None O
in None None O
DNFB None None O
- None None O
sensitized None None O
mice None None O
after None None O
administration None None O
of None None O
a None None O
single None None O
dose None None O
of None None O
allopurinol None None I-TRIVIAL
. None None O

In None None O
contrast None None O
, None None O
TEI None None I-TRIVIALVAR
- None None I-TRIVIALVAR
6720 None None I-TRIVIALVAR
, None None O
a None None O
newly None None O
synthesized None None O
xanthine None None O
oxidase None None O
/ None None O
xanthine None None O
dehydrogenase None None O
inhibitor None None O
, None None O
caused None None O
neither None None O
pyrimidine None None I-FAMILY
metabolism None None O
abnormality None None O
nor None None O
renal None None O
impairment None None O
in None None O
DNFB None None I-ABBREVIATION
- None None O
sensitized None None O
mice None None O
. None None O

Also None None O
, None None O
normal None None O
mice None None O
administered None None O
high None None O
doses None None O
of None None O
allopurinol None None I-TRIVIAL
showed None None O
abnormal None None O
pyrimidine None None I-FAMILY
metabolism None None O
together None None O
with None None O
renal None None O
toxicity None None O
which None None O
could None None O
be None None O
ameliorated None None O
by None None O
uridine None None I-TRIVIAL
, None None O
indicating None None O
that None None O
allopurinol None None I-TRIVIAL
essentially None None O
causes None None O
pyrimidine None None I-FAMILY
metabolism None None O
abnormality None None O
leading None None O
to None None O
renal None None O
impairment None None O
. None None O

In None None O
DNFB None None O
- None None O
sensitized None None O
mice None None O
, None None O
allopurinol None None I-TRIVIAL
increased None None O
urinary None None O
OD None None I-ABBREVIATION
excretion None None O
to None None O
an None None O
extent None None O
similar None None O
to None None O
that None None O
in None None O
normal None None O
mice None None O
administered None None O
the None None O
same None None O
dose None None O
of None None O
allopurinol None None I-TRIVIAL
. None None O

However None None O
, None None O
renal None None O
impairment None None O
by None None O
allopurinol None None I-TRIVIAL
was None None O
more None None O
striking None None O
in None None O
DNFB None None O
- None None O
sensitized None None O
mice None None O
than None None O
in None None O
normal None None O
mice None None O
. None None O

Histopathological None None O
observations None None O
showed None None O
that None None O
allopurinol None None I-TRIVIAL
induced None None O
calculus None None O
formation None None O
in None None O
the None None O
collecting None None O
tubules None None O
and None None O
papillary None None O
duct None None O
. None None O

Calculus None None O
formation None None O
was None None O
increased None None O
by None None O
DNFB None None I-ABBREVIATION
and None None O
decreased None None O
by None None O
uridine None None I-TRIVIAL
. None None O

These None None O
observations None None O
indicate None None O
that None None O
the None None O
enhancement None None O
of None None O
the None None O
renal None None O
toxicity None None O
of None None O
allopurinol None None I-TRIVIAL
by None None O
DNFB None None O
- None None O
sensitization None None O
may None None O
be None None O
due None None O
to None None O
some None None O
biological None None O
interactions None None O
between None None O
DNFB None None I-ABBREVIATION
and None None O
allopurinol None None I-TRIVIAL
. None None O

In None None O
humans None None O
, None None O
it None None O
is None None O
possible None None O
that None None O
there None None O
are None None O
some None None O
biological None None O
interactions None None O
which None None O
serve None None O
to None None O
enhance None None O
the None None O
toxicity None None O
of None None O
allopurinol None None I-TRIVIAL
, None None O
resulting None None O
in None None O
the None None O
development None None O
of None None O
allopurinol None None I-TRIVIAL
hypersensitivity None None O
syndrome None None O
( None None O
AHS None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
TEI None None I-TRIVIALVAR
- None None I-TRIVIALVAR
6720 None None I-TRIVIALVAR
, None None O
had None None O
no None None O
effect None None O
on None None O
pyrimidine None None I-FAMILY
metabolism None None O
and None None O
showed None None O
no None None O
toxic None None O
effect None None O
. None None O


The None None O
determination None None O
of None None O
the None None O
structure None None O
and None None O
function None None O
of None None O
the None None O
sigma None None O
receptor None None O
subtypes None None O
and None None O
their None None O
physiological None None O
role None None O
( None None O
s None None O
) None None O
has None None O
been None None O
impeded None None O
by None None O
the None None O
unavailability None None O
of None None O
selective None None O
ligands None None O
. None None O

We None None O
have None None O
developed None None O
a None None O
new None None O
class None None O
of None None O
sigma None None O
subtype None None O
selective None None O
receptor None None O
ligands None None O
that None None O
are None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
derivatives None None I-MODIFIER
of None None O
the None None O
synthetic None None O
opioid None None O
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
/ None None I-PARTIUPAC
- None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
( None None I-PARTIUPAC
+ None None I-PARTIUPAC
) None None I-PARTIUPAC
- None None I-PARTIUPAC
, None None O
and None None O
( None None I-IUPAC
- None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
morphan None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
one None None I-IUPAC
( None None O
1 None None O
) None None O
. None None O

The None None O
derivatives None None O
can None None O
be None None O
prepared None None O
by None None O
reaction None None O
of None None O
1 None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
, None None O
and None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
with None None O
the None None O
appropriate None None O
benzaldehyde None None I-TRIVIAL
under None None O
Claisen None None O
- None None O
Schmidt None None O
conditions None None O
. None None O

Incorporation None None O
of None None O
substituted None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
moieties None None I-MODIFIER
onto None None O
the None None O
7 None None O
- None None O
keto None None O
precursor None None O
of None None O
( None None I-IUPAC
+ None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
hydroxyphenyl None None I-IUPAC
) None None I-IUPAC
morphan None None I-IUPAC
, None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
, None None O
produces None None O
compounds None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
through None None O
( None None O
- None None O
) None None O
- None None O
7 None None O
( None None O
5.8-32.0 None None O
nM None None O
, None None O
sigma None None O
1 None None O
) None None O
, None None O
which None None O
have None None O
between None None O
a None None O
25 None None O
- None None O
and None None O
131 None None O
- None None O
fold None None O
increase None None O
in None None O
affinity None None O
for None None O
the None None O
sigma None None O
1 None None O
receptor None None O
subtype None None O
relative None None O
to None None O
the None None O
keto None None O
precursor None None O
( None None O
+ None None O
) None None O
- None None O
1 None None O
( None None O
Ki None None O
= None None O
762 None None O
nM None None O
, None None O
sigma None None O
1 None None O
) None None O
. None None O

Compound None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
is None None O
the None None O
most None None O
selective None None O
of None None O
this None None O
group None None O
( None None O
16 None None O
- None None O
fold None None O
) None None O
for None None O
the None None O
sigma None None O
1 None None O
subtype None None O
versus None None O
sigma None None O
2 None None O
. None None O

Substitution None None O
of None None O
an None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
8 None None I-IUPAC
- None None I-IUPAC
benzylidene None None I-IUPAC
moiety None None O
onto None None O
the None None O
7 None None O
- None None O
keto None None O
precursor None None O
of None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
methyl None None O
- None None O
5 None None O
- None None O
( None None O
3 None None O
- None None O
hydroxyphenyl None None O
) None None O
morphan None None O
, None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
, None None O
produces None None O
compounds None None O
( None None O
+ None None O
) None None O
- None None O
2 None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
9 None None O
( None None O
6.4-52.6 None None O
nM None None O
, None None O
sigma None None O
2 None None O
) None None O
, None None O
which None None O
have None None O
at None None O
least None None O
a None None O
475-3906 None None O
- None None O
fold None None O
increase None None O
in None None O
affinity None None O
for None None O
the None None O
sigma None None O
2 None None O
receptor None None O
subtype None None O
relative None None O
to None None O
the None None O
keto None None O
precursor None None O
( None None O
- None None O
) None None O
- None None O
1 None None O
( None None O
Ki None None O
= None None O
25 None None O
x None None O
10 None None O
( None None O
3 None None O
) None None O
nM None None O
) None None O
. None None O

This None None O
enhancement None None O
of None None O
sigma None None O
2 None None O
receptor None None O
affinity None None O
is None None O
accompanied None None O
by None None O
substantial None None O
selectivity None None O
of None None O
all None None O
of None None O
these None None O
dextrorotatory None None O
products None None O
for None None O
the None None O
sigma None None O
2 None None O
relative None None O
to None None O
the None None O
sigma None None O
1 None None O
subtype None None O
( None None O
32-238 None None O
- None None O
fold None None O
) None None O
, None None O
and None None O
thus None None O
, None None O
they None None O
are None None O
among None None O
the None None O
most None None O
sigma None None O
2 None None O
selective None None O
compounds None None O
currently None None O
known None None O
. None None O

Furthermore None None O
, None None O
the None None O
sigma None None O
1 None None O
subtype None None O
is None None O
highly None None O
enantioselective None None O
for None None O
the None None O
levorotatory None None O
isomers None None O
, None None O
( None None O
- None None O
) None None O
- None None O
2 None None O
- None None O
( None None O
- None None O
) None None O
- None None O
7 None None O
( None None O
41-1034 None None O
- None None O
fold None None O
) None None O
, None None O
whereas None None O
the None None O
sigma None None O
2 None None O
subtype None None O
is None None O
only None None O
somewhat None None O
enantioselective None None O
for None None O
the None None O
dextrorotatory None None O
isomers None None O
, None None O
( None None O
+ None None O
) None None O
- None None O
2 None None O
- None None O
( None None O
+ None None O
) None None O
- None None O
7 None None O
( None None O
2.6-9.3 None None O
- None None O
fold None None O
) None None O
. None None O

All None None O
of None None O
these None None O
derivatives None None O
retain None None O
substantial None None O
affinity None None O
for None None O
the None None O
mu None None O
opioid None None O
receptor None None O
. None None O

Despite None None O
the None None O
high None None O
affinity None None O
of None None O
the None None O
dextrorotatory None None O
derivatives None None O
for None None O
the None None O
mu None None O
opioid None None O
receptor None None O
, None None O
the None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
sigma None None O
2 None None O
over None None O
sigma None None O
1 None None O
sites None None O
will None None O
surely None None O
prove None None O
beneficial None None O
as None None O
tools None None O
for None None O
the None None O
delineation None None O
of None None O
the None None O
function None None O
and None None O
physiological None None O
role None None O
of None None O
sigma None None O
2 None None O
receptors None None O
. None None O


The None None O
design None None O
, None None O
synthesis None None O
, None None O
and None None O
biological None None O
evaluation None None O
of None None O
several None None O
unsaturated None None I-FAMILY
acyclonucleosides None None I-FAMILY
related None None O
to None None O
augustmycin None None I-TRIVIAL
A None None I-TRIVIAL
are None None O
described None None O
. None None O

The None None O
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
acyclonucleoside None None I-IUPAC
analogues None None I-MODIFIER
of None None O
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
, None None O
adenine None None I-TRIVIAL
, None None O
6 None None I-IUPAC
- None None I-IUPAC
methoxypurine None None I-IUPAC
, None None O
hypoxanthine None None I-TRIVIAL
, None None O
6 None None I-IUPAC
- None None I-IUPAC
mercaptopurine None None I-IUPAC
, None None O
and None None O
azathioprine None None I-TRIVIAL
have None None O
been None None O
prepared None None O
. None None O

The None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
( None None O
5 None None O
) None None O
and None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
hypoxanthine None None I-IUPAC
( None None O
12 None None O
) None None O
analogues None None I-MODIFIER
were None None O
converted None None O
to None None O
the None None O
corresponding None None O
5' None None I-PARTIUPAC
- None None I-PARTIUPAC
tributylstannyl None None I-PARTIUPAC
intermediates None None I-MODIFIER
( None None O
9 None None O
and None None O
13 None None O
) None None O
, None None O
respectively None None O
, None None O
which None None O
gave None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
adenine None None I-IUPAC
( None None O
10 None None O
) None None O
and None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
Z None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
iodo None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
oxy None None I-IUPAC
] None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
hypoxanthine None None I-IUPAC
( None None O
14 None None O
) None None O
, None None O
respectively None None O
, None None O
after None None O
iododestannylation None None O
. None None O

The None None O
[ None None O
125I None None O
] None None O
- None None O
radiolabeled None None O
congeners None None O
of None None O
10 None None O
and None None O
14 None None O
were None None O
prepared None None O
as None None O
potential None None O
metabolic None None O
markers None None O
. None None O

Among None None O
the None None O
unsaturated None None I-FAMILY
acyclonucleosides None None I-FAMILY
tested None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
chloropurine None None I-IUPAC
( None None O
3 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
mercaptopurine None None I-IUPAC
( None None O
15 None None O
) None None O
, None None O
9 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
( None None I-IUPAC
propargyloxy None None I-IUPAC
) None None I-IUPAC
methyl None None I-IUPAC
] None None I-IUPAC
azathioprine None None I-IUPAC
( None None O
17 None None O
) None None O
, None None O
and None None O
angustmycin None None I-TRIVIAL
A None None I-TRIVIAL
analogue None None O
10 None None O
showed None None O
inhibition None None O
of None None O
cancer None None O
cell None None O
growth None None O
, None None O
but None None O
only None None O
at None None O
a None None O
minimal None None O
level None None O
, None None O
and None None O
17 None None O
also None None O
showed None None O
14% None None O
cancer None None O
cell None None O
death None None O
in None None O
vitro None None O
. None None O

Compound None None O
10 None None O
provided None None O
approximately None None O
50% None None O
protection None None O
against None None O
HIV None None O
at None None O
10 None None O
( None None O
- None None O
4 None None O
) None None O
M None None O
concentrations None None O
. None None O

Biodistribution None None O
results None None O
of None None O
[ None None O
125I None None O
] None None O
- None None O
10 None None O
in None None O
mice None None O
indicate None None O
that None None O
compound None None O
10 None None O
is None None O
readily None None O
metabolized None None O
via None None O
deiodination None None O
in None None O
vivo None None O
, None None O
possibly None None O
by None None O
serving None None O
as None None O
a None None O
substrate None None O
for None None O
the None None O
enzyme None None O
S None None O
- None None O
adenosyl None None O
- None None O
L None None O
- None None O
homocysteine None None O
hydrolase None None O
. None None O


In None None O
an None None O
attempt None None O
to None None O
increase None None O
the None None O
combined None None O
toxicity None None O
of None None O
the None None O
metabolic None None O
end None None O
- None None O
products None None O
[ None None O
acrolein None None I-TRIVIAL
( None None O
4 None None O
) None None O
and None None O
phosphoramide None None O
mustard None None O
( None None O
3 None None O
) None None O
] None None O
from None None O
cyclophosphamide None None I-TRIVIAL
( None None O
1 None None O
) None None O
, None None O
the None None O
analog None None I-MODIFIER
2 None None B-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
bis None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
chloroethyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
] None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
trifluoromethyl None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorine None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
( None None O
2 None None I-IUPAC
, None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
trifluoromethylcyclophosphamide None None I-IUPAC
) None None O
was None None O
synthesized None None O
and None None O
its None None O
metabolism None None O
and None None O
antitumor None None O
activity None None O
studied None None O
. None None O

Following None None O
metabolism None None O
of None None O
2 None None O
by None None O
rat None None O
liver None None O
microsomes None None O
the None None O
predicted None None O
formation None None O
of None None O
4,4,4 None None I-IUPAC
- None None I-IUPAC
trifluorocrotonaldehyde None None I-IUPAC
( None None O
5 None None O
) None None O
was None None O
confirmed None None O
by None None O
isolation None None O
and None None O
identification None None O
, None None O
by None None O
mass None None O
spectrometry None None O
, None None O
of None None O
its None None O
dinitrophenylhydrazone None None I-TRIVIAL
. None None O

The None None O
therapeutic None None O
indices None None O
( None None O
LD50 None None O
- None None O
/ None None O
ID90 None None O
) None None O
for None None O
2 None None O
against None None O
the None None O
ADJ None None O
/ None None O
PC6 None None O
mouse None None O
tumor None None O
and None None O
the None None O
Walker None None O
256 None None O
tumor None None O
in None None O
the None None O
rat None None O
were None None O
28.6 None None O
and None None O
7.7 None None O
, None None O
respectively None None O
, None None O
and None None O
were None None O
lower None None O
than None None O
the None None O
corresponding None None O
values None None O
for None None O
1 None None O
( None None O
91.8 None None O
and None None O
33.2 None None O
, None None O
respectively None None O
) None None O
although None None O
the None None O
toxicities None None O
toward None None O
Walker None None O
cells None None O
in None None O
a None None O
bioassay None None O
system None None O
of None None O
1 None None O
and None None O
2 None None O
following None None O
microsomal None None O
metabolism None None O
were None None O
similar None None O
. None None O

In None None O
order None None O
to None None O
study None None O
the None None O
toxicities None None O
of None None O
4 None None O
and None None O
5 None None O
released None None O
under None None O
drug None None O
metabolizing None None O
conditions None None O
independently None None O
of None None O
the None None O
production None None O
of None None O
a None None O
toxic None None O
mustard None None I-FAMILY
the None None O
analogs None None I-MODIFIER
18 None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorine None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
] None None O
and None None O
6 None None O
[ None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
diethylamino None None I-IUPAC
) None None I-IUPAC
tetrahydro None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
trifluoromethyl None None I-IUPAC
- None None I-IUPAC
2H None None I-IUPAC
- None None I-IUPAC
1,3,2 None None I-IUPAC
- None None I-IUPAC
oxazaphosphorine None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxide None None I-IUPAC
] None None O
were None None O
also None None O
synthesized None None O
. None None O

The None None O
release None None O
of None None O
5 None None O
from None None O
6 None None O
following None None O
metabolism None None O
was None None O
confirmed None None O
and None None O
shown None None O
by None None O
use None None O
of None None O
the None None O
bioassay None None O
system None None O
to None None O
be None None O
an None None O
event None None O
of None None O
similar None None O
toxicity None None O
to None None O
release None None O
of None None O
4 None None O
from None None O
18 None None O
; None None O
in None None O
vivo None None O
, None None O
however None None O
, None None O
6 None None O
( None None O
LD50 None None O
330 None None O
mg None None O
/ None None O
kg None None O
) None None O
was None None O
more None None O
toxic None None O
to None None O
mice None None O
than None None O
18 None None O
( None None O
LD50 None None O
greater None None O
than None None O
500 None None O
mg None None O
/ None None O
kg None None O
) None None O
. None None O


There None None O
is None None O
reported None None O
the None None O
first None None O
four None None O
members None None O
of None None O
heteroarotinoids None None I-FAMILY
, None None O
the None None O
names None None O
of None None O
which None None O
are None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1b None None O
) None None O
, None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylchroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1c None None O
) None None O
, None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
oxothiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1d None None O
) None None O
, None None O
and None None O
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylchroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoic None None I-IUPAC
acid None None I-IUPAC
( None None O
1e None None O
) None None O
. None None O

IR None None O
, None None O
1H None None O
NMR None None O
and None None O
13C None None O
NMR None None O
data None None O
have None None O
been None None O
recorded None None O
for None None O
each None None O
compound None None O
and None None O
support None None O
the None None O
structural None None O
assignments None None O
. None None O

To None None O
provide None None O
a None None O
firm None None O
basis None None O
for None None O
comparison None None O
purposes None None O
of None None O
future None None O
analogues None None O
, None None O
an None None O
X None None O
- None None O
ray None None O
analysis None None O
was None None O
performed None None O
on None None O
a None None O
single None None O
crystal None None O
of None None O
ethyl None None I-IUPAC
( None None I-IUPAC
E None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
propenyl None None I-IUPAC
] None None I-IUPAC
benzoate None None I-IUPAC
( None None O
1b None None O
) None None O
and None None O
a None None O
precursor None None O
4,4 None None I-IUPAC
- None None I-IUPAC
dimethylthiochroman None None I-IUPAC
- None None I-IUPAC
6 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
methyl None None I-IUPAC
ketone None None I-IUPAC
1,1 None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
( None None O
18 None None O
) None None O
. None None O

These None None O
data None None O
for None None O
the None None O
heteroarotinoid None None I-FAMILY
1b None None O
revealed None None O
that None None O
the None None O
two None None O
aryl None None O
ring None None O
systems None None O
were None None O
nearly None None O
perpendicular None None O
in None None O
each None None O
of None None O
the None None O
two None None O
molecules None None O
present None None O
in None None O
the None None O
unit None None O
cell None None O
( None None O
86.37 None None O
degrees None None O
and None None O
84.17 None None O
degrees None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
space None None O
group None None O
for None None O
both None None O
molecules None None O
was None None O
P1 None None O
in None None O
triclinic None None O
systems None None O
. None None O

Unit None None O
cell None None O
dimensions None None O
( None None O
at None None O
15 None None O
degrees None None O
C None None O
) None None O
are None None O
as None None O
follows None None O
: None None O
for None None O
1b None None O
, None None O
a None None O
= None None O
20.568 None None O
( None None O
6 None None O
) None None O
A None None O
, None None O
b None None O
= None None O
14.760 None None O
( None None O
3 None None O
) None None O
A None None O
, None None O
c None None O
= None None O
7.679 None None O
( None None O
2 None None O
) None None O
A None None O
, None None O
alpha None None O
= None None O
113.33 None None O
( None None O
2 None None O
) None None O
degrees None None O
, None None O
beta None None O
= None None O
79.45 None None O
( None None O
2 None None O
) None None O
degrees None None O
, None None O
gamma None None O
= None None O
79.98 None None O
( None None O
2 None None O
) None None O
degrees None None O
, None None O
Z None None O
= None None O
4 None None O
; None None O
for None None O
18 None None O
, None None O
a None None O
= None None O
9.292 None None O
( None None O
5 None None O
) None None O
A None None O
, None None O
b None None O
= None None O
9.291 None None O
( None None O
5 None None O
) None None O
A None None O
, None None O
c None None O
= None None O
7.951 None None O
( None None O
3 None None O
) None None O
A None None O
, None None O
alpha None None O
= None None O
102.16 None None O
( None None O
3 None None O
) None None O
degrees None None O
, None None O
beta None None O
= None None O
77.49 None None O
( None None O
3 None None O
) None None O
degrees None None O
, None None O
gamma None None O
= None None O
79.60 None None O
( None None O
4 None None O
) None None O
degrees None None O
, None None O
Z None None O
= None None O
2 None None O
. None None O

The None None O
sulfur None None I-TRIVIAL
- None None O
containing None None O
ring None None O
is None None O
in None None O
a None None O
distorted None None O
half None None O
- None None O
chair None None O
in None None O
1b None None O
and None None O
the None None O
methyl None None I-PARTIUPAC
carbon None None B-TRIVIAL
C None None O
( None None O
12 None None O
) None None O
is None None O
shown None None O
to None None O
be None None O
trans None None O
to None None O
H None None O
( None None O
13 None None O
) None None O
at None None O
the None None O
C None None O
( None None O
11 None None O
) None None O
- None None O
C None None O
( None None O
13 None None O
) None None O
bond None None O
. None None O

The None None O
biological None None O
activity None None O
of None None O
these None None O
arotinoids None None I-FAMILY
was None None O
determined None None O
in None None O
the None None O
tracheal None None O
organ None None O
culture None None O
assay None None O
and None None O
compared None None O
with None None O
trans None None I-TRIVIAL
- None None I-TRIVIAL
retinoic None None I-TRIVIAL
acid None None I-TRIVIAL
for None None O
ability None None O
to None None O
reverse None None O
keratinization None None O
in None None O
vitamin None None I-TRIVIAL
A None None I-TRIVIAL
deficient None None O
hamsters None None O
. None None O

The None None O
ester None None O
1b None None O
displayed None None O
activity None None O
about None None O
one None None O
- None None O
half None None O
log None None O
unit None None O
less None None O
than None None O
that None None O
of None None O
the None None O
reference None None O
while None None O
1c None None O
and None None O
1e None None O
had None None O
activity None None O
nearly None None O
one None None O
log None None O
until None None O
less None None O
than None None O
trans None None I-TRIVIAL
- None None I-TRIVIAL
retinoic None None I-TRIVIAL
acid None None I-TRIVIAL
. None None O

The None None O
sulfoxide None None I-FAMILY
was None None O
the None None O
least None None O
active None None O
of None None O
the None None O
heteroretinoids None None I-FAMILY
. None None O


Identification None None O
of None None O
MAGI None None O
- None None O
3 None None O
as None None O
a None None O
transforming None None O
growth None None O
factor None None O
- None None O
alpha None None O
tail None None O
binding None None O
protein None None O
. None None O

The None None O
cytoplasmic None None O
domain None None O
of None None O
the None None O
transforming None None O
growth None None O
factor None None O
- None None O
alpha None None O
precursor None None O
( None None O
proTGFalpha None None O
) None None O
contains None None O
a None None O
C None None O
- None None O
terminal None None O
PSD None None O
- None None O
95 None None O
/ None None O
SAP90 None None O
, None None O
Discs None None O
Large None None O
, None None O
and None None O
Zona None None O
Occludens None None O
- None None O
1 None None O
( None None O
PDZ None None O
) None None O
recognition None None O
motif None None O
( None None O
TVV None None O
) None None O
. None None O

By None None O
yeast None None O
two None None O
- None None O
hybrid None None O
screening None None O
of None None O
a None None O
mouse None None O
embryo None None O
library None None O
, None None O
we None None O
have None None O
found None None O
that None None O
a None None O
third None None O
member None None O
of None None O
a None None O
family None None O
of None None O
PDZ None None O
- None None O
containing None None O
proteins None None O
, None None O
membrane None None O
associated None None O
guanylate None None O
kinase None None O
inverted None None O
- None None O
3 None None O
( None None O
MAGI None None O
- None None O
3 None None O
) None None O
, None None O
binds None None O
to None None O
TGFalpha None None O
's None None O
TVV None None O
. None None O

MAGI None None O
- None None O
3 None None O
is None None O
widely None None O
expressed None None O
in None None O
multiple None None O
mouse None None O
tissues None None O
, None None O
including None None O
brain None None O
. None None O

Immunolocalization None None O
showed None None O
that None None O
MAGI None None O
- None None O
3 None None O
and None None O
TGFalpha None None O
were None None O
colocalized None None O
in None None O
neurons None None O
in None None O
the None None O
cortex None None O
and None None O
dentate None None O
gyrus None None O
, None None O
as None None O
well None None O
as None None O
in None None O
ependymal None None O
cells None None O
and None None O
some None None O
astrocytes None None O
. None None O

In None None O
vitro None None O
, None None O
proTGFalpha None None O
bound None None O
the None None O
PDZ None None O
- None None O
1 None None O
domain None None O
of None None O
MAGI None None O
- None None O
3 None None O
and None None O
MAGI None None O
- None None O
2 None None O
, None None O
but None None O
not None None O
MAGI None None O
- None None O
1 None None O
. None None O

MAGI None None O
- None None O
3 None None O
and None None O
the None None O
17 None None O
- None None O
kDa None None O
cell None None O
surface None None O
form None None O
of None None O
proTGFalpha None None O
interact None None O
transiently None None O
in None None O
MDCK None None O
cells None None O
stably None None O
transfected None None O
with None None O
both None None O
MAGI None None O
- None None O
3 None None O
and None None O
human None None O
proTGFalpha None None O
cDNAs None None O
. None None O

MAGI None None O
- None None O
3 None None O
and None None O
wild None None O
- None None O
type None None O
proTGFalpha None None O
colocalize None None O
at None None O
the None None O
cell None None O
surface None None O
. None None O

In None None O
contrast None None O
, None None O
MAGI None None O
- None None O
3 None None O
forms None None O
a None None O
stable None None O
complex None None O
with None None O
membrane None None O
- None None O
fixed None None O
TGFalpha None None O
early None None O
in None None O
the None None O
secretory None None O
pathway None None O
and None None O
interacts None None O
with None None O
immature None None O
and None None O
cell None None O
surface None None O
forms None None O
of None None O
membrane None None O
- None None O
fixed None None O
TGFalpha None None O
. None None O

Overexpression None None O
of None None O
MAGI None None O
- None None O
3 None None O
resulted None None O
in None None O
increased None None O
levels None None O
of None None O
TGFalpha None None O
in None None O
the None None O
basolateral None None O
medium None None O
of None None O
polarized None None O
MDCK None None O
cells None None O
, None None O
suggesting None None O
that None None O
MAGI None None O
- None None O
3 None None O
has None None O
a None None O
role None None O
in None None O
efficient None None O
trafficking None None O
of None None O
TGFalpha None None O
to None None O
the None None O
cell None None O
surface None None O
in None None O
polarized None None O
epithelial None None O
cells None None O
. None None O


A None None O
series None None O
of None None O
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
derivatives None None I-MODIFIER
with None None O
a None None O
modified None None O
side None None O
chain None None O
terminus None None O
was None None O
prepared None None O
. None None O

These None None O
agents None None O
were None None O
evaluated None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
for None None O
their None None O
ability None None O
to None None O
suppress None None O
HMG None None O
CoA None None O
reductase None None O
, None None O
the None None O
rate None None O
- None None O
limiting None None O
enzyme None None O
of None None O
cholesterol None None I-TRIVIAL
biosynthesis None None O
. None None O

In None None O
tissue None None O
culture None None O
assays None None O
, None None O
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
as None None O
well None None O
as None None O
the None None O
side None None O
chain None None O
modified None None O
analogues None None O
were None None O
potent None None O
inhibitors None None O
of None None O
HMG None None O
CoA None None O
reductase None None O
. None None O

However None None O
, None None O
only None None O
those None None O
sterols None None O
with None None O
a None None O
modified None None O
side None None O
chain None None O
terminus None None O
were None None O
effective None None O
suppressors None None O
of None None O
liver None None O
reductase None None O
when None None O
administered None None O
ig None None O
to None None O
rats None None O
. None None O

22 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
25 None None I-IUPAC
- None None I-IUPAC
methylcholesterol None None I-IUPAC
( None None O
4a None None O
) None None O
and None None O
25 None None I-IUPAC
- None None I-IUPAC
fluoro None None I-IUPAC
- None None I-IUPAC
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
( None None O
15a None None O
) None None O
significantly None None O
lowered None None O
serum None None O
cholesterol None None O
levels None None O
when None None O
administered None None O
ig None None O
to None None O
primates None None O
; None None O
25 None None I-IUPAC
- None None I-IUPAC
chloro None None I-IUPAC
- None None I-IUPAC
22 None None I-IUPAC
- None None I-IUPAC
hydroxycholesterol None None I-IUPAC
( None None O
15b None None O
) None None O
and None None O
the None None O
analogue None None O
with None None O
a None None O
cyclopropyl None None I-TRIVIAL
terminus None None O
, None None O
20b None None O
, None None O
were None None O
ineffective None None O
. None None O

The None None O
cholesterol None None I-TRIVIAL
- None None O
lowering None None O
sterols None None I-FAMILY
did None None O
not None None O
significantly None None O
alter None None O
lipoprotein None None O
levels None None O
; None None O
however None None O
, None None O
the None None O
two None None O
compounds None None O
have None None O
been None None O
shown None None O
to None None O
inhibit None None O
acyl None None O
- None None O
coenzyme None None O
A None None O
: None None O
cholesterol None None O
acyl None None O
- None None O
transferase None None O
( None None O
ACAT None None O
) None None O
in None None O
tissue None None O
culture None None O
studies None None O
. None None O


Synthesis None None O
of None None O
pyridino None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
4,9 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
and None None O
6,7 None None I-IUPAC
- None None I-IUPAC
disubstituted None None I-IUPAC
quinoline None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
derivatives None None I-MODIFIER
and None None O
evaluation None None O
on None None O
their None None O
cytotoxic None None O
activity None None O
. None None O

We None None O
report None None O
upon None None O
the None None O
synthesis None None O
of None None O
the None None O
following None None O
derivatives None None O
: None None O
N None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
pyridino None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
4,9 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
, None None O
and None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
diethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
substituted None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
quinoline None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
, None None O
which None None O
contain None None O
the None None O
active None None O
quinoline None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
VII None None O
) None None O
moiety None None I-MODIFIER
. None None O

The None None O
cytotoxic None None O
activities None None O
of None None O
these None None O
compounds None None O
have None None O
been None None O
tested None None O
in None None O
SRB None None O
( None None O
SulfoRhodamine None None O
B None None O
) None None O
assays None None O
against None None O
the None None O
cancer None None O
cell None None O
lines None None O
of None None O
A None None O
- None None O
549 None None O
( None None O
human None None O
lung None None O
cancer None None O
) None None O
, None None O
SK None None O
- None None O
MEL None None O
- None None O
2 None None O
( None None O
human None None O
melanoma None None O
cancer None None O
) None None O
, None None O
SK None None O
- None None O
OV None None O
- None None O
3 None None O
( None None O
human None None O
ovarian None None O
cancer None None O
) None None O
, None None O
XF None None O
- None None O
498 None None O
( None None O
human None None O
brain None None O
cancer None None O
) None None O
and None None O
HCT None None O
15 None None O
( None None O
human None None O
colon None None O
cancer None None O
) None None O
. None None O

The None None O
compound None None O
, None None O
N None None I-IUPAC
- None None I-IUPAC
benzyl None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
ethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
pyridino None None I-IUPAC
[ None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
f None None I-IUPAC
] None None I-IUPAC
indole None None I-IUPAC
- None None I-IUPAC
4,9 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
A None None O
- None None O
9 None None O
) None None O
, None None O
also None None O
showed None None O
higher None None O
activity None None O
than None None O
cis None None I-TRIVIAL
- None None I-TRIVIAL
platin None None I-TRIVIAL
. None None O

The None None O
highest None None O
level None None O
of None None O
cytotoxic None None O
activity None None O
in None None O
these None None O
human None None O
tumor None None O
cell None None O
lines None None O
was None None O
observed None None O
in None None O
the None None O
compound None None O
6 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
alpha None None I-IUPAC
- None None I-IUPAC
diethoxycarbonyl None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
7 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
methyl None None I-IUPAC
- None None I-IUPAC
phenylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
quinoline None None I-IUPAC
- None None I-IUPAC
5,8 None None I-IUPAC
- None None I-IUPAC
dione None None I-IUPAC
( None None O
B None None O
- None None O
3 None None O
) None None O
. None None O


Two None None O
2,3 None None I-IUPAC
- None None I-IUPAC
dihydrobenzofuran None None I-IUPAC
analogues None None I-MODIFIER
of None None O
hallucinogenic None None O
amphetamines None None I-FAMILY
were None None O
prepared None None O
and None None O
evaluated None None O
for None None O
activity None None O
in None None O
the None None O
two None None O
- None None O
lever None None O
drug None None O
- None None O
discrimination None None O
paradigm None None O
in None None O
rats None None O
trained None None O
to None None O
discriminate None None O
saline None None O
from None None O
LSD None None I-IUPAC
tartrate None None I-IUPAC
( None None O
0.08 None None O
mg None None O
/ None None O
kg None None O
) None None O
and None None O
for None None O
the None None O
ability None None O
to None None O
displace None None O
[ None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
DOI None None I-IUPAC
[ None None O
( None None I-IUPAC
125I None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxy None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
iodophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
) None None I-IUPAC
from None None O
rat None None O
cortical None None O
homogenate None None O
5 None None O
- None None O
HT2 None None O
receptors None None O
. None None O

The None None O
compounds None None O
, None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
methoxy None None I-IUPAC
- None None I-IUPAC
2,3 None None I-IUPAC
- None None I-IUPAC
dihydrobenzofuran None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
( None None O
6a None None O
) None None O
and None None O
its None None O
7 None None I-PARTIUPAC
- None None I-PARTIUPAC
brominated None None I-PARTIUPAC
analogue None None I-MODIFIER
6b None None O
, None None O
possessed None None O
activity None None O
comparable None None O
to None None O
their None None O
conformationally None None O
flexible None None O
counterparts None None O
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
2,5 None None I-IUPAC
- None None I-IUPAC
dimethoxyphenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
aminopropane None None I-IUPAC
( None None O
3 None None O
) None None O
and None None O
its None None O
4 None None I-PARTIUPAC
- None None I-PARTIUPAC
bromo None None I-PARTIUPAC
derivative None None I-MODIFIER
DOB None None B-ABBREVIATION
( None None O
5 None None O
) None None O
, None None O
respectively None None O
. None None O

The None None O
results None None O
suggest None None O
that None None O
the None None O
dihydrofuran None None I-TRIVIAL
ring None None O
in None None O
6a None None O
and None None O
6b None None O
models None None O
the None None O
active None None O
conformation None None O
of None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
groups None None I-MODIFIER
in None None O
3 None None O
and None None O
5 None None O
. None None O

Free None None O
energy None None O
of None None O
binding None None O
, None None O
derived None None O
from None None O
radioligand None None O
displacement None None O
KA None None O
values None None O
, None None O
indicated None None O
that None None O
addition None None O
of None None O
the None None O
bromine None None I-TRIVIAL
in None None O
either None None O
series None None O
contributes None None O
2.4-3.2 None None O
kcal None None O
/ None None O
mol None None O
of None None O
binding None None O
energy None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
surface None None O
area None None O
of None None O
the None None O
bromine None None I-TRIVIAL
atom None None B-MODIFIER
, None None O
this None None O
value None None O
is None None O
2-3 None None O
times None None O
higher None None O
than None None O
would None None O
be None None O
expected None None O
on None None O
the None None O
basis None None O
of None None O
hydrophobic None None O
binding None None O
. None None O

Thus None None O
, None None O
hydrophobicity None None O
of None None O
the None None O
para None None O
substituent None None O
alone None None O
cannot None None O
account None None O
for None None O
the None None O
dramatic None None O
enhancement None None O
of None None O
hallucinogenic None None O
activity None None O
. None None O

Although None None O
this None None O
substituent None None O
may None None O
play None None O
a None None O
minor None None O
role None None O
in None None O
orienting None None O
the None None O
conformation None None O
of None None O
the None None O
5 None None I-PARTIUPAC
- None None I-PARTIUPAC
methoxy None None I-PARTIUPAC
group None None I-MODIFIER
in None None O
derivatives None None O
such None None O
as None None O
4 None None O
and None None O
5 None None O
, None None O
there None None O
appears None None O
to None None O
be None None O
some None None O
other None None O
, None None O
as None None O
yet None None O
unknown None None O
, None None O
critical None None O
receptor None None O
interaction None None O
. None None O


Sulfur None None O
- None None O
bridged None None O
pregnanes None None O
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
, None None O
21 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
, None None O
and None None O
the None None O
corresponding None None O
sulfoxides None None I-FAMILY
and None None O
sulfones None None I-FAMILY
were None None O
synthesized None None O
and None None O
tested None None O
as None None O
blockers None None O
of None None O
the None None O
immunosuppresive None None O
activity None None O
of None None O
dexamethasone None None I-TRIVIAL
in None None O
rat None None O
thymocytes None None O
. None None O

A None None O
new None None O
one None None O
- None None O
pot None None O
procedure None None O
is None None O
described None None O
for None None O
the None None O
preparation None None O
of None None O
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
and None None O
related None None O
compounds None None O
by None None O
iodocyclization None None O
of None None O
a None None O
19 None None I-IUPAC
- None None I-IUPAC
sulfanylpregn None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ene None None I-IUPAC
. None None O

Antiimmunosuppresive None None O
activity None None O
was None None O
evaluated None None O
by None None O
the None None O
ability None None O
of None None O
the None None O
different None None O
steroids None None O
to None None O
block None None O
dexamethasone None None I-TRIVIAL
- None None O
mediated None None O
apoptosis None None O
in None None O
thymocytes None None O
and None None O
dexamethasone None None I-TRIVIAL
- None None O
mediated None None O
inhibition None None O
of None None O
the None None O
NFkappa None None O
- None None O
B None None O
transcription None None O
factor None None O
activity None None O
. None None O

DNA None None O
fragmentation None None O
and None None O
annexin None None O
V None None O
- None None O
FITC None None O
positive None None O
cells None None O
were None None O
taken None None O
as None None O
parameters None None O
of None None O
apoptosis None None O
whereas None None O
NFkappa None None O
- None None O
B None None O
activity None None O
was None None O
tested None None O
by None None O
the None None O
expression None None O
of None None O
the None None O
reporter None None O
vector None None O
kappaB None None O
- None None O
luciferase None None O
by None None O
TNF None None O
- None None O
alpha None None O
in None None O
Hela None None O
cells None None O
. None None O

21 None None I-IUPAC
- None None I-IUPAC
Hydroxy None None I-IUPAC
- None None I-IUPAC
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
S None None I-IUPAC
, None None I-IUPAC
S None None I-IUPAC
- None None I-IUPAC
dioxide None None I-IUPAC
had None None O
improved None None O
activity None None O
in None None O
both None None O
parameters None None O
, None None O
while None None O
21 None None I-IUPAC
- None None I-IUPAC
hydroxy None None I-IUPAC
- None None I-IUPAC
6,19 None None I-IUPAC
- None None I-IUPAC
epithioprogesterone None None I-IUPAC
had None None O
improved None None O
activity None None O
only None None O
in None None O
blocking None None O
dexamethasone None None I-TRIVIAL
- None None O
induced None None O
programmed None None O
cell None None O
death None None O
. None None O


A None None O
number None None O
of None None O
derivatives None None O
structurally None None O
related None None O
to None None O
cirazoline None None I-TRIVIAL
( None None O
1 None None O
) None None O
were None None O
synthesized None None O
and None None O
studied None None O
with None None O
the None None O
purpose None None O
of None None O
modulating None None O
alpha2 None None O
- None None O
adrenoreceptors None None O
selectivity None None O
versus None None O
both None None O
alpha1 None None O
- None None O
adrenoreceptors None None O
and None None O
I2 None None O
imidazoline None None I-TRIVIAL
binding None None O
sites None None O
. None None O

The None None O
most None None O
potent None None O
alpha2 None None O
- None None O
agonist None None O
was None None O
2 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
biphenyl None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
yloxy None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4,5 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazole None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
whose None None O
key None None O
pharmacophoric None None O
features None None O
closely None None O
matched None None O
those None None O
found None None O
in None None O
the None None O
alpha2 None None O
- None None O
agonist None None O
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
exo None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
phenylprop None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
exo None None I-IUPAC
- None None I-IUPAC
norbornyl None None I-IUPAC
) None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
oxazoline None None I-IUPAC
( None None O
15 None None O
) None None O
. None None O

( None None O
S None None O
) None None O
- None None O
( None None O
- None None O
) None None O
- None None O
7 None None O
was None None O
the None None O
most None None O
potent None None O
of None None O
the None None O
two None None O
enantiomers None None O
, None None O
confirming None None O
the None None O
stereospecificity None None O
of None None O
the None None O
interaction None None O
with None None O
alpha2 None None O
- None None O
adrenoreceptors None None O
. None None O

This None None O
eutomer None None O
was None None O
tested None None O
on None None O
two None None O
algesiometric None None O
paradigms None None O
and None None O
, None None O
because None None O
of None None O
the None None O
interaction None None O
with None None O
alpha2 None None O
- None None O
adrenoreceptors None None O
, None None O
showed None None O
a None None O
potent None None O
and None None O
long None None O
- None None O
lasting None None O
antinociceptive None None O
activity None None O
, None None O
since None None O
it None None O
was None None O
abolished None None O
by None None O
the None None O
selective None None O
alpha2 None None O
- None None O
antagonist None None O
RX821002 None None I-TRIVIALVAR
. None None O


Tissue None None O
and None None O
serum None None O
levels None None O
of None None O
principal None None O
androgens None None I-FAMILY
in None None O
benign None None O
prostatic None None O
hyperplasia None None O
and None None O
prostate None None O
cancer None None O
. None None O

Androgens None None I-FAMILY
are None None O
considered None None O
to None None O
play None None O
a None None O
substantial None None O
role None None O
in None None O
pathogenesis None None O
of None None O
both None None O
benign None None O
prostatic None None O
hyperplasia None None O
( None None O
BPH None None O
) None None O
and None None O
prostate None None O
cancer None None O
. None None O

The None None O
importance None None O
of None None O
determination None None O
of None None O
androgen None None I-FAMILY
levels None None O
in None None O
tissue None None O
and None None O
serum None None O
for None None O
cancer None None O
progression None None O
and None None O
prognosis None None O
has None None O
been None None O
poorly None None O
understood None None O
. None None O

The None None O
aim None None O
of None None O
study None None O
was None None O
to None None O
find None None O
out None None O
hormonal None None O
differences None None O
in None None O
both None None O
diseases None None O
, None None O
their None None O
correlations None None O
between None None O
intraprostatic None None O
and None None O
serum None None O
levels None None O
and None None O
predicted None None O
value None None O
of None None O
their None None O
investigation None None O
. None None O

Testosterone None None I-TRIVIAL
, None None O
dihydrotestosterone None None I-TRIVIAL
, None None O
androstenedione None None I-TRIVIAL
and None None O
also None None O
epitestosterone None None I-TRIVIAL
were None None O
determined None None O
in None None O
prostate None None O
tissue None None O
from None None O
57 None None O
patients None None O
who None None O
underwent None None O
transvesical None None O
prostatectomy None None O
for None None O
BPH None None O
and None None O
121 None None O
patients None None O
after None None O
radical None None O
prostatectomy None None O
for None None O
prostate None None O
cancer None None O
. None None O

In None None O
75 None None O
subjects None None O
with None None O
cancer None None O
and None None O
51 None None O
with None None O
BPH None None O
the None None O
serum None None O
samples None None O
were None None O
analyzed None None O
for None None O
testosterone None None I-TRIVIAL
, None None O
dihydrotestosterone None None I-TRIVIAL
and None None O
SHBG None None O
. None None O

Significantly None None O
higher None None O
intraprostatic None None O
androgen None None I-TRIVIAL
concentrations None None O
, None None O
i.e. None None O
8.85 None None O
+ None None O
/ None None O
- None None O
6.77 None None O
versus None None O
6.44 None None O
+ None None O
/ None None O
- None None O
6.43 None None O
pmol None None O
/ None None O
g None None O
, None None O
p None None O
< None None O
0.01 None None O
for None None O
dihydrotestosterone None None I-TRIVIAL
, None None O
and None None O
4.61 None None O
+ None None O
/ None None O
- None None O
7.02 None None O
versus None None O
3.44 None None O
+ None None O
/ None None O
- None None O
4.53 None None O
pmol None None O
/ None None O
g None None O
, None None O
p None None O
< None None O
0.05 None None O
for None None O
testosterone None None I-TRIVIAL
, None None O
respectively None None O
, None None O
were None None O
found None None O
in None None O
patients None None O
with None None O
prostate None None O
cancer None None O
than None None O
in None None O
BPH None None O
. None None O

Higher None None O
levels None None O
in None None O
cancer None None O
tissue None None O
were None None O
found None None O
also None None O
for None None O
epitestosterone None None I-TRIVIAL
. None None O

However None None O
, None None O
no None None O
differences None None O
were None None O
found None None O
in None None O
serum None None O
levels None None O
. None None O

Highly None None O
significant None None O
correlations None None O
occurred None None O
between None None O
all None None O
pairs None None O
of None None O
intraprostatic None None O
androgens None None I-FAMILY
and None None O
also None None O
epitestosterone None None I-TRIVIAL
as None None O
well None None O
as None None O
between None None O
serum None None O
testosterone None None I-TRIVIAL
and None None O
dihydrotestosterone None None I-TRIVIAL
( None None O
p None None O
< None None O
0.001 None None O
) None None O
in None None O
both None None O
BPH None None O
and None None O
cancer None None O
groups None None O
. None None O

Correlation None None O
was None None O
not None None O
found None None O
between None None O
corresponding None None O
tissue None None O
and None None O
serum None None O
testosterone None None I-TRIVIAL
and None None O
dihydrotestosterone None None I-TRIVIAL
, None None O
either None None O
in None None O
benign None None O
or None None O
cancer None None O
samples None None O
. None None O

The None None O
results None None O
point None None O
to None None O
importance None None O
of None None O
intraprostatic None None O
hormone None None O
levels None None O
for None None O
evaluation None None O
of None None O
androgen None None O
status None None O
of None None O
patients None None O
, None None O
contrasting None None O
to None None O
a None None O
low None None O
value None None O
of None None O
serum None None O
hormone None None O
measurement None None O
. None None O


XBMP None None O
- None None O
1B None None O
( None None O
Xtld None None O
) None None O
, None None O
a None None O
Xenopus None None O
homolog None None O
of None None O
dorso None None O
- None None O
ventral None None O
polarity None None O
gene None None O
in None None O
Drosophila None None O
, None None O
modifies None None O
tissue None None O
phenotypes None None O
of None None O
ventral None None O
explants None None O
. None None O

Previously None None O
we None None O
have None None O
isolated None None O
a None None O
Xenopus None None O
cDNA None None O
homolog None None O
of None None O
bone None None O
morphogenetic None None O
protein None None O
- None None O
1 None None O
( None None O
XBMP None None O
- None None O
1A None None O
) None None O
. None None O

In None None O
the None None O
present None None O
report None None O
we None None O
describe None None O
a None None O
new None None O
cDNA None None O
clone None None O
called None None O
XBMP None None O
- None None O
1B None None O
( None None O
or None None O
Xtld None None O
) None None O
from None None O
a None None O
Xenopus None None O
embryonic None None O
library None None O
. None None O

Sequence None None O
analysis None None O
indicates None None O
that None None O
these None None O
two None None O
clones None None O
share None None O
an None None O
indentical None None O
N None None O
- None None O
terminal None None O
sequence None None O
, None None O
including None None O
a None None O
region None None O
of None None O
metalloprotease None None O
domain None None O
, None None O
three None None O
copies None None O
of None None O
a None None O
repeat None None O
first None None O
found None None O
in None None O
complement None None O
proteins None None O
C1r None None O
/ None None O
s None None O
and None None O
an None None O
epidermal None None O
growth None None O
factor None None O
( None None O
EGF None None O
) None None O
- None None O
like None None O
sequence None None O
. None None O

XBMP None None O
- None None O
1B None None O
protein None None O
has None None O
an None None O
additional None None O
copy None None O
of None None O
an None None O
EGF None None O
- None None O
like None None O
sequence None None O
followed None None O
by None None O
two None None O
copies None None O
of None None O
complement None None O
1 None None O
r None None O
/ None None O
s None None O
repeat None None O
in None None O
the None None O
C None None O
- None None O
terminus None None O
. None None O

The None None O
overall None None O
protein None None O
structure None None O
predicted None None O
from None None O
the None None O
XBMP None None O
- None None O
1B None None O
sequence None None O
reveals None None O
that None None O
it None None O
encodes None None O
a None None O
protein None None O
homologous None None O
to None None O
Drosophila None None O
tolloid None None O
. None None O

Three None None O
XBMP None None O
- None None O
1 None None O
transcripts None None O
( None None O
2.9 None None O
, None None O
5.2 None None O
and None None O
6.6 None None O
kb None None O
) None None O
were None None O
detected None None O
by None None O
northern None None O
blot None None O
analysis None None O
. None None O

However None None O
, None None O
the None None O
2.9 None None O
kb None None O
transcript None None O
hybridized None None O
specifically None None O
with None None O
XBMP None None O
- None None O
1A None None O
and None None O
the None None O
5.2 None None O
and None None O
6.6 None None O
kb None None O
transcripts None None O
hybridized None None O
with None None O
XBMP None None O
- None None O
1B None None O
. None None O

In None None O
Drosophila None None O
, None None O
a None None O
major None None O
function None None O
of None None O
tolloid None None O
is None None O
to None None O
augment None None O
the None None O
activity None None O
of None None O
the None None O
decapentaplegic None None O
gene None None O
product None None O
, None None O
a None None O
close None None O
relative None None O
of None None O
tumor None None O
growth None None O
factor None None O
( None None O
TGF None None O
) None None O
- None None O
beta None None O
superfamily None None O
members None None O
, None None O
BMP None None O
- None None O
2/4 None None O
. None None O

Although None None O
XBMP None None O
- None None O
1 None None O
and None None O
XBMP None None O
- None None O
4 None None O
are None None O
detected None None O
in None None O
various None None O
adult None None O
tissues None None O
of None None O
Xenopus None None O
, None None O
the None None O
expression None None O
pattern None None O
of None None O
these None None O
two None None O
genes None None O
was None None O
not None None O
tightly None None O
correlated None None O
. None None O

In None None O
the None None O
embryo None None O
, None None O
the None None O
expression None None O
of None None O
XBMP None None O
- None None O
1 None None O
increased None None O
gradually None None O
from None None O
the None None O
morula None None O
to None None O
the None None O
swimming None None O
tadpole None None O
stages None None O
. None None O

Injection None None O
of None None O
XBMP None None O
- None None O
1B None None O
RNA None None O
into None None O
the None None O
ventral None None O
blastomeres None None O
at None None O
the None None O
4 None None O
- None None O
cell None None O
stage None None O
caused None None O
an None None O
elongation None None O
of None None O
the None None O
ventral None None O
marginal None None O
zone None None O
explants None None O
and None None O
converted None None O
globin None None O
- None None O
positive None None O
blood None None O
cells None None O
to None None O
mesenchymal None None O
and None None O
muscle None None O
tissues None None O
at None None O
later None None O
stages None None O
. None None O

It None None O
was None None O
shown None None O
that None None O
XBMP None None O
- None None O
1A None None O
was None None O
less None None O
active None None O
and None None O
a None None O
1A None None O
mutant None None O
lacking None None O
the None None O
signal None None O
sequence None None O
was None None O
inactive None None O
. None None O

Further None None O
studies None None O
revealed None None O
that None None O
injection None None O
of None None O
XBMP None None O
- None None O
1B None None O
RNA None None O
into None None O
the None None O
ventral None None O
marginal None None O
zone None None O
induced None None O
up None None O
- None None O
regulation None None O
of None None O
dorsal None None O
marginal None None O
zone None None O
markers None None O
, None None O
such None None O
as None None O
goosecoid None None O
and None None O
chordin None None O
, None None O
at None None O
the None None O
gastrulation None None O
stage None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
XBMP None None O
- None None O
1 None None O
may None None O
have None None O
a None None O
role None None O
in None None O
determining None None O
dorso None None O
- None None O
ventral None None O
patterning None None O
in None None O
Xenopus None None O
, None None O
but None None O
in None None O
a None None O
different None None O
way None None O
from None None O
the None None O
dpp None None O
/ None None O
tolloid None None O
system None None O
demonstrated None None O
in None None O
Drosophila None None O
. None None O


Spiro None None O
[ None None O
isobenzofuran None None O
- None None O
1 None None O
( None None O
3H None None O
) None None O
, None None O
4' None None O
- None None O
piperidines None None O
] None None O
and None None O
the None None O
corresponding None None O
benzofuran None None I-TRIVIAL
and None None O
benzopyran None None I-TRIVIAL
derivatives None None B-MODIFIER
have None None O
been None None O
synthesized None None O
and None None O
evaluated None None O
as None None O
sigma None None O
ligands None None O
. None None O

The None None O
compounds None None O
are None None O
related None None O
to None None O
Lu None None I-TRIVIALVAR
28-179 None None I-TRIVIALVAR
( None None O
1' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
) None None O
that None None O
has None None O
been None None O
demonstrated None None O
to None None O
be None None O
a None None O
selective None None O
sigma None None O
2 None None O
ligand None None O
with None None O
affinity None None O
in None None O
the None None O
subnanomolar None None O
range None None O
. None None O

The None None O
object None None O
of None None O
the None None O
study None None O
was None None O
to None None O
determine None None O
the None None O
structural None None O
factors None None O
governing None None O
sigma None None O
1 None None O
/ None None O
sigma None None O
2 None None O
affinity None None O
and None None O
selectivity None None O
within None None O
this None None O
class None None O
of None None O
compounds None None O
. None None O

The None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
substituent None None I-PARTIUPAC
in None None O
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidines None None I-IUPAC
] None None I-IUPAC
is None None O
highly None None O
important None None O
, None None O
both None None O
for None None O
affinity None None O
and None None O
selectivity None None O
. None None O

Spiropiperidines None None I-TRIVIAL
with None None O
no None None O
or None None O
small None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
substituents None None I-PARTIUPAC
( None None O
H None None I-SUM
, None None O
Me None None I-ABBREVIATION
, None None O
Et None None I-ABBREVIATION
) None None O
exert None None O
very None None O
low None None O
affinity None None O
for None None O
both None None O
sigma None None O
1 None None O
and None None O
sigma None None O
2 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
, None None O
sigma None None O
2 None None O
) None None O
& None None O
gt None None O
; None None O
100 None None O
nM None None O
) None None O
, None None O
whereas None None O
medium None None O
- None None O
sized None None O
substituents None None O
( None None O
e.g. None None O
, None None O
Pr None None I-ABBREVIATION
, None None O
Bu None None I-ABBREVIATION
, None None O
Ph None None I-SUM
( None None I-SUM
CH2 None None I-SUM
) None None I-SUM
2 None None I-SUM
) None None O
result None None O
in None None O
potent None None O
, None None O
but None None O
unselective None None O
compounds None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
, None None O
sigma None None O
2 None None O
) None None O
= None None O
2-5 None None O
nM None None O
) None None O
. None None O

Increasing None None O
the None None O
chain None None O
length None None O
and None None O
the None None O
lipophilicity None None O
of None None O
the None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
substituent None None I-PARTIUPAC
result None None O
in None None O
compounds None None O
in None None O
which None None O
high None None O
affinity None None O
for None None O
sigma None None O
2 None None O
binding None None O
sites None None O
is None None O
retained None None O
and None None O
with None None O
selectivity None None O
for None None O
sigma None None O
2 None None O
vs None None O
sigma None None O
1 None None O
binding None None O
sites None None O
( None None O
e.g. None None O
, None None O
4 None None I-IUPAC
- None None I-IUPAC
cyclohexyl None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
: None None O
IC50 None None O
- None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
1.5 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.07 None None O
nM None None O
) None None O
. None None O

Introduction None None O
of None None O
substituents None None O
in None None O
the None None O
benzene None None I-TRIVIAL
ring None None O
of None None O
the None None O
spiro None None I-IUPAC
[ None None I-IUPAC
isobenzofuran None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
( None None I-IUPAC
3H None None I-IUPAC
) None None I-IUPAC
, None None I-IUPAC
4' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
ring None None O
system None None O
of None None O
Lu None None I-TRIVIAL
28-179 None None I-TRIVIAL
mainly None None O
affects None None O
affinity None None O
for None None O
sigma None None O
1 None None O
binding None None O
sites None None O
. None None O

Compounds None None O
with None None O
substituents None None O
( None None O
F None None I-SUM
, None None O
CF3 None None I-SUM
) None None O
in None None O
the None None O
4 None None O
- None None O
or None None O
7 None None O
- None None O
position None None O
of None None O
the None None O
isobenzofuran None None I-TRIVIAL
display None None O
high None None O
affinity None None O
for None None O
sigma None None O
2 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.5-2 None None O
nM None None O
) None None O
and None None O
very None None O
low None None O
affinity None None O
for None None O
sigma None None O
1 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
& None None O
gt None None O
; None None O
100 None None O
nM None None O
) None None O
. None None O

Compounds None None O
with None None O
substituents None None O
( None None O
F None None I-ABBREVIATION
, None None O
CF3 None None I-ABBREVIATION
, None None O
Me None None I-ABBREVIATION
) None None O
in None None O
the None None O
5 None None O
- None None O
or None None O
6 None None O
- None None O
position None None O
of None None O
the None None O
isobenzofuran None None I-TRIVIAL
exert None None O
increased None None O
affinity None None O
for None None O
sigma None None O
1 None None O
binding None None O
sites None None O
( None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
5-30 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.3-7 None None O
nM None None O
) None None O
, None None O
thus None None O
rendering None None O
unselective None None O
compounds None None O
. None None O

Exchanging None None O
the None None O
isobenzofuran None None I-TRIVIAL
moiety None None O
of None None O
Lu None None I-TRIVIALVAR
28-179 None None I-TRIVIALVAR
with None None O
thioisobenzofuran None None I-TRIVIAL
, None None O
benzofuran None None I-IUPAC
, None None O
or None None O
benzopyran None None I-TRIVIAL
also None None O
has None None O
a None None O
pronounced None None O
effect None None O
on None None O
both None None O
affinity None None O
and None None O
selectivity None None O
for None None O
sigma None None O
binding None None O
sites None None O
. None None O

The None None O
position None None O
of None None O
the None None O
oxygen None None O
atom None None O
and None None O
the None None O
position None None O
of None None O
the None None O
spiroconnection None None O
with None None O
the None None O
4 None None O
- None None O
position None None O
of None None O
the None None O
piperidine None None I-TRIVIAL
ring None None O
were None None O
varied None None O
, None None O
and None None O
only None None O
compounds None None O
in None None O
which None None O
both None None O
the None None O
benzene None None I-TRIVIAL
ring None None O
and None None O
the None None O
heteroatom None None O
are None None O
attached None None O
directly None None O
to None None O
the None None O
piperidine None None I-TRIVIAL
ring None None O
retain None None O
high None None O
affinity None None O
and None None O
selectivity None None O
for None None O
sigma None None O
2 None None O
binding None None O
sites None None O
( None None O
e.g. None None O
, None None O
3,4 None None I-IUPAC
- None None I-IUPAC
dihydro None None I-IUPAC
- None None I-IUPAC
1' None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
fluorophenyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
indol None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
yl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1 None None I-IUPAC
- None None I-IUPAC
butyl None None I-IUPAC
] None None I-IUPAC
spiro None None I-IUPAC
[ None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
benzopyran None None I-IUPAC
- None None I-IUPAC
1,4 None None I-IUPAC
' None None I-IUPAC
- None None I-IUPAC
piperidine None None I-IUPAC
] None None I-IUPAC
: None None O
IC50 None None O
( None None O
sigma None None O
1 None None O
) None None O
= None None O
53 None None O
nM None None O
, None None O
IC50 None None O
( None None O
sigma None None O
2 None None O
) None None O
= None None O
0.9 None None O
nM None None O
) None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Maitotoxin None None I-TRIVIAL
- None None O
induced None None O
calcium None None O
entry None None O
in None None O
human None None O
lymphocytes None None O
: None None O
modulation None None O
by None None O
yessotoxin None None I-TRIVIAL
, None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
channel None None O
blockers None None O
and None None O
kinases None None O
. None None O

We None None O
have None None O
studied None None O
the None None O
effect None None O
of None None O
the None None O
ciguatera None None O
- None None O
related None None O
toxin None None O
maitotoxin None None I-TRIVIAL
( None None O
MTX None None I-ABBREVIATION
) None None O
on None None O
the None None O
cytosolic None None O
free None None O
calcium None None I-TRIVIAL
concentration None None O
( None None O
[ None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
] None None O
i None None O
) None None O
of None None O
human None None O
peripheral None None O
blood None None O
lymphocytes None None O
loaded None None O
with None None O
the None None O
fluorescent None None O
probe None None O
Fura2 None None O
and None None O
the None None O
regulation None None O
of None None O
MTX None None I-ABBREVIATION
action None None O
by None None O
different None None O
drugs None None O
known None None O
to None None O
interfere None None O
in None None O
cellular None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
signalling None None O
mechanisms None None O
and None None O
by None None O
the None None O
marine None None O
phycotoxin None None O
yessotoxin None None I-TRIVIAL
( None None O
YTX None None I-ABBREVIATION
) None None O
. None None O

MTX None None I-ABBREVIATION
produced None None O
a None None O
concentration None None O
- None None O
dependent None None O
elevation None None O
of None None O
[ None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
] None None O
i None None O
in None None O
a None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
- None None O
containing None None O
medium None None O
. None None O

This None None O
effect None None O
was None None O
stimulated None None O
by None None O
pretreatment None None O
with None None O
YTX None None I-ABBREVIATION
1 None None O
microM None None O
and None None O
NiCl None None I-SUM
( None None I-SUM
2 None None I-SUM
) None None I-SUM
15 None None O
microM None None O
. None None O

The None None O
voltage None None O
- None None O
independent None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
channel None None O
antagonist None None O
1 None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
beta None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
) None None I-IUPAC
propoxyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
4 None None I-IUPAC
- None None I-IUPAC
methoxyphenyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
1H None None I-IUPAC
- None None I-IUPAC
imidazole None None I-IUPAC
hydrochloride None None I-IUPAC
( None None O
SKF96365 None None I-TRIVIALVAR
) None None O
blocked None None O
the None None O
MTX None None I-ABBREVIATION
- None None O
induced None None O
[ None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
] None None O
i None None O
elevation None None O
, None None O
while None None O
the None None O
L None None O
- None None O
type None None O
channel None None O
blocker None None O
nifedipine None None I-TRIVIAL
had None None O
no None None O
effect None None O
. None None O

Pretreatment None None O
with None None O
NiCl None None I-SUM
( None None I-SUM
2 None None I-SUM
) None None I-SUM
or None None O
nifedipine None None I-TRIVIAL
did None None O
not None None O
modify None None O
YTX None None I-ABBREVIATION
- None None O
induced None None O
potentiation None None O
of None None O
MTX None None I-ABBREVIATION
effect None None O
, None None O
and None None O
SKF96365 None None I-TRIVIAL
- None None O
induced None None O
inhibition None None O
was None None O
reduced None None O
in None None O
the None None O
presence None None O
of None None O
YTX None None I-ABBREVIATION
, None None O
which None None O
suggest None None O
different None None O
pathways None None O
to None None O
act None None O
on None None O
[ None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
] None None O
i None None O
. None None O

Preincubation None None O
with None None O
N None None I-IUPAC
- None None I-IUPAC
[ None None I-IUPAC
2 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
p None None I-IUPAC
- None None I-IUPAC
bromocinnamylamino None None I-IUPAC
) None None I-IUPAC
ethyl None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
isoquinolinesulfonamide None None I-IUPAC
. None None O

2HCl None None I-SUM
( None None O
H None None I-TRIVIALVAR
- None None I-TRIVIALVAR
89 None None I-TRIVIALVAR
) None None O
or None None O
genistein None None I-TRIVIAL
( None None O
10 None None O
microM None None O
) None None O
also None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
MTX None None I-ABBREVIATION
- None None O
induced None None O
[ None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
] None None O
i None None O
increment None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
PKC None None O
inhibitor None None O
bisindolilmaleimide None None I-TRIVIAL
I None None I-TRIVIAL
( None None O
GF109203X None None I-TRIVIALVAR
1 None None O
microM None None O
) None None O
potentiated None None O
the None None O
MTX None None I-ABBREVIATION
effect None None O
, None None O
whereas None None O
phosphatidylinositol None None O
( None None O
PI None None O
) None None O
3 None None O
- None None O
kinase None None O
inhibition None None O
with None None O
wortmannin None None I-TRIVIAL
( None None O
10 None None O
nM None None O
) None None O
reduced None None O
the None None O
MTX None None I-ABBREVIATION
- None None O
elicited None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
entry None None O
. None None O

In None None O
summary None None O
, None None O
MTX None None I-ABBREVIATION
produced None None O
Ca None None I-ABBREVIATION
( None None I-ABBREVIATION
2+ None None I-ABBREVIATION
) None None I-ABBREVIATION
influx None None O
into None None O
human None None O
lymphocytes None None O
through None None O
a None None O
SKF96365 None None I-TRIVIALVAR
- None None O
sensitive None None O
, None None O
nifedipine None None I-TRIVIAL
- None None O
insensitive None None O
pathway None None O
. None None O

The None None O
MTX None None I-ABBREVIATION
- None None O
induced None None O
[ None None O
Ca None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
] None None O
i None None O
elevation None None O
was None None O
stimulated None None O
by None None O
the None None O
marine None None O
toxin None None O
YTX None None I-ABBREVIATION
through None None O
a None None O
mechanism None None O
insensitive None None O
to None None O
SKF96365 None None I-TRIVIALVAR
, None None O
nifedipine None None I-TRIVIAL
or None None O
NiCl None None I-SUM
( None None I-SUM
2 None None I-SUM
) None None I-SUM
. None None O

It None None O
was None None O
also None None O
stimulated None None O
by None None O
the None None O
divalent None None O
cation None None O
Ni None None I-SUM
( None None I-SUM
2+ None None I-SUM
) None None I-SUM
and None None O
PKC None None O
inhibition None None O
and None None O
was None None O
partially None None O
inhibited None None O
by None None O
PI None None O
3 None None O
- None None O
kinase None None O
inhibition None None O
. None None O


Selective None None O
protection None None O
of None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxoerythromycin None None I-IUPAC
A None None I-IUPAC
allowed None None O
for None None O
elimination None None O
of None None O
the None None O
12 None None I-PARTIUPAC
- None None I-PARTIUPAC
hydroxyl None None I-PARTIUPAC
group None None I-MODIFIER
to None None O
afford None None O
a None None O
versatile None None O
12,21 None None I-IUPAC
- None None I-IUPAC
olefin None None I-IUPAC
intermediate None None I-MODIFIER
. None None O

Further None None O
modifications None None O
of None None O
the None None O
intermediate None None O
led None None O
to None None O
the None None O
syntheses None None O
of None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
12,21 None None I-IUPAC
- None None I-IUPAC
epoxyerythromycin None None I-IUPAC
B None None I-IUPAC
, None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
hydroxyerythromycin None None I-IUPAC
A None None I-IUPAC
, None None O
and None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
21 None None I-IUPAC
- None None I-IUPAC
hydroxyerythromycin None None I-IUPAC
B None None I-IUPAC
. None None O

All None None O
three None None O
compounds None None O
retained None None O
antibacterial None None O
activity None None O
against None None O
several None None O
organisms None None O
normally None None O
susceptible None None O
to None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
deoxo None None I-IUPAC
- None None I-IUPAC
9 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
N None None I-IUPAC
, None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
dimethylamino None None I-IUPAC
) None None I-IUPAC
erythromycin None None I-IUPAC
A None None I-IUPAC
. None None O

However None None O
, None None O
the None None O
21 None None I-IUPAC
- None None I-IUPAC
hydroxylated None None I-IUPAC
erythromycin None None I-IUPAC
A None None I-IUPAC
analogue None None I-MODIFIER
was None None O
weaker None None O
in None None O
potency None None O
than None None O
the None None O
corresponding None None O
erythromycin None None I-TRIVIAL
B None None I-TRIVIAL
congener None None I-TRIVIAL
and None None O
much None None O
weaker None None O
than None None O
the None None O
epoxy None None I-TRIVIAL
derivative None None B-MODIFIER
. None None O

This None None O
suggests None None O
that None None O
while None None O
substitution None None O
of None None O
a None None O
polar None None O
functionality None None O
at None None O
C None None O
- None None O
21 None None O
does None None O
not None None O
abolish None None O
antibacterial None None O
activity None None O
, None None O
introduction None None O
of None None O
vicinal None None O
polar None None O
groups None None O
at None None O
both None None O
C None None O
- None None O
12 None None O
and None None O
C None None O
- None None O
21 None None O
may None None O
lead None None O
to None None O
reduction None None O
in None None O
potency None None O
. None None O

Nevertheless None None O
, None None O
these None None O
21 None None O
- None None O
functionalized None None O
derivatives None None O
of None None O
( None None I-IUPAC
9R None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
erythromycylamine None None I-IUPAC
provide None None O
an None None O
entry None None O
into None None O
novel None None O
analogues None None O
of None None O
the None None O
important None None O
macrolide None None O
antibiotic None None O
erythromycin None None I-TRIVIAL
. None None O


Serum None None O
lipid None None I-FAMILY
and None None O
leptin None None O
concentrations None None O
in None None O
hypopituitary None None O
patients None None O
with None None O
growth None None O
hormone None None O
deficiency None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
investigate None None O
the None None O
effects None None O
of None None O
growth None None O
hormone None None O
( None None O
GH None None O
) None None O
deficiency None None O
on None None O
serum None None O
lipid None None I-FAMILY
and None None O
leptin None None O
concentrations None None O
in None None O
hypopituitary None None O
patients None None O
taking None None O
conventional None None O
replacement None None O
therapy None None O
and None None O
to None None O
determine None None O
the None None O
relations None None O
between None None O
leptin None None O
and None None O
gender None None O
and None None O
anthropometric None None O
and None None O
metabolic None None O
variables None None O
. None None O

SUBJECTS None None O
: None None O
Twenty None None O
- None None O
one None None O
GH None None O
deficient None None O
adult None None O
hypopituitary None None O
patients None None O
( None None O
15 None None O
women None None O
, None None O
six None None O
men None None O
) None None O
and None None O
21 None None O
( None None O
14 None None O
women None None O
, None None O
seven None None O
men None None O
) None None O
age None None O
, None None O
sex None None O
and None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
matched None None O
healthy None None O
controls None None O
. None None O

MEASUREMENTS None None O
: None None O
After None None O
an None None O
overnight None None O
fast None None O
, None None O
anthropometric None None O
parameters None None O
were None None O
measured None None O
and None None O
body None None O
composition None None O
was None None O
determined None None O
by None None O
a None None O
bioelectrical None None O
impedance None None O
analyser None None O
. None None O

Venous None None O
blood None None O
samples None None O
were None None O
obtained None None O
for None None O
the None None O
measurements None None O
of None None O
glucose None None I-TRIVIAL
, None None O
total None None O
cholesterol None None I-TRIVIAL
, None None O
high None None O
density None None O
lipoprotein None None O
( None None O
HDL None None O
) None None O
cholesterol None None I-TRIVIAL
, None None O
triglyceride None None I-FAMILY
, None None O
intact None None O
insulin None None O
, None None O
insulin None None O
- None None O
like None None O
growth None None O
factor None None O
1 None None O
( None None O
IGF None None O
- None None O
1 None None O
) None None O
and None None O
leptin None None O
concentrations None None O
. None None O

Serum None None O
leptin None None O
and None None O
hormones None None O
were None None O
analysed None None O
by None None O
radioimmunoassay None None O
. None None O

RESULTS None None O
: None None O
Hypopituitary None None O
patients None None O
with None None O
GH None None O
deficiency None None O
showed None None O
significantly None None O
higher None None O
triglyceride None None I-FAMILY
, None None O
total None None O
and None None O
low None None O
density None None O
lipoprotein None None O
( None None O
LDL None None O
) None None O
cholesterol None None I-TRIVIAL
and None None O
lower None None O
HDL None None O
cholesterol None None I-TRIVIAL
concentrations None None O
on None None O
conventional None None O
replacement None None O
therapy None None O
. None None O

The None None O
unfavourable None None O
lipid None None I-FAMILY
profile None None O
was None None O
particularly None None O
evident None None O
in None None O
women None None O
. None None O

Significantly None None O
higher None None O
leptin None None O
concentrations None None O
were None None O
found None None O
in None None O
patients None None O
compared None None O
with None None O
healthy None None O
controls None None O
with None None O
similar None None O
body None None O
fat None None O
content None None O
( None None O
23 None None O
. None None O

5+ None None O
/ None None O
- None None O
11.8 None None O
ng None None O
/ None None O
ml None None O
vs None None O
11.7 None None O
+ None None O
/ None None O
- None None O
6.9 None None O
ng None None O
/ None None O
ml None None O
, None None O
P None None O
= None None O
0.01 None None O
) None None O
. None None O

This None None O
difference None None O
remained None None O
significant None None O
even None None O
when None None O
leptin None None O
values None None O
were None None O
expressed None None O
in None None O
relation None None O
to None None O
fat None None O
mass None None O
percentage None None O
( None None O
0.79 None None O
+ None None O
/ None None O
- None None O
0.40 None None O
vs. None None O
0.42 None None O
+ None None O
/ None None O
- None None O
0.17 None None O
ng None None O
/ None None O
ml None None O
% None None O
, None None O
P None None O
< None None O
0.05 None None O
) None None O
and None None O
fat None None O
mass None None O
kg None None O
( None None O
1.32 None None O
+ None None O
/ None None O
- None None O
0.81 None None O
vs None None O
0.66 None None O
+ None None O
/ None None O
- None None O
0.30 None None O
ng None None O
/ None None O
ml None None O
kg None None O
, None None O
P None None O
< None None O
0 None None O
. None None O

05 None None O
) None None O
. None None O

Significant None None O
positive None None O
correlations None None O
were None None O
observed None None O
between None None O
leptin None None O
concentrations None None O
and None None O
body None None O
fat None None O
percentage None None O
and None None O
age None None O
in None None O
the None None O
control None None O
group None None O
. None None O

In None None O
patients None None O
the None None O
sole None None O
significant None None O
relation None None O
between None None O
leptin None None O
and None None O
study None None O
parameters None None O
was None None O
the None None O
positive None None O
correlation None None O
observed None None O
between None None O
leptin None None O
and None None O
total None None O
cholesterol None None I-TRIVIAL
concentrations None None O
. None None O

Serum None None O
leptin None None O
concentrations None None O
were None None O
significantly None None O
higher None None O
in None None O
women None None O
than None None O
men None None O
in None None O
the None None O
control None None O
group None None O
, None None O
but None None O
not None None O
in None None O
the None None O
patients None None O
. None None O

No None None O
significant None None O
gender None None O
difference None None O
was None None O
observed None None O
when None None O
leptin None None O
concentrations None None O
were None None O
expressed None None O
in None None O
relation None None O
to None None O
fat None None O
mass None None O
( None None O
percentage None None O
and None None O
kg None None O
) None None O
. None None O

CONCLUSION None None O
: None None O
Growth None None O
hormone None None O
deficient None None O
hypopituitary None None O
patients None None O
( None None O
particularly None None O
women None None O
) None None O
on None None O
conventional None None O
replacement None None O
therapy None None O
have None None O
a None None O
more None None O
atherogenic None None O
lipid None None I-FAMILY
profile None None O
. None None O

Leptin None None O
concentrations None None O
are None None O
increased None None O
in None None O
GH None None O
deficient None None O
adults None None O
even None None O
after None None O
adjustment None None O
for None None O
percentage None None O
body None None O
fat None None O
and None None O
body None None O
fat None None O
mass None None O
( None None O
kg None None O
) None None O
. None None O

Although None None O
the None None O
nature None None O
of None None O
our None None O
data None None O
does None None O
not None None O
allow None None O
us None None O
to None None O
draw None None O
any None None O
conclusions None None O
on None None O
the None None O
mechanism None None O
( None None O
s None None O
) None None O
of None None O
increased None None O
leptin None None O
concentrations None None O
in None None O
GH None None O
deficiency None None O
, None None O
decreased None None O
central None None O
sensitivity None None O
to None None O
leptin None None O
and None None O
increased None None O
leptin None None O
production None None O
from None None O
per None None O
unit None None O
fat None None O
mass None None O
, None None O
or None None O
alterations None None O
in None None O
leptin None None O
clearance None None O
, None None O
might None None O
be None None O
operative None None O
. None None O


Conversion None None O
of None None O
the None None O
8 None None I-IUPAC
- None None I-IUPAC
phenolic None None I-IUPAC
1,2,3,4,5,6 None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
methano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzazocines None None I-IUPAC
to None None O
the None None O
corresponding None None O
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
thiophenolic None None I-PARTIUPAC
analogues None None I-MODIFIER
was None None O
achieved None None O
by None None O
three None None O
different None None O
routes None None O
. None None O

Diazotization None None O
of None None O
8 None None I-IUPAC
- None None I-IUPAC
amino None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
methano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzazocine None None I-IUPAC
( None None O
2 None None O
) None None O
followed None None O
by None None O
the None None O
reaction None None O
with None None O
CH3SNa None None I-SUM
afforded None None O
8 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
methylthio None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
1,2,3,4,5,6 None None I-IUPAC
- None None I-IUPAC
hexahydro None None I-IUPAC
- None None I-IUPAC
2,6 None None I-IUPAC
- None None I-IUPAC
methano None None I-IUPAC
- None None I-IUPAC
3 None None I-IUPAC
- None None I-IUPAC
benzazocine None None I-IUPAC
( None None O
3 None None O
) None None O
. None None O

Another None None O
route None None O
using None None O
Grewe None None O
cyclization None None O
was None None O
also None None O
examined None None O
for None None O
the None None O
synthesis None None O
of None None O
3 None None O
. None None O

As None None O
the None None O
most None None O
effective None None O
route None None O
, None None O
Newman None None O
- None None O
Kwart None None O
rearrangement None None O
of None None O
benzazocines None None O
was None None O
selected None None O
and None None O
closely None None O
investigated None None O
. None None O

8 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
N None None I-PARTIUPAC
, None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
Dimethylthiocarbamoyl None None I-PARTIUPAC
) None None I-PARTIUPAC
oxy None None I-PARTIUPAC
derivatives None None I-MODIFIER
( None None O
6a None None O
- None None O
e None None O
) None None O
rearranged None None O
to None None O
8 None None I-PARTIUPAC
- None None I-PARTIUPAC
( None None I-PARTIUPAC
N None None I-PARTIUPAC
, None None I-PARTIUPAC
N None None I-PARTIUPAC
- None None I-PARTIUPAC
dimethylcarbamoyl None None I-PARTIUPAC
) None None I-PARTIUPAC
thio None None I-PARTIUPAC
derivatives None None I-MODIFIER
( None None O
7a None None O
- None None O
e None None O
) None None O
in None None O
good None None O
yields None None O
. None None O

Reductive None None O
cleavage None None O
of None None O
7a None None O
- None None O
e None None O
and None None O
subsequent None None O
methylation None None O
or None None O
acylations None None O
gave None None O
the None None O
title None None O
compounds None None O
( None None O
3 None None O
, None None O
8-24 None None O
) None None O
. None None O

Although None None O
analgesic None None O
activities None None O
of None None O
sulfur None None O
- None None O
containing None None O
benzazocines None None I-FAMILY
decreased None None O
compared None None O
to None None O
the None None O
corresponding None None O
hydroxy None None I-PARTIUPAC
compounds None None B-MODIFIER
, None None O
the None None O
N None None I-PARTIUPAC
- None None I-PARTIUPAC
methyl None None I-PARTIUPAC
derivative None None I-MODIFIER
( None None O
S None None I-IUPAC
- None None I-IUPAC
metazocine None None I-IUPAC
, None None O
8 None None O
) None None O
showed None None O
potent None None O
analgesic None None O
activity None None O
. None None O


N None None O
, None None O
O None None O
- None None O
Dicarbethoxy None None O
- None None O
4 None None O
- None None O
chlorobenzenesulfohydroxamate None None O
( None None O
1c None None O
) None None O
and None None O
O None None I-IUPAC
- None None I-IUPAC
carbethoxy None None I-IUPAC
- None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
hydroxysaccharin None None I-IUPAC
( None None O
6 None None O
) None None O
, None None O
both None None O
potential None None O
carbethoxylating None None O
agents None None O
, None None O
inhibited None None O
yeast None None O
aldehyde None None O
dehydrogenase None None O
( None None O
AlDH None None O
) None None O
with None None O
IC50 None None O
's None None O
of None None O
24 None None O
and None None O
56 None None O
microM None None O
, None None O
respectively None None O
. None None O

The None None O
esterase None None O
activity None None O
of None None O
the None None O
enzyme None None O
was None None O
commensurably None None O
inhibited None None O
. None None O

AlDH None None O
activity None None O
was None None O
only None None O
partially None None O
restored None None O
on None None O
incubation None None O
with None None O
mercaptoethanol None None I-TRIVIAL
( None None O
20 None None O
mM None None O
) None None O
for None None O
1 None None O
h None None O
. None None O

On None None O
incubation None None O
with None None O
rat None None O
plasma None None O
, None None O
1c None None O
liberated None None O
nitroxyl None None I-TRIVIAL
, None None O
a None None O
potent None None O
inhibitor None None O
of None None O
AlDH None None O
. None None O

Under None None O
the None None O
same None None O
conditions None None O
, None None O
nitroxyl None None I-TRIVIAL
generation None None O
from None None O
6 None None O
was None None O
minimal None None O
, None None O
a None None O
result None None O
compatible None None O
with None None O
a None None O
previous None None O
observation None None O
that None None O
nitroxyl None None I-TRIVIAL
generation None None O
from None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysaccharin None None I-IUPAC
( None None O
7 None None O
) None None O
, None None O
the None None O
product None None O
of None None O
the None None O
hydrolysis None None O
of None None O
the None None O
carbethoxy None None I-PARTIUPAC
group None None B-MODIFIER
of None None O
6 None None O
, None None O
was None None O
minimal None None O
at None None O
physiological None None O
pH None None O
. None None O

Since None None O
chemical None None O
carbethoxylating None None O
agents None None O
represented None None O
by None None O
the None None O
O None None I-IUPAC
- None None I-IUPAC
carbethoxylated None None I-IUPAC
N None None I-IUPAC
- None None I-IUPAC
hydroxyphthalimide None None I-IUPAC
, None None O
1 None None I-IUPAC
- None None I-IUPAC
hydroxybenzotriazole None None I-IUPAC
, None None O
and None None O
N None None I-IUPAC
- None None I-IUPAC
hydroxysuccinimide None None I-IUPAC
( None None O
8 None None O
, None None O
9 None None O
, None None O
and None None O
10 None None O
, None None O
respectively None None O
) None None O
likewise None None O
inhibited None None O
yeast None None O
AlDH None None O
, None None O
albeit None None O
with None None O
IC50 None None O
's None None O
1 None None O
order None None O
of None None O
magnitude None None O
higher None None O
, None None O
we None None O
postulate None None O
that None None O
1c None None O
and None None O
6 None None O
act None None O
as None None O
irreversible None None O
inhibitors None None O
of None None O
AlDH None None O
by None None O
carbethoxylating None None O
the None None O
active None None O
site None None O
of None None O
the None None O
enzyme None None O
. None None O


At None None O
physiological None None O
pH None None O
, None None O
the None None O
spatial None None O
arrangement None None O
of None None O
the None None O
three None None O
charges None None O
of None None O
DL None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
( None None O
5 None None O
) None None O
could None None O
be None None O
viewed None None O
as None None O
similar None None O
to None None O
those None None O
found None None O
in None None O
certain None None O
conformations None None O
of None None O
the None None O
two None None O
excitatory None None O
amino None None O
acids None None O
( None None O
EAAs None None O
) None None O
- None None O
- None None O
aspartic None None I-PARTIUPAC
and None None O
glutamic None None I-IUPAC
acids None None I-IUPAC
. None None O

Given None None O
significant None None O
binding None None O
to None None O
one None None O
or None None O
more None None O
EAA None None O
receptors None None O
, None None O
5 None None O
would None None O
offer None None O
unique None None O
modeling None None O
and None None O
perhaps None None O
biological None None O
opportunities None None O
. None None O

We None None O
have None None O
previously None None O
shown None None O
it None None O
to None None O
be None None O
the None None O
most None None O
potent None None O
NMDA None None I-ABBREVIATION
agonist None None O
known None None O
, None None O
with None None O
a None None O
unique None None O
and None None O
marked None None O
in None None O
vitro None None O
neutrotoxicity None None O
at None None O
depolarizing None None O
concentrations None None O
. None None O

Now None None O
we None None O
report None None O
the None None O
details None None O
required None None O
for None None O
its None None O
synthesis None None O
, None None O
together None None O
with None None O
its None None O
potency None None O
and None None O
efficacy None None O
in None None O
two None None O
assays None None O
of None None O
functional None None O
activation None None O
of None None O
the None None O
NMDA None None O
receptor None None O
, None None O
namely None None O
agonist None None O
- None None O
influenced None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
MK801 None None I-IUPAC
binding None None O
and None None O
agonist None None O
- None None O
induced None None O
release None None O
of None None O
the None None O
neurotransmitter None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
- None None I-IUPAC
norepinephrine None None I-IUPAC
from None None O
brain None None O
slices None None O
. None None O

In None None O
both None None O
these None None O
assays None None O
DL None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
proved None None O
to None None O
be None None O
more None None O
potent None None O
and None None O
efficacious None None O
than None None O
NMDA None None I-ABBREVIATION
and None None O
cis None None I-IUPAC
- None None I-IUPAC
methanoglutamate None None I-IUPAC
. None None O

It None None O
was None None O
more None None O
potent None None O
than None None O
, None None O
and None None O
equally None None O
efficacious None None O
to None None O
, None None O
L None None I-IUPAC
- None None I-IUPAC
glutamate None None I-IUPAC
in None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
MK801 None None I-IUPAC
binding None None O
. None None O

The None None O
structural None None O
features None None O
of None None O
5 None None O
may None None O
well None None O
reflect None None O
optimal None None O
agonist None None O
interaction None None O
at None None O
the None None O
NMDA None None O
receptor None None O
site None None O
. None None O

( None None O
We None None O
considered None None O
the None None O
possibility None None O
that None None O
some None None O
decarboxylation None None O
of None None O
DL None None I-IUPAC
- None None I-IUPAC
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
may None None O
have None None O
occurred None None O
during None None O
testing None None O
. None None O

This None None O
would None None O
give None None O
5 None None I-IUPAC
- None None I-IUPAC
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
tetrazole None None I-IUPAC
( None None O
13 None None O
) None None O
, None None O
the None None O
tetrazole None None I-IUPAC
acid None None I-IUPAC
analog None None I-MODIFIER
of None None O
glycine None None I-TRIVIAL
; None None O
and None None O
glycine None None I-TRIVIAL
is None None O
involved None None O
in None None O
NMDA None None O
receptor None None O
activation None None O
. None None O

Compound None None O
13 None None O
does None None O
not None None O
affect None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
glycine None None I-IUPAC
binding None None O
at None None O
the None None O
strychnine None None I-TRIVIAL
- None None O
insensitive None None O
glycine None None I-TRIVIAL
binding None None O
site None None O
, None None O
and None None O
[ None None I-IUPAC
3H None None I-IUPAC
] None None I-IUPAC
MK801 None None I-IUPAC
binding None None O
studies None None O
showed None None O
that None None O
the None None O
( None None I-IUPAC
aminomethyl None None I-IUPAC
) None None I-IUPAC
- None None I-IUPAC
tetrazole None None I-IUPAC
, None None O
even None None O
if None None O
is None None O
formed None None O
, None None O
would None None O
probably None None O
have None None O
no None None O
effect None None O
on None None O
the None None O
activity None None O
of None None O
tetrazol None None I-IUPAC
- None None I-IUPAC
5 None None I-IUPAC
- None None I-IUPAC
ylglycine None None I-IUPAC
at None None O
the None None O
NMDA None None O
receptor None None O
. None None O


Oribatid None None O
Mite None None O
Communities None None O
in None None O
the None None O
Canopy None None O
of None None O
Montane None None O
Abies None None O
amabilis None None O
and None None O
Tsuga None None O
heterophylla None None O
Trees None None O
on None None O
Vancouver None None O
Island None None O
, None None O
British None None O
Columbia None None O
. None None O

To None None O
study None None O
the None None O
oribatid None None O
mite None None O
community None None O
inhabiting None None O
microhabitats None None O
in None None O
the None None O
canopy None None O
of None None O
montane None None O
Abies None None O
amabilis None None O
[ None None O
( None None O
Douglas None None O
ex None None O
D None None O
. None None O

Don None None O
) None None O
Lindl None None O
. None None O

] None None O
and None None O
Tsuga None None O
heterophylla None None O
[ None None O
( None None O
Raf None None O
. None None O

) None None O
Sarg None None O
] None None O
tree None None O
species None None O
across None None O
five None None O
elevational None None O
sites None None O
, None None O
we None None O
collected None None O
180 None None O
branch None None O
tips None None O
and None None O
180 None None O
foliose None None O
/ None None O
crustose None None O
lichen None None O
samples None None O
over None None O
three None None O
time None None O
periods None None O
. None None O

Thirty None None O
- None None O
three None None O
species None None O
of None None O
oribatid None None O
mites None None O
were None None O
identified None None O
from None None O
the None None O
study None None O
area None None O
. None None O

Mite None None O
species None None O
richness None None O
and None None O
abundance None None O
was None None O
significantly None None O
affected None None O
by None None O
microhabitat None None O
, None None O
and None None O
this None None O
association None None O
was None None O
independent None None O
of None None O
sampling None None O
time None None O
. None None O

At None None O
the None None O
microhabitat None None O
scale None None O
, None None O
distinct None None O
species None None O
assemblages None None O
were None None O
associated None None O
with None None O
lichen None None O
and None None O
branch None None O
tip None None O
habitats None None O
, None None O
and None None O
to None None O
a None None O
lesser None None O
degree None None O
, None None O
tree None None O
species None None O
. None None O

Conifer None None O
specificity None None O
was None None O
most None None O
apparent None None O
in None None O
the None None O
closely None None O
related None None O
species None None O
of None None O
Jugatala None None O
, None None O
where None None O
Jugatala None None O
tuberosa None None O
Ewing None None O
was None None O
only None None O
found None None O
on None None O
branch None None O
tips None None O
from None None O
A None None O
. None None O

amabilis None None O
and None None O
Jugatala None None O
sp None None O
. None None O

was None None O
primarily None None O
found None None O
on None None O
branch None None O
tips None None O
from None None O
T None None O
. None None O

heterophylla None None O
. None None O

Microhabitat None None O
specificity None None O
was None None O
most None None O
pronounced None None O
in None None O
Dendrozetes None None O
sp None None O
. None None O

where None None O
most None None O
individuals None None O
were None None O
found None None O
on None None O
branch None None O
tips None None O
and None None O
Anachiperia None None O
geminus None None O
Lindo None None O
et None None O
al. None None O
that None None O
occurred None None O
primarily None None O
on None None O
lichens None None O
. None None O

Principal None None O
components None None O
analysis None None O
of None None O
oribatid None None O
mite None None O
community None None O
composition None None O
further None None O
showed None None O
a None None O
high None None O
degree None None O
of None None O
association None None O
with None None O
microhabitat None None O
and None None O
tree None None O
species None None O
. None None O

Habitat None None O
profiles None None O
are None None O
difficult None None O
to None None O
discern None None O
for None None O
many None None O
species None None O
because None None O
tree None None O
, None None O
microhabitat None None O
, None None O
and None None O
elevation None None O
preferences None None O
confound None None O
distribution None None O
patterns None None O
. None None O

Given None None O
the None None O
significant None None O
tree None None O
- None None O
microhabitat None None O
associations None None O
in None None O
species None None O
composition None None O
in None None O
this None None O
montane None None O
canopy None None O
study None None O
, None None O
we None None O
suggest None None O
that None None O
sampling None None O
multiple None None O
microhabitats None None O
across None None O
elevations None None O
to None None O
look None None O
for None None O
patterns None None O
in None None O
community None None O
structure None None O
offers None None O
opportunities None None O
to None None O
explicitly None None O
test None None O
organizing None None O
principles None None O
in None None O
community None None O
ecology None None O
. None None O


Tinnitus None None O
and None None O
brain None None O
MRI None None O
findings None None O
in None None O
Japanese None None O
elderly None None O
. None None O

Conclusion None None O
. None None O

There None None O
is None None O
evidence None None O
of None None O
an None None O
inverse None None O
association None None O
between None None O
cerebral None None O
infarction None None O
and None None O
tinnitus None None O
in None None O
this None None O
study None None O
. None None O

The None None O
effects None None O
of None None O
cerebral None None O
infarction None None O
on None None O
tinnitus None None O
could None None O
be None None O
explained None None O
by None None O
a None None O
neurophysiological None None O
model None None O
of None None O
tinnitus None None O
. None None O

Objectives None None O
. None None O

We None None O
examined None None O
the None None O
relationship None None O
between None None O
tinnitus None None O
and None None O
brain None None O
MRI None None O
findings None None O
including None None O
cerebral None None O
infarction None None O
, None None O
brain None None O
atrophy None None O
, None None O
ventricular None None O
dilatation None None O
, None None O
and None None O
white None None O
matter None None O
lesions None None O
. None None O

Subjects None None O
and None None O
methods None None O
. None None O

This None None O
was None None O
a None None O
cross None None O
- None None O
sectional None None O
population None None O
- None None O
based None None O
study None None O
of None None O
2193 None None O
subjects None None O
aged None None O
41-82 None None O
years None None O
living None None O
in None None O
Aichi None None O
prefecture None None O
, None None O
Japan None None O
. None None O

Detailed None None O
questionnaires None None O
, None None O
pure None None O
tone None None O
audiometry None None O
, None None O
and None None O
brain None None O
MRI None None O
were None None O
performed None None O
. None None O

Results None None O
. None None O

After None None O
adjusting None None O
for None None O
potential None None O
confounders None None O
in None None O
a None None O
multiple None None O
logistic None None O
analysis None None O
, None None O
cerebral None None O
infarction None None O
was None None O
inversely None None O
associated None None O
with None None O
tinnitus None None O
( None None O
odds None None O
ratio None None O
( None None O
OR None None O
) None None O
= None None O
0.649 None None O
, None None O
95% None None O
confidence None None O
interval None None O
( None None O
CI None None O
) None None O
= None None O
0.477-0.884 None None O
) None None O
. None None O

Cerebral None None O
infarctions None None O
of None None O
the None None O
basal None None O
ganglia None None O
( None None O
OR None None O
= None None O
0.542 None None O
) None None O
, None None O
thalamus None None O
( None None O
OR None None O
= None None O
0.441 None None O
) None None O
, None None O
and None None O
pons None None O
( None None O
OR None None O
= None None O
0.319 None None O
) None None O
were None None O
especially None None O
associated None None O
with None None O
tinnitus None None O
. None None O

Brain None None O
atrophy None None O
, None None O
ventricular None None O
dilatation None None O
, None None O
and None None O
white None None O
matter None None O
lesions None None O
had None None O
no None None O
significant None None O
effects None None O
on None None O
the None None O
prevalence None None O
of None None O
tinnitus None None O
. None None O


A None None O
neural None None O
network None None O
- None None O
based None None O
method None None O
for None None O
risk None None O
factor None None O
analysis None None O
of None None O
West None None O
Nile None None O
virus None None O
. None None O

There None None O
is None None O
a None None O
lack None None O
of None None O
knowledge None None O
about None None O
which None None O
risk None None O
factors None None O
are None None O
more None None O
important None None O
in None None O
West None None O
Nile None None O
virus None None O
( None None O
WNV None None O
) None None O
transmission None None O
and None None O
risk None None O
magnitude None None O
. None None O

A None None O
better None None O
understanding None None O
of None None O
the None None O
risk None None O
factors None None O
is None None O
of None None O
great None None O
help None None O
in None None O
developing None None O
effective None None O
new None None O
technologies None None O
and None None O
appropriate None None O
prevention None None O
strategies None None O
for None None O
WNV None None O
infection None None O
. None None O

A None None O
contribution None None O
analysis None None O
of None None O
all None None O
risk None None O
factors None None O
in None None O
WNV None None O
infection None None O
would None None O
identify None None O
those None None O
major None None O
risk None None O
factors None None O
. None None O

Based None None O
on None None O
the None None O
identified None None O
major None None O
risk None None O
factors None None O
, None None O
measures None None O
to None None O
control None None O
WNV None None O
proliferation None None O
could None None O
be None None O
directed None None O
toward None None O
those None None O
significant None None O
risk None None O
factors None None O
, None None O
thus None None O
improving None None O
the None None O
effectiveness None None O
and None None O
efficiency None None O
in None None O
developing None None O
WNV None None O
control None None O
and None None O
prevention None None O
strategies None None O
. None None O

Neural None None O
networks None None O
have None None O
many None None O
generally None None O
accepted None None O
advantages None None O
over None None O
conventional None None O
analytical None None O
techniques None None O
, None None O
for None None O
instance None None O
, None None O
ability None None O
to None None O
automatically None None O
learn None None O
the None None O
relationship None None O
between None None O
the None None O
inputs None None O
and None None O
outputs None None O
from None None O
training None None O
data None None O
, None None O
powerful None None O
generalization None None O
ability None None O
, None None O
and None None O
capability None None O
of None None O
handling None None O
nonlinear None None O
interactions None None O
. None None O

In None None O
this None None O
article None None O
, None None O
a None None O
neural None None O
network None None O
model None None O
was None None O
developed None None O
for None None O
analysis None None O
of None None O
risk None None O
factors None None O
in None None O
WNV None None O
infection None None O
. None None O

To None None O
reveal None None O
the None None O
relative None None O
contribution None None O
of None None O
the None None O
input None None O
variables None None O
, None None O
the None None O
neural None None O
network None None O
was None None O
trained None None O
using None None O
an None None O
algorithm None None O
called None None O
structural None None O
learning None None O
with None None O
forgetting None None O
. None None O

During None None O
the None None O
learning None None O
, None None O
weak None None O
neural None None O
connections None None O
are None None O
forced None None O
to None None O
fade None None O
away None None O
while None None O
a None None O
skeletal None None O
network None None O
with None None O
strong None None O
connections None None O
emerges None None O
. None None O

The None None O
significant None None O
risk None None O
factors None None O
can None None O
be None None O
identified None None O
by None None O
analyzing None None O
this None None O
skeletal None None O
network None None O
. None None O

The None None O
proposed None None O
approach None None O
is None None O
tested None None O
with None None O
the None None O
dead None None O
bird None None O
surveillance None None O
data None None O
in None None O
Ontario None None O
, None None O
Canada None None O
. None None O

The None None O
results None None O
demonstrate None None O
the None None O
effectiveness None None O
of None None O
the None None O
proposed None None O
approach None None O
. None None O


Involvement None None O
of None None O
the None None O
incudostapedial None None O
joint None None O
anomaly None None O
in None None O
conductive None None O
deafness None None O
. None None O

Conclusion None None O
. None None O

The None None O
outcome None None O
of None None O
surgery None None O
depends None None O
on None None O
complexities None None O
of None None O
middle None None O
ear None None O
anomalies None None O
and None None O
definite None None O
diagnosis None None O
can None None O
only None None O
be None None O
achieved None None O
during None None O
exploratory None None O
tympanotomy None None O
. None None O

We None None O
must None None O
be None None O
aware None None O
that None None O
the None None O
pathology None None O
of None None O
the None None O
congenital None None O
ossicular None None O
anomalies None None O
is None None O
variable None None O
and None None O
careful None None O
surgery None None O
is None None O
needed None None O
for None None O
hearing None None O
improvement None None O
. None None O

Objective None None O
. None None O

This None None O
study None None O
aimed None None O
to None None O
investigate None None O
congenital None None O
ossicular None None O
malformation None None O
. None None O

Subjects None None O
and None None O
methods None None O
. None None O

Fifteen None None O
cases None None O
of None None O
ossicular None None O
anomalies None None O
without None None O
external None None O
ear None None O
malformation None None O
were None None O
studied None None O
. None None O

The None None O
anomaly None None O
of None None O
the None None O
incus None None O
- None None O
stapes None None O
complex None None O
was None None O
the None None O
most None None O
frequent None None O
. None None O

There None None O
were None None O
two None None O
cases None None O
of None None O
fused None None O
incudostapedial None None O
( None None O
IS None None O
) None None O
joint None None O
, None None O
which None None O
is None None O
an None None O
extremely None None O
rare None None O
occurrence None None O
. None None O

Case None None O
1 None None O
was None None O
a None None O
33 None None O
- None None O
year None None O
- None None O
old None None O
man None None O
, None None O
in None None O
whom None None O
otosclerosis None None O
was None None O
suspected None None O
and None None O
exploratory None None O
tympanotomy None None O
was None None O
performed None None O
. None None O

The None None O
IS None None O
joint None None O
was None None O
fused None None O
, None None O
and None None O
the None None O
stapes None None O
was None None O
immobile None None O
. None None O

Small None None O
fenestra None None O
stapedectomy None None O
was None None O
performed None None O
. None None O

In None None O
case None None O
2 None None O
, None None O
a None None O
52 None None O
- None None O
year None None O
- None None O
old None None O
woman None None O
, None None O
otosclerosis None None O
was None None O
also None None O
suspected None None O
and None None O
exploratory None None O
tympanotomy None None O
was None None O
performed None None O
. None None O

The None None O
IS None None O
joint None None O
was None None O
fused None None O
and None None O
the None None O
incus None None O
was None None O
fixed None None O
. None None O

After None None O
the None None O
long None None O
process None None O
of None None O
the None None O
incus None None O
was None None O
cut None None O
, None None O
the None None O
stapes None None O
became None None O
mobile None None O
. None None O

However None None O
, None None O
since None None O
the None None O
incus None None O
remained None None O
immobile None None O
, None None O
it None None O
was None None O
removed None None O
and None None O
was None None O
placed None None O
on None None O
the None None O
stapes None None O
. None None O

In None None O
both None None O
cases None None O
, None None O
the None None O
hearing None None O
improved None None O
after None None O
surgery None None O
. None None O

The None None O
averaged None None O
hearing None None O
gain None None O
of None None O
15 None None O
cases None None O
was None None O
28.8 None None O
dB None None O
. None None O


Combination None None O
of None None O
Bernouilli None None O
effect None None O
producing None None O
maneuver None None O
- None None O
induced None None O
pharyngeal None None O
narrowing None None O
rate None None O
with None None O
body None None O
mass None None O
index None None O
as None None O
predictive None None O
tool None None O
for None None O
obstructive None None O
sleep None None O
apnea None None O
syndrome None None O
. None None O

Conclusions None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
the None None O
combination None None O
of None None O
the None None O
pharyngeal None None O
narrowing None None O
rate None None O
during None None O
the None None O
Bernouilli None None O
effect None None O
producing None None O
maneuver None None O
( None None O
BEPM None None O
) None None O
with None None O
the None None O
body None None O
mass None None O
index None None O
( None None O
BMI None None O
) None None O
might None None O
be None None O
a None None O
promising None None O
predictive None None O
method None None O
for None None O
obstructive None None O
sleep None None O
apnea None None O
syndrome None None O
( None None O
OSAS None None O
) None None O
. None None O

Objectives None None O
. None None O

An None None O
attempt None None O
was None None O
made None None O
to None None O
clarify None None O
the None None O
possibility None None O
that None None O
the None None O
dynamic None None O
narrowing None None O
of None None O
the None None O
pharynx None None O
evaluated None None O
by None None O
nasopharyngoscopy None None O
with None None O
BEPM None None O
, None None O
a None None O
forced None None O
inspiration None None O
through None None O
the None None O
nose None None O
with None None O
the None None O
mouth None None O
closed None None O
, None None O
might None None O
be None None O
a None None O
reliable None None O
clinical None None O
daytime None None O
predictor None None O
for None None O
identifying None None O
patients None None O
at None None O
risk None None O
of None None O
developing None None O
OSAS None None O
. None None O

Subjects None None O
and None None O
methods None None O
. None None O

Subjects None None O
were None None O
57 None None O
patients None None O
complaining None None O
of None None O
snoring None None O
and None None O
sleepiness None None O
during None None O
daytime None None O
. None None O

Endoscopic None None O
images None None O
of None None O
the None None O
retropalatal None None O
pharynx None None O
were None None O
obtained None None O
and None None O
their None None O
area None None O
was None None O
measured None None O
by None None O
NIH None None O
imaging None None O
. None None O

The None None O
pharyngeal None None O
narrowing None None O
rate None None O
during None None O
quiet None None O
nasal None None O
breathing None None O
and None None O
that None None O
during None None O
BEPM None None O
were None None O
compared None None O
to None None O
assess None None O
pharyngeal None None O
dynamics None None O
. None None O

To None None O
increase None None O
the None None O
sensitivity None None O
of None None O
this None None O
method None None O
, None None O
BMI None None O
was None None O
added None None O
to None None O
the None None O
pharyngeal None None O
narrowing None None O
rate None None O
during None None O
BEPM None None O
. None None O

Results None None O
. None None O

The None None O
criterion None None O
of None None O
BEPM None None O
at None None O
a None None O
cut None None O
- None None O
off None None O
value None None O
of None None O
50% None None O
with None None O
BMI None None O
at None None O
a None None O
cut None None O
- None None O
off None None O
value None None O
of None None O
25 None None O
kg None None O
/ None None O
m None None O
( None None O
2 None None O
) None None O
achieved None None O
a None None O
sensitivity None None O
of None None O
93% None None O
, None None O
while None None O
the None None O
specificity None None O
was None None O
67% None None O
in None None O
differentiating None None O
simple None None O
snorers None None O
from None None O
OSAS None None O
patients None None O
( None None O
apnea None None O
index None None O
> None None O
5 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
likelihood None None O
ratio None None O
of None None O
the None None O
method None None O
was None None O
found None None O
to None None O
be None None O
2.81 None None O
. None None O


Frequency None None O
and None None O
bases None None O
of None None O
abnormal None None O
performance None None O
by None None O
healthy None None O
adults None None O
on None None O
neuropsychological None None O
testing None None O
. None None O

The None None O
frequency None None O
and None None O
determinants None None O
of None None O
abnormal None None O
test None None O
performance None None O
by None None O
normal None None O
individuals None None O
are None None O
critically None None O
important None None O
to None None O
clinical None None O
inference None None O
. None None O

Here None None O
we None None O
compare None None O
two None None O
approaches None None O
to None None O
predicting None None O
rates None None O
of None None O
abnormal None None O
test None None O
performance None None O
among None None O
healthy None None O
individuals None None O
with None None O
the None None O
rates None None O
actually None None O
shown None None O
by None None O
327 None None O
neurologically None None O
normal None None O
adults None None O
aged None None O
18-92 None None O
years None None O
. None None O

We None None O
counted None None O
how None None O
many None None O
participants None None O
produced None None O
abnormal None None O
scores None None O
, None None O
defined None None O
by None None O
three None None O
different None None O
cutoffs None None O
with None None O
test None None O
batteries None None O
of None None O
varied None None O
length None None O
, None None O
and None None O
the None None O
number None None O
of None None O
abnormal None None O
scores None None O
they None None O
produced None None O
. None None O

Observed None None O
rates None None O
generally None None O
were None None O
closer None None O
to None None O
predictions None None O
based None None O
on None None O
a None None O
series None None O
of None None O
Monte None None O
Carlo None None O
simulations None None O
than None None O
on None None O
the None None O
binomial None None O
model None None O
. None None O

They None None O
increased None None O
with None None O
the None None O
number None None O
of None None O
tests None None O
administered None None O
, None None O
decreased None None O
as None None O
more None None O
stringent None None O
cutoffs None None O
were None None O
used None None O
to None None O
identify None None O
abnormality None None O
, None None O
varied None None O
with None None O
the None None O
degree None None O
of None None O
correlation None None O
among None None O
test None None O
scores None None O
, None None O
and None None O
depended None None O
on None None O
individual None None O
differences None None O
in None None O
age None None O
, None None O
education None None O
, None None O
race None None O
, None None O
sex None None O
, None None O
and None None O
estimated None None O
premorbid None None O
IQ None None O
. None None O

Adjusting None None O
scores None None O
for None None O
demographic None None O
variables None None O
and None None O
premorbid None None O
IQ None None O
did None None O
not None None O
reduce None None O
rates None None O
of None None O
abnormal None None O
performance None None O
. None None O

However None None O
, None None O
it None None O
eliminated None None O
the None None O
contribution None None O
of None None O
these None None O
variables None None O
to None None O
rates None None O
of None None O
abnormal None None O
test None None O
performance None None O
. None None O

These None None O
findings None None O
raise None None O
fundamental None None O
questions None None O
about None None O
the None None O
nature None None O
and None None O
interpretation None None O
of None None O
abnormal None None O
test None None O
performance None None O
by None None O
normal None None O
, None None O
healthy None None O
adults None None O
. None None O


Is None None O
laparoscopy None None O
dying None None O
for None None O
radical None None O
prostatectomy None None O
? None None O
Training None None O
in None None O
laparoscopic None None O
urology None None O
, None None O
extensive None None O
experimental None None O
work None None O
, None None O
and None None O
dedicated None None O
surgical None None O
performance None None O
constitute None None O
the None None O
foundation None None O
of None None O
advanced None None O
laparoscopic None None O
urology None None O
, None None O
which None None O
is None None O
currently None None O
a None None O
reasonable None None O
surgical None None O
option None None O
in None None O
pediatrics None None O
, None None O
reconstructive None None O
surgery None None O
, None None O
and None None O
oncology None None O
. None None O

This None None O
article None None O
discusses None None O
topics None None O
related None None O
to None None O
laparoscopic None None O
approaches None None O
for None None O
radical None None O
prostatectomy None None O
, None None O
focusing None None O
on None None O
their None None O
introduction None None O
, None None O
development None None O
, None None O
accomplishments None None O
, None None O
and None None O
current None None O
standards None None O
and None None O
future None None O
goals None None O
for None None O
the None None O
minimally None None O
invasive None None O
treatment None None O
of None None O
urologic None None O
diseases None None O
. None None O

We None None O
highlight None None O
the None None O
dynamic None None O
status None None O
of None None O
the None None O
laparoscopic None None O
approach None None O
for None None O
radical None None O
prostatectomy None None O
( None None O
pure None None O
or None None O
robotic None None O
- None None O
assisted None None O
) None None O
that None None O
constitutes None None O
one None None O
of None None O
the None None O
most None None O
rapidly None None O
evolving None None O
fields None None O
in None None O
urology None None O
. None None O


Quantitative None None O
magnetic None None O
resonance None None O
image None None O
analysis None None O
of None None O
the None None O
cerebellum None None O
in None None O
macrocephalic None None O
and None None O
normocephalic None None O
children None None O
and None None O
adults None None O
with None None O
autism None None O
. None None O

A None None O
detailed None None O
morphometric None None O
analysis None None O
of None None O
the None None O
cerebellum None None O
in None None O
autism None None O
with None None O
and None None O
without None None O
macrocephaly None None O
. None None O

Four None None O
subject None None O
groups None None O
( None None O
N None None O
= None None O
65 None None O
; None None O
male None None O
; None None O
IQs None None O
> None None O
or None None O
= None None O
65 None None O
; None None O
age None None O
7 None None O
to None None O
26 None None O
years None None O
) None None O
were None None O
studied None None O
with None None O
quantitative None None O
MRI None None O
; None None O
normocephalic None None O
and None None O
macrocephalic None None O
individuals None None O
with None None O
autism None None O
without None None O
mental None None O
retardation None None O
were None None O
compared None None O
to None None O
normocephalic None None O
and None None O
benign None None O
macrocephalic None None O
typically None None O
developing None None O
individuals None None O
. None None O

Total None None O
cerebellum None None O
volumes None None O
and None None O
surface None None O
areas None None O
of None None O
four None None O
lobular None None O
midsagittal None None O
groups None None O
were None None O
measured None None O
. None None O

Independent None None O
t None None O
- None None O
tests None None O
between None None O
autism None None O
and None None O
control None None O
subjects None None O
matched None None O
for None None O
head None None O
size None None O
revealed None None O
no None None O
significant None None O
differences None None O
. None None O

Multivariate None None O
analyses None None O
of None None O
variance None None O
were None None O
also None None O
performed None None O
, None None O
using None None O
the None None O
diagnostic None None O
group None None O
as None None O
the None None O
fixed None None O
factor None None O
, None None O
cerebellar None None O
measures None None O
as None None O
the None None O
dependent None None O
variables None None O
and None None O
total None None O
intracranial None None O
volume None None O
, None None O
total None None O
brain None None O
volume None None O
, None None O
age None None O
, None None O
verbal None None O
IQ None None O
, None None O
and None None O
performance None None O
IQ None None O
as None None O
covariates None None O
. None None O

No None None O
significant None None O
differences None None O
were None None O
found None None O
; None None O
however None None O
, None None O
a None None O
trend None None O
was None None O
noted None None O
in None None O
which None None O
macrocephalic None None O
individuals None None O
with None None O
autism None None O
consistently None None O
exhibited None None O
slightly None None O
smaller None None O
cerebellar None None O
volume None None O
or None None O
surface None None O
area None None O
when None None O
compared None None O
to None None O
individuals None None O
with None None O
benign None None O
macrocephaly None None O
. None None O

In None None O
autism None None O
, None None O
with None None O
and None None O
without None None O
macrocephaly None None O
, None None O
cerebellar None None O
structures None None O
were None None O
found None None O
to None None O
be None None O
proportional None None O
to None None O
head None None O
size None None O
and None None O
did None None O
not None None O
differ None None O
from None None O
typically None None O
developing None None O
subjects None None O
. None None O


Worker None None O
size None None O
in None None O
the None None O
formosan None None O
subterranean None None O
termite None None O
in None None O
relation None None O
to None None O
colony None None O
breeding None None O
structure None None O
as None None O
inferred None None O
from None None O
molecular None None O
markers None None O
. None None O

The None None O
Formosan None None O
subterranean None None O
termite None None O
, None None O
Coptotermes None None O
formosanus None None O
Shiraki None None O
, None None O
is None None O
an None None O
invasive None None O
species None None O
that None None O
originated None None O
in None None O
China None None O
and None None O
has None None O
been None None O
introduced None None O
to None None O
Hawaii None None O
and None None O
the None None O
U None None O
. None None O

S None None O
. None None O

mainland None None O
. None None O

Colonies None None O
are None None O
headed None None O
either None None O
by None None O
a None None O
pair None None O
of None None O
reproductives None None O
( None None O
simple None None O
families None None O
) None None O
or None None O
by None None O
varying None None O
numbers None None O
of None None O
inbreeding None None O
reproductives None None O
( None None O
extended None None O
families None None O
) None None O
, None None O
and None None O
therefore None None O
have None None O
variable None None O
degrees None None O
of None None O
inbreeding None None O
. None None O

Worker None None O
size None None O
also None None O
varies None None O
among None None O
colonies None None O
of None None O
Formosan None None O
termites None None O
. None None O

We None None O
tested None None O
whether None None O
variation None None O
in None None O
worker None None O
size None None O
can None None O
be None None O
explained None None O
by None None O
the None None O
breeding None None O
system None None O
. None None O

Workers None None O
were None None O
collected None None O
from None None O
colonies None None O
from None None O
three None None O
geographically None None O
separated None None O
populations None None O
( None None O
China None None O
, None None O
Hawaii None None O
, None None O
and None None O
Louisiana None None O
) None None O
, None None O
and None None O
body None None O
weight None None O
and None None O
head None None O
size None None O
were None None O
measured None None O
. None None O

Microsatellite None None O
genotyping None None O
was None None O
used None None O
to None None O
establish None None O
whether None None O
colonies None None O
were None None O
simple None None O
or None None O
extended None None O
families None None O
and None None O
to None None O
determine None None O
the None None O
heterozygosity None None O
of None None O
workers None None O
and None None O
their None None O
degree None None O
of None None O
inbreeding None None O
relative None None O
to None None O
their None None O
colony None None O
( None None O
F None None O
( None None O
IC None None O
) None None O
, None None O
sensitive None None O
to None None O
the None None O
number None None O
of None None O
reproductives None None O
) None None O
. None None O

All None None O
Chinese None None O
colonies None None O
contained None None O
multiple None None O
inbreeding None None O
neotenics None None O
. None None O

In None None O
Hawaii None None O
, None None O
37% None None O
of None None O
the None None O
colonies None None O
were None None O
simple None None O
families None None O
and None None O
63% None None O
were None None O
extended None None O
families None None O
, None None O
both None None O
having None None O
considerable None None O
degrees None None O
of None None O
inbreeding None None O
. None None O

In None None O
Louisiana None None O
, None None O
57% None None O
of None None O
the None None O
colonies None None O
were None None O
simple None None O
families None None O
, None None O
which None None O
were None None O
mostly None None O
headed None None O
by None None O
unrelated None None O
pairs None None O
, None None O
and None None O
43% None None O
were None None O
extended None None O
families None None O
. None None O

In None None O
simple None None O
families None None O
, None None O
size None None O
and None None O
body None None O
weight None None O
of None None O
workers None None O
were None None O
not None None O
associated None None O
with None None O
F None None O
( None None O
IC None None O
) None None O
or None None O
heterozygosity None None O
. None None O

In None None O
extended None None O
families None None O
of None None O
two None None O
populations None None O
, None None O
both None None O
size None None O
parameters None None O
were None None O
negatively None None O
correlated None None O
with None None O
F None None O
( None None O
IC None None O
) None None O
; None None O
however None None O
, None None O
heterozygosity None None O
was None None O
not None None O
associated None None O
with None None O
worker None None O
size None None O
in None None O
any None None O
of None None O
the None None O
populations None None O
. None None O

This None None O
suggests None None O
that None None O
the None None O
number None None O
of None None O
reproductives None None O
within None None O
colonies None None O
has None None O
a None None O
stronger None None O
influence None None O
on None None O
worker None None O
size None None O
than None None O
the None None O
individuals None None O
' None None O
genetic None None O
diversity None None O
in None None O
Formosan None None O
subterranean None None O
termite None None O
colonies None None O
. None None O


Protease None None O
production None None O
by None None O
different None None O
thermophilic None None O
fungi None None O
. None None O

A None None O
comparative None None O
study None None O
was None None O
carried None None O
out None None O
to None None O
evaluate None None O
protease None None O
production None None O
in None None O
solid None None O
- None None O
state None None O
fermentation None None O
( None None O
SSF None None O
) None None O
and None None O
submerged None None O
fermentation None None O
( None None O
SmF None None O
) None None O
by None None O
nine None None O
different None None O
thermophilic None None O
fungi None None O
- None None O
Thermoascus None None O
aurantiacus None None O
Miehe None None O
, None None O
Thermomyces None None O
lanuginosus None None O
, None None O
T None None O
. None None O

lanuginosus None None O
TO None None O
.03 None None O
, None None O
Aspergillus None None O
flavus None None O
1.2 None None O
, None None O
Aspergillus None None O
sp None None O
. None None O

13.33 None None O
, None None O
Aspergillus None None O
sp None None O
. None None O

13.34 None None O
, None None O
Aspergillus None None O
sp None None O
. None None O

13.35 None None O
, None None O
Rhizomucor None None O
pusillus None None O
13.36 None None O
and None None O
Rhizomucor None None O
sp None None O
. None None O

13.37 None None O
- None None O
using None None O
substrates None None O
containing None None O
proteins None None O
to None None O
induce None None O
enzyme None None O
secretion None None O
. None None O

Soybean None None O
extract None None O
( None None O
soybean None None O
milk None None O
) None None O
, None None O
soybean None None O
flour None None O
, None None O
milk None None O
powder None None O
, None None O
rice None None O
, None None O
and None None O
wheat None None O
bran None None O
were None None O
tested None None O
. None None O

The None None O
most None None O
satisfactory None None O
results None None O
were None None O
obtained None None O
when None None O
using None None O
wheat None None O
bran None None O
in None None O
SSF None None O
. None None O

The None None O
fungi None None O
that None None O
stood None None O
out None None O
in None None O
SSF None None O
were None None O
T None None O
. None None O

lanuginosus None None O
, None None O
T None None O
. None None O

lanuginosus None None O
TO None None O
.03 None None O
, None None O
Aspergillus None None O
sp None None O
. None None O

13.34 None None O
, None None O
Aspergillus None None O
sp None None O
. None None O

13.35 None None O
, None None O
and None None O
Rhizomucor None None O
sp None None O
. None None O

13.37 None None O
, None None O
and None None O
those None None O
in None None O
SmF None None O
were None None O
T None None O
. None None O

aurantiacus None None O
, None None O
T None None O
. None None O

lanuginosus None None O
TO None None O
.03 None None O
, None None O
and None None O
13.37 None None O
. None None O

In None None O
both None None O
fermentation None None O
systems None None O
, None None O
A None None O
. None None O

flavus None None O
1.2 None None O
and None None O
R None None O
. None None O

pusillus None None O
13.36 None None O
presented None None O
the None None O
lowest None None O
levels None None O
of None None O
proteolytic None None O
activity None None O
. None None O


Inhomogeneity None None O
of None None O
Fecal None None O
Flora None None O
in None None O
Separately None None O
Reared None None O
Laboratory None None O
Mice None None O
, None None O
as None None O
Detected None None O
by None None O
Denaturing None None O
Gradient None None O
Gel None None O
Electrophoresis None None O
( None None O
DGGE None None O
) None None O
. None None O

Laboratory None None O
mice None None O
were None None O
divided None None O
into None None O
2 None None O
groups None None O
and None None O
introduced None None O
to None None O
different None None O
rooms None None O
immediately None None O
after None None O
being None None O
transferred None None O
from None None O
a None None O
mouse None None O
farm None None O
. None None O

Polymerase None None O
chain None None O
reaction None None O
followed None None O
by None None O
denaturing None None O
gradient None None O
gel None None O
electrophoresis None None O
were None None O
performed None None O
on None None O
the None None O
V6 None None O
- None None O
V8 None None O
regions None None O
of None None O
bacterial None None O
16S None None O
rDNA None None O
obtained None None O
from None None O
fecal None None O
samples None None O
at None None O
0 None None O
, None None O
1 None None O
, None None O
2 None None O
, None None O
3 None None O
, None None O
4 None None O
and None None O
8 None None O
weeks None None O
after None None O
the None None O
introduction None None O
. None None O

Binary None None O
data None None O
were None None O
obtained None None O
from None None O
banding None None O
patterns None None O
, None None O
and None None O
Euclidean None None O
distances None None O
for None None O
each None None O
week None None O
were None None O
calculated None None O
and None None O
analyzed None None O
by None None O
cluster None None O
analysis None None O
and None None O
non None None O
- None None O
metric None None O
multidimensional None None O
scaling None None O
. None None O

Euclidean None None O
distances None None O
were None None O
significantly None None O
higher None None O
at None None O
weeks None None O
1 None None O
and None None O
2 None None O
than None None O
at None None O
week None None O
0 None None O
in None None O
both None None O
groups None None O
, None None O
although None None O
the None None O
distances None None O
between None None O
the None None O
2 None None O
groups None None O
were None None O
significantly None None O
higher None None O
after None None O
week None None O
1 None None O
than None None O
week None None O
0 None None O
. None None O

The None None O
distances None None O
between None None O
the None None O
2 None None O
groups None None O
were None None O
significantly None None O
higher None None O
than None None O
those None None O
within None None O
each None None O
group None None O
at None None O
weeks None None O
4 None None O
and None None O
8 None None O
. None None O

Mice None None O
in None None O
the None None O
2 None None O
groups None None O
formed None None O
clusters None None O
at None None O
weeks None None O
2 None None O
and None None O
3 None None O
respectively None None O
, None None O
and None None O
mice None None O
were None None O
divided None None O
into None None O
2 None None O
clusters None None O
by None None O
their None None O
respective None None O
groups None None O
at None None O
weeks None None O
4 None None O
and None None O
8 None None O
. None None O

Mice None None O
in None None O
the None None O
2 None None O
groups None None O
were None None O
distributed None None O
on None None O
opposite None None O
sides None None O
of None None O
the None None O
origin None None O
on None None O
the None None O
2 None None O
- None None O
dimensional None None O
plane None None O
after None None O
week None None O
2 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
mouse None None O
fecal None None O
flora None None O
changed None None O
characteristically None None O
, None None O
according None None O
to None None O
the None None O
local None None O
environment None None O
after None None O
introduction None None O
. None None O


Mail None None O
- None None O
in None None O
data None None O
collection None None O
at None None O
SPring None None O
- None None O
8 None None O
protein None None O
crystallography None None O
beamlines None None O
. None None O

A None None O
mail None None O
- None None O
in None None O
data None None O
collection None None O
system None None O
makes None None O
it None None O
possible None None O
for None None O
beamline None None O
users None None O
to None None O
collect None None O
diffraction None None O
data None None O
without None None O
visiting None None O
a None None O
synchrotron None None O
facility None None O
. None None O

In None None O
the None None O
mail None None O
- None None O
in None None O
data None None O
collection None None O
system None None O
at None None O
SPring None None O
- None None O
8 None None O
, None None O
users None None O
pack None None O
crystals None None O
into None None O
sample None None O
trays None None O
and None None O
send None None O
the None None O
trays None None O
to None None O
SPring None None O
- None None O
8 None None O
via None None O
a None None O
courier None None O
service None None O
as None None O
the None None O
first None None O
step None None O
. None None O

Next None None O
, None None O
the None None O
user None None O
specifies None None O
measurement None None O
conditions None None O
and None None O
checks None None O
the None None O
diffraction None None O
images None None O
via None None O
the None None O
Internet None None O
. None None O

The None None O
user None None O
can None None O
also None None O
collect None None O
diffraction None None O
data None None O
using None None O
an None None O
automated None None O
sample None None O
changer None None O
robot None None O
and None None O
beamline None None O
control None None O
software None None O
. None None O

For None None O
distant None None O
users None None O
there None None O
is None None O
a None None O
newly None None O
developed None None O
data None None O
management None None O
system None None O
, None None O
D None None O
- None None O
Cha None None O
. None None O

D None None O
- None None O
Cha None None O
provides None None O
a None None O
graphical None None O
user None None O
interface None None O
that None None O
enables None None O
the None None O
user None None O
to None None O
specify None None O
the None None O
experimental None None O
conditions None None O
for None None O
samples None None O
and None None O
to None None O
check None None O
and None None O
download None None O
the None None O
diffraction None None O
images None None O
using None None O
a None None O
web None None O
browser None None O
. None None O

This None None O
system None None O
is None None O
now None None O
in None None O
routine None None O
operation None None O
and None None O
is None None O
contributing None None O
to None None O
high None None O
- None None O
throughput None None O
beamline None None O
operation None None O
. None None O


Implied None None O
preference None None O
for None None O
seismic None None O
design None None O
level None None O
and None None O
earthquake None None O
insurance None None O
. None None O

Seismic None None O
risk None None O
can None None O
be None None O
reduced None None O
by None None O
implementing None None O
newly None None O
developed None None O
seismic None None O
provisions None None O
in None None O
design None None O
codes None None O
. None None O

Furthermore None None O
, None None O
financial None None O
protection None None O
or None None O
enhanced None None O
utility None None O
and None None O
happiness None None O
for None None O
stakeholders None None O
could None None O
be None None O
gained None None O
through None None O
the None None O
purchase None None O
of None None O
earthquake None None O
insurance None None O
. None None O

If None None O
this None None O
is None None O
not None None O
so None None O
, None None O
there None None O
would None None O
be None None O
no None None O
market None None O
for None None O
such None None O
insurance None None O
. None None O

However None None O
, None None O
perceived None None O
benefit None None O
associated None None O
with None None O
insurance None None O
is None None O
not None None O
universally None None O
shared None None O
by None None O
stakeholders None None O
partly None None O
due None None O
to None None O
their None None O
diverse None None O
risk None None O
attitudes None None O
. None None O

This None None O
study None None O
investigates None None O
the None None O
implied None None O
seismic None None O
design None None O
preference None None O
with None None O
insurance None None O
options None None O
for None None O
decisionmakers None None O
of None None O
bounded None None O
rationality None None O
whose None None O
preferences None None O
could None None O
be None None O
adequately None None O
represented None None O
by None None O
the None None O
cumulative None None O
prospect None None O
theory None None O
( None None O
CPT None None O
) None None O
. None None O

The None None O
investigation None None O
is None None O
focused None None O
on None None O
assessing None None O
the None None O
sensitivity None None O
of None None O
the None None O
implied None None O
seismic None None O
design None None O
preference None None O
with None None O
insurance None None O
options None None O
to None None O
model None None O
parameters None None O
of None None O
the None None O
CPT None None O
and None None O
to None None O
fair None None O
and None None O
unfair None None O
insurance None None O
arrangements None None O
. None None O

Numerical None None O
results None None O
suggest None None O
that None None O
human None None O
cognitive None None O
limitation None None O
and None None O
risk None None O
perception None None O
can None None O
affect None None O
the None None O
implied None None O
seismic None None O
design None None O
preference None None O
by None None O
the None None O
CPT None None O
significantly None None O
. None None O

The None None O
mandatory None None O
purchase None None O
of None None O
fair None None O
insurance None None O
will None None O
lead None None O
the None None O
implied None None O
seismic None None O
design None None O
preference None None O
to None None O
the None None O
optimum None None O
design None None O
level None None O
that None None O
is None None O
dictated None None O
by None None O
the None None O
minimum None None O
expected None None O
lifecycle None None O
cost None None O
rule None None O
. None None O

Unfair None None O
insurance None None O
decreases None None O
the None None O
expected None None O
gain None None O
as None None O
well None None O
as None None O
its None None O
associated None None O
variability None None O
, None None O
which None None O
is None None O
preferred None None O
by None None O
risk None None O
- None None O
averse None None O
decisionmakers None None O
. None None O

The None None O
obtained None None O
results None None O
of None None O
the None None O
implied None None O
preference None None O
for None None O
the None None O
combination None None O
of None None O
the None None O
seismic None None O
design None None O
level None None O
and None None O
insurance None None O
option None None O
suggest None None O
that None None O
property None None O
owners None None O
, None None O
financial None None O
institutions None None O
, None None O
and None None O
municipalities None None O
can None None O
take None None O
advantage None None O
of None None O
affordable None None O
insurance None None O
to None None O
establish None None O
successful None None O
seismic None None O
risk None None O
management None None O
strategies None None O
. None None O


X None None O
- None None O
ray None None O
beam None None O
stabilization None None O
at None None O
BL None None O
- None None O
17A None None O
, None None O
the None None O
protein None None O
microcrystallography None None O
beamline None None O
of None None O
the None None O
Photon None None O
Factory None None O
. None None O

BL None None O
- None None O
17A None None O
is None None O
a None None O
new None None O
structural None None O
biology None None O
beamline None None O
at None None O
the None None O
Photon None None O
Factory None None O
, None None O
Japan None None O
. None None O

The None None O
high None None O
- None None O
brilliance None None O
beam None None O
, None None O
derived None None O
from None None O
the None None O
new None None O
short None None O
- None None O
gap None None O
undulator None None O
( None None O
SGU None None O
# None None O
17 None None O
) None None O
, None None O
allows None None O
for None None O
unique None None O
protein None None O
crystallographic None None O
experiments None None O
such None None O
as None None O
data None None O
collection None None O
from None None O
microcrystals None None O
and None None O
structural None None O
determination None None O
using None None O
softer None None O
X None None O
- None None O
rays None None O
. None None O

However None None O
, None None O
microcrystal None None O
experiments None None O
require None None O
robust None None O
beam None None O
stability None None O
during None None O
data None None O
collection None None O
and None None O
minor None None O
fluctuations None None O
could None None O
not None None O
be None None O
ignored None None O
. None None O

Initially None None O
, None None O
significant None None O
beam None None O
instability None None O
was None None O
observed None None O
at None None O
BL None None O
- None None O
17A None None O
. None None O

The None None O
causes None None O
of None None O
the None None O
beam None None O
instability None None O
were None None O
investigated None None O
and None None O
its None None O
various None None O
sources None None O
identified None None O
. None None O

Subsequently None None O
, None None O
several None None O
effective None None O
countermeasures None None O
have None None O
been None None O
implemented None None O
, None None O
and None None O
the None None O
fluctuation None None O
of None None O
the None None O
beam None None O
intensity None None O
successfully None None O
suppressed None None O
to None None O
within None None O
1% None None O
. None None O

Here None None O
the None None O
instability None None O
reduction None None O
techniques None None O
used None None O
at None None O
BL None None O
- None None O
17A None None O
are None None O
presented None None O
. None None O


Neonatal None None O
pulmonary None None O
tuberculosis None None O
evolving None None O
to None None O
a None None O
destroyed None None O
lung None None O
. None None O

Tuberculosis None None O
( None None O
TB None None O
) None None O
in None None O
the None None O
newborn None None O
is None None O
infrequent None None O
, None None O
difficult None None O
to None None O
diagnose None None O
and None None O
often None None O
devastating None None O
. None None O

Congenital None None O
TB None None O
is None None O
rare None None O
, None None O
with None None O
most None None O
neonates None None O
and None None O
young None None O
infants None None O
becoming None None O
infected None None O
after None None O
birth None None O
. None None O

The None None O
incidence None None O
of None None O
neonatal None None O
TB None None O
might None None O
increase None None O
in None None O
industrialised None None O
countries None None O
as None None O
a None None O
result None None O
of None None O
immigration None None O
from None None O
countries None None O
with None None O
higher None None O
TB None None O
incidence None None O
among None None O
women None None O
of None None O
childbearing None None O
age None None O
. None None O

We None None O
report None None O
two None None O
cases None None O
of None None O
post None None O
- None None O
natally None None O
acquired None None O
pulmonary None None O
TB None None O
in None None O
newborns None None O
who None None O
developed None None O
marked None None O
lung None None O
destruction None None O
, None None O
a None None O
complication None None O
of None None O
TB None None O
which None None O
has None None O
seldom None None O
been None None O
described None None O
in None None O
the None None O
first None None O
month None None O
of None None O
life None None O
. None None O

A None None O
high None None O
index None None O
of None None O
clinical None None O
suspicion None None O
is None None O
required None None O
when None None O
evaluating None None O
pregnant None None O
women None None O
at None None O
risk None None O
for None None O
TB None None O
and None None O
their None None O
ill None None O
children None None O
, None None O
as None None O
early None None O
identification None None O
and None None O
treatment None None O
can None None O
prevent None None O
the None None O
devastating None None O
consequences None None O
of None None O
TB None None O
. None None O


Visual None None O
perception None None O
in None None O
prediagnostic None None O
and None None O
early None None O
stage None None O
Huntington None None O
's None None O
disease None None O
. None None O

Disturbances None None O
of None None O
visual None None O
perception None None O
frequently None None O
accompany None None O
neurodegenerative None None O
disorders None None O
but None None O
have None None O
been None None O
little None None O
studied None None O
in None None O
Huntington None None O
's None None O
disease None None O
( None None O
HD None None O
) None None O
gene None None O
carriers None None O
. None None O

We None None O
used None None O
psychophysical None None O
tests None None O
to None None O
assess None None O
visual None None O
perception None None O
among None None O
individuals None None O
in None None O
the None None O
prediagnostic None None O
and None None O
early None None O
stages None None O
of None None O
HD None None O
. None None O

The None None O
sample None None O
comprised None None O
four None None O
groups None None O
, None None O
which None None O
included None None O
201 None None O
nongene None None O
carriers None None O
( None None O
NG None None O
) None None O
, None None O
32 None None O
prediagnostic None None O
gene None None O
carriers None None O
with None None O
minimal None None O
neurological None None O
abnormalities None None O
( None None O
PD1 None None O
) None None O
; None None O
20 None None O
prediagnostic None None O
gene None None O
carriers None None O
with None None O
moderate None None O
neurological None None O
abnormalities None None O
( None None O
PD2 None None O
) None None O
, None None O
and None None O
36 None None O
gene None None O
carriers None None O
with None None O
diagnosed None None O
HD None None O
. None None O

Contrast None None O
sensitivity None None O
for None None O
stationary None None O
and None None O
moving None None O
sinusoidal None None O
gratings None None O
, None None O
and None None O
tests None None O
of None None O
form None None O
and None None O
motion None None O
discrimination None None O
, None None O
were None None O
used None None O
to None None O
probe None None O
different None None O
visual None None O
pathways None None O
. None None O

Patients None None O
with None None O
HD None None O
showed None None O
impaired None None O
contrast None None O
sensitivity None None O
for None None O
moving None None O
gratings None None O
. None None O

For None None O
one None None O
of None None O
the None None O
three None None O
contrast None None O
sensitivity None None O
tests None None O
, None None O
the None None O
prediagnostic None None O
gene None None O
carriers None None O
with None None O
greater None None O
neurological None None O
abnormality None None O
( None None O
PD2 None None O
) None None O
also None None O
had None None O
impaired None None O
performance None None O
as None None O
compared None None O
with None None O
NG None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
early None None O
stage None None O
HD None None O
disrupts None None O
visual None None O
functions None None O
associated None None O
with None None O
the None None O
magnocellular None None O
pathway None None O
. None None O

However None None O
, None None O
these None None O
changes None None O
are None None O
only None None O
observed None None O
in None None O
individuals None None O
diagnosed None None O
with None None O
HD None None O
or None None O
who None None O
are None None O
in None None O
the None None O
more None None O
symptomatic None None O
stages None None O
of None None O
prediagnostic None None O
HD None None O
. None None O


Prospects None None O
for None None O
the None None O
use None None O
of None None O
differentiation None None O
- None None O
modulating None None O
agents None None O
as None None O
adjuvant None None O
of None None O
photodynamic None None O
therapy None None O
for None None O
proliferative None None O
dermatoses None None O
. None None O

Current None None O
interest None None O
in None None O
photodynamic None None O
therapy None None O
( None None O
PDT None None O
) None None O
in None None O
dermatology None None O
stems None None O
from None None O
its None None O
recognized None None O
success None None O
in None None O
dermatological None None O
oncology None None O
, None None O
straightforward None None O
approach None None O
, None None O
easy None None O
accessibility None None O
and None None O
low None None O
cost None None O
. None None O

PDT None None O
is None None O
a None None O
photochemistry None None O
- None None O
based None None O
modality None None O
in None None O
which None None O
a None None O
light None None O
- None None O
activated None None O
photosensitizer None None O
( None None O
PS None None O
) None None O
destroys None None O
tissue None None O
through None None O
oxygen None None O
- None None O
dependent None None O
and None None O
- None None O
independent None None O
mechanisms None None O
. None None O

Although None None O
PDT None None O
has None None O
been None None O
used None None O
in None None O
dermatology None None O
for None None O
several None None O
decades None None O
, None None O
its None None O
application None None O
has None None O
still None None O
not None None O
extended None None O
significantly None None O
into None None O
the None None O
routine None None O
management None None O
of None None O
neoplastic None None O
and None None O
proliferative None None O
dermatoses None None O
because None None O
of None None O
continuing None None O
issues None None O
with None None O
the None None O
selectivity None None O
of None None O
the None None O
PS None None O
for None None O
affected None None O
tissues None None O
. None None O

This None None O
review None None O
analyzes None None O
prospects None None O
for None None O
optimization None None O
of None None O
PDT None None O
for None None O
the None None O
management None None O
of None None O
dermatoses None None O
with None None O
defects None None O
in None None O
keratinocyte None None O
proliferation None None O
/ None None O
differentiation None None O
, None None O
and None None O
discusses None None O
the None None O
use None None O
of None None O
differentiating None None O
agents None None O
that None None O
redirect None None O
metabolic None None O
utilization None None O
within None None O
cells None None O
and None None O
lead None None O
to None None O
high None None O
levels None None O
of None None O
PS None None O
accumulation None None O
. None None O


Photodynamic None None O
diagnostics None None O
of None None O
bladder None None O
tumors None None O
. None None O

Approximately None None O
18,000 None None O
new None None O
cases None None O
of None None O
urothelial None None O
cancer None None O
of None None O
the None None O
bladder None None O
occur None None O
annually None None O
, None None O
making None None O
it None None O
the None None O
most None None O
frequent None None O
urogenital None None O
neoplasia None None O
representing None None O
nearly None None O
4% None None O
of None None O
all None None O
malignomas None None O
. None None O

Tumor None None O
stage None None O
defines None None O
two None None O
subgroups None None O
requiring None None O
specific None None O
therapeutic None None O
approaches None None O
and None None O
implying None None O
distinct None None O
prognoses None None O
. None None O

Non None None O
- None None O
muscle None None O
- None None O
invasive None None O
urothelial None None O
cancer None None O
recurs None None O
frequently None None O
and None None O
occasionally None None O
progresses None None O
to None None O
muscle None None O
- None None O
invasive None None O
stages None None O
. None None O

Remnant None None O
tumor None None O
after None None O
initial None None O
resection None None O
is None None O
seen None None O
as None None O
one None None O
major None None O
factor None None O
in None None O
high None None O
recurrence None None O
rates None None O
. None None O

Although None None O
photodynamic None None O
diagnostics None None O
improving None None O
detection None None O
and None None O
increasing None None O
recurrence None None O
- None None O
free None None O
survival None None O
has None None O
been None None O
introduced None None O
to None None O
broad None None O
application None None O
, None None O
it None None O
has None None O
yet None None O
not None None O
been None None O
established None None O
as None None O
standard None None O
procedure None None O
. None None O

This None None O
article None None O
reviews None None O
the None None O
current None None O
literature None None O
and None None O
discusses None None O
controversial None None O
aspects None None O
. None None O


Thalamic None None O
atrophy None None O
and None None O
cognition None None O
in None None O
unilateral None None O
temporal None None O
lobe None None O
epilepsy None None O
. None None O

This None None O
study None None O
examined None None O
quantitative None None O
magnetic None None O
resonance None None O
volumes None None O
of None None O
the None None O
thalamus None None O
and None None O
hippocampus None None O
and None None O
determined None None O
their None None O
relationship None None O
with None None O
cognitive None None O
function None None O
and None None O
clinical None None O
seizure None None O
characteristics None None O
in None None O
a None None O
sample None None O
of None None O
46 None None O
unilateral None None O
temporal None None O
lobe None None O
epilepsy None None O
( None None O
TLE None None O
) None None O
subjects None None O
( None None O
20 None None O
left None None O
and None None O
26 None None O
right None None O
) None None O
and None None O
29 None None O
controls None None O
. None None O

The None None O
hippocampus None None O
and None None O
thalamus None None O
exhibited None None O
different None None O
patterns None None O
of None None O
volume None None O
abnormality None None O
, None None O
different None None O
associations None None O
with None None O
clinical None None O
seizure None None O
characteristics None None O
, None None O
and None None O
different None None O
patterns None None O
of None None O
relationship None None O
with None None O
cognitive None None O
measures None None O
. None None O

Hippocampal None None O
volume None None O
reduction None None O
was None None O
primarily None None O
ipsilateral None None O
to None None O
the None None O
seizure None None O
focus None None O
, None None O
and None None O
thalamic None None O
volume None None O
reduction None None O
was None None O
bilateral None None O
. None None O

Ipsilateral None None O
hippocampal None None O
volume None None O
was None None O
significantly None None O
correlated None None O
with None None O
both None None O
early None None O
neurodevelopmental None None O
features None None O
( None None O
age None None O
of None None O
seizure None None O
onset None None O
) None None O
and None None O
disease None None O
characteristics None None O
( None None O
duration None None O
of None None O
epilepsy None None O
) None None O
, None None O
whereas None None O
thalamus None None O
integrity None None O
was None None O
related None None O
only None None O
to None None O
disease None None O
variables None None O
. None None O

Hippocampal None None O
volume None None O
showed None None O
a None None O
selective None None O
association None None O
with None None O
verbal None None O
memory None None O
performance None None O
. None None O

In None None O
contrast None None O
, None None O
both None None O
left None None O
and None None O
right None None O
thalamic None None O
volumes None None O
were None None O
significantly None None O
correlated None None O
with None None O
performance None None O
on None None O
both None None O
memory None None O
and None None O
nonmemory None None O
cognitive None None O
domains None None O
. None None O

These None None O
findings None None O
underscore None None O
the None None O
importance None None O
of None None O
thalamic None None O
atrophy None None O
in None None O
chronic None None O
TLE None None O
and None None O
its None None O
potential None None O
implications None None O
for None None O
cognition None None O
. None None O


Unilateral None None O
hearing None None O
disturbance None None O
could None None O
be None None O
an None None O
isolated None None O
manifestation None None O
prior None None O
to None None O
ipsilateral None None O
anterior None None O
inferior None None O
cerebellar None None O
artery None None O
infarction None None O
. None None O

A None None O
50 None None O
- None None O
year None None O
- None None O
old None None O
man None None O
presented None None O
with None None O
a None None O
sudden None None O
onset None None O
of None None O
right None None O
- None None O
sided None None O
hearing None None O
disturbance None None O
. None None O

His None None O
hearing None None O
disturbance None None O
improved None None O
gradually None None O
, None None O
however None None O
, None None O
dysarthria None None O
, None None O
right None None O
- None None O
sided None None O
facial None None O
weakness None None O
and None None O
dysesthesia None None O
, None None O
and None None O
gait None None O
disturbance None None O
was None None O
developed None None O
11 None None O
days None None O
after None None O
the None None O
onset None None O
of None None O
hearing None None O
disturbance None None O
. None None O

MR None None O
imaging None None O
revealed None None O
fresh None None O
infarctions None None O
of None None O
the None None O
right None None O
dorsolateral None None O
pons None None O
and None None O
middle None None O
cerebellar None None O
peduncle None None O
localized None None O
in None None O
the None None O
territory None None O
of None None O
anterior None None O
inferior None None O
cerebellar None None O
artery None None O
. None None O

Unilateral None None O
hearing None None O
disturbance None None O
could None None O
be None None O
an None None O
isolated None None O
manifestation None None O
prior None None O
to None None O
ipsilateral None None O
anterior None None O
inferior None None O
cerebellar None None O
artery None None O
infarction None None O
. None None O


An None None O
OLETF None None O
Allele None None O
of None None O
Hyperglycemic None None O
QTL None None O
Nidd3 None None O
/ None None O
of None None O
Is None None O
Dominant None None O
. None None O

The None None O
OLETF None None O
rat None None O
is None None O
a None None O
well None None O
- None None O
established None None O
model None None O
for None None O
the None None O
study None None O
of None None O
type None None O
2 None None O
diabetes None None O
associated None None O
with None None O
obesity None None O
and None None O
has None None O
been None None O
shown None None O
to None None O
possess None None O
multiple None None O
hyperglycemic None None O
alleles None None O
in None None O
its None None O
genome None None O
. None None O

Here None None O
we None None O
focused None None O
on None None O
and None None O
carefully None None O
characterized None None O
one None None O
of None None O
the None None O
previously None None O
reported None None O
congenic None None O
strains None None O
, None None O
F None None O
. None None O

O None None O
- None None O
Nidd3 None None O
/ None None O
of None None O
that None None O
carries None None O
the None None O
OLETF None None O
allele None None O
of None None O
the None None O
Nidd3 None None O
/ None None O
of None None O
locus None None O
( None None O
also None None O
known None None O
as None None O
Niddm21 None None O
in None None O
the None None O
Rat None None O
Genome None None O
Database None None O
) None None O
in None None O
the None None O
normoglycemic None None O
F344 None None O
genetic None None O
background None None O
. None None O

A None None O
prominent None None O
finding None None O
was None None O
that None None O
the None None O
F1 None None O
progeny None None O
between None None O
the None None O
congenic None None O
and None None O
the None None O
F344 None None O
stain None None O
, None None O
whose None None O
genotype None None O
is None None O
heterozygote None None O
at None None O
the None None O
Nidd3 None None O
/ None None O
of None None O
locus None None O
, None None O
showed None None O
mild None None O
hyperglycemia None None O
equal None None O
to None None O
the None None O
parental None None O
congenic None None O
rat None None O
, None None O
suggesting None None O
that None None O
the None None O
OLETF None None O
allele None None O
is None None O
dominant None None O
. None None O

To None None O
our None None O
knowledge None None O
, None None O
this None None O
is None None O
the None None O
first None None O
study None None O
in None None O
which None None O
a None None O
diabetic None None O
QTL None None O
has None None O
been None None O
directly None None O
demonstrated None None O
to None None O
be None None O
dominant None None O
by None None O
using None None O
congenic None None O
strains None None O
. None None O


Implementation None None O
of None None O
remote None None O
monitoring None None O
and None None O
diffraction None None O
evaluation None None O
systems None None O
at None None O
the None None O
Photon None None O
Factory None None O
macromolecular None None O
crystallography None None O
beamlines None None O
. None None O

Owing None None O
to None None O
recent None None O
advances None None O
in None None O
high None None O
- None None O
throughput None None O
technology None None O
in None None O
macromolecular None None O
crystallography None None O
beamlines None None O
, None None O
such None None O
as None None O
high None None O
- None None O
brilliant None None O
X None None O
- None None O
ray None None O
sources None None O
, None None O
high None None O
- None None O
speed None None O
readout None None O
detectors None None O
and None None O
robotics None None O
, None None O
the None None O
number None None O
of None None O
samples None None O
that None None O
can None None O
be None None O
examined None None O
in None None O
a None None O
single None None O
visit None None O
to None None O
the None None O
beamline None None O
has None None O
increased None None O
dramatically None None O
. None None O

In None None O
order None None O
to None None O
make None None O
these None None O
experiments None None O
more None None O
efficient None None O
, None None O
two None None O
functions None None O
, None None O
remote None None O
monitoring None None O
and None None O
diffraction None None O
image None None O
evaluation None None O
, None None O
have None None O
been None None O
implemented None None O
in None None O
the None None O
macromolecular None None O
crystallography None None O
beamlines None None O
at None None O
the None None O
Photon None None O
Factory None None O
( None None O
PF None None O
) None None O
. None None O

Remote None None O
monitoring None None O
allows None None O
scientists None None O
to None None O
participate None None O
in None None O
the None None O
experiment None None O
by None None O
watching None None O
from None None O
their None None O
laboratories None None O
, None None O
without None None O
having None None O
to None None O
come None None O
to None None O
the None None O
beamline None None O
. None None O

Diffraction None None O
image None None O
evaluation None None O
makes None None O
experiments None None O
easier None None O
, None None O
especially None None O
when None None O
using None None O
the None None O
sample None None O
exchange None None O
robot None None O
. None None O

To None None O
implement None None O
these None None O
two None None O
functions None None O
, None None O
two None None O
independent None None O
clients None None O
have None None O
been None None O
developed None None O
that None None O
work None None O
specifically None None O
for None None O
remote None None O
monitoring None None O
and None None O
diffraction None None O
image None None O
evaluation None None O
. None None O

In None None O
the None None O
macromolecular None None O
crystallography None None O
beamlines None None O
at None None O
PF None None O
, None None O
beamline None None O
control None None O
is None None O
performed None None O
using None None O
STARS None None O
( None None O
simple None None O
transmission None None O
and None None O
retrieval None None O
system None None O
) None None O
. None None O

The None None O
system None None O
adopts None None O
a None None O
client None None O
- None None O
server None None O
style None None O
in None None O
which None None O
client None None O
programs None None O
communicate None None O
with None None O
each None None O
other None None O
through None None O
a None None O
server None None O
process None None O
using None None O
the None None O
STARS None None O
protocol None None O
. None None O

This None None O
is None None O
an None None O
advantage None None O
of None None O
the None None O
extension None None O
of None None O
the None None O
system None None O
; None None O
implementation None None O
of None None O
these None None O
new None None O
functions None None O
required None None O
few None None O
modifications None None O
of None None O
the None None O
existing None None O
system None None O
. None None O


Direct None None O
Comparison None None O
between None None O
ICSI None None O
- None None O
Mediated None None O
DNA None None O
Transfer None None O
and None None O
Pronuclear None None O
DNA None None O
Microinjection None None O
for None None O
Producing None None O
Transgenic None None O
Rats None None O
. None None O

Production None None O
efficiency None None O
of None None O
transgenic None None O
rats None None O
was None None O
compared None None O
directly None None O
between None None O
the None None O
routine None None O
pronuclear None None O
microinjection None None O
of None None O
exogenous None None O
DNA None None O
solution None None O
( None None O
PNMI None None O
- None None O
Tg None None O
method None None O
) None None O
and None None O
the None None O
ooplasmic None None O
injection None None O
of None None O
sperm None None O
cells None None O
exposed None None O
to None None O
exogenous None None O
DNA None None O
solution None None O
( None None O
ICSI None None O
- None None O
Tg None None O
method None None O
) None None O
using None None O
six None None O
DNA None None O
constructs None None O
. None None O

The None None O
overall None None O
production None None O
efficiency None None O
per None None O
treated None None O
oocyte None None O
in None None O
the None None O
ICSI None None O
- None None O
Tg None None O
method None None O
( None None O
mean None None O
1.1% None None O
, None None O
range None None O
0.2 None None O
to None None O
3.1% None None O
) None None O
was None None O
similar None None O
to None None O
that None None O
in None None O
the None None O
PNMI None None O
- None None O
Tg None None O
method None None O
( None None O
mean None None O
1.1% None None O
, None None O
range None None O
0 None None O
to None None O
2.4% None None O
) None None O
. None None O

An None None O
advantage None None O
of None None O
the None None O
ICSI None None O
- None None O
Tg None None O
method None None O
in None None O
the None None O
production None None O
of None None O
transgenic None None O
rats None None O
is None None O
noted None None O
in None None O
cases None None O
in None None O
which None None O
a None None O
low None None O
yield None None O
of None None O
pronuclear None None O
zygotes None None O
is None None O
an None None O
inevitable None None O
fate None None O
of None None O
the None None O
rat None None O
strain None None O
. None None O


EEG None None O
observations None None O
in None None O
a None None O
case None None O
with None None O
thalamic None None O
syndrome None None O
. None None O

A None None O
case None None O
of None None O
thalamic None None O
syndrome None None O
of None None O
the None None O
D None None O
 None None O
 None None O
jerine None None O
- None None O
Roussy None None O
type None None O
is None None O
presented None None O
. None None O

EEG None None O
studies None None O
reveal None None O
that None None O
although None None O
bilaterally None None O
symmetrical None None O
rhythmic None None O
activity None None O
may None None O
be None None O
present None None O
when None None O
the None None O
patient None None O
is None None O
awake None None O
, None None O
during None None O
drowsiness None None O
and None None O
deeper None None O
sleep None None O
a None None O
marked None None O
asymmetry None None O
often None None O
appears None None O
with None None O
early None None O
disappearance None None O
of None None O
alpha None None O
activity None None O
and None None O
reduction None None O
or None None O
abolition None None O
of None None O
spindles None None O
on None None O
the None None O
side None None O
involved None None O
. None None O

Thalamic None None O
integration None None O
in None None O
the None None O
sleep None None O
mechanism None None O
is None None O
briefly None None O
discussed None None O
. None None O


Distinct None None O
cognitive None None O
profiles None None O
and None None O
rates None None O
of None None O
decline None None O
on None None O
the None None O
Mattis None None O
Dementia None None O
Rating None None O
Scale None None O
in None None O
autopsy None None O
- None None O
confirmed None None O
frontotemporal None None O
dementia None None O
and None None O
Alzheimer None None O
's None None O
disease None None O
. None None O

Neuropsychological None None O
studies None None O
have None None O
shown None None O
that None None O
patients None None O
with None None O
Frontotemporal None None O
dementia None None O
( None None O
FTD None None O
) None None O
perform None None O
worse None None O
than None None O
patients None None O
with None None O
Alzheimer None None O
's None None O
disease None None O
( None None O
AD None None O
) None None O
on None None O
tests None None O
of None None O
conceptualization None None O
and None None O
verbal None None O
fluency None None O
, None None O
but None None O
better None None O
on None None O
tests None None O
of None None O
memory None None O
and None None O
visuospatial None None O
functions None None O
. None None O

However None None O
, None None O
it None None O
is None None O
not None None O
known None None O
if None None O
these None None O
distinct None None O
cognitive None None O
profiles None None O
are None None O
robust None None O
enough None None O
to None None O
be None None O
detected None None O
using None None O
a None None O
relatively None None O
brief None None O
dementia None None O
screening None None O
instrument None None O
such None None O
as None None O
the None None O
Mattis None None O
Dementia None None O
Rating None None O
Scale None None O
( None None O
MDRS None None O
) None None O
. None None O

To None None O
address None None O
this None None O
issue None None O
, None None O
the None None O
MDRS None None O
subscale None None O
profiles None None O
of None None O
patients None None O
with None None O
autopsy None None O
- None None O
confirmed None None O
FTD None None O
( None None O
n None None O
= None None O
17 None None O
) None None O
or None None O
AD None None O
( None None O
n None None O
= None None O
34 None None O
) None None O
were None None O
compared None None O
. None None O

Results None None O
showed None None O
distinct None None O
cognitive None None O
profiles None None O
in None None O
which None None O
FTD None None O
patients None None O
performed None None O
worse None None O
than None None O
AD None None O
patients None None O
on None None O
the None None O
Initiation None None O
/ None None O
Perseveration None None O
and None None O
Conceptualization None None O
subscales None None O
while None None O
performing None None O
better None None O
on None None O
the None None O
Memory None None O
and None None O
Construction None None O
subscales None None O
. None None O

The None None O
distinct None None O
subscale None None O
profiles None None O
correctly None None O
classified None None O
85% None None O
of None None O
AD None None O
patients None None O
and None None O
76% None None O
of None None O
FTD None None O
patients None None O
. None None O

Profiles None None O
were None None O
maintained None None O
in None None O
a None None O
subset None None O
of None None O
mildly None None O
- None None O
to None None O
- None None O
moderately None None O
demented None None O
patients None None O
( None None O
MDRS None None O
> None None O
or None None O
= None None O
105 None None O
) None None O
and None None O
correctly None None O
classified None None O
89% None None O
of None None O
these None None O
patients None None O
. None None O

In None None O
addition None None O
, None None O
FTD None None O
patients None None O
( None None O
mean None None O
= None None O
30.0 None None O
points None None O
/ None None O
year None None O
) None None O
declined None None O
faster None None O
than None None O
AD None None O
patients None None O
( None None O
mean None None O
= None None O
14.8 None None O
points None None O
/ None None O
year None None O
) None None O
on None None O
MDRS None None O
total None None O
and None None O
specific None None O
subscale None None O
scores None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
MDRS None None O
may None None O
be None None O
a None None O
useful None None O
adjunct None None O
to None None O
other None None O
clinical None None O
measures None None O
for None None O
distinguishing None None O
FTD None None O
from None None O
AD None None O
and None None O
tracking None None O
the None None O
progression None None O
of None None O
the None None O
disorder None None O
. None None O


Households None None O
' None None O
perceived None None O
personal None None O
risk None None O
and None None O
responses None None O
in None None O
a None None O
multihazard None None O
environment None None O
. None None O

This None None O
study None None O
proposed None None O
and None None O
tested None None O
a None None O
multistage None None O
model None None O
of None None O
household None None O
response None None O
to None None O
three None None O
hazards None None O
- None None O
flood None None O
, None None O
hurricane None None O
, None None O
and None None O
toxic None None O
chemical None None O
release None None O
- None None O
in None None O
Harris None None O
County None None O
Texas None None O
. None None O

The None None O
model None None O
, None None O
which None None O
extends None None O
Lindell None None O
and None None O
Perry None None O
's None None O
( None None O
1992 None None O
, None None O
2004 None None O
) None None O
Protective None None O
Action None None O
Decision None None O
Model None None O
, None None O
proposed None None O
a None None O
basic None None O
causal None None O
chain None None O
from None None O
hazard None None O
proximity None None O
through None None O
hazard None None O
experience None None O
and None None O
perceived None None O
personal None None O
risk None None O
to None None O
expectations None None O
of None None O
continued None None O
residence None None O
in None None O
the None None O
home None None O
and None None O
adoption None None O
of None None O
household None None O
hazard None None O
adjustments None None O
. None None O

Data None None O
from None None O
321 None None O
households None None O
generally None None O
supported None None O
the None None O
model None None O
, None None O
but None None O
the None None O
mediating None None O
effects None None O
of None None O
hazard None None O
experience None None O
and None None O
perceived None None O
personal None None O
risk None None O
were None None O
partial None None O
rather None None O
than None None O
complete None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
data None None O
suggested None None O
that None None O
four None None O
demographic None None O
variables None None O
- None None O
gender None None O
, None None O
age None None O
, None None O
income None None O
, None None O
and None None O
ethnicity None None O
- None None O
affect None None O
the None None O
basic None None O
causal None None O
chain None None O
at None None O
different None None O
points None None O
. None None O


An None None O
exploratory None None O
evaluation None None O
of None None O
the None None O
contribution None None O
of None None O
personality None None O
and None None O
childhood None None O
sexual None None O
victimization None None O
to None None O
the None None O
development None None O
of None None O
sexually None None O
abusive None None O
behavior None None O
. None None O

Scores None None O
on None None O
the None None O
Millon None None O
Adolescent None None O
Clinical None None O
Inventory None None O
( None None O
MACI None None O
) None None O
and None None O
the None None O
Childhood None None O
Trauma None None O
Questionnaire None None O
( None None O
CTQ None None O
) None None O
were None None O
collected None None O
from None None O
two None None O
samples None None O
of None None O
incarcerated None None O
delinquent None None O
males None None O
: None None O
74 None None O
adjudicated None None O
sexual None None O
abusers None None O
and None None O
53 None None O
nonsexual None None O
abusers None None O
. None None O

In None None O
comparison None None O
to None None O
non None None O
- None None O
sexually None None O
abusive None None O
youths None None O
, None None O
a None None O
larger None None O
percentage None None O
of None None O
the None None O
sexually None None O
abusive None None O
youths None None O
indicated None None O
a None None O
history None None O
of None None O
childhood None None O
sexual None None O
victimization None None O
. None None O

The None None O
scores None None O
were None None O
then None None O
entered None None O
into None None O
a None None O
logistic None None O
regression None None O
to None None O
assess None None O
the None None O
contribution None None O
of None None O
personality None None O
characteristics None None O
to None None O
a None None O
social None None O
learning None None O
" None None O
victim None None O
- None None O
to None None O
- None None O
victimizer None None O
" None None O
etiological None None O
model None None O
. None None O

After None None O
controlling None None O
for None None O
time None None O
in None None O
treatment None None O
, None None O
the None None O
model None None O
correctly None None O
classified None None O
76.6% None None O
of None None O
the None None O
youths None None O
. None None O

The None None O
variables None None O
that None None O
contributed None None O
significantly None None O
to None None O
the None None O
social None None O
learning None None O
model None None O
were None None O
the None None O
CTQ None None O
Sexual None None O
Abuse None None O
and None None O
Physical None None O
Neglect None None O
scales None None O
and None None O
the None None O
Submissive None None O
and None None O
Forceful None None O
scales None None O
on None None O
the None None O
MACI None None O
. None None O

Research None None O
and None None O
treatment None None O
implications None None O
of None None O
these None None O
findings None None O
are None None O
discussed None None O
. None None O


